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Usher syndrome is an autosomal recessively inherited disorder that is character-
ized by (congenital) moderate-to-profound hearing loss combined with a progressive 
loss of vision. Also vestibular impairment can be associated with the syndrome. Usher 
syndrome is the most common cause of hereditary deaf-blindness in man, representing 
approximately 50% of cases, with a prevalence of about 1 in 20,000 individuals. Although 
the syndrome and its heredity were already described by Von Graefe in 1858 (Graefe 
1858), shortly before Mendel proposed the principles of heredity and introduced the 
concepts of dominantly and recessively inherited traits, it was finally named after the 
Scottish ophthalmologist Charles Howard Usher in 1935.
THE EAR: ANATOMy AND SOUND PERCEPTION
With our ears we can perceive sounds in order to create awareness of our surround-
ings. Sound waves are captured by the outer ear (containing the external ear, also 
named the auricle, and the external auditory canal) and transported to the tympanic 
membrane (ear drum), which separates the outer ear from the middle ear. The middle 
ear contains the ossicles, the malleus (hammer), incus (anvil), and stapes (stirrup), the 
three smallest bones in the human body. The ossicles connect the tympanic membrane 
and the oval window of the inner ear. The inner ear is buried in the hardest bone of the 
human body, the temporal bone, and consists of a labyrinth of ducts that contain ion-
rich fluids that move in response to sound waves and movements of the head. The inner 
ear can be divided into the balance organ (the vestibulum) and the hearing organ (the 
cochlea) (Fig. 1). The cochlea is spiraling around a cartilage structure, the modiolus, and 
is divided into three parallel ducts: the scala vestibule, the scala tympani and the scala 
media. Within the scala media the actual sensory epithelium is located within the Organ 
of Corti. This epithelium consists of three rows of outer hair cells, one row of inner hair 
cells and supporting cells. On top of the hair cells, actin-based protrusions are present, 
the stereocilia. Stereocilia are typically organized in a V-shaped staircase-like pattern. 
Upon deflection of the hair bundles, the hair cells convert mechanical signals (sound 
waves) into electrical signals (action potential) by the physical opening of mechano-
transduction channels. In patients with Usher syndrome, however, the organization of 
hair bundles is affected and therefore lead to a reduced ability of sound perception. 
These patients are therefore often provided with hearing aids or cochlear implants. 
Patients with cochlear implants have shown to improve their speech intelligibility and 
report an improved quality of life (Hartel et al. 2017). The molecular composition of the 
hair bundles and the role of Usher-associated proteins in the process of hair bundle 
formation is explained later on in more detail.
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THE EyE: ANATOMy AND LIGHT PERCEPTION
The eye is the sensory organ that is able to receive and convert light into an electri-
cal signal that is processed by the brain. The anterior region of the eye, consisting 
of the cornea, the sclera, the iris and the pupil, is visible from outside the body. The 
lens, which is located behind the pupil, can accommodate to adjust the focal point of 
entering light beams. The retina, which decorates the back of the eye, will capture the 
light and has an organized layered structure that contains highly specialized cells. The 
actual light-sensitive cell is the photoreceptor. Two types of photoreceptor cells can be 
distinguished: cones and rods. The human retina contains three types of cones: blue (S-
A
B
Figure 1. Anatomical overview of the ear (A) and eye (B). The ear overview is taken from (Chittka 
and Brockmann 2005) and the eye overview is adapted from Wikipedia (https://commons.wikimedia.
org/wiki/File:Schematic_diagram_of_the_human_eye_en.svg).
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cone), green (M-cone) and red (L-cone). Some vertebrates - such as the zebrafish - have 
an additional UV-light sensitive cone. Rods cannot distinguish between colors, but are 
responsible for dim-light (scotopic) vision. In rod photoreceptors, rhodopsin acts as the 
photopigment that initiates the phototransduction cascade. In cones, different types 
of photopsin molecules are present, depending on the cone subtype, which all have a 
different spectral sensitivity. In the human retina, cone photoreceptors are mostly clus-
tered in the central region of the retina, called the fovea, whereas rod photoreceptors 
are more abundantly present in the peripheral retina. For a more detailed description of 
the retinal architecture and molecular processes that play a role in light perception, the 
reader is referred to chapter 2a. The role of Usher syndrome-associated proteins in the 
retina will be discussed in more detail below. 
CLINICAL CHARACTERISTICS OF USHER SyNDROME
Clinical heterogeneity of Usher syndrome was recognized by Julia Bell. She reported 
differences in the severity of hearing loss among patients and these differences formed 
the basis for the present distinction of three clinical types: type I (USH1), type II (USH2) 
and type III (USH3). USH1 is characterized by congenital severe-to-profound hearing 
loss combined with the absence of vestibular function. RP is the type of retinal degen-
eration seen in Usher syndrome, most often starting with night blindness as the first 
clinical symptom. In patients with USH1, RP is generally diagnosed before puberty.
Typical for USH2 is congenital moderate-to-severe bilateral hearing loss, with high 
frequencies being most severely affected. For USH2a it has been shown that hearing 
impairment is more progressive in patients with two protein-truncating mutations as 
compared to patients with one or two missense mutations (Hartel et al. 2016). Vestibular 
function is within the normal range, as are motor milestones of the patients. However, 
also mildly abnormal vestibular function has been reported. The first clinical symptoms 
of RP in USH2a patients become apparent at an age of approximately 15 years, which 
is 10 years earlier than in nsRP cases with mutations in USH2A (Pierrache et al. 2016). 
USH3 is more variable than USH1 and USH2. In USH3 the hearing loss is progressive 
with a variable age of onset. Also, the age at which RP is diagnosed is variable and can 
precede that of the hearing loss. Vestibular function can be normal, absent or partially 
impaired.
The majority of patients with Usher syndrome can be classified as USH1, USH2 or 
USH3. However, there are also patients with an atypical form of Usher syndrome with, 
for example, congenital severe-to-profound hearing loss and late onset or subclinical 
RP. 
Chapter 1a
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Besides hearing, balance and vision problems, also additional phenotypic traits 
have been reported in patients with Usher syndrome, including anosmia, ataxia, sperm 
abnormalities and osteopenia (Reiners et al. 2006, Ribeiro et al. 2016, Urano et al. 2012). 
Several of the Usher genes have been shown to be expressed in the mouse olfactory 
epithelium and the encoded proteins interact with olfactory signaling proteins (Jansen 
et al. 2016). Functional evaluation of mouse models showed that there was olfactory 
impairment in SANS- and harmonin-deficient mice (Jansen et al. 2016). In patients 
with Usher syndrome, only a reduced ciliary beat frequency of the nasal epithelia has 
been observed (Aparisi et al. 2013) without appearance of any functional impairment 
in a sniffing test (Dad et al. 2016). Although ataxia was mentioned as a feature in a 
patient clinically diagnosed with Usher syndrome, subsequent genetic screening led to 
a different - non-Usher syndrome - diagnosis. Since Usher genes are also expressed in 
the central nervous system and Usher patients with psychiatric symptoms have been 
reported, it has been proposed that Usher proteins fulfill a distinct role in the brain 
as well (reviewed by Domanico et al. 2015). However, underlying mechanisms are not 
known and psychiatric symptoms might be of secondary nature as a consequence of the 
(partial) loss of the two major sensory systems.
USHER SyNDROME IS GENETICALLy HETEROGENEOUS
Besides being clinically heterogeneous, Usher syndrome also exhibits genetic het-
erogeneity (Table 1). For USH1, nine genetic loci have been described so far, USH1b–
USH1h, USH1j and USH1k. For USH2, three loci are known, USH2a, USH2c and USH2d. 
So far, two loci have been described for USH3: USH3a and USH3b. In addition, defects of 
other genes than those listed here might contribute to an Usher-like phenotype. Muta-
tions in PDZD7 have been shown to modify the retinal phenotype in USH2A patients. 
Furthermore, PDZD7 has been proposed as a contributor to digenic Usher syndrome in 
combination with ADGRV1 or USH2A mutations (Ebermann et al. 2010). Mutations in 
HARS, associated with USH3b, and a combination of mutations in CEP250 and C2ORF71 
are also associated with (atypical) Usher syndrome (Aparisi et al. 2014).
USH1b, caused by mutations in MYO7A, is the most common type of USH1 account-
ing for 30–50% of USH1 cases. Mutations in the USH2A gene, encoding usherin, are the 
most common cause of Usher syndrome, explaining ~50% of all USH cases and up to 
85% of USH2 patients. Apart from deaf-blindness, mutations in the USH1 genes MYO7A, 
USH1C, CDH23, PCDH15, USH1G, CIB2 and USH modifier PDZD7 can also result in non-
syndromic hearing loss (Ebermann et al. 2010, Cosgrove and Zallocchi 2014). Defects 
in USH2A are associated with nsRP when at least one ‘retinal disease-specific’ USH2A 
allele is present, resulting in the preservation of normal hearing (Lenassi, Vincent, et al. 
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2015). However, there is one report of a patient having compound heterozygous muta-
tions in USH2A leading to isolated hearing impairment, whereas her brother with the 
same mutations developed Usher syndrome (Lenassi, Robson, et al. 2015). However, the 
distinct phenotypic differences between brother and sister question the pathogenicity 
of either one of the reported variants.
Usher syndrome is nowadays often genetically diagnosed after failure of the New-
born Hearing Screening Test. Standard DNA diagnostic efforts include the analysis of 
exonic sequences, splice sites and chromosomal aberrations. In a research setting, whole 
genome sequencing could be used to reveal not only known genetic defects, but also 
previously unknown mutations in both exonic and (deep-)intronic regions. For instance, 
Figure 2 (previous page). Schematic representation of the architecture of Usher proteins and 
their different isoforms. (A) The USH1b protein, MYO7A, is composed of a motor head domain, five 
calmodulin-binding IQ motifs, two FERM domains, two MyTH4 domains and a Src homology 3 (SH3) 
domain. (B) Three different classes of isoforms of the USH1c protein, harmonin, are identified. All 
three isoforms consist of two PDZ (PSD95, discs large, ZO-1) domains (PDZ1 and 2) and one coiled-
coil domain. Class A isoforms contain an additional PDZ domain (PDZ3). The class B isoforms contain 
also this third PDZ domain, a second coiled-coil domain and a proline, serine, threonine-rich region 
(PST). Isoform A1 and B4 contain a C-terminal class I PDZ binding motif (PBM). (C) Representation 
of the three different isoforms of cadherin 23 (USH1d). Isoform A is composed of 27 Ca2+-binding 
extracellular cadherin domains (EC1-27), a transmembrane domain (TM) and a short intracellular 
region with a C-terminal class I PBM. Isoform B is similar to isoform A, but lacks the first 21 EC do-
mains. Isoform C only consists of the intracellular region and C-terminal PBM. (D) Like cadherin 23, 
the nonclassical cadherin protocadherin 15 (USH1f) consists of either 11 (isoform A) or 1 (isoform B) 
EC domains, a transmembrane domain and a C-terminal class I PBM. (E) The scaffold protein SANS 
(USH1G) consists of three ankyrin domains (ANK), a central region (CENT), a sterile alpha motif (SAM) 
and a C-terminal class I PBM. (F) Three isoforms are known for CIB2, the USH1j protein. All three 
isoforms contain two EF-hand domains (EFh). Variation in protein length is determined by alternative 
splicing in the 5’ and 3’ end of CIB2 transcripts, resulting in isoform A, B and C. (G) Isoform A of the 
USH2a protein contains an N-terminal thrombospondin/pentaxin/laminin G-like domain, a laminin 
N-terminal (LamNT) domain, ten laminin-type EGF-like (EGF Lam) and four fibronectin type III (FN3) 
domains. In addition to the domain structure of isoform A, isoform B contains two laminin G (LamG), 
28 FN3, a transmembrane domain and an intracellular region with a C-terminal class I PBM. (H) Three 
isoforms of the adhesion G protein-coupled receptor V1 (ADGRV1, USH2c), are identified. The lon-
gest isoform, isoform B, consists of a thrombospondin/pentaxin/laminin G-like domain (depicted in 
green), 35 Ca2+-binding calcium exchanger b (Calx) domains, seven EAR/EPTP repeats, a seven trans-
membrane region and an intracellular region containing a C-terminal class I PBM. Isoform A is com-
posed of the last six C-terminal Calx domains, the seven transmembrane region and the intracellular 
region with the C-terminal class I PBM. The predicted extracellular isoform C only contains the first 
16 N-terminal Calx domains and the thrombospondin/pentaxin/laminin G-like domain. (I) Isoform 
A of whirlin, the USH2d protein, contains three PDZ domains and a proline-rich region (indicated 
by ‘P’). Isoform B lacks the two N-terminal PDZ domains. Both isoforms contain a C-terminal class II 
PBM. (J) The protein product of USH3a, Clarin-1, is present in three isoforms. Isoform A is the longest 
and consists of four transmembrane domains. Isoforms C consists of two of these transmembrane 
domains, whereas isoform B consists of none of the transmembrane domains. (K) The USH2 modifier 
PDZD7 is structurally related to harmonin and whirlin and consists of three PDZ domains (isoform A). 
The smaller isoform B lacks the third PDZ domain. This figure was adapted from (Kremer et al. 2006).
Chapter 1a
20
four deep-intronic mutations have been identified in USH2A, all leading to pseudoexon 
inclusion into the mature mRNA transcript and a subsequent disruption of the reading 
frame (Vache et al. 2012, Liquori et al. 2016).
USH PROTEIN STRUCTURE AND ISOFORMS
USH proteins (Fig. 2) are members of protein families with very diverse functions 
(for review see Cosgrove and Zallocchi 2014). MYO7A is an actin-based motor pro-
tein, whereas cadherin-23 and protocadherin-15 are members of the cadherin protein 
superfamily that consists of cell adhesion molecules (Geng et al. 2013). ADGRV1 and 
usherin are both transmembrane proteins with large extracellular regions consisting of 
domains that suggest a role in outside-in signaling. The extracellular region of ADGRV1 
is mainly built up by CalX-β domains, whereas usherin contains stretches of EGF-Lam 
and fibronectin type3 (FN3) motifs in its extracellular region. Whirlin, harmonin, PDZD7 
and SANS function as scaffold proteins, of which the first three are structurally related. 
Clarin-1 is predicted to be a four-transmembrane protein and part of the vertebrate-
specific clarin protein family. The most recently identified Usher protein CIB2 is named 
after its calcium- and integrin-binding capacity (Giese et al. 2017). Except for USH1G, 
alternative transcripts are known for all USH genes that (are predicted to) encode sev-
eral protein isoforms. 
USH PROTEInS ARE PART OF USH PROTEIn nETwORKS
At first sight, the diverse nature of the USH proteins seems surprising in view of 
the limited phenotypic differences that are observed between the genetic subtypes of 
Usher syndrome. These clinical similarities suggest that all associated genes encode 
proteins that function in a common process or pathway. 
Indeed, USH proteins have been found to interact with each other in highly dynamic 
protein networks (Pan and Zhang 2012, Maerker et al. 2008, Sorusch et al. 2017). USH-
associated proteins have PDZ (PSD95, Discs large, ZO-1) domains, that are able to form 
protein-protein interactions with a PDZ-binding motif (PBM). Indeed, a complex consist-
ing of the USH1 proteins cadherin-23, harmonin and MYO7A for instance, is mediated 
by PDZ-PBM interactions and is pre-assembled in the ER. Misfolding or lack of one of 
the three proteins leads to disruption of the protein complex and consequently to ER-
stress and photoreceptor degeneration (Blanco-Sanchez et al. 2014). Like cadherin-23, 
also protocadherin-15 uses its intracellular C-terminal PDZ-binding motif to interact 
with harmonin (Reiners, Marker, et al. 2005). In 2004, we identified the transmembrane 
21
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isoform of usherin with a PBM at the C-terminus suggesting a link with the USH1 protein 
network. We confirmed this link for both usherin and ADGRV1 (Reiners, van Wijk, et al. 
2005). The similarity between harmonin and whirlin then directed us to test whirlin as a 
candidate interaction partner of these USH2 proteins, with positive results (van Wijk et 
al. 2006). Also harmonin and SANS are connected by a PDZ-PBM interaction, synergisti-
cally strengthened by interactions of the PDZ domains of harmonin with SANS’ SAM 
domain (Zou et al. 2017). Also a PDZ domain-mediated interaction is present between 
the USH2 scaffold protein whirlin and SANS (Maerker et al. 2008). The USH protein 
network, as it has been unraveled so far, is schematically depicted in Fig. 3. Interac-
tions between multiple Usher and non-Usher proteins depend on the same protein 
domains, for instance whirlin’s PDZ1 and 2 domains associate with usherin, ADGRV1 
and SANS (Maerker et al. 2008, van Wijk et al. 2006), suggesting that the USH protein 
network is highly dynamic. Spatiotemporal differences in network composition have 
Figure 3. Schematic representation of the Usher protein network. All identified protein–protein 
interactions are indicated (references: see text). Boxes in red indicate an association with Usher syn-
drome type I (USH1), green indicates association with Usher syndrome type II (USH2), blue indicates 
association with isolated retinitis pigmentosa (RP), black indicates association with isolated deafness 
and orange indicates association as an Usher syndrome modifier. This figure was adapted from (Kre-
mer et al. 2006).
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been observed, possibly needed to fulfill distinct roles at separate subcellular locations 
and during different stages of retinal and inner ear development.
THE USH PROTEIn nETwORK In THE InnER EAR: LOCALIZATIOn AnD 
FUNCTION
In the inner ear, the main localization of USH proteins is in the neurosensory hair 
cells, that mediate mechanotransduction (Fig. 4) (for review see Cosgrove and Zallocchi 
2014). Hair cells, present in both the cochlea and the vestibular system are named after 
the ‘hair bundles’ that are located at the apical surface of these cells. Bending of the 
hair bundle as the result of sound waves in the cochlea or displacement of fluid in the 
vestibulum, leads to the opening of mechano-electrical transducer (MET)-channels. A 
Figure 4. Schematic representation of the sensory cells in the inner ear and retina. (A) The 
apical side of the inner ear hair cell carries the highly organized, actin filled stereocilia, in which the 
mechanotransduction takes place. The stereocilia are connected by the tip links, horizontal links, 
transient links and ankle links. The stereocilia are anchored in the actin-rich cuticular plate. The only 
true cilium, the kinocilium, is located lateral to the largest stereocilium and extends from the basal 
body. The synaptic junctions between hair cells (mainly in inner hair cells) and afferent neurons at the 
basal side of the hair cell, contain the synaptic ribbons. (B) The rod and cone photoreceptors, which 
are the main morphological subtypes of photoreceptors, are highly polarized. The photoreceptor 
outer segment, a highly modified cilium containing the phototransduction proteins, is separated 
from the inner segment by the connecting cilium. The periciliary region is situated next to the con-
necting cilium and the proximal outer segment. The nuclei of the photoreceptors are situated in the 
outer nuclear layer. The synaptic terminals, containing the ribbons, connect the photoreceptors with 
horizontal cells, bipolar cells and ganglion cells. This figure was adapted from (Kremer et al. 2006).
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signaling cascade is initiated culminating in the release of neurotransmitter at the base 
of the hair cell. The hair bundle consists of actin-based microvilli, the stereocilia. Every 
bundle contains one true, microtubule-based, cilium that is known as the kinocilium. 
The kinocilium in mammals is required for proper hair bundle formation and orienta-
tion and disappears at the end of hair cell development in the cochlea. Hair bundles 
maintain their cohesion by fibrous interstereociliar links and by links between the tallest 
stereocilia and the kinocilium. The pattern of these fibrous links in cochlear hair cells 
changes during development in a species- and hair cell type-specific manner.
Cochlear development and formation of stereocilia bundles has been extensively 
studied in mice. Mice with mutations in orthologous USH genes exhibit abnormally 
developed hair bundles in which the stereocilia are splayed (e.g. Waltzer and Ames 
Waltzer) or shorter (e.g. Deaf circler and Whirler) (El-Amraoui and Petit 2005). This points 
towards a function of the USH proteins in hair bundle development and cohesion. The 
picture that emerged from extensive immunohistochemistry and immunoelectronmi-
croscopy in normal mice and mice with mutations in USH genes, is that the fibrous 
links are (partially) composed of transmembranous USH proteins that are anchored via 
scaffold proteins and MYO7A to the actin core of the stereocilia. During cochlear hair 
cell differentiation, before the hair bundle has developed, the kinocilium repositions to 
the periphery of the cell. This is essential for correct positioning and orientation of the 
hair bundle. The studies of Lefevre and coworkers (Lefevre et al. 2008) suggest a link 
between hair bundle orientation and the formation of the links between stereocilia and 
kinocilium as well as the interstereociliar links. The first steps of polarization of the hair 
bundle does not seem to be affected in mice deficient for USH1 proteins, as is the case 
for the localization of proteins involved in planar cell polarity. It has been hypothesized 
that the disturbance of differential elongation of different rows of stereocilia (staircase 
pattern) in mice deficient for USH1 genes is caused by a lack of tension forces from the 
tip link of the tallest stereocilia on the tips of the rows of smaller stereocilia (Lefevre 
et al. 2008). These tip links between stereocilia are formed by heteromeric interactions 
of the extracellular fragments of cadherin-23 and protocadherin-15, the former at the 
upper part and the latter at the lower part of the link (Geng et al. 2013). At the upper 
tip link density (UTLD) cadherin-23 is linked to the actin skeleton by an interaction with 
MYO7A, aided by harmonin and SANS (Bahloul et al. 2010). In mice deficient for either 
MYO7A, harmonin or SANS, tip links were present but sparser (Lefevre et al. 2008). At 
the lower tip link density (LTLD), protocadherin-15 is connected to the MET-channel 
(Fettiplace and Kim 2014). Probably also SANS is present in this complex, since SANS 
interacts with protocadherin-15 in vitro and SANS is missing from stereocilia in either 
protocadherin-15 or cadherin-23 knock-out mice (Caberlotto et al. 2011). In order to 
function properly, the interaction between MET-channels and CIB2 is essential (Giese 
et al. 2017).
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Ankle links are temporal and disappear after hair bundle development is completed. 
The spatio-temporal expression pattern of usherin, ADGRV1, whirlin and also vezatin, a 
MYO7A- and usherin-interacting protein, suggests that these molecules are associated 
with the ankle links (Toms et al. 2015). This is supported by the absence of ankle links 
in Adgrv1 knock-out (gpr98-/-) mice and the lack of usherin, whirlin and vezatin at the 
base of stereocilia in developing cochlear hair cells of these mice (Mathur and Yang 
2015). However, the localization of whirlin at the tip of the stereocilia is unaltered in 
gpr98-/- mice. In addition, with the exception of mice lacking MYO7A, all mice that are 
deficient for USH1 proteins still have the ability to form ankle links (Lefevre et al. 2008, 
Zou et al. 2017).
Besides at the UTLD, SANS is also localizated beneath the cuticular plate, especially 
below the basal body of the kinocilium where the cuticular plate is thinner (El-Amraoui 
and Petit 2005). Because of the enrichment of vesicles and microtubules in the api-
cal peri- and subcuticular regions including the subkinocilial region, SANS has been 
suggested to be involved in the trafficking of USH proteins along microtubules and 
actin filaments towards the stereocilia (El-Amraoui and Petit 2005). Supporting evidence 
comes from experiments that reveal an association between SANS and the microtubules 
in photoreceptors (Maerker et al. 2008). Furthermore, harmonin accumulates in the api-
cal region of the hair cell and is no longer detected in the stereocilia of mice lacking 
SANS (El-Amraoui and Petit 2005).
USH proteins have also been suggested to play an important role in hair bundle 
formation and stereocilia elongation. Harmonin, for example, has actin-bundling activ-
ity that is needed for hair bundle and hair cell morphogenesis (Phillips et al. 2011). Both 
SANS and whirlin, present at the tip of stereocilia during hair bundle development, are 
essential for stereocilia elongation (Caberlotto et al. 2011). ADGRV1 has been detected 
in the peripheral microvilli at the apical surface of hair cells. These microvilli do not 
develop into stereocilia and degenerate in normal hair cells. In gpr98-/- mice, these 
microvilli undergo stereocilia-like maturation and therefore ADGRV1 is suggested to 
be required for the regression of peripheral microvilli during hair cell development 
(Michalski et al., 2007).
Several of the USH proteins have also been identified in the synaptic region of hair 
cells (reviewed by Cosgrove and Zallocchi 2014). Mouse hair cell synaptogenesis was 
shown to be (partially) orchestrated by a complex comprising of clarin-1 and specific 
isoforms of the Usher proteins cadherin-23, protocadherin-15 and ADGRV1 (Zallocchi 
et al. 2012). Usherin, ADGRV1, harmonin and SANS were found to be present in the pre- 
and postsynaptic region of both inner and outer hair cells and whirlin in the synaptic 
region of outer hair cells only (van Wijk et al. 2006, Zallocchi et al. 2012). It has been 
postulated that the large extracellular fragments of usherin and ADGRV1 are involved 
in maintaining a proper spacing between pre- and postsynaptic membranes, similar to 
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their role in the ankle link complex at the base of stereocilia and as one of their pro-
posed roles at the periciliary membrane of photoreceptors (Maerker et al. 2008, Yang et 
al. 2010). In inner hair cells, harmonin was shown to have a multifaceted presynaptic role 
in regulating cell surface Cav1.3 Ca2+-channel levels and exocytosis (Gregory et al. 2013). 
THE USH PROTEIn nETwORK In RETInAL PHOTORECEPTORS
In photoreceptors, light is captured in the outer segment (OS) by disc-shaped 
membranes that contain the components of the phototransduction cascade. The OS is 
connected to the inner segment (IS) via the connecting cilium. The OS and connecting 
cilium together are regarded as a highly specialized non-motile cilium that develops 
from a basal body during photoreceptor differentiation. The photoreceptor IS contains 
the organelles necessary for eukaryotic cell metabolism, including the machinery for 
protein synthesis. Consequently, all OS proteins are synthesized in the IS and have to be 
transported through the connecting cilium.
The USH proteins most prominently localize at the photoreceptor connecting cilium 
region, more specifically in the basal body, the accessory centriole, the calyceal process-
es and at the periciliary membrane (Fig. 4; reviewed by Mathur and Yang 2015, Kremer 
et al. 2006). The b isoforms of harmonin are specifically found in rod OS, potentially 
anchored by protocadherin-15, and act as a scaffold (Reiners et al. 2006). Protocad-
herin-15 is indeed present in the membranes of OS and calyceal processes, where it has 
been recently hypothesized to connect the calyceal processes with each other and to 
the OS by heteromeric interactions with cadherin-23 similar as in stereociliary tip-links 
(Schietroma et al. 2017). Knockdown of Pcdh15 in Xenopus leads to disorganization 
of calyceal processes and uncontrolled outgrowth of parts of the photoreceptor OS, 
indicating a role in photoreceptor development and/or maintenance (Schietroma et al. 
2017). Additionally, like in hair cells, Usher proteins are found in the ribbon synapses of 
photoreceptors.
The apical part of the inner segment is shaped as a periciliary collar that surrounds 
the connecting cilium in mammalian photoreceptors. It has been suggested that this 
collar corresponds to the amphibian periciliary ridge complex, consisting of ridges 
and grooves (Maerker et al. 2008). Usherin, ADGRV1, SANS and whirlin are detected in 
the periciliary collar in mouse photoreceptors and in the ridges of the periciliary ridge 
complex in Xenopus (Maerker et al. 2008, Yang et al. 2010, Kremer et al. 2006). Also in 
macaque and human photoreceptors, the USH2 proteins are found at the periciliary 
collar that is wrapped around the connecting cilium (Sahly et al. 2012, Sorusch et al. 
2017). Fibrous links connect the membranes of the connecting cilium and the periciliary 
collar in mammals. The fibrous links that connect these membranes are absent from 
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homozygous vlgr1/del7TM mice lacking ADGRV1 (Maerker et al. 2008). Therefore, the 
links in the periciliary region of photoreceptor cells are probably homologous to the 
ankle links in hair cells, composed of the extracellular regions of ADGRV1 and usherin. 
The scaffold proteins whirlin and SANS are thought to anchor these links in the opposed 
cytoplasmic compartments of the connecting cilium and the periciliary region. 
The USH protein networks in the periciliary region and at the basal body and the 
accessory centriole have not only a function in providing structural support. Evidence 
is also pointing towards a concept in which Usher and Bardet-Biedl syndrome (BBS) 
proteins co-function in the organization of planar cell polarity (Giese, Riazuddin, 
and Ahmed 2013). Furthermore, Usher proteins have been implicated in intracellular 
transport mechanisms. MYO7A, for instance, was found to function in the transport of 
(rhod)opsin and RPE65 in photoreceptors and in the migration of melanosomes and 
phagosomes in the RPE (Mathur and Yang 2015). SANS can bind to the microtubule cy-
toskeleton and is proposed to be involved - together with myomegalin - in transport of 
cargo vesicles from the trans-Golgi network towards the outer segment, either via direct 
entering into the connecting cilium or after docking and fusion of transport vesicles to 
the periciliary membrane (Overlack et al. 2011, Maerker et al. 2008, Yang et al. 2010, 
Mathur and Yang 2015). Whirlin interacts with RPGR, a protein known to be involved 
in protein trafficking through the connecting cilium (Cosgrove and Zallocchi 2014). 
Usherin is transported by the NINL-associated vesicle transport complex. This transport 
complex also involves proteins associated with Leber congenital amaurosis (lebercilin) 
and Joubert/Meckel syndrome (CC2D2A) (van Wijk et al. 2009, Bachmann-Gagescu et al. 
2015). Although Usher proteins have been implicated to aid in targeting and/or docking 
of vesicular transport mechanisms through the connecting cilium, photoreceptors can 
develop normally when one of the USH proteins is defective. This makes the role of 
Usher proteins difficult to interpret, since their contribution to transport mechanisms 
during development seems compensatory.
The protein domain architecture of several Usher molecules, such as usherin and 
ADGRV1, also suggests a role in outside-in-signaling. Besides harmonin, whirlin was also 
shown to directly interact with the calcium channel Cav1.3 and both proteins colocalize 
in the synapse and the connecting cilium region of mouse photoreceptors (reviewed by 
Cosgrove and Zallocchi 2014). This suggests that Usher proteins are involved in Ca2+-
signaling and signal transduction at both the synapse and connecting cilium region of 
photoreceptors (Sorusch et al. 2017). In addition, ADGRV1, regulated by PDZD7 and 
Ca2+, has been shown to be involved in G-protein signaling via coupling to Gi, Gq and 
Gs proteins as has been observed after overexpression in HEK293 cells (Hu et al. 2014). 
However, an in vivo role for Usher proteins in inner ear or retinal signaling cascades has 
so far not been confirmed (Mathur and Yang 2015).
27
Molecular genetics of Usher syndrome
Ch
ap
te
r 1
a
CELLULAR AND ANIMAL MODELS FOR USHER SyNDROME
In order to study the function of Usher proteins or to evaluate therapeutic strate-
gies, suitable models are needed. Usher proteins have a distinct expression pattern 
in mostly difficult to obtain tissues such as retina, brain and inner ear. Nevertheless, 
alternative cell types and tissues that express Usher genes and can be collected semi-
invasively, such as human nasal epithelium or hair roots, have been identified and used 
for limited applications (Vache et al. 2010, Nakanishi et al. 2010). Also, patient-derived 
fibroblasts with compound heterozygous USH2A mutations have been dedifferentiated 
into induced pluripotent stem cells and subsequently differentiated into photoreceptor-
like cells to examine the mechanism of disease (Tucker et al. 2013). However, these 
cultured photoreceptors are not completely functional and lack retinal architecture and 
surrounding cells. Therefore, to understand the role of Usher proteins at the functional 
level and to evaluate therapeutic strategies it will be essential to study animal models. 
Nowadays, for almost all known Usher genes a corresponding mouse knock-out model 
has been generated and characterized (Table 1) (summarized by Toms et al. 2015). 
Although showing hearing impairment to various degrees, these knock-out mice spo-
radically recapitulate the retinal phenotype as observed in Usher syndrome patients, 
probably as a consequence of absent calyceal processes and an underdeveloped 
periciliary membrane in mouse photoreceptors (Chapter 2a). An alternative model 
organism used in Usher syndrome research is zebrafish (Danio rerio). Several zebrafish 
Usher knock-down and knock-out models have been generated and characterized. All 
of them show early-onset retinal dysfunction resulting in reduced electroretinogram 
(ERG) traces in ush2a, Pcdh15b, Myo7a (mariner) and ush1c (ush1cfh293) models (Blanco-
Sanchez et al. 2017, Chapter 2b). Due to an ancient genome duplication in teleost fish, 
orthologs of approximately 30% of mammalian genes are now present in two copies 
in the zebrafish genome. The expressed proteins from both gene copies often have 
obtained a split function. In zebrafish, PCDH15 for instance has two paralogs: Pcdh15a 
and Pcdh15b. Pcdh15a knock-out zebrafish (Ush1f, orbiter) display hearing impairment 
and vestibular dysfunction without visual defects, while knock-down of Pcdh15b only 
results in impaired visual function (Seiler et al. 2005). Next to mice and zebrafish, also 
fruit fly (Drosophila melanogaster) knock-out models for the orthologous Usher genes 
MYO7A (crinkled; showing dentritic cap morphology defects in the Johnston’s organ), 
PCDH15 (Cad99C; having shorter and disorganized microvilli in the fly), USH1G (Sans; 
having no obvious phenotype), CDH23 (Cad88C; uncharacterized) and USH1C (CG5921; 
uncharacterized) have been used to study the function of Usher proteins (Demontis 
and Dahmann 2009). With animal models that recapitulate visual defects as seen in 
Usher syndrome patients becoming available, it can be expected that the role of Usher 
proteins in the photoreceptor will be better understood.
Chapter 1a
28
THERAPEUTIC DEvELOPMENTS FOR USHER SyNDROME
During the past five years, a range of preclinical therapeutic strategies has been 
developed for the different types of Usher syndrome. Recently, gene augmentation in 
an Ush1c knock-out mouse model shortly after birth was shown to restore sensory and 
vestibular hair cell function (Pan et al. 2017). Likewise, supplementing a healthy Whrn 
cDNA copy prevented auditory and vestibular problems in the Whirler mouse (Isgrig et 
al. 2017). Prior to this study, augmentation of Whrn in the retina of a Whrn knock-out 
mouse rescued the disrupted USH2 protein complex (whirlin, usherin and ADGRV1) in 
photoreceptors (Zou et al. 2011). In these three studies, researchers employed adeno-
associated virus (AAV)-derived particles as a vehicle for delivery. Although these AAV 
vectors have been optimized to transduce specific target cells, their cargo capacity of 
4.7 kb make them only potentially suitable for a subset of Usher genes. The limited 
cargo capacity led to the development of a dual or triple AAV vector approach. Different 
vectors each contain parts of a large transgene expression cassette which can recom-
bine in target cells and thereby double or triple the total cargo capacity. This approach 
has been exemplified for MYO7A (Dyka et al. 2014). Alternatively, it is possible to use 
different viral gene delivery vehicles with larger cargo capacities, such as lentiviruses. 
MYO7A for instance, is packaged into a lentivirus (known as UshStat®) and effectively 
expressed in the retina of the shaker1 mouse model for USH1b (Zallocchi et al. 2014). 
Currently, UshStat® is being evaluated in a phase I/II clinical trial (ClinicalTrials.gov 
Identifier: NCT01505062).
Although gene augmentation has been shown to hold promising therapeutic po-
tential, there are drawbacks that limit clinical application. The large coding sequence 
of several Usher genes, the difficulty to control correct temporal and spatial gene 
expression and the presence of alternatively spliced transcripts with unknown signifi-
cance obstruct a gene augmentation approach for several Usher genes. Consequently, 
other therapeutic strategies for the future treatment of Usher syndrome, such as splice 
correction using antisense oligonucleotides (AONs), translational read-through induc-
ing drugs (TRIDs) or gene editing, are under development. AONs are small, RNA-like 
oligomers that are complementary to their target sequence. Upon binding their target 
pre-mRNA, it depends on the AON chemistry whether they initiate RNAse H-mediated 
degradation of their target or interfere with splicing. For Usher syndrome, AONs have 
shown to hold great promise as splice correcting molecules in fibroblasts of patients 
with the frequent deep-intronic c.7595-2144A>G mutation in USH2A (Chapter 3b). 
Also, morpholino-induced skipping of the mutated ush2a exon13 in zebrafish larvae 
restored visual function (Chapter 4). In addition, treatment of neonatal mice with a 
single systemic dose of splice modulating AONs partially corrected aberrant Ush1c pre-
mRNA splicing caused by the c.216G>A mutation, thereby rescuing vestibular function 
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and low-frequency hearing in mice (Vijayakumar et al. 2017). For nonsense mutations 
resulting in pre-mature termination of translation, the applicability of TRIDs is being 
explored. TRIDs are effective in reading through nonsense mutations in USH1G in vitro 
(Sorusch et al. 2017) and USH1C both in vitro and in vivo (reviewed by Nagel-Wolfrum 
et al. 2014). Gene repair would be the most elegant way to treat a genetic disorder, since 
it solves the primary problem. The CRISPR/Cas9 system is a widely used gene editing 
method that could be tailored for different target sequences relatively easy (overview 
in Chapter 2a). However, observed off-target effects and low on-target efficiencies so 
far hamper clinical application of gene editing approaches. Nevertheless, Overlack and 
colleagues have initiated an in vitro Ush1c gene correction strategy using zinc finger 
nucleases (Overlack et al. 2012). Besides that, targeted animal knock-out (performed in 
chapter 2b) as well as targeted knock-in (performed in chapter 3c) (animal) models can 
be generated when using CRISPR/Cas9.
All therapeutic approaches discussed so far, depend on the presence of sensory 
cells. The early genetic diagnosis of Usher syndrome prior to the manifestation of retinal 
dysfunction, provides a window of opportunity in which treatment can be initiated. In 
contrast to the retina, Usher proteins are essential for inner ear hair bundle develop-
ment. Therefore, it is expected that effective genetic therapies for the inner ear defects 
will need to be applied prior to or during cochlear development, which occurs in utero. 
A more feasible option is the postnatal stabilization of mutant Usher proteins using 
small molecules, potentially resulting in the presence of protein with enough residual 
function to alleviate the hearing phenotype. This strategy was proven to be protective 
against rapid deterioration of hearing as a result of the clarin-1 p.N48K mutation in a 
mouse model for USH3a (Alagramam et al. 2016). Similarly, the retina of an USH2 patient 
was supplemented with ciliary neurotrophic factor (CNTF) which is known to promote 
neuronal survival and to protect against retinal degeneration. Although a reduction of 
cone photoreceptor loss was observed after CNTF treatment, deterioration of visual 
function was not significantly prohibited in this clinical study (Talcott et al. 2011). In 
contrast, injection of neuronal progenitor cells into the subretinal space appeared to 
be protective against the decline of visual acuity in the Ush2a-mouse model for Usher 
syndrome (Lu et al. 2010). However, when RP has progressed into a more advanced 
state, treatment options are limited to retinal implants or cell replacement therapies. In 
vitro differentiated and grown retinal cells can be transplanted into the defective retina. 
Although some early studies show the promise of cell replacement therapies, chal-
lenges such as the robust in vitro generation of donor cells, the survival of donor cells in 
a degenerated retina and the ability of donor cells to properly connect with the existing 
circuitry, need to be addressed before patients can benefit from this therapeutic option 
(reviewed by Jayakody et al. 2015).
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Usher syndrome is a devastating disease affecting both visual and auditory function. 
In this thesis, I describe the research that I have performed with the ultimate goal to 
better understand the underlying molecular pathogenesis and to preclinically develop 
a potential splice modulating therapy to halt or delay the progression of retinal degen-
eration in (a subset of) patients with Usher syndrome. 
In order to learn more about the function of Usher syndrome proteins and to 
elucidate the pathogenic mechanism underlying the disease, as well as the evaluation 
of novel therapeutic strategies, a suitable animal model is needed. In chapter 2a, an 
overview of pros and cons of different vertebrate animal models that are being used in 
functional and therapeutic research on inherited retinal dystrophies is presented. Chap-
ter 2b shows the characterization of two targeted usherin knock-out zebrafish models 
(ush2armc1 and ush2ab1245), both showing an early-onset retinal dysfunction. Chapter 2c 
describes the isolation and characterization of USH2d-associated proteins and protein 
complexes from the adult zebrafish retina.
Chapter 3 describes the pre-clinical development of an AON-based splice correc-
tion strategy to prevent aberrant splicing of USH2A pre-mRNA as a consequence of the 
c.7595-2144A>G mutation. First, a protocol for an optimal design and in vitro validation 
of the exon-skipping or retention potential of AONs is presented (Chapter 3a). Chapter 
3b shows the design of AONs targeting USH2A pseudoexon 40 that effectively correct 
aberrant USH2A splicing in fibroblasts of patients having the c.7595-2144A>G mutation. 
Splice correction is expected to result in the restoration of wild-type usherin protein 
translation. Chapter 3c describes the generation and characterization of a humanized 
USH2A pseudoexon 40 knock-in zebrafish model using CRISPR/Cas9 technology in or-
der to validate this hypothesis. As clear differences in the recognition of human USH2A 
pseudoexon 40 splice sites between human and zebrafish are observed, a novel pipeline 
for the generation of future knock-in zebrafish models to study human splice defects 
is proposed. 
Chapter 4 shows that skipping of mutated ush2a exon13 in zebrafish larvae restores 
ERG-traces in our previously generated and characterized ush2armc1 knock-out model. 
In patients with retinitis pigmentosa, USH2A exon13 is the most frequently mutated 
exon in which two founder mutations (c.2299delG; p.Glu767SerfsTer21 and c.2276G>T; 
p.Cys759Phe) have been identified. 
Finally, chapter 5 provides a general discussion and future directions for follow-up 
research.
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ABSTRACT
Over the last decade, huge progress has been made in the understanding of the 
molecular mechanisms underlying inherited retinal dystrophy (IRD), as well as in the 
development and implementation of novel therapies, especially in the field of gene 
therapy. The use of mutant animal models, either naturally occurring or generated by 
genetic modification, have contributed greatly to our knowledge on IRD. Yet, these 
mutant animal models do not always mimic the retinal phenotype that is observed in 
humans with mutations in the orthologous gene, often due to species-specific charac-
teristics of the retina, and/or diverse functions of the gene products in different species. 
In this manuscript, we compare general and ocular characteristics of a series of widely 
used vertebrate animal models, i.e. zebrafish, chicken, rodents, cats, dogs, sheep, pigs 
and monkeys, in terms of genetic architecture and sequence homology, methods to 
modify genomes, anatomy of the eye, and structural details of the retina. Furthermore, 
we present an overview of mutant vertebrate animal models that have been used to 
study or develop treatments for the various genetic subtypes of IRD, and correlate 
the suitability of these models to the specific characteristics of each animal. Herewith, 
we provide tools that will help to select the most suitable animal model for specific 
research questions on IRDs in the future, and thereby assist in an optimal use of animals 
and resources to further increase our understanding of inherited retinal dystrophies, 
and develop novel treatments for these disorders.
45
The pros and cons of vertebrate animal models for functional and therapeutic research on inherited retinal dystrophies
Ch
ap
te
r 2
a
1. InTRODUCTIOn
Inherited retinal dystrophies (IRDs) are a group of heterogeneous disorders charac-
terized by a progressive loss of visual function due to degeneration of the light-sensing 
photoreceptor cells in the retina, often resulting in complete blindness. Over the past 
two decades, the molecular and phenotypic characterization of mutant animal models 
resembling IRD has contributed greatly to our understanding of the physiological 
processes that regulate vision and of the pathophysiological mechanisms that underlie 
IRD. In addition, several of these models have shown to be instrumental for the develop-
ment of novel treatments, such as gene augmentation therapies that are now in clinical 
trials (Bainbridge et al., 2008; Hauswirth et al., 2008; MacLaren et al., 2014; Maguire et 
al., 2008). On many occasions however, animal models that carry mutations in genes 
underlying IRD in humans do not, or only partially, mimic the human phenotype. Why 
is that? Do the gene products have diverse functions in different species? Is this due to 
structural differences in the retinal cells of the various animals? In this manuscript, we 
will describe the general and ocular characteristics of a series of vertebrate species com-
monly used in functional and/or therapeutic research on IRDs. In addition, we provide 
a comprehensive overview of currently existing IRD models, and assess whether they 
resemble the human phenotype. With this, we aim to provide insight in the utility of 
the various different animal models for IRD, and why some species may be particularly 
suited for certain types of functional or therapeutic research in the future.
1.1. The retina
Vision is a complex and highly regulated biological process. When light enters the 
eye through the cornea and the pupil, it is refracted by the lens and focused onto 
the retina that lines the inner surface of the eye. In the retina, light is converted into 
an electrical signal that is transmitted via the optic nerve to the visual cortex in the 
brain where the actual images are formed. The retina is a thin, multilayered and highly 
structured tissue composed of several different cell types that each play a crucial role 
in the conversion and amplification of light to electrical signals (Marc, 2008). The light-
sensing photoreceptor cells are arranged in a defined layer, that at one end contacts 
the retinal pigment epithelium (RPE) and at the other end feeds into the outer plexiform 
layer (OPL). Here, the photoreceptor terminals form synapses with the second order 
neurons (bipolar cells, horizontal cells and amarcrine cells), the nuclei of which together 
with the nuclei of the Müller cells define the inner nuclear layer (INL). These neurons 
again form synapses in the inner plexiform layer (IPL) with the ganglion cells, whose 
nuclei are situated within the ganglion cell layer (GCL). The axons of the ganglion cells 
define the retinal nerve fiber layer (RNFL) and exit the retina through the optic nerve 
head (ONH) or papilla. The borders of the Müller cells delineate the internal (ILM) and 
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external limiting membrane (ELM). A cartoon describing the layered structure of the 
human retina is provided in Fig. 1A.
When light reaches the retina, it first passes through the ganglion and inner nuclear 
cell layer to reach the photoreceptor cells. In the photoreceptor cells, photons are 
captured by the photopigment molecules after which the phototransduction cascade 
is initiated, a complex chain of events that results in the closing of voltage-gated ion 
channels producing a change in membrane potential. Subsequently, this electrical signal 
is structured and specifically amplified by the different cell types in the inner retina to 
be ultimately transported to the brain via the retinal ganglion cells for the generation of 
images. Oxygen and nutrients for the outer retina (i.e. the photoreceptors) are provided 
through diffusion from the choroidal vessels via the RPE. The inner retina is supplied by 
the retinal vasculature consisting of a superficial (within the RNFL) and a deep (within 
the INL, IPL) plexus. Therefore, the human retina is classified as holangiotic (different 
forms of vascularised retinae exist in certain animals, see section 2). The most important 
features of the human retina are the macular zone and the foveal pit in the centre of the 
macula, both being specific for the primate retina, containing an avascular zone around 
the most sensitive cones and considered to be necessary for high-contrast vision. The 
avascularity of the fovea is possible because the inner retinal layers have moved aside, 
thus forming the macular wall with a high density of ganglion cells. 
1.1.1. Photoreceptor cells
Morphologically, photoreceptor cells can be segmented into different parts, i.e. a 
synaptic end that faces the bipolar cells, the cell body that contains the nucleus, an in-
ner segment where protein synthesis occurs and a large outer segment where the actual 
phototransduction takes place (Fig. 1B). The inner and outer segments are linked by the 
connecting cilium (CC), a microtubule-based structure that is crucial for the transport 
of proteins into the outer segments (Satir and Christensen, 2008). Near the connecting 
cilium, cellular extensions are formed, the calyceal processes, which can be found at 
other ciliated cells as well (e.g. hair cells in the inner ear).
All the proteins needed to initiate phototransduction are present in the outer seg-
ments of the photoreceptor cells. When light reaches the photoreceptors, photons are 
captured by the opsin molecules, initiating a complex chain of events that includes 
conformational changes in the chromophores, activation of G-proteins and the closing 
of voltage-gated ion channels causing a hyperpolarisation of the membrane potential 
that ultimately results in a decreased neurotransmitter secretion at the synaptic terminal 
of the photoreceptor cells (Cruce et al., 1996; Dell’Orco and Koch, 2011). A similarly 
complex chain of molecular events is needed to re-open the cation channels and pre-
pare the photoreceptor cell for another round of phototransduction. Every night, the 
upper 10% of all outer segment discs are phagocytised by the RPE cells (see section 
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1.1.2), and new discs are evaginated from the connecting cilium region at the base of 
the outer segment. 
In the human eye, two types of photoreceptor cells can be distinguished, i.e. rods and 
cones, named such based on the shape of their outer segments (Fig. 1B). Rods are very 
sensitive to low levels of light, and are most abundant in the peripheral retina, whereas 
cone photoreceptor cells function well under bright light conditions, and are mostly 
present in the central part of the retina, i.e. the macula. Hence, cones mainly mediate 
our central vision, including color vision, and allow high visual acuity, whereas rods are 
responsible for peripheral vision and vision under dim light conditions, i.e. night vision, 
in addition to sensing contrast and motion. Besides a difference in spatial distribution, 
rods and cones also differ to some extent in their molecular content, for instance with 
regard to their photopigment molecules. In rod photoreceptor cells, rhodopsin acts 
as the key molecule initiating the phototransduction cascade, whereas in cone cells 
different types of photopsin molecules are present, depending on the cone subtype. In 
the human eye, three different types of cones can be distinguished, each sensitive to 
light of a different wavelength, i.e. the S-cones (short wavelength), M-cones (medium 
wavelength) and L-cones (long wavelength) (Roorda and Williams, 1999; Solomon and 
Lennie, 2007). Even within the macula, there are local differences in the distribution of 
each of the different cone photoreceptor subtypes (Curcio et al., 1990), illustrating the 
complexity of the human retina. The synapses formed between photoreceptors and the 
bipolar and amacrine cells within the OPL are either invaginating or non-invaginating, 
depending on the impact they play in the forwarding of the light-triggered signal. 
Invaginating synapses form specialized ribbon synapse structures, one per rod spherule 
and several per cone pedicule (Fig. 1B). A fully developed retina contains approximately 
92 million rods and 4.6 million cones (Curcio et al., 1990), that are post-mitotic and 
therefore do not divide or regenerate following injury. 
1.1.2. RPE cells
The retinal pigment epithelium (RPE) consists of a monolayer of hexagonally shaped 
cells that are in direct contact with the photoreceptor outer segments (Fig. 1A), and 
has several distinct and important functions in the retina. As mentioned above, the RPE 
cells are responsible for the phagocytosis of the most upper part of outer segment discs 
that contain the highest concentration of toxic by-products resulting from many cycles 
of phototransduction (Anderson et al., 1978; Steinberg et al., 1980). In addition, the RPE 
plays an important role in the visual cycle, a molecular cascade that allows to replenish 
the photoreceptor cells with chromophore molecules following a series of enzymatic 
reactions that also partially takes place in the photoreceptor cells (Kiser et al., 2012). 
Other functions of the RPE include the maintenance of the outer blood-retina barrier by 
the formation of tight junctions between adjacent RPE cells, and the active transport of 
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metabolites, nutrients and waste products between the choriocapillaris and the photo-
receptor cells and vice versa (Hughes et al., 1998). The pigmented nature of the RPE is 
caused by melanosomes, melanin-containing organelles that have the ability to absorb 
light. As such, the RPE can absorb scattered light and thereby minimize phototoxic 
damage to the retina (Sarna, 1992), revealing yet another important function of the RPE.
1.2. Inherited retinal dystrophies
As indicated in section 1.1, the molecular processes in the retina that initiate vision, 
including the phototransduction cascade and the visual cycle, involve hundreds of dif-
ferent proteins in any of the different retinal cells. Because many of these proteins are 
retina specific mutations in the encoding genes often result in dysfunction of retinal 
cells and concomitantly cause a retinal phenotype. Depending on the severity of the 
mutations, the cell type that is primarily affected by the mutation (RPE, cone and/or rod 
photoreceptors, or one of the other cells in the retina) and the function of the protein 
that is encoded by the corresponding gene, IRDs can be divided into different clinical 
subtypes with a varying age of onset, rate of progression and clinical hallmarks. The 
most severe subtype of IRD is Leber congenital amaurosis (LCA), with an onset of symp-
toms in the first year of life and resulting in complete blindness in childhood. Other 
subtypes of IRD include retinitis pigmentosa (RP, also known as rod-cone dystrophy), 
cone-rod dystrophy (CRD), cone dystrophy (CD), achromatopsia (ACHM) or congenital 
stationary night blindness (CSNB) that all display a large degree of clinical and genetic 
heterogeneity. In addition, there are some other subtypes of IRD that are caused by 
mutations in only a single gene, e.g. Stargardt disease (caused by mutations in ABCA4), 
choroideremia (caused by mutations in CHM) or Best disease (caused by mutations 
in BEST1). IRDs can be inherited in an autosomal recessive, autosomal dominant, or 
X-linked fashion, whereas mitochondrial or digenic inheritance also have been reported 
occasionally. To date, more than 200 genes are collectively known to be mutated in 
one or more of these IRD subtypes (https://sph.uth.edu/retnet/). Retinal dystrophies 
can manifest either as the sole clinical symptom (non-syndromic IRD) or in conjunction 
with other abnormalities elsewhere in the human body (syndromic IRD). Examples of 
syndromic types of IRD include Bardet-Biedl syndrome (BBS), Joubert syndrome (JBTS), 
Usher syndrome (USH) or Senior-Løken syndrome (SLS). Often, the genes mutated in 
these syndromes can also underlie non-syndromic IRD. Although the more severe (i.e. 
protein-truncating) mutations might be more often causative for syndromic forms, 
establishing a clear genotype-phenotype correlation is not trivial. Given this extreme 
genetic (and clinical) heterogeneity, establishing the correct molecular or clinical di-
agnosis can be complicated. Yet, finding the genetic cause underlying IRD has become 
increasingly important, due to several new treatment options that have reached the 
clinical trial phase over the last few years, or are currently emerging.
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1.3. Therapeutic interventions in IRD
For many years, IRDs have been considered incurable diseases. Yet, from a thera-
peutic perspective, the eye has several key advantages including its accessibility and 
its immune-privileged nature that is ensured by the blood-retina barrier, which would 
allow a robust delivery of therapeutic molecules that remain within the eye and thereby 
reducing the probability of unwanted side effects. In general, IRDs are progressive 
disorders that, following the onset of visual complaints in individuals with IRD, become 
more severe with age. In the early phases of the disease, the cells in the retina are not 
functioning well but are still structurally intact, while as the disease progresses, cells 
start to degenerate. Most of the genes in which mutations have been found to underlie 
IRD are expressed in the RPE or photoreceptor cells, inducing cell death in these cell 
types as the primary cause of the IRD- associated vision loss. Other neuronal cell types 
such as the bipolar, amacrine, horizontal and retinal ganglion cells remain intact for 
a longer period of time, or are even spared. The stage of the disease therefore has 
repercussions for selecting the most promising therapeutic approach. When the pho-
toreceptor or RPE cells (mostly the primarily affected cell type in IRD) are still structur-
ally intact, gene therapy appears to be the most promising therapeutic strategy, often 
involving a (virus-based) delivery of the wild-type cDNA of the gene that is mutated 
to the right retinal cell type via subretinal injections. This strategy has already revealed 
its promise in IRD patients with mutations in RPE65 (Bainbridge et al., 2008; Bennett et 
al., 2012; Hauswirth et al., 2008; Maguire et al., 2009; Maguire et al., 2008), and more 
recently, in patients with choroideremia and mutations in CHM (MacLaren et al., 2014). 
However, if the RPE or photoreceptor cells are fully degenerated, gene therapy can no 
longer be considered an option, and alternative strategies need to be employed such 
as cell replacement therapy (Tucker et al., 2014; Wiley et al., 2015), optogenetic therapy 
(Roska et al., 2013), or, at a very advanced stage of the disease, retinal implants (Zrenner 
et al., 2011). Ideally however, one would like to treat IRDs as early as possible when 
the majority of RPE and photoreceptor cells are still intact, i.e. with gene therapeutic 
approaches. As this requires the development of independent tailor-made therapies for 
each gene, suitable cellular and animal models that mimic the molecular and clinical 
defects observed in patients are needed to assess therapeutic efficacy and safety. In this 
review, we aim to provide a comprehensive overview of the currently existing vertebrate 
animal models, their characteristics, and their suitability for functional and therapeutic 
research on IRDs. We will focus our attention on animal models carrying mutations in 
genes that have been associated with non-syndromic IRD in humans.
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2. VERTEBRATE AnIMALS FOR IRD RESEARCH
2.1. General characteristics
A wide variety of animal models have so far played an important role in the field 
of IRD, either for increasing our understanding of the molecular mechanisms underly-
ing these disorders, or for the pre-clinical development of novel therapies. Vertebrate 
animals that will be subject to investigation are macaque, mouse, rat, dog, cat, pig, 
sheep, chicken and zebrafish, as these are the most commonly used models to study 
retinal function, the mechanisms underlying IRD and/or in the development of novel 
treatments. Besides detailed genetic, ocular and retinal characteristics, a range of gen-
eral aspects need to be considered when selecting the ideal animal model, including 
breeding time and techniques, the time needed to complete embryonic development 
and to reach fertility, and housing costs and requirements. As shown in Table 1, these 
general characteristics differ heavily between species, with the general observation that 
smaller animals are easier to maintain, have a shorter life cycle and generally produce 
a larger number of offspring. One other advantage of for instance zebrafish over avian 
and mammalian species is that offspring develops ex utero and therefore the develop-
ment of the eye can be monitored more easily. On the other hand, (larger) mammalian 
species more closely resemble humans in terms of genetic architecture and sequence, 
or gross retinal anatomy. In the paragraphs below, we will discuss the ocular (section 
2.2) and genomic features (section 2.3) of each of the selected animals compared to the 
human eye and genome, respectively. 
2.2. Ocular and retinal characteristics
As discussed in section 1.1, humans possess a retina that consists of several layers of 
neurons and interneuronal connections closely connected to the RPE. Three highly spe-
cific mechanisms are unique or almost unique to the photoreceptor/RPE complex: the 
visual cycle, the phototransduction cascade, and the ciliary transport through the con-
necting cilium. As described in section 1.2, the majority of genes mutated in IRD encode 
proteins participating in one of these pathways. To be used in preclinical research on IRD, 
animal models should ideally display similar anatomic features and mechanisms of light 
transduction as humans. Such anatomic features include specificities at the cellular level 
(i.e. photoreceptor inner segments, outer segments, synaptic terminals and connecting 
cilium) as well as at the tissue organisation level (i.e. presence of a macula, fovea). Most 
currently used animal models for therapeutic research on IRDs lack one or more of 
these specific features of the human retina and/or have other specific features instead. 
These are important to consider when deciding on which animal model to use in future 
IRD research, and to include in the analysis of unexpected but nonetheless frequently 
occurring results, such as a lack of phenotype or difficulties in therapeutic applications.
Chapter 2a
52
Below, an overview is provided of the specific ocular features of the selected animal 
models starting with the evolutionary most distantly related species (zebrafish and 
chicken), and moving along the mammalian evolutionary tree to the most closely 
related animal model, the nonhuman primate. All these animals fulfil the most impor-
tant request of a suitable model: they possess a morphologically very similar retinal 
structure with all discernible retinal layers and neuronal cell types. Yet, specific and 
important differences exist that in some cases determine their suitability to be used in 
IRD research. A graphical overview of the retinal structure and species-specific features 
of each animal is provided in Fig. 2 and ocular characteristics together with general 
reproductive peculiarities of each species are summarized in Table 1, based on our 
own investigations and data published by others (Bailey et al., 2012; Bawa et al., 2013; 
Chopovska et al., 2011; Collery et al., 2014; Ferguson et al., 2013; Gekeler et al., 2007; 
Gelatt, 2007; Hernandez-Merino et al., 2011; Howland et al., 2004; Iribarren et al., 2014; 
Lozano and Twa, 2012; McKibbin et al., 2014; Montiani-Ferreira et al., 2003; Puk et al., 
2006; Williams, 2004).
2.2.1. Zebrafish
Morphologically, the zebrafish retina is composed of all major cell and tissue layers 
that can be found in humans. The retina lacks a cone-rich structure and is considered 
holangiotic since one plexus of retinal vessels is present at the ILM (Alvarez et al., 2007). 
The zebrafish is diurnal and contains four diverse cone subtypes which by far outnum-
ber the rod population. In addition to cones receptive to the three color wavelengths 
perceived by humans, a fourth UV-sensitive cone is present (Fadool and Dowling, 2008). 
The M- and L-cones form double cones which consist of a principle (L-cone) and an 
accessory segment (M-cone), and the nuclei of the accessory cones form a morphologi-
cally distinguishable cell layer. Rods, cones and double cones possess calyceal processes 
surrounding the OS and an accessory outer segment (Hodel et al., 2014; Tarboush et 
al., 2012). Photoreceptor terminals form ribbon synaptic connections with bipolar and 
horizontal cells (Tarboush et al., 2012). In contrast to mammals, the IS contain megami-
tochondria, the function of which is currently unknown (Tarboush et al., 2012).
Unlike any of the mammalian species mentioned below, zebrafish are well known to 
have a remarkable capability to regenerate their retina after damage (Goldman, 2014). 
Damaged retinal cells will be replaced by newly differentiated cells originating from de-
differentiated Müller glia cells (Goldman, 2014). As described in section 1.1 and Fig. 1A, 
Müller glia cells physically span all three different retinal cell layers (ONL, INL until GCL) 
with their nuclei residing in the INL, making them suitable for sensing and responding 
to retinal damage from any retinal cell (Fausett and Goldman, 2006; Goldman, 2014). 
The molecular mechanism underlying the activation of the regeneration process is still 
largely unknown (Nelson et al., 2013).
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2.2.2.  Chicken
The avian retina is highly specialized and varies among birds. Raptors, such as 
the common buzzard, possess one or several foveal structures, while other birds like 
chicken, do not. Because chicken are diurnal birds, their retina contains a relatively 
high number of cones (considered cone-dominated). The chicken retina is avascular 
(anangiotic) but contains a specific structure called pecten oculi (Wolburg et al., 1999). 
This structure is highly vascularised and responsible for oxygen and nutrient supply to 
the retina. Concerning the overall morphological structure of the retina, a wide IPL layer 
is observed together with a prominent INL layer, both being generally thicker compared 
to the human or mammalian retina (Rauscher et al., 2013). In contrast, the ONL is rather 
thin and contains, similar to the zebrafish retina, double cones (Kram et al., 2010). These 
double cones are considered to be responsible for motion detection in birds. A specific 
feature of the avian photoreceptor is the oil droplet within the single and most double 
cones, right at the border between the IS and OS and spanning the entire width of the 
photoreceptor. These droplets consist of lipids in which carotenoid pigments are dis-
solved (Goldsmith et al., 1984). The precise function of the droplets, which are coloured 
according to the opsin expressed within the cell, is still unknown, but they may serve as 
cut-off filters in order to optimize light input to the OS. The RPE possesses long, slender 
cytoplasmic processes filled with melanosomes that surround the OS (Gelatt, 2007).
The chick retina is believed not to have any retinal regeneration capacities. However, 
postnatal chicks can regenerate damaged neuronal cells via differentiation of their Mül-
ler glia cells (Fischer and Reh, 2001; Luz-Madrigal et al., 2014). This capacity is lost in 
adulthood, although retinal progenitor cells have been found in the retinal peripheral 
edge (Fischer and Reh, 2000, 2002). 
2.2.3. Sheep
Sheep belong to the order ungulata and possess a tapetum lucidum between the 
RPE and the choroid, that is composed of collagenous fibers, in contrast to carnivores 
(Ollivier et al., 2004). This special layer between the RPE and choroid reflects the light in 
order to increase photon capture of the photoreceptors. The retina is holangiotic. Sheep 
are diurnal animals and their retina contains rods and two different types of cones (S 
and M/L cones) (Jacobs et al., 1998). The cones are found in higher numbers in the visual 
streak and area centralis in the dorsotemporal retina, which is also the region of highest 
ganglion cell density (Shinozaki et al., 2010). 
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2.2.4.  Pigs
Since the pig is a diurnal mammal, the porcine retina is optimized for day vision, 
consisting of a large population of cones with highest density within the area centralis 
dorsal to the optic nerve head (Chandler et al., 1999). The retina is holangiotic and pigs 
do not possess a tapetal structure (Ollivier et al., 2004). The cones comprise calyceal 
processes around the CC and OS similar to the human retina (Sahly et al., 2012). The 
cone IS are usually large and can be easily identified on histological sections. Overall, 
due to the cone-rich nature of the retina, the presence of an area centralis and the lack 
of a tapetal zone, the porcine retina is considered to be a ideal model for studying IRDs, 
especially cone-dominated disorders.
Figure 2. Comparative description of ocular features in vertebrate animal models. (A) Fundus 
image, OCT scan, histological section and special features of the zebrafish retina. Special features 
include the presence of double cones (DC), calyceal processes (CP), and accessory outer segments 
(AOS). CP and AOS start at the level of the connecting cilium (CC) (TEM image adapted from Hodel et 
al., 2014). Retinal vessels located at the border of the RNFL within the OCT scan. Fundus image and 
OCT scan courtesy of Phoenix Research Labs, La Jolla, US. Histological section shows the long and 
pigmented RPE microvilli extending into the OS layer (adapted from Schonthaler et al., 2010). (B) 
Fundus image, OCT scan, histological section and special features of the chicken (bird) retina. Special 
features include the presence of five different cone subtypes, double cones (DC) and oil droplets 
(adapted from Kram et al., 2010). Note the presence of the pecten oculi within the fundus image 
(http://people.eku.edu). OCT scan adapted from Moyaed et al., 2011. Histological section reveals 
the wide IPL and INL layer and the comparatively thin ONL layer (adapted from Bueno et al., 2011). 
(C) Fundus image, OCT scan, histological section and special features of the sheep retina. Special 
features include the presence of a tapetum lucidum fibrosum (cartoon modified after Ollivier et al., 
2004). Fundus image adapted from (Galan et al., 2006). OCT scan and histological section kindly pro-
vided by Dr. M.H. Greenlee (Iowa State University, US). The retinal vessels are very prominent at the 
border of the RNFL within the OCT scan. (D) Fundus image, OCT scan, histological section and special 
features of the porcine retina. Special features include the presence of calyceal processes (TEM im-
age adapted from Sahly et al., 2012) and large cone inner segments (histological section from Ross 
et al., 2012). Fundus image adapted from (http://www.ocularservices.com). OCT scan adapted from 
(McLellan and Rassmussen, 2012). The retinal vessels are very prominent at the border of the RNFL 
within the OCT scan. (E) Fundus image, OCT scan, histological section and special features of the dog 
retina. Special features include the presence of a tapetum lucidum cellulosum (TLC) (Cartoon modi-
fied after Ollivier et al., 2004). (F) Fundus image, OCT scan, histologic section and special features of 
the rodent (mouse) retina. Special features include large outer segments and the absence of calyceal 
processes. Instead, a periciliary membrane complex (PMC) is present at the CC (TEM image adapted 
from Sahly et al., 2012). (G) Fundus image, OCT scan, histological section and special features of the 
macaque retina. Special features include the presence the foveal pit, Henle fiber layer and calyceal 
processes (CP) (TEM image from Sahly et al., 2012). OCT scan kindly provided by Dr. F. Rolling (Uni-
versity of Nantes, Fr). (H) Fundus image, OCT scan, histological section and special features of the 
human retina. Special features include the presence the foveal pit, Henle fiber layer and calyceal pro-
cesses (CP) (TEM image from Sahly et al., 2012). Histologic section adapted from (http://webvision.
med.utah.edu). RNFL: retinal nerve fibre layer; GCL: ganglion cell layer; IPL: inner plexiform layer; INL: 
inner nuclear layer; OPL: outer plexiform layer; ONL: outer nuclear layer; HFL: Henle fiber layer; ELM: 
external limiting membrane; IS: inner segments; ISe: inner segment ellipsoids; OS: outer segments; 
RPE: retinal pigment epithelium; Ch: choroid.
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2.2.5 Cats & dogs
Cats and dogs are originally nocturnal carnivores. Their retinas are holangiotic. Both 
species possess in the superior part of the retina a tapetal zone that contains cells, the 
iridocytes, that harbor crystals rich in zinc cysteins in dogs and riboflavin in cats (Ollivier 
et al., 2004). The tapetal zone is almost triangular in form and the RPE adjacent to it 
is unpigmented. The remaining part of the retina is attached to a pigmented RPE and 
therefore, the retina can be divided into two areas, depending on the pigmentation of 
the fundus. The presence of the tapetal zone renders examination methods that depend 
on light reflectivity such as OCT more challenging. 
Most parts of the dog retina are dominated by rods. Cones are not evenly distrib-
uted, but their retinas have a central area with a high density of cones (Mowat et al., 
2008). This area centralis can be found in the superior temporal retina and is defined by 
an increased number of ganglion cells (Peichl, 1992). A recent study even described a 
fovea-like structure composed exclusively of cones within the area centralis, albeit with-
out a foveal pit (Beltran et al., 2014). Overall, the cat retina has similar characteristics.
2.2.6.  Rodents (mouse & rat)
The rodent retina is optimized for activity at night (nocturnal). Like most mammals, 
the retinal vasculature is holangiotic. The retina contains highly sensitive rods with 
long outer segments loaded with many discs and cones that are not evenly dispersed 
throughout the retina but do not form a defined cone-rich region such as the human 
macula. This characteristic has largely challenged the generation of animal models for 
cone disorders, as the phenotype may not reflect the human situation. However, in 
the Nrl-/- mouse, the lack of transcription factor neural retina leucine zipper drives the 
cell fate of rod photoreceptors to become cone-like photoreceptors (Oh et al., 2007). 
Moreover, rodents are dichromats, since the cones are either UV-sensitive or sensitive 
to long-wavelength light (Gouras and Ekesten, 2004). L/M cones are distributed mostly 
in the superior hemisphere of the retina, while the UV cones are found mostly in the 
inferior hemisphere (Szel et al., 1992). Some cones may express both types of opsins. 
The CC of cones is surrounded by a periciliary membrane complex (PMC) instead of 
calyceal processes, which may hamper studies on IRDs related to ciliary transport (Sahly 
et al., 2012). 
2.2.7. nonhuman primates (macaque)
Nonhuman primates that are used in research on the treatment of IRDs belong most 
often to the species macaque and are classified, like humans, to the suborder haplorhini. 
Members of this group have evolved vision as one of their main senses and have among 
other specifications forward facing eyes positioned on the front of the skull, thus en-
abling optimized binocular (i.e. three-dimensional) vision. Like humans, macaques see 
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with three different cone subtypes (trichomatic) and have a cone-only foveal pit in the 
centre of the macula. While there are no IRDs so far described in nonhuman primates, 
the presence of the specific macular structures makes this model crucial for developing 
treatment strategies.
2.3 Genomic architecture and evolution of IRD genes
In addition to anatomic and morphological features of the eye and the retina, one 
very important aspect in determining the suitability of an animal model is the genomic 
architecture and gene content of each species. As illustrated in Fig. 3, between 20 and 
100 million years of evolution separate humans from most vertebrate species. The 
evolutionary distance to chicken is more than 300 million years whereas the human 
and zebrafish lineages have separated 450 million years ago (Hedges, 2002). Hence, 
in terms of genetic architecture and sequence identity, mammalian models resemble 
human more closely than chicken and fish. The complexity of genomic evolution is 
further illustrated by several events that result in copy number differences, i.e. deletions 
or duplications of certain genes in the genome of particular species (Katju and Bergth-
orsson, 2013). One vision-related example of this is the primate-specific copy number 
polymorphism of the OPN1LW and OPN1MW gene cluster on the X-chromosome. This 
variation in copy number, combined with specific amino acid sequence changes in some 
of these copies contributes to the trichromatic nature of primate vision, and is thought 
to be the result of convergent evolution as a consequence of visual adaptation to the 
environment (Hunt et al., 1998).
In order to assess the degree of evolutionary conservation and copy number of 
genes associated with IRD amongst the selected species, we studied the amino acid 
sequence and orthology relationships for all genes currently listed in the RetNet data-
base that are associated with any form of monogenic IRD (https://sph.uth.edu/retnet/). 
The percentages of identity at the amino acid or nucleotide level were based on those 
levels as recorded in Ensembl (Cunningham et al., 2015). To obtain an average across 
the various proteins, their levels of identity were weighted by their sequence length. 
In case multiple orthologous proteins were present in one species (i.e. deriving from 
duplicated genes), the one with the highest level of identity to the human protein was 
used to calculate the average. The orthology relationships are based on the annota-
tion in the ENSEMBL database (Vilella et al., 2009). For all genes that were absent or 
predicted to be duplicated in any given species, we manually checked whether this was 
indeed consistent with other datasources of orthology. Specifically, for genes predicted 
to be duplicated, we examined Treefam (Ruan et al., 2008) for orthology relationships, 
including examining the existence of RNA transcripts for inferred species-specific 
duplications. For species not present in Treefam, Blast analysis was performed to find 
homologues that were used to create Neighbor Joining phylogenies after which we 
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inferred orthology relationships from those. For genes that appeared to be missing 
in the genomes from certain species, we examined the nucleotide collection for those 
species at the NCBI database fusing tBlastn (Altschul et al., 1990), i.e. to detect genes 
that may have gone unnoticed in the DNA or that have only been sequenced as cDNAs.
When comparing the sequence identity of the selected 215 genes at the amino acid 
level, zebrafish proteins show an overall identity of 54% to their human counterparts, a 
number that increases up to 92% for the macaque (Fig. 3). In terms of absent and dupli-
cated genes, it immediately becomes apparent that zebrafish shows a high number of 
duplicated genes (Fig. 3 and Supplemental Table 1). This is due to the ancient genome 
Macaca mulata (Macaque)
Homo sapiens (Human)
23+1.2
% a.a. sequence
identity IRD proteins
Deleted IRD 
genes
Duplicated
IRD genes
92
Mus musculus (Mouse)
91+2
41+1
Rattus norvegicus (Rat) 79 Eys C8orf37, Ndp, 
79 Eys Timm8a
F li tt (C t)
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92+1 45+6
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O i i (Sh )
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Danio rerio (Zebrafish) 54 Crx, Pla2g5 67**
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Figure 3. Comparative genomics and evolutionary distance genes involved in IRD. Phylogeny 
and divergence time of the selected animals. The numbers on branches indicate the evolutionary 
divergence time in million years. The average percentage of amino acid (a.a.) sequence identity of 
proteins encoded by IRD genes was calculated, and ranges from 92% in macaque to 54% in zebrafish. 
Genes that are predicted to be deleted or duplicated in the genome of certain species are indicated. 
*Due to the poor quality annotation of the chicken and porcine genome, some genes that are pre-
dicted to be deleted may in fact be missed in our analysis. **Given the high number of duplicated 
genes in the zebrafish genome (n = 67), these genes are listed separately in Supplementary table 1.
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duplication event in the teleost fish that gave rise to many genes with two copies in the 
present day zebrafish genome (Meyer and Schartl, 1999). In contrast, only two genes 
appear to be deleted in zebrafish, among which the transcription factor Crx that plays 
a crucial role in photoreceptor development in mammals. A relatively large number of 
genes appear absent in the genomes of chicken and pig (Fig. 3), although we cannot 
rule out that these are not actually lost but rather the result of the incompleteness of the 
genomes. Intriguingly, EYS, one of the most frequently mutated arRP genes in humans 
(Abd El-Aziz et al., 2008; Collin et al., 2008) has no orthologues in the rodent genomes, 
i.e. in mouse and rats. Interesting duplications are those of TIMM8A in three species 
(sheep, mouse and rats) and RPGR, in which mutations are a recurrent cause of X-linked 
RP, in pig. Whether these deletions and duplications have any functional relevance or 
selective advantage in the corresponding species needs to be established, but most 
certainly they are important when one considers generating a mutant animal model for 
a particular gene or genetic defect.
3. GEnETIC MODIFICATIOn AnD nATURALLy OCCURRInG MUTAnT 
ANIMAL MODELS 
In order to study IRD, many different animal models have been used. Some animals 
have developed IRD as the result of a naturally occurring mutation, whereas in others, 
specific mutations have been introduced in their genomes, via different ways, i.e. either 
non-targeted or targeted. Attempts have been undertaken to systematically create 
mutant animals independent of the genomic sequence by using mutagenic chemicals 
such as N-Ethyl-N-nitrosourea (ENU) or by disruption of genes with a viral DNA inser-
tion or transposons. Employing such forward genetic screens can be advantageous for 
mutating lots of different loci at the same time, in order to obtain as many different 
mutant animals as possible. Because of the high number of animals to be screened, such 
screens are only cost- and labor-effective for small animals with a large offspring and 
short regeneration times. In contrast, reverse genetic screens can be used to specifically 
modify a genomic region of interest in a cost-effective way for nearly all animals, be-
cause of its targeted approach. The characteristics of the different approaches to modify 
a genome (non-targeted vs. targeted) that are described in this chapter are listed in 
Table 2. A summary of the use of these methods per species is provided in Table 3.
3.1. naturally occurring models
Like in humans, naturally occurring mutations can result in the disruption of gene 
function and a concomitant phenotype. Especially in mice, many naturally occurring 
models have been identified and used for research over the last three decades (Veleri et 
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al., 2015). A prerequisite for employing these animals however is the identification of the 
causative genetic defect, which in the past was often done by linkage analysis combined 
with Sanger sequencing of candidate genes. In some species, this has been very chal-
lenging, due to the relative lack of knowledge on polymorphic regions (e.g. SNPs and CA-
repeats) within their genome, and/or little knowledge on the exact genomic sequence. 
Nowadays, the method of exome sequencing, when possible in combination with linkage 
analysis, is generally applied to identify naturally occurring variants, also in pigs and 
dogs (Ahonen et al., 2013; Robert et al., 2014). The poor annotation of the genome of 
some species however still complicates manners, as for instance exome sequencing data 
cannot be robustly analyzed. Once the causative mutation has been identified, these 
animals are ideal for experimental research since no genetic modification and, as a result 
of that, potential off-target effects are involved. Exome sequencing data derived from 
blind pet canines are nowadays employed in order to find suitable large animal models 
for gene characterization and gene therapy trials (Ahonen et al., 2013). Visually impaired 
chickens suffering from naturally occurring founder mutations have been identified and 
are nowadays used for research purposes (Hocking and Guggenheim, 2013). Further-
more, retinal degenerative disorders have been observed occasionally in cats and sheep.
Table 2. Characteristics of different genome modifying methods. Characteristics of different 
genome modifying methods. Each method has been described in the text and is classified into non-
targeted, used in forward genetic screens, or targeted, used in reverse genetic studies. Practical char-
acteristics mentioned which are used to choose a method of choice are compared by giving them 
an artificial score from ++ to --. ++ very well applicable; + well applicable; ± moderately applicable; 
- less applicable; -- hardly/not applicable.
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High throughput / large scale + + + - - - -
Efficiency in genome modification ++ ++ + ± + + +
Specificity in genome modification -- -- -- + + + ++
Cost/labour intensity --# - --# + ± ± ++
Sequence specificity - - - + + + +
Identification specific mutational events -- ++ ++ ++ ++ ++ ++
Genotoxicity + + + - ± ± ±
Off-target effects + + + - ± ± ±$
$ Large linkage studies and sequence efforts are needed to identify causative mutations.
# Improvements have been made, resulting in minimal off-target effects (Fu et al., 2014).
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3.2. Forward genetic approaches / phenotype-based screens
3.2.1. EnU mutagenesis
ENU is an efficient mutagenic agent used in the premeiotic male germ line, where 
it is estimated to induce one sequence change per 100 kb on average (Beier, 2000). 
However, only ten percent of these mutations are thought to have functional conse-
quences, i.e. the induced point mutations lead to a nonsense, missense or splice site 
mutation resulting in a phenotype (Beier, 2000; Kettleborough et al., 2013; Zan et al., 
2003). A subsequent assessment of visual function in these mutant animals can reveal 
many new suitable model systems for retinal degeneration, e.g. in zebrafish and mice 
(Li, 2001; Maaswinkel et al., 2005; Won et al., 2011). An unavoidable coincidence of using 
such mutagenic agents however, is the chance of having multiple induced mutations 
per genome, potentially leading to a combined phenotype or the involvement of dif-
ferent genes contributing to one phenotype in some cases. A large ENU-screen on the 
zebrafish genome covered over 38% of the protein-coding genes and revealed 10,043 
genes to be mutated (Kettleborough et al., 2013). The identification of affected genes 
and corresponding mutations as such remains challenging in using ENU-treated mutant 
animals.
Table 3. Genome modifying methods used in different species. Each genome modifying method 
has been described in the text and is classified into non-targeted, used in forward genetic screens, 
or targeted, used in reverse genetic studies. The species mentioned in the text are summed and 
examples that are applied marked with “X”. Information in this table is derived from literature and is 
not restricted to IRD genes.
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Zebrafish X X X X X X X 
Chick X X X X 
Sheep X X X
Pig X X X X X
Cat
Dog X 
Rat X X X X X X X
Mouse X X X X X X X
Macaque X X X
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3.2.2. Viral and transposon-based insertions
Insertional mutagenesis is another approach for large mutagenic screens. By using 
viral DNA, capable of randomly integrating into a host genome, some genes will be tar-
geted by chance and thereby deregulated. Nowadays the mostly used viral vectors are 
pseudotyped retroviruses, which are able to introduce their cDNA into a host genome. 
For example, zebrafish embryos infected with a pseudotyped murine leukemia (MLV)-
based virus at the 1,000 to 2,000 cell stage, gave rise to an average of 63 integrations 
per cell (Wang et al., 2007). The mozaic male parent animals are then outcrossed with 
wildtype females to generate heterozygote F1 fish with on average 10.4 ± 5.0 provi-
ral insertions per genome (Wang et al., 2007). In this zebrafish study, approximately 
twenty percent of the viral integrations led to more than 70% reduction in mRNA levels, 
originating from viral integrations into exons, introns or sites close to annotated genes 
(Wang et al., 2007). Intriguingly, from all insertions into introns, by far (59%) the most 
hits were in the first intron of the corresponding gene (Wang et al., 2007). Offspring ani-
mals are phenotyped to identify specific functional and/or morphogenetic defects, such 
as defects in optokinetic responses (Gross et al., 2005). For mutants with the desired 
phenotype, the identification of disrupted genes can be easily done using the inserted 
DNA sequence as a molecular tag, which is a huge advantage over other mutagenic 
screening methods. Such forward genetic-driven research has yielded animal models 
for studying several retinal defects (Gross et al., 2005). In a similar way, also transposon 
elements can be used to integrate foreign DNA in a genome for genome-modifying 
purposes (Izsvak et al., 2010). However, the reason why transposon-based methods are 
not often used is the lack of active transposon elements for the vertebrate genome. 
One exception is the tol2 element derived from the medaka fish, which is found to be 
naturally and autonomously active in all tested vertebrate genomes (Kawakami, 2007). 
The Tol2 system can be modified to incorporate a sequence of interest very efficiently 
into the genome of at least zebrafish, frog or mouse (Hamlet et al., 2006; Keng et al., 
2009; Kotani et al., 2006). In addition, researchers have activated another transposon 
element from teleost fish, named Sleeping Beauty (SB), to randomly integrate into the 
human genome, which therefore can be used for insertional mutagenesis as well as for 
gene delivery by pronuclear injections in at least zebrafish, mouse and rats (Ivics et al., 
2004; Kitada et al., 2007; Lu et al., 2007). Transposon elements, such as the Tol2 system, 
SB and also the PiggyBac system, are now used in preclinical studies as an alternative 
for viral gene therapy delivery (Chénais, 2013).
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3.3. Reverse genetic approaches
3.3.1. Homologous recombination
Homologous recombination is naturally used by cells to repair DNA double-
stranded breaks and interstrand crosslinks, but can also be used to introduce foreign 
DNA into the genome of a host cell, e.g. embryonic stem cells, by using two flanking 
homologous arms allowing a targeted way of integration. Once the DNA sequence of 
the gene of interest is known, homologous recombination can exchange or introduce 
DNA up to several kilobases of DNA. With the same mechanism, also knock-out or 
knock-in animals can be generated. For screening purposes of the growing stem cell 
colonies, mostly a selection gene (e.g. neomycin resistance) is co-incorporated within 
the homologous flanking arms. The surviving cells can be injected into a fertilized 
blastocyst and implanted in a pseudo-pregnant female animal to generate chimeric off-
spring (Tong et al., 2011). Because the homology arms are sequence-specific, the major 
limitation of homologous recombination is the low ability (<1%) of targeting some loci 
(Osterwalder et al., 2010). Nevertheless, the European Conditional Mouse Mutagenesis 
(EUCOMM) and the National Institutes of Health Knockout Mouse (KOMP) consortia 
are using homologous recombination in a high throughput and systematic manner to 
generate knock-out mice (Skarnes et al., 2011). Additionally, gene trap methods have 
been using homologous recombination to insert DNA cassettes into genes of interest 
(Osterwalder et al., 2010). 
3.3.2. Sequence-specific endonucleases: zinc-finger nucleases and TALEns
Large mutagenesis screens are all based on the introduction of random mutations 
and are phenotype-driven. Since more detailed genetic information becomes apparent 
from patients, also the need for generating models with specific mutations arose with 
it. One of the first approaches of targeted gene modification made use of one class of 
specific DNA binding proteins, zinc fingers, that are peptides that can recognize and 
bind 3-bp DNA motifs. These peptides are usually clustered into three to six DNA bind-
ing domains capable of recognizing around 9 to 18 bps. The fusion of zinc-fingers with 
the endonuclease enzyme FokI into a zinc finger nuclease (ZFN) complex led to the pos-
sibility of targeted DNA cleavage. Cellular non-homologous end-joining (NHEJ) repair 
processes will join the DNA ends, sometimes introducing mutations such as insertions 
and/or deletions at this position (Sander et al., 2011). The nucleotide specificity remains 
critical, since off-target effects can result in false phenotypes. The targeting options 
using FokI, however, were limited to its DNA restriction motifs. In order to increase 
DNA restriction possibilities, a more flexible form of DNA cleavage was used. By fus-
ing a transcription activator-like (TAL) effector DNA-binding domain to a general DNA 
cleavage domain, a wide range of possible restriction motifs is estimated to be present 
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once in every 35 bp of DNA (Sander et al., 2011). The encoded amino acids of the DNA 
binding domain of these artificial endonucleases are easier to design than previously 
used ZFNs and are, together with an endonuclease domain, referred to as transcription 
activator-like effector nucleases (TALENs). TALENs have been shown to be suitable for 
gene-specific mutagenesis in zebrafish (Huang et al., 2011), rat (Ponce de Leon et al., 
2014; Tesson et al., 2011), mouse (Davies et al., 2013) or human derived embryonic stem 
cells and induced pluripotent cells (Hockemeyer et al., 2011). Attempts to make a less 
genotoxic TALEN-mediated endonuclease system recently yielded a re-engineered very 
specific endonuclease (I-SceI) without efficiency loss compared to traditional TALENs 
(Lin et al., 2014). Following induction of DSBs by either ZFNs or TALENs, repair can also 
be directed towards homologous recombination by the addition of donor template 
DNAs (section 3.3.1.).
3.3.3. Crispr/Cas9
Over the last two years, a new tool has become available to efficiently modify a ge-
nome. Although the principle has not changed, clustered regulatory interspaced short 
palindromic repeat (CRISPR)/Cas9-based RNA-guided DNA endonucleases are very easy 
in both design and use, and have increased efficiencies compared to previously used 
methods like ZFNs or TALENs (Smith et al., 2014). CRISPR arrays were first discovered 
in the Escherichia coli genome (Ishino et al., 1987) and were found to play a role in the 
adaptive immune system by protecting bacteria from invading viruses when combined 
with Cas9 genes (Barrangou et al., 2007). The transition of this system from a biological 
phenomenon to a genome engineering tool was the result of combining targeted speci-
ficity (crRNA) with the structural Cas9-binding properties of the tracrRNA in a chimeric 
single guide RNA (gRNA) (Jinek et al., 2012). The Crispr/Cas9 system has been adapted 
for efficient use in a wide variety of organisms, including zebrafish, mouse, rat, human, 
pig and sheep (Han et al., 2014; Sander and Joung, 2014; Whitworth et al., 2014; Wu 
et al., 2013). Two recent studies however, show major off-target binding of catalytically 
active Cas9 endonuclease, leading to possible genotoxicity (Fu et al., 2013; Wu et al., 
2014). Although only a few off-target mutations were found in one of these two studies, 
the other shows higher off-target mutagenesis efficiency in some cases, even when 
Cas9 was targeted to positions with up to five nucleotide mismatches compared to the 
~20-nucleotide guide RNA sequence (Fu et al., 2013). A method which can improve 
the target specificity of active endonucleases to the genome is needed for future use. 
Shortening guide RNAs to less than twenty nucleotides can reduce off-target binding 
up to 5,000 fold or more, without reducing any on-target functionality (Fu et al., 2014). 
Another improvement, which can be combined with truncated guide RNAs, was made 
when researchers introduced the use of a Cas9 endonuclease mutant able to induce 
only a single strand break called nickase (Ran et al., 2013). Targeting two nickases to 
67
The pros and cons of vertebrate animal models for functional and therapeutic research on inherited retinal dystrophies
Ch
ap
te
r 2
a
the same genomic position is thus required for a double strand break, via which the 
specificity can be increased by 50- to 1,500-fold, as two different guide RNAs can be 
used (Ran et al., 2013). Since the genome-directed Cas9 nickases are catalytically active, 
they will still induce single-strand breaks, contributing to genotoxicity and potential 
mutations. To circumvent these limitations, a FokI endonuclease can be fused to a cata-
lytically dead Cas9 protein used by guide RNAs to target the desired genomic location 
(Tsai et al., 2014). The advantage of using FokI over previous versions of the Crispr/
cas9 system is that FokI endonucleases are only catalytically active after dimerization, 
overcoming therefore all earlier mentioned genotoxicity. Following the induction of the 
double strand break by the cas9 endonuclease activity, the break can be repaired by 
either nonhomologous endjoining (NHEJ) or homology-directed repair. NHEJ will in-
duce insertions and/or deletions since no template is present, while homology directed 
repair can use any template to repair the breaks (see section 3.3.1.). Thus, by providing 
Crispr/cas9 treated genomes with an organism-foreign DNA donor fragment containing 
DNA of interest, the possibilities for genome editing are enormous. Indeed, this is an 
established technique and larger DNA templates have been successfully incorporated 
in genomes of zebrafish (Auer et al., 2014) or mouse (Yang et al., 2013). With higher 
specificities, it now becomes possible to not only mutate a gene, but also to repair a 
mutated allele back to the wild-type sequence. First tests in a mouse model for cataracts 
showed successful repair of the mutated Crygc gene by using its healthy counterpart 
as a template, which led to fertile wildtype mice (Wu et al., 2013). Along the same line, 
researchers have been able to repair mutations in human derived induced pluripotent 
stem cells (Smith et al., 2014). 
4. MUTAnT VERTEBRATE AnIMAL MODELS USED In IRD RESEARCH
4.1 Historical overview on the use of mutant IRD animal models
For centuries, scientists have attempted to better understand human physiology 
and pathology by employing animals in research. Already in the first half of the 20th 
century, the first studies on retinal degeneration in animals were published (Bourne et 
al., 1938; Chatzinoff et al., 1958), and soon after that, the first animal models display-
ing retinal degeneration segregating in a Mendelian fashion were identified, i.e. the 
rd (retinal degeneration) mice, and the rds (retinal degeneration slow) mice (Sanyal 
et al., 1980; Sidman and Green, 1965). Although the genomic regions harbouring the 
causative genetic defects were mapped, it took until the late eighties before the actual 
genes carrying these mutations were identified, i.e. Prph2 in the rds mice (Travis et al., 
1989; Travis et al., 1991) and Pde6b in the rd mice (Bowes et al., 1990). From that point 
on, the genetic defect underlying retinal degeneration in many mouse models was 
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elucidated, and mutations in the human orthologous genes were identified at a very 
rapid pace. At the same time, positional cloning combined with sequencing analysis in 
humans revealed other genes to be mutated in IRDs (Cremers et al., 1990; Dryja et al., 
1990), genes that automatically served as good candidates to be mutated in animal 
models with naturally occurring types of IRD, not only in mice but for instance also in 
dogs (Clements et al., 1993) and, somewhat later, in rats (D’Cruz et al., 2000). Ever since, 
many different animal models carrying spontaneous mutations in genes associated with 
IRD have been identified, and studied in great detail to increase our understanding on 
retinal function and dysfunction. The discovery of homologous recombination in mouse 
embryonic stem cells upon transfection of exogenous DNA (Thomas and Capecchi, 
1987) and possibilities to use this technology for the generation of genetically modified 
mice (Koller and Smithies, 1989) led to novel opportunities to study the function of 
proteins encoded by the various genes that are mutated in IRDs. Targeted disruption 
(knock-out) or targeted insertion of specific pieces of endogenous or exogenous DNA 
(knock-in) via homologous recombination in mouse ES cells, has resulted in the genera-
tion of many animal models with genetic defects in genes underlying IRD in humans. 
The development of other novel technologies to modify genomes (see Chapter 3) 
has even further expanded the number of animal models for IRD, and to date, more 
than 250 different animal models have been described (Supplemental Table 2). Yet, 
in several animal models, the phenotype does not (exactly) resemble the phenotype 
that one would expect based on the clinical characteristics of human IRD patients with 
mutations in the corresponding gene. Below, we discuss these discrepancies, and aim to 
find correlations between the disparity of the phenotype and the molecular, anatomical 
or retinal characteristics of the particular animals.
4.2 Mutant IRD models that do not mimic the human phenotype
Comparing the clinical characteristics of a mutant animal model with those of IRD 
patients with mutations in the orthologous gene is complicated due to intrinsic differ-
ences in retinal development and structure, as well as by the different procedures that 
are applied to describe this phenotype. Hence, establishing whether a mutant animal 
model exactly mimics the human phenotype is not always straightforward. In several 
cases however, a detailed molecular or phenotypical analysis of the mutant animal 
models clearly shows the absence of any, or presence of unexpectedly mild, retinal 
abnormalities (Supplemental Table 2). In the following paragraphs, we cluster these 
discrepancies into groups, describe several examples, and hypothesize on the molecular, 
or retinal structure-related reasons for the differences in phenotypic outcome.
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4.2.1. Gene- or mutation-related discrepancies
As described in section 2.3, the genomic architecture of the selected species can 
differ significantly, resulting in the absence of certain genes in some species, or the 
presence of multiple copies of one gene in a given genome (Fig. 3 and Supplemental 
Table 1). In addition, supported by alternative splicing, the same or slightly different 
protein products derived from the same gene can have diverse functions, in different 
organisms, within the same organism, and even within the same cell. It is therefore not 
surprising that different mutations can result in various molecular defects, either because 
the mutation affects only a single isoform of the gene, or because the type of mutation 
results in complete loss-of-function, partial loss-of-function, a gain-of-function, or has a 
dominant-negative effect on the wild-type allele in case of heterozygous mutations. In 
several cases, a discordance between a mutant animal model and the clinical phenotype 
in humans can be explained by such gene- or mutation specific reasons, as illustrated 
below.
4.2.1.1. Embryonic lethality
In case a particular mutation, or compound heterozygous mutations, in humans 
result in only a partial loss-of-function, this may affect the function of only one or a few 
specific organs or tissues, resulting in for instance IRD. If the corresponding genes are 
ubiquitously or broadly expressed in the human body, a complete loss-of-function of 
these genes could result in a much more severe phenotype, or even be incompatible 
with life. Similarly, a targeted disruption of the orthologous mouse genes can result in 
embryonic lethality, as has been shown for Chm, Elovl4, Prpf3 and Prpf8 (Supplemental 
Table 2). In some cases, this embryonic lethality is unexpected, for instance in Chm, 
since the mutations that cause choroideremia in humans are also true loss-of-function 
mutations. Further studies revealed that this observation is most likely explained by 
preferential inactivation of the paternal X-chromosome in murine extraembryonic 
membranes, together with a crucial function for the Rep-1 protein (encoded by Chm) 
during early embryonic development (van den Hurk et al., 1997). 
4.2.1.2. Differences in mutational mechanisms 
One other explanation for discrepancies in the phenotypic outcome between hu-
mans and animals are differences in the mutational mechanisms, which is particularly 
true for disorders that are inherited in an autosomal dominant matter. When causative 
heterozygous missense mutations are identified, the pathophysiological mechanisms 
underlying IRD in those cases could be haploinsufficiency in case of loss-of-function 
mutations, the mutation could act in a dominant-negative way, or the mutation can 
cause a gain-of-function. Without a clear understanding on these exact mechanisms, 
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correlating the phenotype observed in mutant animal models with different mutations 
in the same gene to the human situation is challenging.
Mutations in the cone-rod homeobox-containing (CRX) gene, encoding a tran-
scription factor essential for the development of photoreceptor cells, in humans are 
associated with different subtypes of IRD, depending on the type and zygosity of the 
mutations, i.e. Leber congenital amaurosis, cone-rod dystrophy or RP (Freund et al., 
1997; Freund et al., 1998; Sohocki et al., 1998; Swain et al., 1997; Swaroop et al., 1999). 
The majority of these mutations are thought to act in a dominant-negative manner, i.e. 
the mutant CRX protein impairs the transcriptional activity of the wild-type copy.
Homozygous Crx-/- mice clearly demonstrate a functional impairment of photore-
ceptor cells, resulting in a progressive photoreceptor degeneration (Furukawa et al., 
1999). This knock-out mouse however fails to model the dominant inheritance of CRX-
associated IRD in humans, as heterozygous mice display only a mild phenotype and 
normal retinal morphology (Furukawa et al., 1999). Thereafter, the generation of mouse 
models carrying mechanistically distinct mutations has further revealed the complex-
ity of studying CRX-associated phenotypes. CrxR90W knock-in mice, carrying the exact 
missense mutation associated with autosomal recessive LCA in humans (Swaroop et al., 
1999), appear healthy in heterozygous state, whereas the phenotype in homozygous 
mutant mice closely resembles that of the Crx-/- mice (Tran et al., 2014). In contrast, 
studies in CrxE168d2 mice carrying a frame-shift mutation, have revealed that a truncation 
in the CRX trans-activation domain will preserve DNA-binding activity and disrupts the 
trans-activation activity of the wild type protein (Tran et al., 2014). As a result, both 
CrxE168d2/+ and CrxE168d2/E168d2 mice show clear signs of retinal degeneration, although 
more severe in the homozygous mutant mice. The characterization of a spontaneous 
heterozygous frameshift mutation in the CrxRip mice with congenital blindness (Roger 
et al., 2014), and a naturally occurring cat model CrxRdy with a frameshift mutation more 
closely resembling the human CRX-associated phenotype (Menotti-Raymond et al., 
2010) has further revealed the complexity of modeling phenotypes caused by mutations 
in the same gene that display different mutational mechanisms.
Another example is the diversity of mutations in RHO that encodes rhodopsin. 
IRD-associated mutations in RHO can be subdivided into two classes. Some mutations, 
clustering in the first transmembrane domain or near the carboxy-terminal end of the 
protein, like the Q334* mutation tend to aggregate at the plasmamembrane of the 
photoreceptor cell body, as was shown in a mutant mouse model with this mutation 
(Sung et al., 1994), as well as in transgenic zebrafish carrying the exact same mutation 
(Raghupathy et al., 2013). Likewise, knock-in mice expressing rhodopsin with a *349Q 
mutation demonstrate a severe and early-onset retinal degeneration with mislocaliza-
tion and improper disc formation (Hollingsworth and Gross, 2013). 
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The majority of RHO mutations however, including the most recurrent mutation 
P23H, are predicted to undergo protein misfolding, thereby accumulating in the endo-
plasmic reticulum and inducing apoptotic cell death. Studies in transgenic mice, rats, 
dogs and, more recently, pigs with this mutation indeed supported this pathophysi-
ological mechanism (Kijas et al., 2002; Olsson et al., 1992; Roof et al., 1994; Ross et al., 
2012), again illustrating that different mutations in the same gene can exert different 
pathophysiological mechanisms, in humans as well as in different animal models.
4.2.1.3.  Isoform-specific expression and differential pre-mRnA splicing
As described in section 4.2.1, the majority of protein-coding genes encode several 
protein isoforms that are the result of alternative splicing, a process that determines the 
inclusion or exclusion of specific exons in the mature transcript. For several genes that 
are associated with IRD, retina-specific isoforms have been described that often contain 
exons exclusively present in these isoforms, e.g. CERKL, RPGR, and BBS3 (Garanto et al., 
2011; Kirschner et al., 1999; Pretorius et al., 2010). The use of alternative promoters driv-
ing the expression of one or more of these isoforms complicates matters even further. 
For genes with such a complex transcriptional profile, generating a mutant animal model 
that mimics the human phenotype can be a challenging task. For instance, attempts to 
knock-out Cerkl in mice revealed only very mild phenotypic abnormalities, and further 
studies revealed the use of several promoters driving the expression of a multitude of 
Cerkl transcripts, in mice as well as in humans (Garanto et al., 2011; Garanto et al., 2012).
Besides naturally occurring alternative splicing, many mutations have been described 
that somehow affect the recognition of splice sites by the spliceosome, and thereby 
alter the composition of the transcript and final protein product. One example of such 
a mutation is a recurrent change in CEP290, a deep-intronic mutation c.2991+1655A>G 
that activates a cryptic splice donor site in intron 26, and results in the inclusion of a 
pseudo-exon to ~50% of all CEP290 transcripts these LCA patients (den Hollander et 
al., 2006). Attempts to mimic this recurrent mutation and the associated phenotype in 
a humanized knock-in mouse model failed, apparently because the mouse splicing ma-
chinery did not effectively recognize the pseudo-exon present in LCA patients with this 
mutation (Garanto et al., 2013). Further studies recently showed that the recognition of 
such cryptic splice sites can vary heavily in different species (Garanto et al., 2015).
Another intriguing relationship between splicing and IRD exists through the PRPF-
associated retinal dystrophies. Proteins encoded by PRPF genes are an essential com-
ponent of the spliceosome in all cells of the human body, yet mutations in several of 
these genes cause a phenotype that appears to be restricted to the retina (Chakarova 
et al., 2002; Chen et al., 2014; McKie et al., 2001; Tanackovic et al., 2011; Vithana et al., 
2001). Hypotheses to explain this phenomenon include dual, retina-specific functions 
for these proteins, a higher demand of splicing in retinal cells, or specific mis-splicing 
Chapter 2a
72
of some key components within the retina. Many studies involving animal models have 
attempted to uncover the molecular mechanisms involved in the retinal-restricted phe-
notype caused by mutations in these PRPF genes (Bujakowska et al., 2009; Chakarova 
et al., 2002; Graziotto et al., 2011; Graziotto et al., 2008; McKie et al., 2001; Vithana et 
al., 2001), yet these studies were severely hampered by either early lethality or severe 
phenotypes not restricted to the eye. A more recent study demonstrated the RPE to be 
the primary retinal cell type affected by these mutations, thereby revealing new insights 
into the pathophysiology of splice factor-associated IRD (Farkas et al., 2014).
4.2.1.4. Genetic redundancy
Genetic redundancy is occurring when the protein products of two different genes 
have an identical or at least overlapping function in the same biological process. In 
such cases, defects in one of the two genes could have a less detrimental effect on the 
phenotypic outcome of the organism than what could expected based on the physi-
ological function of the encoded proteins. Redundant genes are found in almost all 
signaling, developmental, or metabolic contexts (Kafri et al., 2009). The fact that these 
genes are believed to originate from a single ancestral gene, explains why there might 
be overlapping functions remaining (Kafri et al., 2009). 
Due to an ancient genome duplication event, the zebrafish genome is largely du-
plicated, giving rise to many genes with two copies (Meyer and Schartl, 1999). Some of 
these duplicated genes have acquired split functions. One example is protocadherin-15 
(PCDH15), a gene that in zebrafish has two orthologues (pcdh15a and pcdh15b). Ze-
brafish lacking Pcdh15a (orbiter) reveal no defects in optokinetic responses, whereas 
the absence of Pcdh15b results in reduced optokinetic and ERG responses (Seiler et al., 
2005). It might therefore be expected that genes for which one of the copies has been 
lost following the genome duplication, or duplicated genes with a clear split function, are 
less tolerant to mutations and would therefore be overrepresented in the non-targeted 
screens that most of the mutant zebrafish models originate from (Supplemental Table 
2). Yet, only four out of the seven zebrafish IRD models carry mutations in genes that are 
not duplicated when compared to the human genome. However, as exemplified above, 
some of the genes that are assigned as being duplicated indeed might actually have 
acquired a split function or are at least not be fully redundant in the zebrafish retina 
anymore, such as gc1/gc3 or Cacna1fa/b, as described below.
One example of two functionally redundant genes in humans that have arisen after 
a gene duplication event in humans are GUCA1A (expression in cones and only weakly 
in rods) and GUCA1B (expression in both rods and cones) (Imanishi et al., 2002; Kachi et 
al., 1999; Surguchov et al., 1997). These two genes, that share more than 90% sequence 
similarity, are sequentially located tail-to-tail at human chromosome 6 and encode the 
calcium-sensing part of guanylate cyclase enzyme (GC) that is involved in the recovery 
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phase of the phototransduction cascade (Subbaraya et al., 1994; Surguchov et al., 1997). 
Mouse models with a disruption in only one of the two Guca genes do not show any 
abnormal histological retinas (Supplemental Table 2: Guca1atm1Itl and Guca1btm1Amd), 
although single Guca knock-out rods became more sensitive to flashes and to steps 
of illumination as a result of reduced calcium sensitivity (Makino et al., 2008; Mendez 
et al., 2001). However, the combined loss of both genes does result in a clear and se-
vere photoreceptor degeneration (Mendez et al., 2001) which is indicative for Gcap1 
and Gcap2 (encoded by Guca1a and -1b, respectively) being functionally redundant. 
This was further strengthened by the complete rescue of the Guca1a/Guca1b double 
knockout phenotype with a healthy copy of only the Guca1a gene (Howes et al., 2002; 
Pennesi et al., 2003). Intriguingly however, expression of only Guca1b was not enough to 
completely restore the phenotype (Mendez et al., 2001). In humans, GUCA1A mutations 
result in cone-dystrophy, with GUCA1B apparently not being fully redundant in these 
cones (Payne et al., 1998). Mutations in GUCA1B in contrast have been reported to 
lead to autosomal dominant retinitis pigmentosa (Sato et al., 2005), although the exact 
involvement of these mutations in retinal disease remains controversial (Kitiratschky 
et al., 2011). One other difference between mice and human cone photoreceptor cells 
that could influence the phenotypic outcome, is the presence of a third calcium sensing 
domain (GCAP3) in human, but not in mouse, cone photoreceptors (Imanishi et al., 
2002). A similar mechanism for reduced guanylate cyclase activity is also seen in the 
rd chickens that carry a spontaneous mutation in the GC1 gene (Semple-Rowland et 
al., 1998). Mechanistically, this phenotype can be explained by the same mechanism 
as seen with mutations in GUCA1A. Already before any pathological disruption can 
be observed, the retinal cGMP levels are below normal (Semple-Rowland et al., 1998). 
Altogether, these data suggest that there is some redundancy between GCAP1 and 
GCAP2 (and perhaps also GCAP3 in humans), but GCAP1 seems to be the main actor 
which cannot be fully replaced by GCAP2 (or GCAP3).
Following rhodopsin activation and the conformational change of 11-cis-retinal 
to all-trans-retinal, this all-trans-retinal can be re-converted into 11-cis-retinol via the 
visual cycle. The rate-limiting step in this cycle is the enzymatic conversion of all-trans-
retinal into all-trans-retinol. This process is performed by retinal dehydrogenases: RDH8, 
RDH12 and retSDR1 (retinal short-chain dehydrogenase reductase 1) in photoreceptor 
outer segments, and RDH10 in the RPE (Maeda et al., 2007). Oxidation of 11-cis-retinol 
in the RPE is catalyzed by 11-cis-RDHs (RDH5 and RDH11) to yield 11-cis-retinal. Since 
the two enzymes RDH8 + RDH12 and RDH5 + RDH11 in fact catalyze the same reaction, 
one might expect that a functional loss in one of these enzymes due to mutations 
can be compensated for by the other unaffected gene. Indeed, knocking out either 
Rdh5 (Driessen et al., 2000; Shang et al., 2002) or Rdh11 (Kim et al., 2005), and Rdh8 or 
Rdh12 (Maeda et al., 2007) in mice for example only results in a delayed dark adaptation 
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after high bleaching levels. In contrast, the double (Rdh5&Rdh11 or Rdh8&Rdh12) or 
triple (Rdh5, Rdh8 & Rdh12) knock-out mice do indeed suffer from rod-cone dystrophy, 
indicating that the different RDHs are functionally redundant in the mouse retina (Kim 
et al., 2005; Maeda et al., 2007). In humans however, mutations in either RDH5 (fundus 
albipunctatus) Yamamoto et al., 1999), RDH11 (Retinal Dystrophy, Juvenile Cataracts 
and Short Stature Syndrome (RDJCSS), or RDH12 (LCA) do already result in apparent 
phenotypes (Janecke et al., 2004; Perrault et al., 2004; Xie et al., 2014; Yamamoto et al., 
1999).
4.2.2. Retinal function- & structure-related discrepancies
As described in 2.2, differences in retinal architecture and the presence or absence of 
anatomical structures in retinal cells are apparent in the selected species. It is therefore 
not surprising that animal models with a differential distribution of rod vs. cone cells, 
mainly due to a difference in nocturnal versus diurnal activity, as well as models for IRDs 
in which the human pathology resides in anatomical structures that are underdevel-
oped or even absent, will not entirely mimic the human clinical phenotype. In the next 
paragraphs, some examples will be outlined in which a different clinical outcome in 
mutant animal models as compared to the human situation can be explained by retinal 
structure-related differences.
4.2.2.1. Calyceal processes in rodent Usher models
Calyceal processes are axially oriented microvillus-like structures that emerge from 
the inner segment and form a collar around the base of both rod and cone outer seg-
ments. Scanning electron-microscopy analyses revealed that these F-actin-rich struc-
tures are conserved in at least NHP, pigs and zebrafish, (Allwardt and Dowling, 2001; 
Cohen, 1963), but absent in mice and rats. Recently all five known proteins involved in 
Usher syndrome type 1 (myosin7a, harmonin (=Ush1c), cadherin-23 (=Cdh23), proto-
cadherin-15 (=Pcdh15) and Sans (=Ush1g) were shown to co-localize to the junction 
between the inner and outer segment of retinal photoreceptors in human and macaque 
but not in mouse. Closer examination by electron microscopy revealed that these pro-
teins localize to the photoreceptor calyceal processes (Sahly et al., 2012). The differential 
distribution in photoreceptors of humans and rodents strongly supports evidence that 
the difference in phenotypic outcome of mutations in these genes are explained by the 
presence/absence of these calyceal processes. Although their exact function remains 
elusive, they have been proposed to serve a structural role by providing the outer seg-
ment strength and rigidity (Sahly et al., 2012). Another attractive hypothesis, that was 
raised based on the presence of the fastest known neuronal Ca2+ pump (PMCA2), is that 
the calyceal processes might be mechanosensitive, similar to the inner ear hair cells and 
therefore fulfill a role in signaling (Caride et al., 2001). 
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The membrane of the periciliary region, a collar-like extension of the apical inner 
segment that surrounds the connecting cilium, is also thought to function in the or-
ganization of the transport of post-Golgi-derived vesicles which are indicated to dock 
at the membrane of the periciliary membrane (Maerker et al., 2008). All known Usher 
syndrome type 1 and type 2 proteins are located in this (peri)ciliary region (Goodyear 
and Richardson, 1999; Maerker et al., 2008; McGee et al., 2006; Sahly et al., 2012), which 
is also underdeveloped in rodents as compared to humans (Petit, 2001). Fibrous links 
connect the membrane of the periciliary region to the membrane of the connecting 
cilium. Gpr98 (Ush2c) was found to be essential for the formation of these links because 
they were absent in Gpr98-deficient (Vlgr1/del7TM) mice (Maerker et al., 2008). Since 
also usherin (Ush2a) and whirlin (Ush2d) are present in this periciliary region the fibrous 
links are thought to be the analogs of the ankle links in the hair bundle of cochlear hair 
cells. The fibrous links may be formed by homo- and/or heteromeric binding of the 
extracellular domains of Ush2a and Gpr98 which are intracellularly tethered by whirlin. 
SANS and whirlin directly interact and SANS thereby may provide the molecular link 
to the microtubule transport machinery (Maerker et al., 2008; van Wijk et al., 2006). 
The fibrous links may function as structural support of the periciliary region and the 
connecting cilium (Maerker et al., 2008) and analogous to the function of the links in the 
hair bundle, they could play a role in development of this region of the photoreceptor. 
However there are no, or in case of Ush2a-/- and whirlin-/- mouse mutants only with 
very mild (Liu et al., 2007; Yang et al., 2010), retinal aberrations due to ablation of the 
Usher genes. In addition to their structural role, it was postulated that these proteins 
play a role in defining the membranous regions and thereby contribute to the control 
of vesicle docking and cargo transfer from the inner segment transport system to that 
of the cilium (Maerker et al., 2008) or play a role in outer segment disk formation and 
renewal (Sahly et al., 2012). Since whirlin associates with the calcium channel subunit 
CaV1.3 it is likely to have a role either in the transport to or the organization of the 
voltage-gated calcium channels at the plasma membrane and thus contributes to the 
control of vesicle docking and/or fusion via regulation of local Ca2+ concentrations 
(Kersten et al., 2010). 
4.2.2.2. Differential distribution of cone and rod photoreceptor cells
Cones and rods serve different functions in the retina and are differentially distrib-
uted amongst species. As described in this review, the human retina contains a cone-
rich area (fovea centralis) whereas in zebrafish the retina is built up almost exclusively 
by cones that are distributed throughout their entire retina. Moreover, rod development 
is not matured until 20 days post fertilization (dpf) which therefore gives rise to a retina 
overrepresented by cones at 5 dpf when functional measurements in forward genetic 
screens are often conducted (Branchek and Bremiller, 1984). However, the overall anat-
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omy of the retina is similar in both species. This would make rod-specific degeneration 
less pronounced in the zebrafish retina as compared to other species such as humans. 
A cone and rod difference is for example seen in the zebrafish cacna1fa mutant. In both 
humans and mice, the CACNA1F gene is expressed in both rods and cones, whereas 
zebrafish contains two cacna1f orthologues that are differentially expressed: cacna1fa 
(cone-specific) and cacna1fb (rod-specific). This is most probably also the reason that, 
in contrast to the cacna1fa zebrafish mutant, Cacna1f knock-out mice mimic the human 
ERG measurements and congenital stationary night blindness (Chang et al., 2006; Jia 
et al., 2014). On the other hand, when comparing animal models for genes specifically 
expressed in cones (PDE6C or GNAT2), a similar phenotype is observed in case of any 
mutation. Humans, dogs, mouse and zebrafish all show cone-specific degeneration and 
therefore suffer from achromatopsia (Supplemental Table 2).
A more subtle difference between cone and rod photoreceptor cells amongst spe-
cies is observed with mutations in the PDE6 complex. In the rod photoreceptor cells, 
PDE6 forms a heterotetrameric complex of PDE6α, PDE6β and two PDE6γ subunits to 
make an active cGMP phosphodiesterase capable of cGMP hydrolysis. 
Both mice and dogs have a relatively rod dominated retina, which is the result of their 
high nocturnal activity as compared to the more cone-rich human retina. As a result, 
one could expect that rod-specific null alleles have a great impact on vision in mice and 
dogs as compared to humans. Indeed, it can be observed that mutations in the mouse 
and dog Pde6b gene lead to rapid rod photoreceptor degeneration and eventually to 
complete retinal degeneration and loss of visual function (Hart et al., 2005; Suber et 
al., 1993). Also, in humans with PDE6B mutations, the initial symptoms include night 
blindness as a result of rod-specific dysfunction and eventually show a more advanced 
retinal degradation probably induced by the proposed bystander effect (Ripps, 2002), 
but with a progression rate that is significantly slower than in mice and dogs (Hart et 
al., 2005). However, phenotypic variability in terms of disease progression often occurs 
even within the same species. For instance, the rd1 mouse carrying nonsense mutation 
displays a rapid photoreceptor degeneration at postnatal day 8, and absence of nearly 
all rods by week 3 (Pittler and Baehr, 1991). In comparison, rd10 mice with a Pde6b 
missense mutation (p.R560C) show a relatively slower disease progression, starting at 
postnatal day 16 and complete absence of photoreceptor cells within 2 months (Chang 
et al., 2007). A PDE6B nonsense mutation in rcd1 Irish setter dogs leads to a rapid 
disease progression, which starts one month after birth and continues until 3 months 
(Suber et al., 1993). In contrast, crd1 American Staffordshire terrier dogs carrying an 
in-frame deletion have a milder phenotype and later onset compare to rcd1 dogs. 
Histological examination of the retina at 11 weeks shows that photoreceptors and the 
ONL in homzygous crd1 dogs are more preserved compared to those in crd1/rcd1 or 
rcd1/rcd1 dogs (Goldstein et al., 2013). Similar results were seen in Pde6a mutant mouse 
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and dog models, encoding the other PDE6 rod-specific subunit (Petersen-Jones et al., 
1999; Sakamoto et al., 2009). These studies highlight the importance of considering 
genetic background, and the type of mutation when selecting suitable animal models 
that mimic the human phenotype. 
5. MUTAnT AnIMAL MODELS FOR THERAPEUTIC STUDIES On IRD 
As outlined above and shown in Supplemental Table 2, the vast majority of verte-
brate animal models for IRD research at least to a significant part mimics the phenotype 
present in humans. Most models can be found in the mouse, since this species has 
several practical advances in terms of generating, maintaining and analysing the un-
derlying pathologic mechanisms. Consequently, over the last years a growing number 
of pharmacologic and gene therapeutic studies have been performed in these mouse 
models, demonstrating the conceptual possibility to treat the mimicked human retinal 
disorders (Boye et al., 2013; Stieger et al., 2010). Most often, viral vectors were employed 
as vehicles for the transfer of genes, with AAV- and lentivirus-based vectors being the 
most regularly used ones (Trapani et al., 2014). Zebrafish models have also been used 
to study pharmacological interventions, such as translational read-through approaches, 
but have so far not been used for gene therapeutic applications (Moosajee et al., 2008). 
Gene therapeutic approaches were described in one chicken model carrying mutations 
in GUCY2D (Williams et al., 2006). 
However, when translating these results to humans, several key features cannot 
be sufficiently modelled in small animal models and, therefore, large animal models 
become more and more important (Komaromy, 2010; Kostic et al., 2013; Petersen-Jones, 
2013). Successful proof-of-principle therapeutic studies have been published in several 
canine models of IRD (Acland et al., 2001; Beltran et al., 2012; Komaromy, 2010; Le 
Meur et al., 2007; Lheriteau et al., 2014; Narfstrom et al., 2003; Petit et al., 2012). But 
even in large animal models, certain features cannot be comprehensively analysed due 
to interspecies-related differences. These features include the limited similarity of the 
retinal anatomy among the different species and humans (primates), as well as major 
differences concerning efficacy and cellular tropism of viral vectors between species. 
The published use of animal models for different types of experimental therapeutic ap-
proaches is summarized in Table 4. In the following paragraphs, the different vertebrate 
animal models will be discussed with regard to the current hot topics in retinal gene 
therapy research, i.e. viral vector tropism and gene transfer approaches with regard to 
the varying retinal anatomy.
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5.1  Vector tropism in different species
For specific as well as non-specific gene therapeutic approaches, subretinal viral 
vector-mediated gene transfer is still considered to be the most efficient way to enable 
transgene expression in retinal cells. While AAV-based vectors are considered the gold 
standard due to their varying cellular tropism depending on the serotype, its limited 
packaging capacity represents a major roadblock for the development of therapeutic 
strategies for IRDs in which the disease-causing mutations are often located in genes 
that have open reading frames larger than 4kb. For those genes, lentivirus-based vec-
tors have been generated and successfully tested in mouse models for several IRDs, 
such as Usher syndrome type 1B or Stargardt disease (Binley et al., 2012; Zallocchi et al., 
2014). In order to evaluate safety aspects, the authors also included data on non-human 
primates (NHP) in these papers. Since an efficient uptake of most vectors is dependent 
on receptor-mediated endocytosis, the tropism of a vector is usually defined by the 
presence or absence of cell surface receptors. For AAV, a large number of different 
receptors have been defined that interact with the different serotypes (Akache et al., 
2006; Di Pasquale et al., 2003; Kaludov et al., 2001; Summerford and Samulski, 1998; 
Walters et al., 2001). Knowledge about these capsid-surface interactions led to the 
development of tyrosine-mutated capsid variants with better transduction efficiencies 
(Petrs-Silva et al., 2009). Nonetheless, the efficacy of serotypes to transduce a given cell 
type varies among species, which makes it crucial to test all serotypes in the species in 
which a treatment strategy is to be explored. For example, the expression profiles of the 
serotypes currently considered to be most efficient for photoreceptors in mice, AAV2/5, 
Table 4. Overview on therapeutic and vector-related studies on IRD in the various animals
Model Treatment approach / Vectorology
Pharmacologic§ Optokinetics Cell therapy Gene therapy$ Vectorology*
Zebrafish X
Chicken X
Sheep
Pig X
Cat X
Dog X X X
Rat X X X
Mouse X X X X X
NHP X
§: includes translational read through drugs, retinoids, neuroprotection.
$: includes gene addition, gene silencing, gene editing.
*: includes studies on cellular tropism, vector distribution, and host immune responses to AAV-,    
    lentivirus-, adenovirus- and nanoparticle-mediated gene transfer.
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2/8, and 2/9 (either tyrosine-mutated or not), differ among several large animal model 
species such as cat, dog and pig (Manfredi et al., 2013; Minella et al., 2014; Mowat et al., 
2014; Stieger et al., 2008).
Thanks to the experiences gained with different viral vectors in the aforementioned 
species, a set of AAV vector tools is now present for targeting photoreceptor cells and 
RPE, and researchers are able to choose among more than a dozen different serotypes 
and isolates. With the increasing focus of translating preclinical proof-of-concept stud-
ies to the clinic, it becomes more and more an issue to identify the most optimal AAV 
serotype for expression of transgenes in primate photoreceptors. Following several 
studies with sometimes contradictory results, it seems that AAV serotype 9 may be 
the most efficient vector to target photoreceptors (both rods and cones) and RPE cells 
following subretinal injection (Vandenberghe et al., 2013). Targeting exclusively RPE 
cells was shown to be possible using AAV serotype 4 in all species tested so far (Weber, 
2003). There is at present no vector known to exclusively target photoreceptor cells 
following subretinal injection.
Lentivirus-based vectors are usually pseudotyped with the vesicular stomatitis virus 
glycoprotein (VSVG), which has been shown to target predominantly RPE cells, but also 
allows photoreceptor transduction in mice and rats (Calame et al., 2011; Duisit et al., 
2002). Other pseudotyping approaches, such as hemagglutinin (HA) or venezuelean 
equine encephalitis virus (VEEG), did so far not show an advantage, regardless of the 
species tested (Duisit et al., 2002; Lipinski et al., 2014).
Since subretinal injections only allow to target a locally defined area of the retinal 
surface, the treatment of the entire retina by this transfer approach is not possible. A 
second way of introducing vectors to the retina represents the intravitreal approach, 
through which at least theoretically the entire retina can be brought into contact with 
the vector. Unfortunately, none of the standard AAV serotypes or lentivirus-based vec-
tors is capable of transducing a significant number of photoreceptor or RPE cells via this 
approach. The AAV serotype 2 showed significant transduction of retinal ganglion cells, 
which does not help for specific gene therapy of photoreceptor or RPE cells (Dudus et 
al., 1999). The reason is seen in the ILM barrier, which hampers an efficient invasion of the 
retina by most AAV serotypes (Dalkara et al., 2009). Recently however, in vivo directed 
evolution of AAV capsids allowed the generation of AAV vectors with the capacity to 
target most retinal cell types panretinally in mice and at certain spots in NHP following 
intravitreal injection (Dalkara et al., 2013). At least in mice, transgene expression in 
photoreceptor cells was sufficiently high to change the phenotype of several IRD mod-
els (rs1h-/- and rd12). However, since there is no IRD model in NHP, it is unknown how 
the efficacy of intravitreal injection concerning photoreceptor transduction would be 
in degenerative retinae of humans. A different approach, using again capsid-modified 
variants where tyrosine or phenylalanine residues were mutated, likewise yielded AAV 
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capsid mutants able to transduce photoreceptors following intravitreal injection in mice 
(Kay et al., 2013).
Although a panretinal transduction of retinal cells is likely only possible following 
intravitreal injection, this transfer approach may be blocked by the immune system, 
which is more effective in responding to foreign proteins in the vitreous compared to 
the subretinal space. Especially in NHPs, where the immune system is similar to the 
human one, immune reactions against capsid proteins following intravitreal injection 
were recently observed (Kotterman et al., 2014). 
5.2  The impact of anatomical differences on gene transfer
As discussed in sections 1 and 2, primates possess a foveal depression that exclusively 
contains cones with long dendrites (Henle fibers) and the inner retinal layers, and have a 
comparably large eye and a small lens, which results in a high axial length ratio between 
eye globe and lens (Table 1). These anatomical differences hinder the advancement of 
preclinical studies and are currently at the height of translational research. 
Since there is no foveal depression in any of the animal models for IRD, the subretinal 
injection cannot be studied preclinically in diseased retinae and therefore always poses 
an unknown risk factor. While foveal subretinal injections in healthy primates do not re-
sult in significant destruction, the data from clinical trials on RPE65 gene augmentation 
therapy indicate that a foveal treatment may not be beneficial (Jacobson et al., 2012). 
In contrast, another study related to treatment of patients with choroideremia observed 
no unwanted side effects in treated patients (MacLaren et al., 2014). 
While a panretinal transduction is possible in mice following intravitreal injection of 
AAV serotype 2 or the newly generated capsids, the situation in NHP is more complex. 
Here, a relatively strong transduction of the macular ring of ganglion cells surrounding 
the fovea can be observed, which may be due to a different molecular composition of 
the ILM in this zone compared to more peripheral parts of the retina (Yin et al., 2011). 
Alternatively, the tyrosine-mutated AAV serotype 9 vector was shown to transduce the 
central nervous system following systemic administration in mice, and combined with 
a rhodopsin promoter, transgene expression was limited to retinal photoreceptor cells 
(Dalkara et al., 2012). It remains to be seen, whether this observation is similar in large 
animal models.
6. COnCLUDInG REMARKS
In this review, we have attempted to provide a comprehensive overview on the 
use of animal models in functional and therapeutic research on IRD, and discuss the 
lessons learned so far by comparing the genetic architecture, and the gross and fine 
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structural and functional characteristics of the retina in different species. Obviously, the 
human retina has clear anatomical differences with most animal models considered so 
far. However, the anatomy is not the only major feature important for deciding which 
model species would be the ideal one for a given question. The possibilities to generate 
transgenic or genetically modified animals may sometimes outweigh the differences 
in ocular and retinal anatomy. Or, the absence of a phenotype in a certain species may 
prevent this model from being used for therapeutic research. While the pros and cons of 
each animal model are summarized in Fig. 4, the following section attempts to address 
a number of questions that need to be answered when deciding for the optimal model 
species for a given research question. 
When studying the phenotype of IRDs, the eye size or the ratio between lens and 
visual axis may not impact the outcome as much as it would be the case when studying 
therapeutic approaches. However, since most animal models for IRDs will be used at 
some point for therapeutic applications, this question needs to be answered in the 
beginning. Generally, from the mouse onwards, techniques have been developed to 
reliably perform gene transfer to retinal cells. This may not be the case for the zebrafish, 
and was only once performed in chicken.
Apart from their different gross anatomy of the eye, zebrafish and chicken possess 
a higher number of cone photoreceptors, have double cones and oil droplets (chicken) 
which may interfere with the interpretation of data in cone-related disorders. On the 
other hand, all mammalian models except NHP only have two cone types and thus 
less than humans, which again may complicate analysis of cone-related disorders. In 
Chick Sheep Pig Cat Dog Rat/Mouse MacaqueZebrafish
Pros
Cons
- Generation time
- Lots of offspring
- Egg incubation into
any desired stage
- Ex utero
development
- Human eye size
- Area centralis
- Genetic modification 
- Human eye size
- Cone-dominant  
retina
- Genetic modification
- Human eye size
- Area centralis
- Many naturally 
occurring models
- Human eye size
- Area centralis
- Mutations similar to 
humans
- Many naturally
occurring models
- Genetic modification 
- Lots of offspring 
- Generation time 
- Genetic modification
- Housing
- Lots of offspring
- Generation time 
- Animal laws (≤5 dpf)
- Ex utero
development
- Evolutionary distinct
from human
- Photoreceptor
anatomy (oil
droplets)
- Poorly annotated 
genome
- Housing
- Regeneration time
- Tapetal structure 
complicates imaging
- Moderately 
annotated genome
- Housing
- Regeneration time
- Poorly annotated 
genome
- Housing
- Regeneration time
- Tapetal structure 
complicates imaging
- Moderately 
annotated genome
- Housing
- Regeneration time
- Tapetal structure 
complicates imaging
- Moderately 
annotated genome 
- Nocturnal
- Photoreceptor
anatomy (calyceal
processes)
- Evolutionary distinct
from human
- Largely duplicated
genome
- Retinal regeneration
capacity
- Ectothermic
- Human eye size
- Anatomically similar 
to humans
- No IRD model 
existing
- Moderately
annotated genome
- Ethical restrictions
Figure 4. Summary of pros and cons of nine species for research on IRD. Per species, the most 
prominent pros and cons are listed. These include general characteristics, as well as retina- or IRD-
specific features.
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addition, only the large animal models cat, dog, sheep, and pig possess an area centralis 
corresponding at least in part to the cone-only foveal region in humans. Studying cone-
rod or pure cone dystrophies will always be biased in the remaining model species, 
since a cone-enriched region does not exist and the interaction between rods and cones 
may complicate analysis of data. 
Several animal models possess a tapetal structure behind the retina that increases 
photon capture by the photoreceptors through the reflection of light. This may increase 
photopic stress to the diseased retina and results in localized differences of neuronal 
cell death among the different photoreceptor cell types, which was at least suggested 
by a recent study in a dog model of RPE65 insufficiency (Klein et al., 2014). In addi-
tion, the presence of this reflecting structure renders OCT imaging, which is more and 
more accepted as a tool for in vivo thickness measurements, problematic (McLellan and 
Rasmussen, 2012).
A major drawback for IRD research in large animal models is the slow reproduction 
rate and the high costs of housing of these animals. While it takes only few weeks 
to generate hundreds of zebrafish or chicken, and few months to have double-digit 
numbers of mice and rats, it takes between 6 months and a year to generate a small 
number of offspring in cats, dogs, sheep or pigs. Hence, research on the phenotype 
of IRDs, let alone therapeutic research in these large animal species is cost-intensive 
and requires a significant time investment. However, the human size of their eye, the 
similarity of their immune system to the human one, and the possibility to work with 
vector titers close to what will be injected in human patients warrants the use of large 
animals for therapeutic research.
Special features related to the photoreceptor structure such as calyceal processes 
can be found in species that are considered to be closely related to humans (pig) but 
also in evolutionary distant species like zebrafish. Since this structure has recently 
gained attention in the scientific community due to the localization of certain Usher 
syndrome proteins, it became clear that when working on these disorders, choosing the 
right models species is crucial. Mice do not possess such calyceal processes and a lack 
of phenotype development in mouse models of the disease became understandable. 
As discussed in section 2.3, and shown in Fig. 3, certain genes are either duplicated 
or not present at all in the genome of some species, and therefore cannot be studied in 
these species. For instance, EYS, one of the most frequently mutated genes in patients 
with autosomal recessive RP (Abd El-Aziz et al., 2008; Collin et al., 2008) is not present 
in the rodent genome, and has prevented a better understanding on the mechanisms 
underlying EYS-associated IRD. A detailed knowledge on the absent and duplicated 
genes in the selected vertebrate species as provided here (Fig. 3 and Supplemental 
Table 1) may potentially avoid the generation of animal models without a phenotype, 
and instead guide scientists to using alternative model species.
83
The pros and cons of vertebrate animal models for functional and therapeutic research on inherited retinal dystrophies
Ch
ap
te
r 2
a
Because vertebrate animal models all have limitations in their use to study IRDs, 
the search for alternatives to model ocular disorders is a very active one. With the 
development of a technique to induce pluripotency in somatic cells (i.e. to generate 
induced pluripotent stem cell (ipSC) out of adult somatic cells) and differentiate these 
into any given cell type, and thus to have the principal capacity to generate photorecep-
tor or RPE cells from patients suffering from IRDs has gained much attention in recent 
years (Wiley et al., 2015). These cells contain the exact same mutation present in the 
human patients and therefore, the specific consequences can be studied in the affected 
cell type. Furthermore, gene editing technology allows to correct the mutation and to 
observe the consequences this treatment has on the intracellular pathways. Over all, 
the use of ipSCs to study pathomechanisms of IRD represents an important alternative 
to in vivo animal studies, but limitations are also eminent. While the advantage of this 
technique is obvious, the organ-specific influences and the interaction with other cells, 
the consequences of altered cell function on the surrounding cells and the immune 
system cannot be extensively studied using this approach, and it will therefore not be 
able to fully replace animal experimentation.
With the increasing knowledge about the genetic causes of retinal blinding disorders 
in men, the use of vertebrate animal models becomes more and more important, not 
only for studying the pathophysiological mechanisms but also to develop therapeutic 
strategies. While a number of different species have been used for modeling IRDs, it 
became clear that not every species can be used for a given genetic defect. The present 
review aimed at generating a comprehensive overview on the currently used animal 
models and to identify pros and cons for each species. Only when the ideal animal 
model system for a given question is chosen, optimal output can be generated from 
in vivo experiments, which will serve both human health and will prevent unnecessary 
research on animals, an ethically important goal to achieve. 
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SUPPLEMENTAL TABLES
Supplemental Table 1. Duplicated IRD genes in the zebrafish genome.
ABCA4
ACBD5
C12orf65
CA4
CACNA1F
CACNA2D4
CAPN5
CDHR1
CNGA1
CNGA3
CNGB1
CNGB3
CNNM4
COL11A1
COL2A1
COL9A1
CSPP1
CYP4V2
DFNB31
EFEMP1
ELOVL4
FSCN2
GDF6
GPR179
GPR98
GRK1
GRM6
GUCA1A
GUCY2D
IMPDH1
IMPG1
ITM2B
JAG1
KCNV2
KIAA1549
LRIT3
MYO7A
NR2F1
OPA1
OPN1LW
OPN1MW
PAX2
PCDH15
PCYT1A
PDZD7
PROM1
PRPH2
RGR
RGS9
RIMS1
RLBP1
ROM1
RPE65
RPGR
RS1
SAG
SEMA4A
SLC7A14
TEAD1
TMEM237
TOPORS
TRPM1
TULP1
UNC119
USH1G
VCAN
WFS1
Supplemental Table 2. Overview of vertebrate mutant animal models used in IRD research. This 
table can be found online using the following link: https://doi.org/10.1016/j.preteyeres.2015.04.004

Chapter 2b
Usherin defects lead to early-onset 
retinal dysfunction in zebrafish
M. Dona1,2*, R.W.N. Slijkerman1,2*, K.M. Lerner3, S. Broekman4,5, J. Wegner3, T.A. Howat3, T. Peters1,5, L. 
Hetterschijt1,5, N. Boon4, E. de Vrieze1,5, N. Sorusch6, U. Wolfrum6, H. Kremer1,4,5, S.C. Neuhauss7, J. Zang7, 
M. Kamermans8, M. Westerfield3,#, J.B. Phillips3,# and E. van Wijk1,5,#
* The first two authors are co-first authors.
# The last three authors are co-last authors.
1 Department of Otorhinolaryngology, Radboud university medical centre, Nijmegen, the Netherlands.
2 Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands.
3 Institute of Neuroscience, University of Oregon, Eugene, Oregon, United States of America.
4 Department of Human Genetics, Radboudumc, Nijmegen, the Netherlands.
5 Donders Institute for Brain, Cognition, and Behaviour, Nijmegen, the Netherlands.
6 Institute of Molecular Physiology, Johannes Gutenberg University, Mainz, Germany.
7 University of Zurich, Institute of Molecular Life Sciences, Zurich, Switzerland.
8 Retinal Signal Processing Lab, Netherlands Institute for Neuroscience, Amsterdam, The Netherlands. 
Published in Experimental Eye Research, 2018
doi: https://doi.org/10.1016/j.exer.2018.05.015 
PMID: 29777677
Chapter 2b
106
ABSTRACT
Mutations in USH2A are the most frequent cause of Usher syndrome and autosomal 
recessive nonsyndromic retinitis pigmentosa. To unravel the pathogenic mechanisms 
underlying USH2A-associated retinal degeneration and to evaluate future therapeu-
tic strategies that could potentially halt the progression of this devastating disorder, 
an animal model is needed. The available Ush2a knock-out mouse model does not 
mimic the human phenotype, because it presents with only a mild and late-onset 
retinal degeneration. Using CRISPR/Cas9-technology, we introduced protein-truncating 
germline lesions into the zebrafish ush2a gene (ush2armc1: c.2337_2342delinsAC; 
p.Cys780GlnfsTer32 and ush2ab1245: c.15520_15523delinsTG; p.Ala5174fsTer). Homozy-
gous mutants were viable and displayed no obvious morphological or developmental 
defects. Immunohistochemical analyses with antibodies recognizing the N- or C-termi-
nal region of the ush2a-encoded protein, usherin, demonstrated complete absence of 
usherin in photoreceptors of ush2armc1, but presence of the ectodomain of usherin at 
the periciliary membrane of ush2ab1245-derived photoreceptors. Furthermore, defects 
of usherin led to a reduction in localization of USH2 complex members, whirlin and 
Adgrv1, at the photoreceptor periciliary membrane of both mutants. Significantly 
elevated levels of apoptotic photoreceptors could be observed in both mutants when 
kept under constant bright illumination for three days. Electroretinogram (ERG) record-
ings revealed a significant and similar decrease in both a- and b-wave amplitudes in 
ush2armc1 as well as ush2ab1245 larvae as compared to strain- and age-matched wild-type 
larvae. In conclusion, this study shows that mutant ush2a zebrafish models present 
with early-onset retinal dysfunction that is exacerbated by light exposure. These models 
provide a better understanding of the pathophysiology underlying USH2A-associated 
RP and a unique opportunity to evaluate future therapeutic strategies.
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INTRODUCTION
Usher syndrome is a rare genetic condition characterized by hearing impairment 
and a progressive loss of visual function as a consequence of Retinitis Pigmentosa (RP). 
The latter often results in legal blindness by the sixth decade of life (Sandberg et al., 
2008). Currently there are no treatments for retinal degeneration in patients with Usher 
syndrome, although they benefit from hearing aids or cochlear implants. Usher syn-
drome is classified into three types (USH1, USH2 and USH3), varying in severity of hear-
ing impairment, age at which RP is diagnosed, and presence or absence of vestibular 
dysfunction (Tazetdinov et al., 2008). Approximately two-thirds of USH patients present 
with USH2 (Millan et al., 2011), up to 85% of whom can be explained by mutations in 
USH2A (McGee et al., 2010; Yan and Liu, 2010). Mutations in USH2A are also the most 
frequent cause of autosomal recessive RP (arRP), accounting for 7-23% of arRP cases 
(McGee et al., 2010). Approximately 600 different, mostly private, mutations are evenly 
distributed over the gene and include point-nonsense, frame-shift, splice-modulating, 
and missense variants 6. However, there are a number of mutations that originate from 
a common ancestor and are therefore observed more frequently (Aller et al., 2010; Baux 
et al., 2014; Pennings et al., 2004). The two most commonly found USH2A mutations 
are c.2299delG; p.Glu767fs and c.2276G>T; p.Cys759Phe, both residing in exon 13. 
Bi-alellic truncating defects of USH2A (nonsense mutations, frameshift mutations, or 
mutations that affect splicing), most often result in USH2, whereas the presence of at 
least one hypomorphic USH2A allele generally results in non-syndromic arRP (Lenassi 
et al., 2015). The distribution of known mutations and neutral variants from the LOVD 
database for USH2A does not reveal a particular mutation tolerant or intolerant region 
of the gene that could pinpoint particularly important functional domains (Baux et al., 
2014). Despite ongoing efforts, little is known about either the physiological role(s) of 
the usherin protein in photoreceptors or the pathophysiological mechanism underlying 
USH2A-associated RP (Hartong et al., 2006; McGee et al., 2010).
The USH2A transcript in retina consists of 72 exons and encodes a protein of 5,202 
amino acids (usherin) (Adato et al., 2005; van Wijk et al., 2004). Moreover, a cochlea-
specific exon has been identified between exons 70 and 71 that encodes 24 additional 
amino acids (Adato et al., 2005). Usherin contains an N-terminal signal peptide, a Lam-G 
like domain, a LamNT domain, 10 EGF-lam domains, 4 FN3 domains, two laminin G 
(LamG) domains, 28 FN3 domains, a transmembrane domain, and a short intracellular 
region with a C-terminal class I PDZ-binding motif. It is generally thought that usherin 
has a structural role at the periciliary region of the photoreceptor, where it is held in 
place via its interactions with harmonin (USH1C encoded), SANS (USH1G encoded) and 
whirlin (WHRN encoded, USH2d) (Chen et al., 2014; Reiners et al., 2005; Sorusch et al., 
2017; van Wijk et al., 2006; Yang et al., 2010; Zou et al., 2011). At the periciliary region, 
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usherin possibly stabilizes the photoreceptor connecting cilium by an extracellular 
interaction with Adhesion G protein-coupled receptor V1 (ADGRV1; previously known 
as GPR98 or VLGR1) (Adato et al., 2005; Liu et al., 2007; Maerker et al., 2008; Overlack 
et al., 2011).
Understanding the molecular mechanisms underlying photoreceptor dysfunction in 
USH2A-associated RP and the development of treatment strategies have been severely 
hampered by the absence of suitable cellular or animal models mimicking the human 
phenotype. Although mutant mouse models are commonly used to study RP and test 
therapeutic strategies, for USH and several other types of RP the retinal phenotypes 
in mouse models do not mimic that of patients with defects in the orthologous genes 
(Slijkerman et al., 2015). In contrast, retinal dysfunction from a very young age is ob-
served in zebrafish USH1 gene mutants (Blanco-Sanchez et al., 2017). Zebrafish larvae 
lacking Myo7aa (USH1b), harmonin (USH1c) or Pcdh15b (USH1f) function show reduced 
electroretinogram (ERG) traces by 5 to 7 days post fertilization (dpf) (Phillips et al., 2011; 
Seiler et al., 2005; Wasfy et al., 2014). Additionally, photoreceptor-specific degeneration 
has been shown to occur in ush2a depleted morphant larvae (Ebermann et al., 2010) as 
well as in myo7aa mutant larvae exposed to elevated light levels (Wasfy et al., 2014).
In this study, we generated and characterized two ush2a mutant zebrafish models (ush-
2armc1: c.2337_2342delinsAC; p.Cys780GlnfsTer32 and ush2ab1245: c.15520_15523delinsTG; 
p.Ala5174fsTer) to study usherin function in the retina. Subsequent functional analyses 
showed that usherin is absent from photoreceptors in ush2armc1, but that the extracel-
lular domain of usherin can still be detected at the periciliary membrane of ush2ab1245-
derived photoreceptors. The levels of usherin interaction partners Whrna and Whrnb 
(whirlin) are reduced at the photoreceptor periciliary membrane of homozygous 
ush2armc1 larvae, whereas in homozygous ush2ab1245 larvae only the level of Whrna is 
affected. Furthermore, mutant zebrafish display elevated levels of apoptotic cells in the 
outer retina as compared to strain and age-matched wild-type zebrafish upon constant 
light rearing. We further found that ERG traces are notably attenuated in both mutants, 
indicating impaired outer retinal function. These mutants are the first genetic animal 
models for ush2a that present with early-onset retinal dysfunction.
MATERIALS AND METHODS
Zebrafish maintenance and husbandry
Experimental procedures were conducted in accordance with international and in-
stitutional guidelines (Dutch guidelines, protocol #RU-DEC 2012-301; Swiss guidelines, 
Veterinäramt Zürich TV4206 and University of Oregon IACUC guidelines). Wild type 
adult Tupfel Long fin (TLF) or Oregon AB* zebrafish were used. The zebrafish eggs were 
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obtained from natural spawning of wild-type or mutant breeding fish. Larvae were 
maintained and raised by standard methods (Kimmel et al., 1995).
CRISPR/Cas9 design and microinjection
For the ush2armc1 allele, oligos for generating guide RNAs were designed using the 
ZiFiT targeter software (Sander et al., 2007). Oligos were subsequently ordered from In-
tegrated DNA Technologies. Annealing of oligos was performed in a buffer (1 M NaCl, 10 
mM EDTA and 100 mM Tris-HCl pH7.5) by incubation at 90°C for four minutes, followed 
by a ten minute-incubation step at 70°C and gradual cooling (5°C per two minutes) 
to 16°C. The annealed oligos were immediately ligated into the a BsaI (New England 
Biolabs, #R0535S) linearized pDR271 vector (Addgene plasmid #42250) using T4 ligase 
(New England Biolabs, #M0202). The oligo and surrounding sequences were excised 
from the pDR274 vector using DraI (New England Bioloabs, #R0129S). The excised DNA 
band (284 basepairs) was subsequently used as a template for in vitro transcription using 
the MAXIscript® T7 Transcription Kit (Ambion life technologies, #AM1314) according 
the manufacturer’s protocol. Obtained transcripts were purified using the MEGAclear™ 
Transcription Clean-Up Kit (Ambion life technologies, #AM1908). For the ush2ab1245 al-
lele, gene specific oligos were designed by flanking the 20 bp target sequence with T7 
promoter and gRNA sequence: 5`-AATTAATACGACTCACTATA-[20 bp Target Sequence]-
GTTTTAGAGCTAGAAATAGC-3`. The templates for gRNA syntheses were PCR amplified 
using the gene specific oligo with a gRNA scaffolding primer: 5`-GATCCGCACCGACTC-
GGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTA-
AAAC-3`. As input 13.4 µl water, 4ul 5x Phusion DNA polymerase buffer, 0.4 µl dNTPs 
(10 µM), 1 µl of gene specific oligo (10 µM), 1 µl of gRNA scaffold oligo (10 µM), 0.2 µl 
Phusion DNA polymerase. The cycling conditions were as follows: 98°C 30 seconds, 40 
cycles of 98°C 10 seconds, 60°C 10 seconds, 72°C 15 seconds and 72°C 10 minutes. PCR 
products were column purified and used to prepare gRNA with the Ambion T7 mega-
script kit (AM1344) as per manufacturer’s instructions. A zebrafish codon-optimized 
Cas9 containing vector (pT3TS-nCas9n; Addgene plasmid #46757) was used to generate 
Cas9 mRNA. The vector was linearized using XbaI (NEB, #R0145S) and used as a template 
for an in vitro transcription reaction using the mMESSAGE mMACHINE® T3 Transcrip-
tion Kit (Ambion life technologies, #AM1348) according to manufacturer’s instructions. 
Transcripts were purified using the MEGAclear™ Transcription Clean-Up Kit (#AM1908). 
Zebrafish embryos at a 1-cell stage were injected with 1 nl of a mixture containing 
gRNA (6 ng/µl), Cas9 mRNA (150 ng/µl), KCl (0.2 M) and phenol red (0.05%) using a 
Pneumatic PicoPump pv280 (World Precision Instruments) for the generation of the 
ush2armc1 allele. To generate the ush2ab1245 allele, one-cell stage zebrafish embryos were 
injected with 1 nl of a mixture containing gRNA (100 ng/µl), Cas9 mRNA (150 ng/µl), 
KCl (0.2 M) and phenol red (0.05%) using an MPPI-2 Pressure Injector with a BP-15 
Chapter 2b
110
Back Pressure Unit (Applied Scientific Instrumentation, Oregon USA). After injection, 
embryos were raised at 28.5°C in E3 embryo medium (5 mM NaCl, 0.17 mM KCl, 0.33 
mM CaCl2, 0.33 mM MgSO4), supplemented with 0.1% (v/v) methylene blue. At 2.5 days 
post fertilization, part of the injected embryos were analyzed for the presence of de-
sired mutational events. When mutations could be detected, the remainder of injected 
embryos was raised.
Genotyping
Genomic DNA was isolated from pools of 15 larvae after incubation in 75 µl lysis 
buffer (10 mM Tris HCl pH=8.2, 10 mM EDTA, 100 mM NaCl and 0.5 % SDS) supple-
mented with freshly added proteinase K (final concentration of 0.20 mg/ml, Invitrogen 
#25530049) at 55oC for two hours. The isolated genomic DNA was subsequently used 
as a template in a PCR. Primers used for the amplification of ush2a exon13 are 5’-TC-
CACCAACAGAATCTAAATCTTTC-3’ and 5’-CTGATTTGTAAATGGTGTTGGG-3’ and primers 
used for the amplification of ush2a exon71 are 5’-CATGTTTTGGTTATCTGTTCTTCT-3’ 
and 5’-GACAGCGGAATGGTGAGATAAAC-3’. The obtained amplicons were cloned into a 
pCR®4-TOPO® vector (Invitrogen, #450030) according to manufacturer’s instructions. 
Individual clones were analyzed for the presence of mutational events using the ABI 
PRISM Big Dye Terminator Cycle Sequencing V2.0 Ready Reaction kit and the ABIPRISM 
3730 DNA analyzer (Applied Biosystems).
Transcript analysis
Pools of 15 larvae were snap frozen in liquid nitrogen and subsequently homog-
enized in 500 µl QIAzol (Qiagen, #79306) using a 25 gauge 16 mm needle. Total RNA 
was isolated using phenol:chloroform extraction and precipitated using isopropanol. 
Extracted total RNA was further purified and DNAse treated using a NucleoSpin® RNA 
II Isolation kit (Macherey-Nagel, #740955.50, Düren, Germany) according to manufac-
turer’s protocol. Subsequently, 0.5-1.0 µg of total RNA was used as a template for cDNA 
synthesis using SuperScript III RT (Life Technologies, #11755050, Carlsbad (California) - 
United States). An ush2a amplicon (1096 bp) of homozygous rmc1 larvae was amplified 
using with primers located in exon11 (5’-AGCGCTGTCGGAGTCTCTTC-3’) and exon14 
(5’-CCATCACTGACCGGTCACAG-3’). An ush2a amplicon (710 bp) of homozygous b1245 
larvae was amplified using primers located in exon68 (5’-TGGACTGGAGTGGCTCTTTC-3’) 
and exon73 (5’-GATGAGGACTTTGGAGAGACCA-3’). 
Antibodies and Immunohistochemistry 
Dissected adult eyes (12-18 mpf) and larval zebrafish (4-6 dpf) from homozygous 
ush2armc1 and ush2ab1245 mutants and their age and strain-matched wild-type controls 
were cryoprotected with 10% sucrose in PBS for 30 minutes prior to embedding in 
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OCT compound (Tissue-Tek, 4583, Sakura). After embedding, samples were slowly 
frozen down using melting isopentane. To assess retinal morphology, cryosections 
(seven µm thickness along the lens/optic nerve axis) were fixed for 10 minutes with 
paraformaldehyde (PFA) 4%, stained with hematoxylin and eosin and analysed on a 
Zeiss Axioskop light microscope. For analysis by scanning confocal microscope, em-
bryos were fixed in 4% PFA overnight at 4°C, washed 3x in PBS-T, dehydrated in 100% 
methanol, rehydrated in descending methanol series and washed several times in PBS-T 
before being cryoprotected in 30% sucrose for several hours at room temperature. 
Larvae were then embedded in molten agarose blocks, frozen, and sectioned on a 
cryomicrotome. For immunofluorescence on unfixed cryosections (seven µm thickness) 
were permeabilised for 20 minutes with 0.01% Tween20 in PBS. Sections were rinsed 3 
times for 5 minutes with PBS and blocked for 1 hour with blocking buffer (10% normal 
goat serum and 2% bovine serum albumin in PBS). Antibodies diluted in blocking buffer 
were incubated overnight at 4 °C. Secondary antibodies were also diluted in blocking 
buffer and incubated together with DAPI (1:8000; D1306; Molecular Probes) for 1 hour. 
Sections were post fixed with PFA 4% for 10 minutes and mounted with Prolong Gold 
Anti-fade (P36930; Molecular Probes). For immunofluorescence on fixed cryosectioned 
tissue (16µm thickness), slides were hydrated 10 minutes in PBS-T, then immersed in 
Sodium Citrate solution at pH 8.5 and heated in a pressure cooker for 10 minutes. After 
cooling to 37°C, slides were washed twice in PBS-T, blocked in 10% NFDM in PBS-T and 
incubated with primary antibodies. The following primary antibodies and dilutions were 
used: rabbit anti-active caspase 3 (1:500; #559565; BD Pharmingen), rabbit anti-Whrnb 
(1:300; #42690002 Cip98a; Novus Biological), rabbit anti-Whrna (1:300; #42700002 
Cip98b; Novus Biological), rabbit anti-usherin-C (1:500; #27640002; Novus Biological), 
rabbit anti-Adgrv1 (1:1000) (Ebermann et al., 2010) and as marker for connecting cilium 
region in photoreceptor cells we used mouse anti-centrin (1:500; # 04-1624; Millipore) 
or acetylated α-tubulin (Sigma T7451). Secondary antibodies (Alexa Fluor 568 goat anti-
rabbit (A11011), Alexa Fluor 488 goat anti-guinea pig (A11073) and Alexa Fluor 488 
goat anti-mouse (A11029)), derived from Molecular Probes, were used in a 1:800 dilu-
tion. Images were taken using a Zeiss Axio Imager fluorescence microscope equipped 
with an AxioCam MRC5 camera (Zeiss) or a Zeiss LSM5 Confocal. The intensity of Whrna 
and Whrnb immunofluorescence was measured in FIJI version 1.47v 58 . First, the outer 
segment layer was isolated based on the centrin immunostaining. Subsequently, a mask 
was made based on the centrin staining using the “Find Maxima” option (noise=50), and 
dilated five times. To find the exact location of Whrna or Whrnb staining, the centrin 
mask and Whrn layer were combined. Find Maxima (noise=10) was used to identify the 
Whrn staining within the Centrin mask. The resulting mask was dilated three times and 
touching objects were separated using the watershed option. Subsequently, the maxi-
mum gray value of the identified regions was measured on the original image of Whrn 
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immunofluorescence (Analyze Particles option; size=0-50, pixel circularity=0.00-1.00). 
Active caspase-3 labeled cells were analyzed on a Zeiss fluorescence microscope by 
manually counting positively stained cells in the ONL. 
Constant light rearing
For constant light treatment, embryos were raised in transparent 10-cm petri dishes 
under normal conditions and were placed under constant light from 5-8 dpf. From 5 dpf 
onwards, ush2armc1 larvae were either maintained in facility conditions of 300 lux white 
light in a 14/10h day/night rhythm or were exposed to continuous white light with an 
intensity of 3000 lux, using a 150 W LED light source (Zeiss). ush2ab1245 larvae were either 
maintained in facility conditions of 300 lux white light in a 14/10h day/night rhythm 
or were exposed to continuous white light with an intensity of 3000 lux using two LED 
strips (Westek) mounted in parallel. Light input: 12V DC, transformer input 120V ~60Hz, 
transformer output 12V DC, 6W max. Light intensities were measured at water level 
using a lumino meter (Testo 540, Lenzkirch, Germany or Advanced Light Meter 840022, 
Sper Scientific, Arizona, USA).
Fixation and pre-embedding labeling for immunoelectron microscopy 
For immunoelectron microscopy of adult zebrafish retinas, we followed the previ-
ously published protocol for pre-embedding labeling (Maerker et al., 2008; Sedmak et 
al., 2009; Sedmak and Wolfrum, 2010). In brief, rabbit anti-usherin C (1:500; #27640002; 
Novus Biological) was applied on vibratome sections of pre-fixed (4% PFA) murine 
eye-cups, followed by incubation with biotinylated secondary antibodies. Antibody 
reactions were visualized by a Vectastain ABC-Kit (Vector Laboratories) and 0.01% 
hydrogen peroxide to 0.05 M diaminobenzidine (DAB) solution was added. Stained 
retinas were fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4), followed 
by silver enhancement of DAB precipitates and post-fixation in cacodylate buffered 
0.5% OsO4 on ice. Dehydrated specimens were flat-mounted between two sheaths 
of ACLAR-films (Ted Pella Inc., Redding, USA) in Araldite resin. Ultrathin sections were 
made using a Reichert Ultracut S ultramicrotome (Leica), collected on Formvar-coated 
copper or nickel grids and counterstained with 2% uranyl acetate in 50% ethanol aund 
aq. 2% lead citrate. Ultrathin sections were analysed in a Tecnai 12 BioTwin transmission 
electron microscope (FEI, Eindhoven, The Netherlands). Images were obtained with a 
CCD camera (charge-coupled-device camera; SIS MegaView3; Surface Imaging Systems, 
Herzogenrath, Germany) and processed with Adobe Photoshop CS (Adobe Systems).
Electroretinogram (ERG) recordings
ERG recordings were performed on isolated larval eyes (5-7 dpf) as previously de-
scribed (Sirisi et al., 2014). Larvae were dark-adapted for a minimum of 30 min prior to 
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the measurements and subsequently handled under dim red illumination. The isolated 
eye was positioned to face the light source. Under visual control via a standard micro-
scope equipped with red illumination (Stemi 2000C, Zeiss, Oberkochen, Germany), the 
recording electrode with an opening of approximately 20 µm at the tip was positioned at 
the center of the cornea. This electrode was filled with E3 embryo medium (5 mM NaCl, 
0.17 mM KCl, 0.33 mM CaCl, and 0.33 mM MgSO4). The electrode was positioned using a 
micromanipulator (M330R, World Precision Instruments Inc., Sarasota, USA). A custom-
made stimulator was invoked to provide light pulses of 100 ms duration, with a light 
intensity of 6000 lux. It uses a ZEISS XBO 75W light source and a fast shutter (Uni-Blitz 
Model D122, Vincent Associates, Rochester, NY, USA) driven by a delay unit interfaced 
to the main ERG recording setup. Electronic signals were amplified 1000 times by a 
pre-amplifier (P55 A.C. Preamplifier, Astro-Med. Inc, Grass Technology) with a band pass 
between 0.1 and 100 Hz, digitized by DAQ Board NI PCI-6035E (National Instruments) 
via NI BNC-2090 accessories and displayed via a self-developed NI Labview program 
(Rinner et al., 2005). Statistical analysis was performed using SPSS Statistics 22 (IBM All 
the experiments were performed at room temperature (~22°C).
Statistical analyses
The Graphpad Prism software (version 5.03 for Windows, GraphPad Software, La 
Jolla California USA, www.graphpad.com) was used to generate scatter plots, calculate 
mean values, and perform statistical analysis using two-tailed unpaired Student’s t-tests 
or two-tailed Mann-Whitney tests. 
RESULTS
Zebrafish and human usherin are highly conserved
Bioinformatic analyses of the zebrafish and human usherin protein sequence re-
vealed that the proteins have a high degree of sequence similarity (52% identity; 68% 
similarity) and share a similar protein domain architecture (Fig. 1). We characterized 
the subcellular localization of usherin in the zebrafish retina with an antibody directed 
against the intracellular C-terminal region of usherin (anti-usherin-C). In adult zebrafish 
retina, usherin is not only present at the periciliary membrane of both cones and rods, 
but also apical to the cone connecting cilium (Fig. 2A, B, C and Supplemental Fig. 1). 
Subsequent immunoelectron microscopy identified these structures as cone accessory 
outer segments (AOS) (Fig. 2D, E). AOS are structures that run along the photoreceptor 
outer segment and are predominantly found in cone photoreceptors of adult frogs and 
teleost fish (Januschka et al., 1987). 
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Generation of zebrafish ush2armc1 and ush2ab1245 mutants
Using CRISPR/Cas9 technology, we generated two ush2a mutant alleles (sequences 
in Supplemental Fig. 3). ush2armc1 contains a frameshift mutation in ush2a exon13 
(c.2337_2344delinsAC; p.Cys780GlnfsTer32), that is predicted to result in the premature 
termination of translation of usherin (Fig. 3A). ush2ab1245 harbors a frameshift mutation 
in ush2a exon71 (ENSDART00000086201.4; c.15520_15523delinsTG; p.Ala5174fsTer), 
predicted to encode an usherin protein that retains the transmembrane domain but 
lacks the C-terminal 62 amino acids of the intracellular region including the class I PDZ 
binding motif. This allele provides an opportunity to assess the functional importance 
of the intracellular region, including the PDZ-binding motif, relative to the ectodomain 
of usherin (Fig. 3A). Both homozygous mutants were viable and no abnormalities in 
morphology, development, or swimming behavior were observed.
ush2armc1 and ush2ab1245 do not affect ush2a pre-mRnA splicing
In patient-derived fibroblasts, the USH2A c.2299delG mutation results in skipping of 
USH2A exon12 and exon13 in some transcripts, or in skipping of exon13 only (Lenassi 
et al., 2014). Recent studies showed that CRISPR/Cas9-induced exonic lesions could also 
induce an (in-frame) skipping of the targeted exon thereby preventing generation of a 
functional knock-out model (Mou et al., 2017). If the lesion introduced in the ush2armc1 
mutant causes an in-frame skipping of exon 13, this could potentially result in expres-
sion of a shortened usherin with residual function. Similarly, the c.15520_15523delinsTG 
(ush2ab1245) mutation is predicted to disrupt an exonic splice enhancer site and poten-
tially induce skipping of exon71, thereby also leaving the ush2a open reading frame 
intact. We, thus, analyzed ush2a transcripts in homozygous ush2armc1 and ush2ab1245 
larvae to assess whether the introduced lesions would result in alternative ush2a pre-
mRNA splicing events. Amplicons spanning exon13 or exon71 and their surrounding 
exons were amplified by RT-PCR. Because no alternatively spliced ush2a transcripts 
were amplified from cDNA derived from homozygous ush2armc1 or ush2ab1245 larvae (Fig. 
3B, C), we expect that the introduced mutations in the rmc1 and b1245 alleles result in 
premature termination of usherin translation.
Signal peptide EGF-lam LamG FN3PDZ binding LamG-like LamNT TransmembraneLegend:
1 500 1000 1500 2000 2500 3000 3500 4000 4500 5000 5202
Cys-richHuman usherin 
Zebrafish usherin 
1 500 1000 1500 2000 2500 3000 3500 4000 4500 5000 5236
Cys-rich
Figure 1. Schematic presentation of zebrafish usherin. Motif alignment of human and zebra-
fish usherin. Both proteins have an identical predicted domain architecture. EGF-lam, laminin-type 
epidermal growth factor-like domain; LamG, laminin G domain; LamG-like, LamG-like jellyroll fold 
domain; LamNT, laminin N-terminal domain; FN3, fibronectin type 3 domain. 
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Figure 2. Usherin localizes at the periciliary membrane and accessory outer segments of adult 
zebrafish photoreceptor cells. (A) Retinal sections of wild-type adult zebrafish are labeled for ush-
erin (green signal) and the connecting cilium marker centrin (magenta signal). (B) Usherin labeling 
at the periciliary region of rod photoreceptors is present adjacent to the connecting cilium marked 
by centrin (indicated by an arrow head). (C) In cones, usherin is also detected at the periciliary region 
(arrow heads) as well as apical to the connecting cilium marked by centrin labeling (arrows). Nuclei 
were stained with DAPI (blue signal). (D, E) Electron microscopy images of adult zebrafish retinas 
show that usherin localizes at the periciliary membrane (arrowheads) as well as in the accessory outer 
segments (AOS; arrow) of cone photoreceptors. Scale bars in A: 10 µm; B: 3 µm; C: 3 µm; D: 1 µm E: 
0.1 µm. CC: connecting cilium, COS: cone outer segment, CP: calyceal processes, ONL: outer nuclear 
layer, OS: outer segment, ROS: rod outer segment, RPE: retinal pigment epithelium.
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Ush2armc1 leads to absence of usherin, whereas ush2ab1245 results in 
truncated usherin at the periciliary region
Using zebrafish-specific anti-usherin antibodies directed against the N- or C-termi-
nus of the protein, we evaluated the presence of usherin in the retina of homozygous 
ush2armc1 and ush2ab1245 larvae and strain-matched (TLF or AB*, respectively) wild-type 
larvae at 5 dpf. Anti-usherin-N is directed against an amino acid sequence present at the 
N-terminus of usherin. In wild-type larvae, both antibodies detected usherin adjacent 
to the basal body and connecting cilium marker, centrin (Fig. 4). In contrast, no usherin 
signal was detected in the retina of ush2armc1 mutant larvae using either anti-usherin 
antibody. Also in the retina of ush2ab1245 larvae, no signal was detected when using 
anti-usherin-C antibodies (Fig. 4A, B). However, a signal at the photoreceptor pericili-
ary region of homozygous ush2ab1245 larvae was obtained when using anti-usherin-N 
antibodies. These results suggest that the truncated usherin protein still localizes ap-
propriately at the membrane even though it lacks the C-terminal intracellular region and 
the PDZ binding motif (Fig. 4A, B). We conclude that ush2armc1 mutants completely lack 
usherin at the photoreceptor periciliary region and the mutation should be considered 
a true null allele, whereas ush2ab1245 should be considered a hypomorphic allele with 
potential residual function. 
1 500 1000 1500 2000 2500 3000 3500 4000 4500 5000 5236
Cys-rich
Zebrafish usherin
rmc1Zebrafish mutant ush2a
rmc1 (c.2337_2344delinsAC; p.Cys780GlnfsTer32) 
Zebrafish mutant ush2ab1245 (c.15520_15523delinsTG; p.Ala5174fsTer) 
    WT              Mut            mQ     WT              Mut             mQ
ush2armc1 ush2ab1245
Exon68>72Exon11>14
1096 bp
800 bp -
1200 bp -
1400 bp -
1000 bp -
500 bp -
700 bp -
800 bp -
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741 bp
B
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C
Figure 3. ush2a transcript analyses in homozygous ush2armc1 and ush2ab1245 mutant zebrafish. 
(A) The locations of the mutations in ush2armc1 and ush2ab1245 are schematically depicted. (B) RT-PCR 
analyses of ush2a transcripts derived from homozygous ush2armc1 or (C) homozygous ush2ab1245 lar-
vae (5 dpf) provided no indications for an effect of the introduced lesions on pre-mRNA splicing. WT: 
wild-type, Mut: homozygous mutant, mQ: milliQ water.
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Figure 4. Localization of usherin in frontal cryosections of wild-type and mutant zebrafish 
retinas (5 dpf). Zebrafish-specific anti-usherin-C (A) or anti-usherin-N (B) antibodies are employed 
(red signal). (A) In ush2armc1 as well as ush2ab1245 homozygous mutant larvae no signal was detected 
with the anti-usherin-C antibody, whereas in both TLF and AB* wild-type controls usherin was pres-
ent adjacent to the connecting cilium marked by centrin (green signal). (B) No signal was detected 
in the retina of homozygous ush2armc1 mutants using the anti-usherin-N antibody, however, a signal 
at the photoreceptor periciliary region was observed in the retina of homozygous ush2ab1245 larvae 
when this antibody was used. In wild-type controls, the anti-usherin-N antibody also detected ush-
erin at the photoreceptor periciliary region. (n= 35 larvae, from 5 biological replicates with TLF and 
ush2armc1 larvae, n= 64, from 8 biological replicates with AB* and ush2ab1245 larvae). Nuclei are stained 
with DAPI (blue signal). Scale bars: 10 µm.
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Ablation of usherin affects the localization of whrna and whrnb in the 
retina 
Human usherin was previously shown to interact directly with whirlin in vitro (van 
Wijk et al., 2006). The biological relevance of this interaction was confirmed by the 
absence of whirlin at the photoreceptor periciliary membrane of Ush2a knock-out mice 
(Yang et al., 2010). Here, we determined whether or not whirlin localization was also af-
fected in the retina of homozygous ush2armc1 and ush2ab1245 zebrafish larvae (5 dpf). The 
zebrafish genome harbors two whirlin-encoding orthologs. whrna (previously known as 
dfnb31a (ENSDARG00000075362)) encodes Whrna and whrnb (previously known as df-
nb31b (ENSDARG00000068166)) encodes Whrnb. Whrna was found to be located at the 
photoreceptor periciliary region in wild-type larvae (Fig. 5A and Supplemental Fig. 2). 
Reduced intensity of the Whrna signal was observed in the retinas of homozygous larvae 
of both ush2a mutants, which was further confirmed by quantification of fluorescence 
signal intensities (Fig. 5A). The same results were observed in homozygous ush2armc1 
larvae when an anti-Whrnb antibody was employed (Fig. 5B and Supplemental Fig. 
2). In contrast, the intensity of the Whrnb signal was unaltered in photoreceptors of 
homozygous ush2ab1245 larvae as compared to AB* wild-type larvae (Fig. 5B).
Zebrafish ush2a mutants exhibit elevated levels of photoreceptor apoptosis
Based on the assumption that usherin is required for long-term maintenance of 
photoreceptor cells, we assessed whether absence of usherin in the zebrafish retina 
would lead to increased levels of apoptosis in the outer nuclear layer (ONL). Larvae 
were raised under a 14/10 hours light/dark cycle until 5 dpf. After 5 dpf, they were either 
raised for an additional 72 hours in regular facility conditions of 300 lux light intensity 
of a 14hr/10hr light/dark cycle, or exposed to constant light with an intensity of 3000 lux 
for 72 hours. A slight but significant increase in the amount of apoptotic photoreceptor 
cells was observed in 8 dpf ush2armc1 larvae raised in normal facility conditions (Fig. 
6A). These results were consistent with our previously reported data on photoreceptor 
degeneration in larvae treated with a morpholino targeting an early splice junction 
in ush2a (Ebermann et al., 2010). Subsequently, we assessed the number of apoptotic 
events in ush2ab1245 mutant larvae. No significantly elevated levels of cell death in the 
ONL were observed when these larvae were raised under normal facility conditions 
(Fig. 6B). Constant light rearing with an elevated light intensity of 3000 lux significantly 
increased the amount of apoptotic cells in the ONL of both mutant alleles as com-
pared to their strain-matched wild-type controls (Fig. 6A, B). Variations in the genetic 
backgrounds of the rmc1 and b1245 alleles, variances in the light sources used in the 
elevated light exposure assay, and other environmental differences between the two 
facilities where these experiments were conducted could contribute to the observed 
difference in the absolute number of apoptotic cells. 
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Figure 5. Ablation of usherin affects the localization of whrna and whrnb in the zebrafish ret-
ina (5 dpf). (A) Intensity of Whrna labeling was significantly reduced in both ush2armc1 and ush2ab1245 
mutants as compared to corresponding wild-types (n=35 larvae from 5 biological replicates with 
ush2armc1 mutant larvae and TLF larvae, and n=54 larvae from 7 biological replicates with ush2ab1245 
mutant larvae and AB* larvae). Intensities of fluorescence using antibodies directed against Whrna 
(red signal) were quantified and plotted as scatter plots next to the corresponding images. Each dot 
represents the average grey-value per eye (n=5 ush2armc1 eyes and n=6 TLF larvae eyes, p<0.05 and 
n=10 ush2ab1245 and n=9 AB* eyes, p=<0.01, two-tailed unpaired Student’s t-test). (B) Whrnb labeling 
was reduced in ush2armc1 mutants, but unaltered in ush2ab1245 mutants compared to corresponding 
wild-types (n=35 larvae from 5 biological replicates with ush2armc1 mutant larvae and TLF larvae, and 
n=54 larvae from 7 biological replicates with ush2ab1245 mutant larvae and AB* larvae). Intensity of 
Whrnb labeling (red signal) was significantly reduced in ush2armc1 larvae as compared to wild-type 
(TLF) larvae (n=5 ush2armc1 eyes and n=6 TLF eyes, p<0.01, two-tailed unpaired Student’s t-test). 
In ush2ab1245 larvae, the intensity of Whrnb labeling appeared unaltered as compared to wild-type 
(AB*) larvae (n=27 eyes for both ush2ab1245 and AB* wild-type; p=0.57, two-tailed unpaired Student’s 
t-test). Nuclei were stained with DAPI (blue signal) and anti-centrin (green signal) was used as a 
marker for the connecting cilium. Scale bars: 10 µm, dpf: days post fertilization, a.u.: arbitrary units, * 
indicates p<0.05, ** indicates p<0.01, and ns: not significant.
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Because significantly elevated levels of apoptotic events were seen in the ONL of 
ush2armc1 mutant larvae when kept at facility conditions, we examined whether retinal 
degeneration was progressive under these conditions. Retinal histology was analyzed 
for both homozygous ush2a mutants at 5 dpf and at 18 months of age, which revealed 
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Figure 6. Quantification of apoptotic events in the OnL of zebrafish ush2a mutants (8 dpf). 
Homozygous ush2armc1 and ush2ab1245 larvae were exposed either to 300 lux in a (14/10h) day/night 
rhythm or to continuous light at 3000 lux from 5-8 dpf. Individual dots represent the number of 
apoptotic cells in the ONL per eye. Strain matched wild-type TLF or AB* zebrafish were used as con-
trols. (A) TLF and ush2armc1 larvae kept at 300 lux with a day/night cycle showed on average 0.2 (± 
0.1; 30 eyes) and 0.8 (± 0.2; 28 eyes) apoptotic cells per eye, respectively (p<0.05). When kept under 
3000 lux of continuous light, 1.7 (± 2.0; 34 eyes) and 5.1 (± 4.5; 28 eyes) apoptotic cells per eye were 
observed in TLF and ush2armc1, respectively (p<0.01). (B) AB* and ush2ab1245  larvae maintained at 300 
lux with a day/night cycle showed on average 2.5 (± 1.9; 28 eyes) versus 3.8 (± 2.3; 16 eyes) apototic 
cells per eye, respectively (n.s.). When kept under 3000 lux of continuous light, on average 4.2 (± 1.7; 
23 eyes) versus 24.8 (± 7.9; 18 eyes) apoptotic cells per eye were observed in AB* and ush2ab1245, 
respectively (p<0.0001). Each point represents the number of apoptotic cells in the ONL per eye and 
the standard error of the mean are given as error bars.  * indicates p<0.05, ** indicates p<0.01, *** 
indicates p<0.0001, n.s.: not significant (two-tailed Mann-Whitney test); ONL: outer nuclear layer; 
dpf: days post fertilization.
121
Usherin defects lead to early-onset retinal dysfunction in zebrafish
Ch
ap
te
r 2
b
that cellular organization and retinal lamination in mutants was indistinguishable from 
those in wild-type controls. Moreover, photoreceptor outer segments of both ush2a 
mutants had a normal morphology (Supplemental Fig. 4). The observed lack of pro-
gressive retinal degeneration in these mutants suggests that the rate of photoreceptor 
apoptosis might be compensated by the rate of photoreceptor regeneration when fish 
are raised in low-intensity light.
Ush2a mutants show reduced visual function 
To assess whether absence of usherin has implications for visual function in the ush-
2armc1 and ush2ab1245 mutants, electroretinograms (ERGs) were recorded in 5 dpf ush2a 
mutant larvae and strain- and age-matched wild-type controls that were raised under 
normal facility conditions. In the zebrafish retina, a small negative a-wave generated by 
photoreceptor hyperpolarization is immediately followed by a large positive b-wave, 
generated largely by the depolarization of second-order ON-bipolar cells in response 
to photoreceptor hyperpolarization (Dowling, 2012). The ERG maximum b-wave ampli-
tudes were significantly reduced in homozygous ush2armc1 larvae as compared to age- 
and strain-matched wild-type controls (Fig. 7A, B). The same result was observed in 
homozygous ush2ab1245 larvae (5 dpf) (Fig. 7C, D). To investigate whether the decreased 
inner retinal function was primarily mediated by a decrease in photoreceptor function, 
we recorded pharmacologically isolated a-waves by abolishing b-waves with glutamate 
receptor antagonists t-APB and TBOA. Maximum a-wave amplitudes in homozygous 
ush2armc1 larvae were significantly reduced compared to wild-type larvae (Fig. 7E, F). 
Again, a similar defect was detected in homozygous ush2ab1245 larvae, in which the 
maximum a-wave amplitudes were also significantly decreased compared to wild-type 
controls (Fig. 7G, H). Despite the absence of detectable retinal morphological defects, 
early-onset retinal photoreceptor dysfunction was recorded in both ush2a mutants.
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Figure 7. ush2a mutants show reduced retinal function. Average ERG traces from a cohort of ho-
mozygous ush2armc1 and ush2ab1245 larvae (5 dpf) with age- and strain-matched wild-type controls are 
depicted. Averages of the maximum ERG amplitudes are plotted as bar graphs ± standard deviation. 
(A-D) Normalized b-wave amplitudes recorded in both mutants are significantly reduced compared 
to ERG-traces from wild-type controls (n=72 TLF and n=75 ush2armc1, from 3 biological replicates, 
p<0.001, two-tailed unpaired Student’s t-test, and n=20 ush2ab1245 larvae and n=18 wild-type larvae, 
from 3 biological replicates, p<0.01, two-tailed unpaired Student’s t-test). (E-H) In both ush2a mu-
tants, the a-wave amplitudes are significantly reduced as compared to strain-matched wild-type con-
trols (n=10 for TLF and ush2armc1, from 2 biological replicates, p<0.05, two-tailed unpaired Student’s 
t-test, and n=19 for AB* and n=23 for ush2ab1245, from 2 biological replicates, p<0.001, two-tailed 
unpaired Student’s t-test). * indicates p<0.05, ** indicates p<0.01 and *** indicates p<0.001.
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DISCUSSION
In this study we generated and characterized two zebrafish ush2a mutant models, 
ush2armc1 and ush2ab1245, in which different domains of usherin were ablated. No signal 
was detected in photoreceptors of either ush2armc1 or ush2ab1245 larvae when using an 
antibody targeting the intracellular C-terminal region. In contrast, truncated usherin 
was detected at the photoreceptor periciliary region of homozygous ush2ab1245 larvae 
when using an N-terminal usherin antibody, but not in ush2armc1. Absence of full length 
usherin resulted in reduced whirlin levels at the photoreceptor periciliary region. Fur-
thermore, the rmc1 allele showed mild levels of photoreceptor degeneration at 8 dpf 
raised under normal facility conditions, whereas constant light rearing from 5-8 dpf with 
a light intensity of 3000 lux exacerbated photoreceptor degeneration in both mutants. 
Finally, both models presented with early-onset retinal dysfunction, as evidenced by 
significantly reduced ERG a- and b-wave responses recorded at 5 dpf. After complete 
phenotypic evaluation of both alleles we conclude that the intracellular region of ush-
erin is the most critical region in usherin required for visual function in zebrafish larvae.
Prior to this study, several USH mouse models were generated, which all presented 
with early-onset hearing defects, with or without vestibular dysfunction, closely re-
sembling human inner ear USH defects (Slijkerman et al., 2017). These models have 
contributed significantly to understanding the molecular pathology underlying USH-
associated hearing loss (Schwander et al., 2009; Tian et al., 2010; Yang et al., 2010). 
Unfortunately, these mouse models only sporadically recapitulated retinal degeneration 
seen in USH patients. A spontaneous mutant mouse model, Kunming, was described for 
Usher syndrome type IIa (Yao et al., 2016). This model shows a rapid, early-onset retinal 
degeneration, but contains mutations in two genes known to be involved in inherited 
retinal dystrophies: Ush2a and Pde6b. A targeted Ush2a knock-out mouse demonstrates 
only mild retinal degeneration with late age of onset (Liu et al., 2007). A likely explana-
tion for the discrepancy in phenotypic outcome between mice and humans lies within 
the anatomical differences between human and mouse photoreceptor cells. The most 
prominent subcellular locations in human photoreceptor cells where USH1 and USH2 
proteins have been found are the calyceal processes and the periciliary membrane 
(Maerker et al., 2008; May-Simera et al., 2017; Sahly et al., 2012; Sorusch et al., 2017). 
In rodents, photoreceptor calyceal processes and periciliary membranes are absent or 
underdeveloped, respectively, compared to humans. In contrast, these structures are 
well-developed and present in frogs and teleost fish (Slijkerman et al., 2015). Zebrafish 
mutants or morphants for USH1-associated genes myo7aa (Ernest et al., 2000; Wasfy 
et al., 2014), cdh23 (Glover et al., 2012; Sollner et al., 2004), pcdh15 (Seiler et al., 2005) 
and ush1c (Blanco-Sanchez et al., 2014; Phillips et al., 2011) have been described in the 
literature, most of them showing early-onset retinal dysfunction (Blanco-Sanchez et al., 
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2017). Furthermore, we showed that morpholino-induced knock-down of ush2a expres-
sion induces photoreceptor cell death in zebrafish larvae (Ebermann et al., 2010). In this 
study we generated and characterized two zebrafish mutant models that will allow us 
to continue to investigate the molecular pathology underlying ush2a-associated retinal 
dysfunction and future therapeutic strategies.
Although the anatomical similarities between human and zebrafish photoreceptor 
cells are numerous, some differences have also been noted. Cone photoreceptors of 
adult teleost fish contain a cilium-like structure with a 9+0 arrangement of microtubule-
doublets. This structure, the accessory outer segment (AOS), protrudes from the con-
necting cilium and projects apically alongside the outer segment, eventually associating 
with the retinal pigment epithelium (RPE) (Hodel et al., 2014). The function of the AOS 
is still unclear, but previous reports have suggested that the AOS provides structural 
support to the outer segment (Yacob et al., 1977) and that it is involved in exchange of 
metabolites between RPE and cones (Burnside et al., 1993; Hodel et al., 2014; Yacob et 
al., 1977). Moreover, in response to changes in ambient light conditions and to circadian 
signals during light-to-dark adaptation of the teleost retina, reversible retinomotor 
movements take place that result in contraction and elongation of rods and cones to 
expose the outer segment optimally to incoming light (Hodel et al., 2006; Wagner et al., 
1983). It has been postulated that by anchoring the cones to the pigment epithelium, 
the AOS may preserve the highly organized arrangement of the various types of cones in 
the fish retina (Yacob et al., 1977). Previous experiments showed that the USH1b protein, 
myosin VIIa, is localized in the cone AOS (Hodel et al., 2014), and we now discovered 
that usherin is present in these structures as well. It has been shown that myosin VIIa 
and usherin, together with Adgrv1 and whirlin, physically interact to form the ankle-
link complex in cochlear hair cells (Michalski et al., 2007). It is therefore tempting to 
speculate that within the AOS, myosin VIIa and usherin also form a complex that could 
be of importance for alignment and connection of the AOS to cone outer segments.
In humans, usherin and the other known USH2 proteins, whirlin and ADGRV1, form a 
dynamic protein complex that is mainly mediated by PDZ-PBM-based interactions (van 
Wijk et al., 2006; Yang et al., 2010). Previous research using knockout mice showed that 
usherin, whirlin, and Adgrv1 are mutually dependent on each other for their localiza-
tion at the photoreceptor periciliary membrane (Chen et al., 2014; Yang et al., 2010). 
Whereas ush2a and adgrv1 are present as single copy genes, there are two zebrafish 
whirlin orthologs (whrna and whrnb). In larvae of the ush2armc1 allele, in which no ush-
erin could be detected, we observed reduced levels of both Whrna and Whrnb at the 
periciliary membrane. In ush2ab1245 larvae, however, Whrna is significantly reduced at 
the periciliary membrane, whereas Whrnb appears unaffected. These observations fit a 
model in which the ectodomains of usherin and Adgrv1 interact while the intracellular 
regions of both proteins are anchored by whirlin (Fig. 8), as was previously proposed 
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by Maerker and co-workers (Maerker et al., 2008; Sorusch et al., 2017). Based on the 
results of the current study, Whrna seems to bind the intracellular region of usherin 
preferentially, whereas Whrnb predominantly associates with the intracellular region 
of Adgrv1. Complete absence of usherin (rmc1 allele) results in absence of both Whrna 
and Whrnb at the periciliary membrane and probably the complete USH2 complex 
including Adgrv1, similar to what was observed in the Ush2a knockout mouse (Yang et 
al., 2010). Immunohistochemical analyses using anti-Adgrv1 antibodies corroborated 
this hypothesis (Supplemental Fig. 5). Absence of the C-terminal cytoplasmic region 
of usherin (b1245 allele) apparently affects the association with only the intracellu-
lar binding partner Whrna, leaving the remainder of the USH2 complex (Adgrv1 and 
Whrnb) intact (Fig. 8 and Supplemental Fig. 5). Thus, absence of zebrafish usherin 
affects localization of interaction partner whirlin. The observed differences in localiza-
tion of both whirlin co-orthologs in the rmc1 and b1245 alleles suggest that Whrna and 
Whrnb have high binding-affinities for usherin and Adgrv1, respectively, and that they 
most probably have acquired divergent functions during evolution, consistent with the 
subfunctionalization hypothesis (Force et al., 1999).
The presence of usherin at the periciliary region suggests a role in providing the 
connecting cilium with structural support. It has been proposed that the periciliary 
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Figure 8. Schematic model of molecular consequences for other USH2 proteins in ush2a mu-
tants. The ectodomain of wild-type usherin associates with the ectodomain of Adgrv1 (indicated by 
dashed lines). Whrna and Whrnb bind via a PDZ-PBM-mediated interaction to usherin and Adgrv1, 
respectively. The ush2armc1 allele results in the complete absence of usherin at the periciliary region. 
As a consequence, localization of Adgrv1, Whrna and Whrnb at the periciliary membrane is also 
affected. The ush2ab1245 allele, however, generates a truncated usherin protein that lacks only the C-
terminal 62 amino acids and that is still located at the proper subcellular location in the photorecep-
tor cell. Because Whrna is mislocalized in this mutant and Whrnb localization is largely unaffected, 
we propose a model in which Whrna has a higher binding affinity for usherin, and Whrnb a higher 
binding affinity for Adgrv1. IS: inner segment, OS: outer segment, PBM: PDZ-binding motif.
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membrane is physically connected to the connecting cilium by means of interactions 
between the ectodomains of usherin and Adgrv1 (Fig. 8) (Maerker et al., 2008; Sorusch 
et al., 2017). The photoreceptor apical inner segment and periciliary region are also 
thought to be involved in docking of trans-Golgi-derived vesicles that contain cargo 
essential for outer segment formation, maintenance, and function (Falk et al., 2015). The 
USH protein complex, including usherin, has been proposed to play a role in this pro-
cess (Maerker et al., 2008). Based on our functional and immunohistochemical data, we 
propose a dual role for usherin in zebrafish photoreceptors: providing the connecting 
cilium with (ectodomain-mediated) structural support and participating in vesicle dock-
ing and/or signaling mediated by the intracellular region. Moreover, reduced retinal 
function and increased cell death in the retinal outer nuclear layer combined with the 
localization of truncated usherin at the periciliary membrane of the ush2ab1245 mutant, 
point towards a critical role for the intracellular region of usherin in retinal function, a 
significant finding for future therapeutic interventions.
The first clinical sign of retinal dysfunction in patients with Usher syndrome is 
typically night blindness, indicative of rod dysfunction. In zebrafish, rod photoreceptors 
contribute little to visual function before about 14 dpf (Bilotta et al., 2001; Moyano et 
al., 2013). In both ush2a mutants, however, we observed impaired ERGs at 5 dpf, which 
is suggestive of early-onset cone dysfunction. Although ERG data of pre-symptomatic 
patients are typically not available, a recent study demonstrated markedly reduced 
ERG responses for both rods and cones in adolescent Usher syndrome type 2a patients 
(Sengillo et al., 2017), consistent with our observations of cone defects by the onset of 
vision in zebrafish ush2a mutants. Furthermore, USH2A-associated retinal degenera-
tion in humans has a slow, progressive pathology. Zebrafish, unlike humans, have the 
ability to regenerate retinal cells lost to injury or disease. Steady cell proliferation from 
stem-like populations in the ciliary marginal zone persists throughout adult stages 
(Wan et al., 2016). Acute damage to the retina triggers the reprogramming of Müller 
glial cells into retinal progenitor cells that are able to differentiate into all major types 
of retinal neurons including photoreceptors (Wan and Goldman, 2016). Either or both 
of these regenerative pathways could explain the finding that ush2a mutants showed 
no progressive loss of retinal photoreceptor cells (Supplemental Fig. 4) under normal 
light conditions, although increased levels of photoreceptor apoptosis and impaired 
visual function were observed within the first week of life when larvae were challenged 
by exposure to constant illumination with 3000 lux of white light. These observations 
suggest that sustained exposure to higher light levels throughout life might disrupt 
the homeostasis between slow degeneration and steady repopulation by regeneration 
in these mutants. Importantly these observations may have significant implications for 
light exposure and the use of sunglasses or high-energy wavelength filtering lenses as 
treatments in Usher syndrome patients. In conclusion, we have shown that zebrafish 
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ush2a mutants show an early onset retinal dysfunction, mainly in the absence of pho-
toreceptor degeneration. As such they can be used for studying the retinal function of 
usherin and for the evaluation of therapeutic strategies that are currently being devel-
oped for the future treatment of USH2A-associated retinal degeneration. For the latter, 
restored Whrn levels at the photoreceptor periciliary membrane and reduced numbers 
of apoptotic cells in the outer nuclear layer can be used as measures for therapeutic 
efficacy.
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SUPPLEMENTAL FIGURES
Supplemental Figure 1. Specific organization of usherin within wild-type photoreceptors is 
revealed by scanning confocal microscopy. (A,B) Anti-usherin antibody localizes in a flattened 
disc pattern spanning the photoreceptor periciliary region in cross sections of 6dpf wild-type retinas. 
Tissue co-labeled sequentially with anti-centrin (A) to mark the basal body or acetylated α-tubulin 
to mark the connecting cilium (B) further defines the region of usherin enrichment between these 
two structures. (C,D) Transverse sections through the 6dpf larval retina (dotted line on schematic) 
reveal the usherin localization pattern as a ring at the periciliary region (cilia labeled green in panel 
C). (E,F) Cross sections of adult retinas labeled for usherin and centrin (E only) show the persistance 
of the ring structure superior to the basal body in addition to the localization within the accessory 
outer segments of cone photoreceptors. Scale bars: 5µm.
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Supplemental Figure 2. Zebrafish USH2 proteins encircle the base of the connecting cilium. 
(A-D) Transverse sections through the inner-outer segment boundary of 6dpf larval photoreceptors 
shows whirlin proteins (red; WhrnA: A, B, WhrnB: C, D) at the periciliary region. Centrin marks the 
basal body/connecting cilium in green. (E-H) In transverse sections of 6dpf larval retinas, Adgrv1 
(red) organizes into a concentric ring (E, F) surrounding the connecting cilium (acetylated α-tubulin, 
green in F); Adgrv1 (red) and usherin (green) localization overlaps in this region (G, H). Scale bars: 
5µm. Plane of sectioning shown in schematics.
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ush2armc1 (c.2337_2342delinsAC; p.Cys780GlnfsTer32)
wt:  ACTGGACAGTGTGAGTGCAAAGCTGGTGTGCGGG
mut: ACTGGACAGTGTGA    ACAGCTGGTGTGCGGG
wild-type
ush2ab1245
ush2ab1245 (c.15520_15523delinsTG; p.Ala5174fsTer)
wt:  GCCAGCTGAGCCATGCCTACTCCCAGAATTCC
mut: GCCAGCTGAGCCAT  TGACTCCCAGAATTCC
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Supplemental Figure 3. DnA sequence traces of homozygous ush2armc1 and ush2ab1245 alleles. 
(A) The ush2armc1 allele contains a six basepair deletion (‘GTGCAA’) and a two basepair insertion 
(‘AC’) in ush2a exon13 (c.2337_2342delinsAC; p.Cys780GlnfsTer32). Lower sequence traces are de-
rived from larvae homozygous for the ush2armc1 allele, whereas the upper sequence traces are derived 
from strain-matched wild-type larvae. (B) Zebrafish homozygous for the ush2ab1245 allele have a four 
basepair-deletion (‘GCCT’) and a two basepair insertion (‘TG’) in ush2a exon71, creating an instant 
TGA termination codon (c.15520_15523delinsTG; p.Ala5174fsTer). Lower sequence traces are derived 
from larvae homozygous for the ush2ab1245 allele, whereas the upper sequence traces are derived 
from strain-matched wild-type larvae.
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Supplemental Figure 4. Histological examination of ush2armc1 and ush2ab1245 zebrafish retinas. 
Light microscopy of retinal sections from larval (5 dpf) and adult (18 mpf) zebrafish stained with 
hematoxylin and eosin. Retinas of wild-type and both mutant alleles are morphologically indistin-
guishable from wild-type retinas at both ages. (n=7 larvae and n=4 adult eyes (18 mpf) with ush2armc1 
mutant, ush2ab1245 mutant, TLF and AB* fish). Dpf: days post fertilization, mpf: months post fertiliza-
tion, GCL: ganglion cell layer, IPL: inner plexiform layer, OPL: outer plexiform layer, ONL: outer nuclear 
layer, RPE: retinal pigment epithelium. Scale bars: 10 µm.
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Supplemental Figure 5. Ablation of usherin affects the localization of Adgrv1 in the zebrafish 
retina (5 dpf). Confocal microscopy of retinal sections from ush2a mutants and strain-matched wild-
type controls shows a marked reduction in Adgrv1 localization at the periciliary region of ush2armc1 
photoreceptors (D-F) compared to those of ush2ab1245  (K-M) and to wild-type controls (A-C: TLF; H-J: 
AB*). Signal intensity for the Adgrv1 labeling (red) was calculated for each genotype to quantify the 
reduction in specific localization (G, n). Scale bars: 10µm.
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ABSTRACT
Mutations in WHRN lead to Usher syndrome type 2d (USH2d) or to non-syndromic 
hearing impairment (DFNB31). The WHRN-encoded gene product whirlin directly inter-
acts with the intracellular regions of the other two USH2 proteins, usherin and ADGRV1, 
to collectively make up a transient ankle link complex necessary for maturation of the 
inner ear hairbundle. In photoreceptors, usherin and ADGRV1 are scaffolded by whirlin 
and proposed to constitute similar fibrous links between the apical inner segment and 
the connecting cilium. However, the molecular mechanism of retinal degeneration as a 
consequence of a compromised USH2 protein complex formation and function remains 
elusive. Therefore, we aimed to better understand the retinal function of the USH2 
proteins by identification of proteins that associate with the key scaffolding protein 
of the USH2 complex in photoreceptors, whirlin. We generated a transgenic zebrafish 
that expresses Strep/FLAG-tagged Whrna under the control of a photoreceptor-specific 
promoter. Eyes of these transgenic fish were employed to perform affinity purification 
of native Whrna-associated protein complexes. Whrna is one of the two zebrafish ortho-
logs of human whirlin with the highest affinity for usherin, the USH2 protein most often 
affected in patients with USH2. Mass spectrometry analysis identified 19 co-purified 
proteins and the human orthologs of at least two of these, Preso1 and Kir2.3, directly 
interacted with human whirlin in a yeast two-hybrid assay. Future studies assessing the 
interactions between the here identified co-purified proteins and whirlin in a biologi-
cally relevant context will be necessary to evaluate whether a disrupted interaction with 
whirlin contributes to the development of a retinal phenotype as observed in USH2d 
patients.
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INTRODUCTION
Usher syndrome (USH) is the most frequent cause of inherited deaf-blindness 
in man. Hallmark symptoms of USH are congenital sensorineural hearing loss and 
progressive retinal degeneration classified as retinitis pigmentosa (RP). Based on the 
severity of hearing loss, the onset of retinal degeneration and the presence of vestibular 
dysfunction, three types of USH can be distinguished: USH1, USH2 and USH3 (Smith et 
al. 1994). Besides being clinically heterogeneous, USH is also genetically heterogeneous 
(overview in Slijkerman, Kremer, and Van Wijk 2017). In addition, mutations in several 
USH-associated genes can also result in non-syndromic forms of hearing impairment or 
retinal degeneration. USH2 is the most prevalent type of USH and clinically manifests as 
congenital moderate-to-severe bilateral hearing impairment combined with a progres-
sive loss of visual function that becomes apparent from puberty onwards (Hartel et al. 
2016, Pierrache et al. 2016). So far, mutations in USH2A, ADGRV1 or WHRN have been 
associated with USH2.
The proteins encoded by the USH2 genes form dynamic protein complexes in the 
auditory hair cells and in photoreceptors (Maerker et al. 2008, Zou et al. 2017). In de-
veloping hair cells, a quaternary protein complex of the three known USH2 proteins 
and the paralog of the WHRN-encoded protein whirlin, PDZD7, is essential for the 
maturation of the inner ear sensory hair bundles (Chen et al. 2014, Zou et al. 2017). The 
extracellular regions of the USH2A-encoded protein usherin and the ADGRV1-encoded 
protein ADGRV1 are proposed to interact and form fibrous links, named ankle links, 
between adjacent stereocilia and between stereocilia and the kinocilium, whereas the 
intracellular domains are connected with whirlin and PDZD7 (Michalski et al. 2007, Grati 
et al. 2012, Chen et al. 2014, Zou et al. 2017). In both rod and cone photoreceptors, 
USH2 proteins are found in close proximity to the connecting cilium, the structure 
through which proteins are transported from the metabolic inner segment towards the 
light-sensitive outer segment (van Wijk et al. 2006, Yang et al. 2010). Immuno-electron 
microscopic analyses demonstrated that whirlin is localized at the photoreceptor peri-
ciliary membrane (PCM) (Yang et al. 2010), which is the apical part of the inner segment 
that folds as a collar-like structure around the connecting cilium. Presumably, whirlin 
scaffolds a complex of USH2 proteins in photoreceptors similar to that of the ankle 
links in auditory hair cells, since usherin and ADGRV1 are almost completely absent at 
the region of the connecting cilium of whirlin knock-out mice (Yang et al. 2010, Chen et 
al. 2014). The interdependency of USH2 proteins for their proper subcellular localiza-
tion is further underlined by a reduction of the amount of whirlin and ADGRV1/Adgrv1 
proteins at the PCM of usherin-deficient mice and zebrafish (Yang et al. 2010, Dona et 
al. 2018) and the absence of whirlin and usherin at the periciliary membrane of Adgrv1 
knock-out mice (Yang et al. 2010).
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Besides interacting with USH2 proteins, whirlin has also been described to associ-
ate with multiple USH1-associated proteins (Belyantseva et al. 2005, Brown, Hardisty-
Hughes, and Mburu 2008, Maerker et al. 2008, Riazuddin et al. 2012, Sorusch et al. 2017). 
The identified interaction partners of whirlin also extend beyond USH-associated pro-
teins. For example, whirlin has been shown to interact with GPSM2, Gαi3 and Myosin15a 
to form a complex that is involved in stereocilia elongation in mice (Mauriac et al. 2017) 
and whirlin acts as a scaffold protein for the actin-regulating proteins MPP1 (also known 
as p55) and Eps8 in the mouse stereocilia tip complex (Gosens et al. 2007, Mburu et al. 
2010, Manor et al. 2011). In addition to functioning in the inner ear, whirlin connects 
to the RP-associated protein RPGR and both proteins co-localize at the photorecep-
tor connecting cilium (Wright, Hong, and Perkins 2012). However, none of the binding 
partners of whirlin have been identified through the isolation of native, endogenously 
formed whirlin-associated protein complexes, but were rather identified after GST pull-
down assays, yeast two-hybrid screenings and co-immunoprecipitation experiments. 
Isolation and identification of in vivo-assembled whirlin protein complexes from the 
tissue of interest has therefore the potential to significantly improve the understanding 
of the function of whirlin and the molecular pathogenesis of USH2. For this reason, we 
generated a transgenic zebrafish line that stably expresses Strep/FLAG-tagged zebrafish 
whirlin (SF-Whrna) in photoreceptors. Affinity purification of in vivo-assembled SF-
Whrna protein complexes from retinal lysates followed by mass-spectrometry analysis, 
resulted in the identification of multiple novel candidate members of whirlin complexes 
of which Lrrc8-channels, Preso1 and Kir2.3 seem most prominent. We confirmed a direct 
interaction between the human orthologs of Preso1 and Kir2.3 with human whirlin and 
hypothesize that Kir2.3 could be part of a vesicle handling complex consisting of at least 
whirlin, CASK and Kir2.3 at the photoreceptor connecting cilium.
MATERIALS AND METHODS
Zebrafish strain and husbandry
Larvae (Tupfel Long Fin, (TLF)) were maintained and raised by standard methods 
(Kimmel et al., 1995). All experimental procedures were approved by the Animal Experi-
mentation Committee of the Royal Netherlands Academy of Arts and Sciences (Protocol 
#RU-DEC2016-091).
Antibodies for immunohistochemistry
The following primary antibodies were used for immunohistochemistry: rabbit anti-
FLAG (1:1000; #F7425, Sigma Aldrich), mouse anti-centrin (1:500; #04-1624, Merck), 
rabbit anti-Whrna (1:300; #42700002, Novus Biological), mouse anti-synaptic vesicle 
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glycoprotein 2A (Sv2a) (1:10; Developmental Studies Hybridoma Bank), anti-GFAP 
(1:1000; #Z033429, Agilent Technologies), rabbit and guinea-pig anti-Preso1 (1:50, 
1:100, 1:200 for all antibodies, kind gifts from Prof. Dr. P. Worley and Prof. Dr. E. Kim). 
As secondary antibodies for immunohistochemistry, the following Alexa Fluor (AF) 
conjugated immunoglobulins from Molecular Probes were used at a 1:800 dilution: AF 
568-goat anti-rabbit (#A11011), AF 488-goat anti-mouse (#A11029), AF 488-goat anti-
rabbit (#A11008) and AF568-goat anti-guinea pig (#A11075).
Generation of transgenic zebrafish
The coding sequence of Whrna (ENSDARG00000075362) was amplified by RT-
PCR (primers: 5’-GGGGACAGCTTTCTTGTACAAAGTGGTCATGAGCACAGACCTGGAGC-3’ 
and 5’-GGGGACAACTTTGTATAATAAAGTTGCCTACAGAGCCACATTGAACTCTG-3’) from 
whole larvae-derived RNA and used for the generation of a 3’ entry vector in a BP 
recombination using the pDONRP2R-P33’ donor vector following instructions in the 
Multisite GatewayTM cloning (Thermo Fisher Scientific) Manual. Subsequently, using 
Multisite GatewayTM cloning technology we cloned a 3x photoreceptor regulatory ele-
ment-1 (PRE-1)-containing zebrafish rhodopsin promoter element (rho) (Morrissey et 
al. 2011), a double Strep and single FLAG-tag (SF) (Gloeckner, Boldt, and Ueffing 2009) 
and Whrna into the pDestTol2CG2destination vector (Kwan et al. 2007). A volume of 
1nl, containing 40pg pDestTol2CG2_rho:SF-Whrna and 50pg of in vitro-transcribed 
transposase mRNA (T7 mMessage mMachine; #AM1344; Ambion Life Sciences,using a 
linearized pCS2FA-transposase plasmid as template (Kwan et al. 2007)), was injected 
into 1-cell-stage embryos (F0 generation) (Suster et al. 2009). Subsequently, embryos 
were analyzed for genome integration of the cassette based on GFP expression in the 
cardiomyocytes at 2.5 dpf. Positively selected animals were grown into adulthood and 
outcross with wildtype TLF, of which the offspring (F1) was similarly positively selected 
for germline transmission of the transgene. Eyes of adult F2 transgenic zebrafish were 
used for affinity purification experiments.
Retinal histology and immunohistochemistry
Eyes of adult zebrafish (rho:SF-whrna and TLF wild-type) or mice (Preso1-/- and 
C57BL/6 wild-type) were cryoprotected in 10% sucrose in PBS for 30 minutes and sub-
sequently embedded in OCT compound (Tissue-Tek®; #4583; Sakura Finetek U.S.A. inc.) 
without prior fixation. The embedded samples were frozen using melting isopentane. 
Cryosections of zebrafish retinas were fixed for 10 minutes with 4% PFA, rinsed 3 times 
for 10 minutes with PBS and permeabilised with 0.01% Tween-20 in PBS for 20 minutes. 
Next, sections were rinsed again 3 times for 5 minutes with PBS, incubated with blocking 
buffer (10% normal goat serum, 2% bovine serum albumin in PBS) for 1 hour and incu-
bated with primary antibodies diluted in blocking buffer at 4oC overnight. Subsequently, 
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cryosections were rinsed 3 times for 10 minutes with PBS and incubated with secondary 
antibodies and DAPI (1:8000; #D1306; Molecular Probes) diluted in blocking buffer at 
room temperature for 1 hour. Finally, sections were mounted with anti-fade Prolong 
Gold (#P36930; Molecular Probes). Retinal sections were imaged with a Zeiss Axiocam 
MRC5 camera, mounted on a Zeiss Axio Imager fluorescence microscope.
For immunohistochemical analysis of the Frmpd4 knock-out and wild-type mice, 
unfixed cryosections were blocked with 0.1% (w/v) ovalbumin and 0.5% (w/v) fish 
gelatin in PBS for 30 minutes. Before mounting, sections were fixed with 4% PFA for 
10 minutes. The experimental procedure was otherwise similar to the procedure for 
zebrafish sections. 
For histological analysis of the murine retinae, cryosections were fixed with 4% PFA 
for 10 minutes, stained with toluidine blue and analyzed with a Zeiss Axioskop light 
microscope. Images were taken with an AxioCam MRC5 camera (Zeiss) camera.
Single-step anti-FLAG affinity purification from zebrafish retina
Adult zebrafish (18-24 months of age) were euthanized by severing of the spinal 
cord after general anesthesiain 0.1% (v/v) 2-phenoxyethanol. Subsequently, the eyes 
were removed and the lens and vitreous humor were surgically dissected as described 
(Cao et al. 2010). Per condition, fourteen eyes were individually homogenized with a 
pestle using 80µl lysis buffer (0.15M NaCl, 0.03M HEPES pH7.8, 1%(v/v) NP40, 10%(v/v) 
glycerol, 1%(v/v) phosphatase inhibitor cocktail 2 (#P5726-5ML, Sigma-Aldrich), 1%(v/v) 
Phosphatase Arrest™ III (#786-452, VWR) and a cOmplete™ mini protease cocktail 
tablet (#11836153001, Sigma Aldrich)). After homogenization, total eye extracts were 
incubated on ice for 15 minutes, pooled and centrifuged (10,000xg) at 4oC for 10 
minutes. In parallel, microspin columns (#27-3565-01, VWR) were prepared by add-
ing an anti-FLAG M2 affinity matrix (#A2220, Sigma Aldrich)/lysis buffer mixture (1:1). 
After centrifugation, beads were washed three times with TBS. All centrifugation steps 
were performed for 1 minute at 112xg and 4oC, unless otherwise stated. Next, the 
supernatant of the pooled pre-cleared retinal extracts was added to the column and 
allowed to bind to the anti-FLAG beads while rotating on an intelli-mixer (25rpm) at 
4oC for 1 hour. Subsequently, beads were washed three times with washbuffer (0.15M 
NaCl, 0.03M HEPES pH 7.8, 0.1% (v/v) NP40, 1%(v/v) phosphatase inhibitor cocktail 2, 
1%(v/v) PhosphataseArrest™ III and cOmplete™ mini protease inhibitors) followed by 
two washing steps with TBS. Elution by competition was performed on ice by addition 
of 200 µl FLAG peptide (250 µg/ml, #F3290, Sigma-Aldrich) in TBS for 15 minutes with 
gentle agitation every 5 minutes. The eluted proteins were collected by centrifugation, 
precipitated using chloroform/methanol as described (Gloeckner, Boldt, and Ueffing 
2009) and sent out for mass spectrometry analysis.
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western blotting
Protein samples supplemented with sample buffer (sample buffer NuPage LDS 
(#NP0007, Life Technologies) with a final concentration of 2mM DTT) were denatur-
ated at 70oC for 10 minutes. Proteins were resolved on 4-12% NuPage gradient gels 
(#NP0321BOX, Life Technologies). Subsequently, proteins were electrophoretically 
transferred onto nitrocellulose membranes, blocked with 5% (w/v) non-fat dry milk 
(#1706404, Biorad) in PBS-T (PBS supplemented with 0.1% Tween) and analyzed with 
anti-FLAG monoclonal primary antibodies (1:1,000) and goat anti-rabbit IRDye 800 
(1:20,000, #926-3221, LI-COR) secondary antibodies in 0.5% (w/v) non-fat dry milk in 
PBS-T. Proteins were visualized using the Odyssey Infrared Imaging System (LI-COR, 
USA).
GST pull-down
For the generation of GST fusion proteins, the coding sequence of zebrafish whrna 
was cloned into a pDest15 expression vector using Gateway cloningTM technology (Ther-
mo Fisher Scientific) and subsequently used for the expression of GST-fused Whrna 
as previously described (van Wijk et al. 2006). GST-fusion proteins were coupled to 
glutathion Sepharose 4B beads (#17-0756-01, GE Healthcare) for 2 hours on a rotating 
wheel at 4oC. Beads with bound fusion proteins were washed twice with STE-buffer 
(1% (v/v) Sarkosyl, 1% (v/v) Triton X-100, 5 mM 1,4-dithiothreitol (DTT), supplemented 
with cOmplete™ mini protease inhibitors) and three times with TBS-TD (1x TBS supple-
mented with 1% (v/v) Triton X-100, 2 mM DTT and cOmplete™ mini protease inhibi-
tors). Pre-cleared zebrafish retinal extracts were incubated overnight at 4°C with equal 
amounts of blocked beads with GST or beads with GST-fusion proteins. GST fusion 
proteins were eluted from the glutathion sepharose 4B beads with 100 mM reduced 
Glutathione (#G4251, Sigma Aldrich), 5 mM NaCl and 1M TRIS-HCl (pH 8.0) overnight 
at 4oC. Proteins were precipitated using chloroform/methanol as previously described 
(Gloeckner, Boldt, and Ueffing 2009) and analyzed by mass spectrometry.
Mass spectrometry analysis
Precipitated proteins were solubilized and proteolytically cleaved using trypsin. LC-
MS/MS analysis was performed on Ultimate3000 nanoRSLC systems (Thermo Scientific) 
coupled to an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific) by a nano 
spray ion source. Tryptic peptide mixtures were injected automatically and loaded at a 
flow rate of 30 µl/min in 0.1% trifluoroacetic acid in HPLC-grade water onto a nano trap 
column (300 µm i.d. × 5 mm Precollumn, packed with Acclaim PepMap100 C18, 5 µm, 
100 Å; Thermo Scientific). After 3 minutes, peptides were eluted and separated on the 
analytical column (75 µm i.d. × 25 cm, Acclaim PepMap RSLC C18, 2 µm, 100 Å; Thermo 
Scientific) by a linear gradient from 2% to 30% of buffer B (80% acetonitrile and 0.08% 
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formic acid in HPLC-grade water) in buffer A (2% acetonitrile and 0.1% formic acid in 
HPLC-grade water) at a flow rate of 300 nl/min over 82 minutes. Remaining peptides 
were eluted by a short gradient from 30% to 95% buffer B in 5 minutes. Analysis of 
the eluted peptides was done on an LTQ Fusion mass spectrometer. From the high 
resolution MS pre-scan with a mass range of 335 to 1500, peptide ions were selected 
for fragment analysis in the Orbitrap depending on intensity (at least 5000 counts) and 
if they were at least doubly charged. The normalized collision energy for HCD was set 
to a value of 30 and the resulting fragments were detected in the ion trap analyzer. The 
lock mass option was activated; the background signal with a mass of 445.12003 was 
used as lock mass (Olsen et al. 2005). MaxQuant software (version 1.5.3.30) was used to 
search the raw spectra against the translated Ensembl Danio rerio-specific database for 
identification of gene IDs (Cox and Mann 2008). 
yeast two-hybrid assay
A GAL4-based yeast two-hybrid system (HybriZap, Stratagene) was used to identify 
the interactions between whirlin and LRRC8A, LRRC8D, Kir2.3 and Preso1. cDNAs encod-
ing LRRC8A (LRRC8A_TM2>3: amino acid (aa) 137-272, LRRC8A_C-term: aa 333-810), 
LRRC8D (LRRC8D_C-term: aa 378-858) and Kir2.3 (Kir2.3_C-term: aa 162-434) were am-
plified from HEK293T-derived cDNA and cloned in the pDONR201 vector. Preso1 cDNA 
fragments (Preso1_fl: aa 1-1322, Preso1_flΔPBM: aa 1-1316, Preso1_PDZ: aa 75-165, 
Preso1_FERM: aa 192-434, Preso1_PDZ+FERM: aa 75-434, Preso1_C-term: aa 1273-1322, 
Preso1_C-termΔPBM: aa 1273-1316, Preso1_WW: aa 23-76) were amplified using cDNA 
clone BC113700 (TransOMIC technologies Inc.) as a template and cloned in pDONR201. 
Next, LRRC8A/D, Kir2.3 and Preso1 fragments were cloned in a pBD-GAL4/DEST expres-
sion vector and full length whirlin was cloned in the pAD-GAL4/DEST expression vector, 
as previously described (van Wijk et al. 2006). Interactions were analyzed (in triplo), 
using the yeast strains PJ69-4A and -4α as a host, by the assessment of reporter gene 
activation, using growth on selective media (HIS3 and ADE2 reporter genes) and an X-β-
gal colorimetric filter lift assay (LacZ reporter gene). All used pBD-expression vectors 
were confirmed not to autoactivate the reported genes after analysis of growth of the 
transformed yeast on selective media lacking tryptophan and histidine (WH) or lacking 
tryptophan, histidine and adenine (WHA).
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RESULTS
Generation of transgenic zebrafish expressing SF-whrna in 
photoreceptors
The zebrafish genome contains two orthologs of human WHRN, whrna and whrnb. 
We have previously demonstrated that Whrna has the highest binding affinity for the 
zebrafish ush2a-encoded protein usherin (Dona et al. 2018) and therefore Whrna was 
selected as a target for affinity purification of in vivo-assembled protein complexes. We 
used the Tol2 transposon system to generate a transgenic zebrafish line stably express-
ing Strep/FLAG-tagged zebrafish Whrna (tg(rho:SF-Whrna)) in photoreceptors (Suster 
et al. 2009), to which we hereafter refer as SF-Whrna. Expression and localization of 
SF-Whrna in adult zebrafish photoreceptors was confirmed by immunohistochemistry 
(Fig. 1). Part of SF-Whrna, visualized by anti-FLAG staining, colocalizes with the con-
necting cilium marker centrin in both rods and cones of SF-whrna transgenic zebrafish 
(Fig. 1A, B). This indicates that SF-Whrna can recapitulate the localization of native 
Whrna in the zebrafish photoreceptor (Fig. 1C) and is likely to interact with the same 
proteins as endogenous Whrna at the connecting cilium. However, the majority of 
SF-Whrna accumulates in the inner segment of photoreceptors. In several, but not all, 
studies on murine photoreceptors, whirlin was also observed at the synapse (van Wijk 
et al. 2006, Maerker et al. 2008, Yang et al. 2010). However, in wild-type adult zebra-
fish retinas, endogenous Whrna could not be detected at the photoreceptor synapse 
(Fig. 1C). Moreover, immunohistochemistry did not reveal co-localization of SF-Whrna 
and the synaptic marker Sv2a (synaptic vesicle glycoprotein 2A) in SF-whrna retinas 
(Supplemental Fig. 1).
Affinity purification of SF-whrna-associated protein complexes from the 
adult zebrafish retina
After confirming expression of SF-tagged Whrna, we investigated whether this 
protein and associated protein complexes could be isolated from adult SF-whrna reti-
nas using a single FLAG-affinity purification step (Fig. 2A). Samples of three different 
stages of anti-FLAG affinity purification were analyzed on western blot (Fig. 2B). A 
protein corresponding to the predicted molecular weight of SF-tagged Whrna (83kDa) 
was identified in SF-whrna retinal extracts (inp.) using anti-FLAG antibodies, but not 
in extracts derived from wild-type retinas. SF-Whrna was abundantly present in the 
eluted sample after affinity purification (elu.), whereas little of the SF-Whrna protein 
could be detected in the flow-through (flo.) that contains the unbound proteins. This 
indicates that, using this procedure, we were able to purify SF-Whrna from lysates of 
adult transgenic zebrafish eyes.
Chapter 2c
148
Figure 1. SF-whrna is 
present in the region of 
the connecting cilium 
and in the inner segment 
of adult SF-whrna zebra-
fish photoreceptors. (A) 
Immunohistochemistr y 
using FLAG-recognizing 
antibodies (green) in the 
retina of SF-whrna zebraf-
ish. Flag-labeling is present 
in the photoreceptor inner 
segment and at the base 
of the connecting cilium 
where it is partially overlap-
ping with anti-centrin sig-
nals (red). (B) The retinas 
of wild-type TLF zebrafish 
were used as negative con-
trol. No anti-FLAG signal 
could be detected. (C) Im-
munohistochemical analy-
sis of wild-type zebrafish 
retinas using antibodies 
directed against Whrna. 
Whrna (red) colocalizes 
with the connecting cilium 
marker centrin (green). No 
specific staining could be 
observed at the photore-
ceptor synapses (OPL). COS 
= cone outersegment, ONL 
= outer nuclear layer, OPL 
= outer plexiform layer, 
ROS = rod outer segment. 
Scalebars represent 20 µm 
in the overview pictures 
and 10 µm in close-up pic-
tures.
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Figure 2. FLAG-affinity purification from SF-whrna zebrafish retinas. (A) Schematic overview of 
the protocol for affinity purification of in vivo-assembled SF-Whrna-associated protein complexes. 
Eyes were sampled from SF-whrna zebrafish, after which the lens was surgically removed. The re-
maining tissue was homogenized in lysis buffer using a pestle and the resulting extract was used 
as input for an anti-FLAG affinity purification experiment. (B) Western blot analysis of FLAG-tagged 
proteins in the retinal extract before (inp.) and after (flo.) anti-FLAG affinity purification and after elu-
tion of the anti-FLAG-containing beads (elu.). SF-Whrna (83 kDa) is indicated by an arrow. The flow-
through (flo.) contains all proteins that are not bound to the anti-FLAG beads and only a minimal 
amount of SF-Whrna. Non-annotated bands were not further investigated.
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Subsequently, a mass spectrometry analysis was performed to identify the isolated 
SF-Whrna-associated proteins. The resulting peptide sequences were blasted against 
the translated EMBL zebrafish database (trEMBL) in order to also include non-annotated 
zebrafish proteins. Keratins are known contaminants of mass spectrometry samples and 
were therefore removed from the database prior to analysis (Supplemental Table 1). 
Data analysis revealed 795 unique proteins that co-purified with SF-Whrna at least once 
in the three replicate affinity purification experiments (Supplemental Table 2). Nine-
teen proteins were considered as potential Whrna interaction partners (Fig. 3), since 
they were identified in at least two out of three replicates, but not in eluates derived 
from wild-type retinas. Except for Whrnb, none of the nineteen repeatedly identified 
proteins are orthologs of previously identified whirlin-interaction partners.
GST-whrna pull-down analysis from zebrafish retinal extracts
To validate the results obtained from the affinity purification experiments, we per-
formed a gluthatione S-transferase (GST) pull-down assay using wild-type zebrafish 
retinal extracts. The resulting protein samples were analyzed by mass spectrometry and 
proteins that were identified in two GST-Whrna replicate assays, but not in GST only 
assays (GST-solo), were regarded as being specific for Whrna (Supplemental Table 3). 
Figure 3. Overview of retrieved SF-whrna-associated proteins after FLAG-affinity purification 
or GST pull-down. Proteins that have been identified as candidate Whrna interaction partners, ar-
ranged by the purification method (i.e. by FLAG-affinity purification (SF-Whrna) or by GST pull-down 
(GST-Whrna)). 1 Proteins retrieved by GST pull-down are listed in Supplemental Table 3.
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This resulted in a list of 149 Whrna candidate interaction partners, of which Whrnb is 
the only zebrafish ortholog of a previously known binding partner of whirlin, as human 
whirlin is known to homodimerize. 
Only six proteins were identified in both the GST-Whrna pull-down assay and the 
FLAG-affinity purification experiments (Fig. 3). Next to Whrnb, two members of the 
volume regulated anion channel (VRAC) family were retrieved: Lrrc8e (leucine-rich 
repeat-containing 8 subunit e) and the si:ch211-106h11.1-encoded protein named 
‘Novel protein similar to vertebrate leucine rich repeat containing 8 family’ (Uniprot: 
B0S5F3), which shows a high sequence similarity to proteins of the vertebrate leucine-
rich repeat-containing 8 family. The VRAC subunits Lrrc8aa and Lrrc8ab were identified 
after SF-Whrna affinity purification, but were omitted from the list of proteins identified 
after GST-Whrna pull-down experiments as several peptides of these proteins were also 
pulled down from retinal extracts by GST only. Both Lrrc8aa and Lrrc8ab are orthologs 
of the human LRRC8 subunit A (LRRC8A), which is also known as SWELL1. With the 
aforementioned filtering criteria, both protein extraction methods also revealed the 
Frmpd4-encoded protein Preso1, Git1 (G protein-coupled receptor kinase-interacting 
ArfGAP 1) and si:dkey-121a11.3 (ortholog of human KIAA1614).
In total, SF-Whrna affinity purification resulted in the identification of 13 proteins 
that were not identified after GST-Whrna pull-down. Most noteworthy are the two 
members of the potassium voltage-gated channel subfamily J, named Kir2.1 (encoded 
by Kcnj2a or Kcnj2b) and Kir2.3 (encoded by Kcnj4), and two paralogs of the zebrafish-
specific protein Rapunzel: Rapunzel (encoded by Rpz) and Rapunzel 4 (encoded by 
Rpz4). Within the list of 143 proteins that were only isolated after GST-Whrna pull-down 
analyses, no known USH-related protein complexes or networks were identified upon 
manual screening.
whirlin directly associates with Preso1 and Kir2.3
We selected several of the identified candidate interactors for a cross species valida-
tion by investigating the ability of human whirlin to directly bind the human orthologs 
of candidate interactors in a yeast two-hybrid assay. For this experiment, we selected 
LRRC8A and LRRC8D because of the consistent retrieval of several Lrrc8-channel sub-
units. Since many of the established protein-protein interactions of whirlin depend on 
a PDZ (PSD95, Discs large, ZO-1) domain -PDZ binding motif (PBM)-based interaction 
(van Wijk et al. 2006), we expanded our experiment with proteins containing a predicted 
PDZ domain or PBM. For this reason, we also included Preso1 (PDZ-domain and PBM) 
and Kir2.3 (PBM) (Fig. 4A). The orthologs of Lrrc8e and Kir2.1 were not included, since 
only very few peptides of these proteins were identified in the affinity purification and 
GST-pull-down experiments. For the transmembrane (TM) proteins LRRC8A, LRRC8D 
and Kir2.3, only the intracellular regions were analyzed for the ability to interact with 
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full length whirlin. For LRRC8A, we used the intracellular region between TM2 and TM3 
(LRRC8A_TM2>3) and the C-terminal region that contains a leucine-rich repeat (LRR) 
domain (LRRC8A_C-term). For LRRC8D and Kir2.3, only the C-terminal intracellular 
regions were used (LRRC8D_C-term and Kir2.3_icd, respectively) (Fig. 4A). The possible 
Figure 4. Human whirlin binds directly to Preso1 and Kir2.3, but not to LRRC8A and LRRC8D. 
(A) Graphical representation of the predicted protein structures of human LRRC8A, LRRC8D, whirlin, 
Preso1 and Kir2.3. Protein fragments that are used in yeast two-hybrid experiments are underlined. 
(B) Yeast two-hybrid reporter gene activation upon binding of whirlin to candidate interactors. The 
panel shows selective yeast growth after the most stringent amino acid restriction (-WHLA). Plas-
mids encoding fragments of candidate interactors fused to a DNA binding domein (pBD) are co-
expressed in yeast with a plasmid encoding full length whirlin fused to an activator domain (pAD). 
All combinations of protein fragments, except for controls, were analyzed in triplo. (C) Analysis of 
β-galactosidase reporter gene activation in yeast grown on the selective medium as shown in (B). 
Blue color results from the hydrolysis of the X-β-gal substrate by β-galactosidase and is indicative for 
an interaction between the two protein fragments. + control 1 and 2 = positive controls and - control 
= negative control.
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interaction between Preso1 and full length whirlin was investigated in more detail, using 
full-length Preso1 with or without PBM and multiple (combinations of) protein domains.
The yeast two-hybrid experiments were performed in triplo and identified a direct 
interaction between human full length whirlin and the intracellular region of Kir2.3 and 
multiple fragments of Preso1 (Fig. 4B, C). Interestingly, whirlin directly interacts with 
full length Preso1, but the interaction is lost when the PBM of Preso1 is removed. The 
protein fragment containing only the PDZ and FERM domains (PDZ+FERM) of Preso1 
was also able to interact with full length whirlin, while the individual PDZ or FERM 
domains were not. We could not perform reciprocal assays with whirlin fused to the 
DNA binding domain (BD), as BD-whirlin auto-activates the reporter genes (data not 
shown). For the same reason, it was not possible to analyze the interaction between 
whirlin and a Kir2.3_icd fragment without PBM, as expression of BD-Kir2.3_icdΔPBM also 
results in an auto-activation of the reporter genes. Taken together, these results indicate 
that whirlin directly binds to the C-terminal PBM of Preso1 and the intracellular region 
of Kir2.3.
Analysis of mutant animal models for candidate interactors
To further investigate the functional relevance of the interaction between whirlin 
and the identified candidate interaction partners, we searched for known mutant ani-
mal models. No animals lacking Kir2.3 are described so far. For the whirlin candidate 
interactor Preso1 (encoded by Frmpd4), a knock-out mouse has been described (Hu et 
al. 2012). This mouse model demonstrated sustained pain signaling due to the loss of 
a negative feedback on metabotropic glutamate receptor 5 (mGluR5) signaling. Since 
the retina was never evaluated in these mice, we aimed to determine the subcellular 
localization of Preso1 in the murine retina and to investigate the effect of absence of 
Preso1 on retinal morphology. However, using two previously described antibodies we 
were unable to detect Preso1 in the retina of P19 or P108-old wild-type mice (data not 
shown)(Lee et al. 2008, Hu et al. 2012). In parallel, we investigated whether the loss of 
Preso1 affects retinal morphology. Retinal lamination in Frmpd4-/-mice was investigated 
using toluidine blue staining (Fig. 5A) and retinal stress was evaluated by immunohis-
tochemical analysis of glial fibrillary acidic protein (GFAP) that has been described as an 
early marker for photoreceptor degeneration (Fig. 5B) (Liu et al. 2007). Both analyses 
did not reveal any sign of aberrant retinal lamination or retinal degeneration in the 
Frmpd4-/- mouse retina at post-natal day 19 (P19) or at 3 months (P108) of age.
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Figure 5. Analysis of the Frmpd4-/- mouse retina. (A) The morphology of the Frmpd4-/- mouse 
retina is visualized by toluidine blue staining. No differences were observed in the thickness of the 
nuclear layers or outer segments between wild-type (left) and Frmpd4-/- (right) retinas at post-natal 
day 108 (P108). (B) Antibodies recognizing GFAP (green signal) were used to analyze retinal sections 
derived from eyes of either wild-type (upper panel) or Frmpd4-/- (lower panel) mice at P19 and P108. 
In both the wild-type and mutant retina a similar GFAP immunoreactivity is observed exclusively at 
the OPL, confirming the absence of retinal degeneration in the Frmpd4-/- mouse. INL = inner nuclear 
layer, ONL = outer nuclear layer, OPL = outer plexiform layer, COS = cone outer segment, ROS = rod 
outer segment,scale bars in (A) represent 60µm. In (B), scale bars represent 20µm.
155
Ch
ap
te
r 2
c
Affinity purification of in vivo-assembled whirlin-associated protein complexes from the zebrafish retina
DISCUSSION
This study introduces a novel strategy to isolate and identify native Whrna-associated 
protein complexes from photoreceptors of adult transgenic zebrafish. We compared 
our approach with a GST pull-down assay that is commonly used for the identification 
of protein-protein interactions. Our strategy identified several novel candidate Whrna 
interaction partners (Fig. 6), of which human Preso1 and Kir2.3 were validated as direct 
interactors of human whirlin using a yeast two-hybrid assay. Kir2.3 was not identified 
in the GST-Whrna pull-down experiments, indicating that our approach likely identified 
interaction partners of Whrna that were otherwise missed.
Protein-protein interaction studies have unraveled many novel connections with and 
between proteins involved in Usher syndrome (summarized by Kremer et al. 2006, Boldt 
et al. 2016, Slijkerman, Kremer, and Van Wijk 2017). However, the mechanism through 
which the loss of Usher syndrome-associated proteins results in retinal degeneration has 
not yet been uncovered. The protein-protein interaction assays used to identify novel 
USH-associated proteins so far relied on non-retinal cell models, such as HEK293T, that 
lack expression of photoreceptor-specific proteins and on artificial in vitro methodolo-
gies that are mainly based on over-expression (e.g. yeast two-hybrid, co-immunopre-
cipitation and GST pull-down). Therefore, we expected that these approaches could 
have missed biologically relevant interaction partners resulting in a lack of complete 
understanding of the role of the Usher protein complex in photoreceptors. Although it 
is in theory possible to culture induced pluripotent stem cell-derived retinal organoids, 
Figure 6. Most prominent candidate interactors of whrna that have been identified in this 
study. Whrna candidate binding partners that have been identified in this study are shown. Pro-
teins that only co-purified with SF-Whrna affinity purification are connected by an open dashed 
line, proteins identified by both SF-Whrna affinity purification and GST-Whrna pull-down assays are 
connected by a packed dashed line and the proteins of which the human ortholog directly interacted 
with human full length whirlin are connected by a solid line. 1 lrrc8-similar = Novel protein similar to 
vertebrate leucine rich repeat containing 8 family.
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this procedure is too expensiveand labor intense to yield the number of photoreceptors 
required for proteomic studies. In contrast, the zebrafish retina contains photoreceptors 
that are anatomically and functionally comparable to those present in man (Slijkerman 
et al. 2015). For this reason, we generated a transgenic zebrafish line that expresses an 
SF-tagged ortholog of one of the key organizers of the Usher protein complex, whirlin 
(SF-Whrna), in photoreceptors to enable the isolation of in vivo-assembled whirlin-
associated protein complexes from the biologically relevant cells.
The cassette used for zebrafish transgenesis contains SF-Whrna under the control of 
the zebrafish (3x PRE-1)-1.2 kb ZOP promoter that was previously shown to drive rod-
specific gene expression (Morrissey et al. 2011). However, FLAG-recognizing antibodies 
labeled the periciliary region of both rod (upper row) and cone (lower row) photorecep-
tors in our experiments, indicating that the promoter in our set-up drives the expression 
of SF-tagged Whrna in both rods and cones. Since whirlin is endogenously expressed in 
both photoreceptor types, we used the unexpected additional expression of SF-Whrna 
in cones to our advantage and did not further investigate the difference with previous 
studies.
We successfully purified SF-Whrna-associated protein complexes from transgenic 
adult zebrafish retinas. Subsequently, mass spectrometry of the purified proteins identi-
fied the co-purified proteins that are potential direct or indirect interaction partners 
of Whrna. Strikingly, with the exception of Whrnb, none of the other USH1 and USH2 
proteins that have been previously shown to interact with whirlin were identified after 
applying all the necessary data filtering steps. The USH1 proteins Myo7aa and Myo7ab 
were retrieved by affinity purification from both SF-Whrna and wild-type retinas and 
were therefore not regarded as specific interactors of Whrna in this experiment. The 
absence of the other USH2 proteins, ADGRV1 and usherin, from the list of co-purified 
proteins might well be due to the large size of these proteins. In addition, also the zebraf-
ish orthologs of previously published non-Usher syndrome-related whirlin interaction 
partners, such as Ngl-1, Caska/b, Myo15aa and Mpp1, were not found to co-purify with 
SF-Whrna. We also did not observe any overlap in proteins that co-purified with whirlin 
in our approaches and those purified from HEK293T cells, except for two peptides of 
Git1 (Boldt et al. 2016). Several of the mentioned interaction partners of whirlin have 
previously been demonstrated to exert important functions in the auditory hair cells, 
but may not form a protein complex with whirlin in photoreceptors. 
Interestingly, other studies already indirectly associated Preso1 (encoded by 
FRMPD4) with whirlin by unraveling that both whirlin and Preso1 directly interact with 
GPSM2, otherwise known as Leu-Gly-Asn repeat-enriched protein (LGN) (Yuzawa et al. 
2011, Takayanagi, Yuzawa, and Sumimoto 2015, Mauriac et al. 2017). GPSM2 was not 
retrieved in our study, but was previously shown to depend on whirlin for its proper 
localization in the tips of stereocilia and to be required for stereocilia elongation in the 
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inner ear of mice (Mauriac et al. 2017). In the retina, GPSM2 is present in the photorecep-
tor inner segments, where it associates with transducin (Nair et al. 2005). Based on the 
identification of Preso1 as a direct interactor of whirlin, we postulate that Preso1 also 
co-functions with whirlin in the retina. Using a Frmpd4 knock-out mouse model, Hu and 
colleagues previously showed that Preso1 regulates phosphorylation and signaling of 
group I metabotropic glutamate receptor 5 at the post synaptic density (Hu et al. 2012). 
However, the retina and cochlea of this mouse model were never evaluated. Preso1 has 
been prominently detected in the adult retina (Human Proteome Map: Kim et al. 2014) 
and therefore we investigated whether Preso1 is essential in the murine retina by a 
morphological analysis of Frmpd4-/- retinas and performed immunohistochemistry to 
determine the localization of Preso1 in the retina. While ample immunoreactivity for 
Preso1 was observed in the hippocampal neurons that were used as a positive control, 
no specific Preso1 immunoreactivity was detected in photoreceptors. Preso1 is either 
not present in the murine photoreceptor or is present in a retina-specific isoform that is 
not recognised by the employed anti-Preso1 antibodies. Alternative explanations could 
be that Preso1 is only expressed during certain stages of development, that it is only 
expressed in dark-adapted retina or that it is only detectable in case of cellular stress. In 
these cases, loss of Preso1 from the retina could still result in retina defects. However, 
we did not observe any sign of retinal degeneration in the retina of three months old 
Frmpd4-/- mice, both in thickness of the outer nuclear layer and in expression of the 
retinal cell stress marker GFAP. Of note, USH2 knock-out mice demonstrate only a mild 
form of retinal degeneration with a very late onset, which may be similar for the retina 
of Frmpd4-/- mice.
The second protein that was identified as a direct interaction partner of whirlin is 
Kir2.3, an inwardly-rectifying potassium channel subunit. Kir2.3 proteins are arranged as 
homomeric channels or form heteromeric channels by association with Kir2.1 (Preisig-
Muller et al. 2002), of which also several peptides were co-purified with SF-Whrna. 
Kir2.3 was previously shown to localize at the post-synaptic membrane of excitatory 
synapses in the olfactory bulb (Inanobe et al. 2002) and, together with Kir2.1, in the 
somata of retinal ganglion cells and in photoreceptors (Chen et al. 2004). Functionally, 
Kir2-channels were indicated to maintain the membrane resting potential near the K+ 
equilibrium potential (Inanobe et al. 2002, Hibino et al. 2010).
The expression of Kir2.3 at the basolateral membrane of renal epithelial cells is posi-
tively regulated by a direct interaction with LIN7C, which acts in concert with calcium/
calmodulin-dependent serine protein kinase (CASK) (Olsen et al. 2002, Alewine et al. 
2006, Alewine et al. 2007). In mammalian neurons, a trimeric complex of CASK, either 
LIN7A, LIN7B or LIN7C, and APBA1, was shown to be involved in the regulation of pre- 
and postsynaptic vesicle transport (Misawa et al. 2001). Interestingly, whirlin was initially 
described as a CASK-interacting protein (CIP98) that was isolated from rat brain-derived 
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protein extracts (Yap et al. 2003). As such, whirlin was proposed to act as a synaptic 
adaptor protein for CASK scaffolding proteins (Yap et al. 2003), although we did not 
detect SF-Whrna at the synapse of adult zebrafish photoreceptors. Expression of mutant 
LIN7C that lacks the ability to interact with Kir2.3 in polarized MDCK cells, resulted in 
the accumulation of Kir2.3 in large intracellular vesicles (Alewine et al. 2007). Extensive 
morphological analyses of whirlin-deficient murine photoreceptors revealed the accu-
mulation of vacuole-like structures at the periciliary membrane (PCM), but no obvious 
defects at the synapse (Yang et al. 2010). CASK has been found in all retinal synapses, 
but it is still unclear whether CASK is also present in the region of the photoreceptor 
connecting cilium (Anjum, Ayoubian, and Schmitz 2014). Possibly, a complex containing 
whirlin and CASK is anchored at the periciliary membrane by the transmembrane USH2 
proteins to regulate the acceptance of Kir2.3-positive vesicles. Downregulation of Kir2.3 
expression in mouse medium spiny neurons was shown to induce a hyperpolarized 
membrane resting potential (Cazorla et al. 2012), resulting in an impaired ability to 
generate action potentials. Therefore we hypothesize that a controlled acceptance of 
Kir2.3-containing vesicles at the PCM is highly important for maintaining the excit-
ability of photoreceptors. Future functional analyses using suitable cellular and animal 
models will unveil whether the interactions between whirlin, Kir2.3 and CASK are indeed 
biologically relevant in the retina and to what extent a disrupted association with whirlin 
contributes to the observed retinal phenotype in USH2d patients.
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SUPPLEMENTAL FIGURE AND TABLES
Supplemental figure 1. SF-whrna is absent from the adult photoreceptor synapse. Immunohis-
tochemical stainings of adult (1.5 years old) (A) SF-Whrna and (B) wild-type zebrafish retinas with 
anti-FLAG antibodies (green signal) and antibodies targeting the synaptic marker Sv2a (red signal). 
OS = outer segment, IS = inner segment, ONL = outer nuclear layer, SN = synaptic region, scale bar 
represents 20 µm.
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Supplemental table 1. List of keratins that were removed from the mass spectrometry results. 
(available upon request)
Supplemental table 2. Proteins identified by SF-whrna affinity purification or GST-whrna 
pull-down assays from adult zebrafish retinal extracts. All proteins that have been identified by 
mass spectrometry are provided with their respective protein sequence coverage for each experi-
ment. (available upon request)
Supplemental table 3. GST-whrna pull-down assays from lysates of adult zebrafish eyes. The 
protein identifier and the sequence coverage of 149 proteins are listed that were co-purified with 
GST-Whrna in two out of two experiments, and not by GST alone. Proteins that have also been identi-
fied by FLAG-affinity purification are highlighted in orange. (available upon request)
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ABSTRACT
Antisense oligonucleotide (AON)-based splice modulation has been proven to hold 
great promise as a therapeutic strategy for a number of hereditary conditions. AONs 
are small modified single-stranded RNA or DNA molecules that are complementary to 
splice enhancer or silencer target sites. Upon pre-mRNA binding, AONs will prevent or 
stimulate binding of the spliceosome thereby modulating splicing events. AONs can 
be designed and applied for different genes and genetic disorders as the specificity 
depends on their nucleotide sequence. Here we provide a guideline for setting up AON-
based splice-modulation experiments by describing a detailed protocol to design and 
evaluate AONs using a combination of in silico and in vitro analyses.
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1. InTRODUCTIOn
Splicing defects represent a significant proportion of genetic variation underlying 
inherited disorders [1]. It has, for instance, been estimated that ~20% of the muta-
tions identified for inherited retinal diseases (IRDs) affect pre-mRNA splicing. Non-
canonical splice site defects are found in several IRD genes and might be amenable 
to antisense oligonucleotide (AON)-based splice correction. AONs are small modified 
single-stranded RNA or DNA molecules that are complementary (antisense) to their 
target, allowing them to bind to the corresponding pre-mRNA molecule and prevent or 
enhance the binding of RNA-protein complexes essential for splicing. The lack of bind-
ing by the spliceosome often results in the (partial) skipping of the targeted exon, as 
has been shown for the deep-intronic mutations identified in USH2A [2,3] and CEP290 
[4,5], thereby restoring normal splicing. In addition, AONs can force the retention of 
exons that, due to mutations, are absent in the transcripts of the corresponding gene, 
by either blocking intronic splice silencer (ISS) sites, exonic splice silencer (ESS) sites or 
by fusing the sequence of the AON to elements recruiting factors that enhance splicing 
(“bifunctional” AONs). This has been successfully shown for Spinal Muscular Atrophy [6]. 
Also, AONs can redirect aberrant splicing as a consequence of (non-canonical) splice 
site mutations that weaken the original splice acceptor or donor site, by blocking these 
alternative splice sites. Finally, AONs can also be used to skip (combinations of) exons 
harboring loss-of-function (e.g. nonsense or frameshift) mutations that do not disrupt 
the reading frame when skipped. This approach has been successfully applied for large 
genes encoding (structural) proteins that contain series of repetitive protein domains 
such as NOTCH3, dystrophin or usherin [7-9]. The slightly shortened proteins that result 
from these skipping events have sufficient residual activity, thereby converting a null 
allele into a hypomorphic allele. 
In order to evaluate the effectiveness of the designed AONs, cellular models ex-
pressing the gene of interest, including the identified pathogenic genetic variants, are 
essential. Genes involved in IRDs, however, are often not or at a very low level expressed 
in patient-derived cells that are relatively easily accessible (e.g. HUVECs, lymphoblasts or 
fibroblasts) [2,10]. An alternative method to show the ability and effectiveness of AONs 
to induce the desired splice-modulation is to develop and use gene- and mutation-
specific minigene splice assays (Fig. 1) [2]. In this chapter we discuss the guidelines to 
effectively setup and assess AON-based splice modulation experiments.
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2. MATERIALS
For generating solutions the use of autoclaved milliQ water is suggested unless 
stated differently.
2.1 In silico analysis
A computer with internet access and a webbrowser are required.
2.2 Ordering AOns
1. Find a supplier and determine the chemical backbone and sugar modifications 
of choice (see Note 1).
Figure 1. Schematic overview of the experimental procedure to validate AOn-induced exon 
skipping using a minigene splice assay. (A) Using Gateway® cloning technology, an expression 
clone can be generated after recombination of the att-sites in the entry clone (pDONRTM221) and 
destination (pDEST) vector. The resulting expression plasmid contains the exon of interest (‘Exon 
X‘) flanked by RHO exons 3 and 5, under the control of a CMV promoter (‘CMV’). (B) The minigene 
splice vector can be transfected into HEK293T cells in the presence or absence of AONs. Subsequent 
transcript analysis by RT-PCR results in transcripts either containing RHO exons 3 and 5 or containing 
the exon of interest (‘Exon X’) flanked by RHO exons 3 and 5. (C) RT-PCR products can be visualized 
on an agarose gel. In this example a deep-intronic mutation in gene X that results in the inclusion of 
a pseudoexon, is modeled. RT-PCR analyses after transfection of the wildtype minigene splice vector 
does not result in the inclusion of Exon X, whereas transcript analysis after expression of the mutant 
minigene splice vector shows a larger product containing Exon X. Co-transfection of the mutant mi-
nigene splice vector with AONs that target Exon X (‘AON1’ and/or ‘AON2’) results in splice-corrected 
transcripts without Exon X (lower band). Water (mQ) was used as a negative PCR control, SON2 is a 
non-binding sense oligonucleotide control.
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2.3 Cloning of a minigene splice assay
1. Forward and reverse primers including attB tails, for the generation of Gateway®-
compatible PCR amplicons that span the exon of interest including (>500 bp) 
up- and downstream intronic sequence (see Note 2).
2. NucleoSpin® Gel and PCR Clean-up kit (MACHEREY-NAGEL, Düren, Germany).
3. Gateway®BP clonase™ enzyme mix (Thermo Fisher scientific, Carlsbad (CA), 
USA).
4. Gateway®LR clonase™ enzyme mix (Thermo Fisher scientific, Carlsbad (CA), 
USA).
5. Gateway pDONR™221 vector (Thermo Fisher scientific, Carlsbad (CA), USA).
6. A pCI-neo-based minigene splice assay destination vector [11].
7. LB agar plates: Dissolve 20 g NaCl, 20 g tryptone and 10 g yeast extract into 
750 ml water. Add 30 g agar and fill up to 1 liter. Autoclave the solution and 
let it cool down to approximately 55 oC. Just before pouring the solution into 
ᴓ 10 cm plates, add the corresponding antibiotics. Let the plates solidify and 
subsequently dry for approximately 10 minutes and store them at 4 oC until use.
8. LB medium: Dissolve 20 g NaCl, 20 g tryptone and 10 g yeast extract into 750 ml 
water. Subsequently, fill up to 1 liter total volume and autoclave the solution. LB 
medium can be stored at room temperature.
9. NucleoSpin® Plasmid EasyPure DNA extraction kit (MACHEREY-NAGEL, Düren, 
Germany).
2.4 Cell culture
1a. Dulbecco’s modified Eagle’s medium (DMEM) (see Note 3).
1b. RPMI 1640 (see Note 3).
2. Fetal bovine serum.
3. Penicillin-streptomycin.
4. Sodium pyruvate.
5. Phosphate buffered saline (PBS) 10x: Dissolve 8.1 g NaCl (138 mM), 0.2 g KCl (2.7 
mM), 1.15 g Na2HPO4.2H2O (6.5 mM) and 0.2 g KH2PO4 (1.5 mM) in 1 liter water. 
Adjust pH to 6.7 with HCl and autoclave the solution. Dilute 10 times with water 
before use. PBS can be stored at room temperature.
6. Trypsin 250. Dissolve 2.5 g trypsin in 100 ml 10x PBS and 900 ml water. Sterilize 
by filtration.
7. Opti-MEM.
8a. FuGENE® HD Transfection Reagent.
8b. Polyethylenimine (PEI). Dissolve 0.1 g PEI in 1 liter 150 mM NaCl pH 5.5 and 
adjust pH to 7.8 with HCl. Heat the solution to 80 °C for 4 to 8 hours. Let the 
solution cool down to room-temperature, sterilize by filtration and store at 4 °C.
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9. [optional] Cyclohexamide (see Note 4).
2.5 RnA isolation
1. Nucleospin RNA II isolation kit (MACHEREY-NAGEL, Düren, Germany).
2.6 cDnA synthesis
1. SuperScript VILO cDNA synthesis kit (Thermo Fisher Scientific, Carlsbad (CA), 
USA).
2.7 Polymerase Chain Reaction
1. Q5® High-Fidelity DNA polymerase.
2. dNTPs mix (10 mM each).
3. Gene-specific forward and reverse primer. PCR amplicon should ideally cover 
multiple flanking exons and not exceed a length of ~1400 bp (see note 5).
2.8 Agarose gel electrophoresis
1. Agarose-gel: Add 150 ml 0.5xTBE buffer to 1.5 g of agarose MP and boil the 
solution until the agarose is completely dissolved. Cool down to approximately 
60 oC before adding ethidium bromide to a final concentration of 0.3 µg/ml. Pour 
the gel into a gel-tray and let it solidify at room temperature for approximately 
half an hour (see Note 6).
2.9 Quantitative RT-PCR
1. Forward and reverse primers spanning about 100 bp of sequence. Preferably, 
the amplicon includes an exon-exon boundary to exclude DNA or incompletely 
processed pre-mRNA molecules (see note 7). 
2. GoTaq polymerase mix.
3. METHODS
3.1 Identify target sequence motifs
1. The ‘Human Splicing Finder’ website (http://www.umd.be/HSF3/) can be used 
to identify exonic splice enhancer (ESE) sites, intronic splice silencer (ISS) sites, 
or exonic splice silencer (ESS) sites. Click on ‘Start an Analysis with HSF3.0’ 
and select ‘analyze a sequence’ under “Select an analysis type”. Subsequently, 
select ‘Pasting your own sequence’ under “Choose a sequence by” and paste 
your sequence of the exon of interest with 50 nucleotides of flanking up- and 
downstream sequence in the appearing box. Use the ‘Proceed to analysis!’ but-
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ton to see the results. In the second window from the top, named “Graphical 
representations”, click on the tab “Splicing motifs” to unveil all predicted ESE and 
ISS sequence motifs. 
2. For exon skipping purposes, manually identify sequences that contain as many 
ESE motifs (i.e. SF2/ASF, SRp40, SC35, SRp55, ESE hexamers and putative ESE 
(PESE) octamers) without covering silencer motifs (i.e. ESS motifs 1-3, Fas ESS 
and putative ESS (PESS) octamers) motifs [12]. For exon retention purposes, 
identify sequences that cover as many silencer motifs without covering ESE mo-
tifs. Design as many potential AONs as possible, that can be screened for their 
thermodynamic and intrinsic properties and RNA structure (see Note 8). AONs 
have an optimal length of 17-23 nucleotides. However, the length of AONs can 
be adjusted to optimize any of the below mentioned properties and is thus not 
critical in this phase of the design.
3.2 Thermodynamic AOn properties and secondary RnA structures
Different AON sequences should be designed that cover the core target sequence as 
determined above. Since these guidelines are no guarantee that AONs will be effective, 
it is recommended to design at least three different AONs per target sequence for 
subsequent in vitro evaluation.
1. Analyze the thermodynamic parameters of all candidate AON sequences, starting 
with the accessibility of the target RNA. Analyze the target sequence for nucleo-
tides that are expected to hybridize to other nucleotides (referred to as ‘closed’) 
and those not expected to do so (referred to as ‘open’). Go to the online ‘mFold’ 
prediction tool (http://unafold.rna.albany.edu/?q=mfold/RNA-Folding-Form) 
to predict the secondary RNA structure of the exon including 50 nucleotides 
of up- and downstream intronic sequence. Use the default parameters, except 
for “maximum distance between paired bases” that should be put to value 100, 
and click on ‘fold RNA’. Open ‘(ss-count file)’ under the heading “View ss-count 
information”. This opens a new window in which your input sequence is analyzed 
for an ‘open’ conformation per nucleotide, counted for each predicted secondary 
structure. A higher score represents a more open structure and vice versa as 
previously explained by Aartsma-Rus [13]. Ideally, each AON targets a combina-
tion of predominantly ‘open’ and ‘closed’ conformations.
2. Take the AON secondary structure into account using the RNAstructure predic-
tion software (http://rna.urmc.rochester.edu/RNAstructureWeb/index.html). 
Choose for ‘Predict a Secondary Structure’. Paste the AON sequence in capital 
characters (lower case characters will be forced into single strand positions) and 
tick ‘RNA’ before hitting ‘Submit Query’ using default parameters. In order to be 
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able to effectively bind the target pre-mRNA, the AON structure should have a 
calculated energy of > -4 kcal/mol.
3. Calculate the free energy of AON-AON complex using the same software tool 
(http://rna.urmc.rochester.edu/RNAstructureWeb/index.html). Choose for ‘Pre-
dict a Bimolecular Secondary Structure’. Paste the AON sequence in both the 
white box below ‘sequence 1’ as well as the box below ‘sequence 2’, then click on 
‘submit query’. The free energy should be > -15 kcal/mol.
4. Predict the binding stability of an AON to its target RNA using the mFold software 
for bimolecular secondary structures. First, predict the free energy for the target 
sequence without AON by pasting the target sequence in the box under ‘Predict 
a Secondary Structure’ (http://rna.urmc.rochester.edu/RNAstructureWeb/index.
html). Second, use the ‘Predict a Bimolecular Secondary Structure’-tool to paste 
the target sequence as ‘sequence 1’ and the potential AON sequence as ‘se-
quence 2’. The calculated difference between the first (free energy target) and 
the second (free energy AON bound to target) analysis should ideally be > 21 
kcal/mol.
3.3 Intrinsic AOn properties
1. Analyze the AON sequence for the amount of G or C residues. Typically, AONs 
having a GC-content between 40 and 60% are considered to be appropriate for 
exon skipping or retention purposes (see note 9).
2. Determine the Tm temperature of the AON sequence using the Tm calculator tool 
(https://tmcalculator.neb.com/#!/). The optimal Tm of an AON is 60 oC. Avoid 
AONs with a Tm < 48 oC.
3. Analyze the uniqueness of the AONs by performing BLASTn searches against 
the genome of interest. Use the online blast-tool (https://blast.ncbi.nlm.nih.gov/
Blast.cgi) and choose for “nucleotide BLAST” (= BLASTn). Make sure the proper 
genome has been selected and paste the AON sequence (FASTA format) into 
the white box before clicking on ‘BLAST’. Homologous genomic sequences are 
listed. Ideally, there should be only a single hit that is completely identical to the 
AON. Avoid AONs for which off-target regions with stretches of 15 consecutive 
identical nucleotides are identified (see Note 10).
3.4 Generation of a minigene splice vector
1. Perform a PCR using primers that contain Gateway®-attB tails generating an 
amplicon consisting of the exon of interest together with >500bp up- and down-
stream intronic sequences. Extract and purify the PCR product from an agarose 
gel.
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2. Perform a Gateway® BP-recombination reaction to generate an entry clone 
containing the purified PCR product. Mix 2 µl of the BP clonase buffer, together 
with 1 µl of the recovered PCR product ~15-150 ng), 150 ng pDONR™221 vector, 
4 µl water and 2 µl Gateway®BP clonase™ enzyme mix. Incubate the reaction at 
25 oC for two hours. (see Note 11).
3. Terminate the Gateway® BP-recombination reaction by adding 1 µl of the Pro-
teinase K solution (2 µg). Vortex briefly. Incubate sample at 37 °C for 10 minutes.
4. Transform 2.5 µl of the BP reaction into DH5α competent cells and plate 200 µl 
on LB agar plates that contain 100 µg/ml kanamycin as a selection marker for the 
pDONR™221 vector. Incubate overnight at 37 °C.
5. Inoculate single colonies and culture them overnight (see Note 12).
6. Extract plasmid DNA from the bacterial cultures.
7. Sequence-verify the extracted plasmids by Sanger sequencing.
8. Perform a Gateway® LR-recombination reaction to generate a pCI-neo-based 
minigene splice vector. Mix 2 µl LR clonase buffer with 150 ng of the entry clone, 
150 ng pCI-neo-RHO ex3-5 destination vector and 2 µl Gateway®LR clonase™ 
enzyme mix. Incubate the reaction at 25 oC for two hours (see Note 11).
9. Repeat steps 3 to 7 in order to obtain the desired pCI-neo-based minigene splice 
vector.
3.5 Validating AOns in vitro using a minigene splice assay
1. Prior to use, dissolve AONs in sterile phosphate-buffered saline (PBS) in an ap-
propriate concentration (see Note 13). Aliquot dissolved AONs and store them 
at -80 °C for later use.
2. Seed transfectable cells, typically HEK293T cells, into a 12-wells plate and culture 
them until a 50-70% confluency (see Note 3) (see Note 14) (see note 15). 
3. Co-transfect AONs and the minigene splice vector into HEK293T cells using 
polyethylenimine (PEI). Mix the AON of choice (typically 1 µl of 1 mM stock) (see 
Note 16) and 500 ng of the minigene splice vector with 45 µl PEI and incubate at 
room temperature for 10 minutes. Add the mixture drop-wise to the cells. There 
is no need to refresh the medium before collecting the cells for RNA isolation.
4. Harvest the cells approximately 48 hours after transfection. Discard the medium 
and wash the cells with PBS. Isolate total RNA using the Nucleospin RNA II isola-
tion kit.
5. Perform a cDNA synthesis using the SuperScript VILO cDNA synthesis kit. Add 4 
µl of the VILO enzyme mastermix with 500 ng total RNA and adjust the volume 
to 20 µl using sterile RNase-free water (see note 17). Incubate the mixture in a 
thermocycler at 25°C for 10 minutes, followed by 42 °C for 60 minutes, 85 °C for 
5 minutes and 16 °C forever.
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6. The cDNA product that is generated after the reverse transcriptase reaction is 
directly used as a template in a PCR. Typically, one PCR (25 µl) contains dNTPs 
(final concentration of 0.2 mM for each nucleotide), forward and reverse primers 
(final concentration of 0.2 mM for each primer), 0.5 to 1 µl (25 to 50 ng) cDNA, 
0.25 µl (0.5 units) Q5 polymerase, and 5 µl Q5 reaction buffer. Cycling conditions 
are: 94 °C for 3 minutes, followed by 30 cycles with 94 °C for 20 seconds, Tm 
°C for 20 seconds and 72 °C for 1 minute. The Tm temperature depends on the 
primers used and should be optimized on beforehand. The reaction is finalized 
by a 5 minute incubation step at 72 °C after which the reaction is cooled down 
to 16 °C until further processing.
7. Analyze the PCR products on an agarose gel (Fig. 1C). An estimation of the ratio 
between normal and splice-modulated transcripts, which is indicative for AON 
efficacy, can be made. Determine the quantitative splice-modulating efficiency 
of the AON by RT-qPCR (see section 2.9). Sanger sequencing of the amplified 
products will reveal whether or not the used AON is capable of inducing the 
desired splice-modulation. 
3.6 In vitro validation of AOns using cells endogenously expressing the 
target pre-mRnA
1. Seed cells of interest into a 12-wells plate (see Note 14) and culture to a 50-70% 
confluency (see note 15). WERI-Rb-1 cells, however, are non-adhesive cells and 
grow in suspension. We therefore recommend seeding them at a density of 0.9 x 
106 cells per well (see Note 3). Since many different cell types can be used, AON 
transfection protocols might need some optimization (see Note 18). We have 
transfected AONs into patient-derived fibroblasts using FuGENE® HD Transfec-
tion Reagent or WERI-Rb-1 cells using polyethylenimine (PEI).
2a. Transfection using FuGENE® HD Transfection Reagent: mix the AON of choice 
(typically 1 µl of a stock-solution) with 3 µl FuGENE® HD Transfection Reagent 
and 100 µl Opti-MEM and incubate at room temperature for 20 minutes. In 
the meantime, replace the medium on the cells by 900 µl DMEM medium with 
supplements. Add the transfection mixture drop-wise to the cells (see note 19).
2b. Transfection using PEI: mix the AON of choice (typically 1 µl of a stock-solution) 
with 45 µl PEI and incubate at room temperature for 10 minutes. Subsequently, 
add the mixture drop-wise to the cells. 
3. Approximately 48 hours after transfection (see Note 4), collect the cells for tran-
script analysis using a cell-scraper. Total RNA is isolated, followed by (q)RT-PCR 
analysis as described under 3.5 points 4-8.
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4. nOTES
1. AONs can be chemically modified in different ways to enhance stability and/
or binding affinity. Generally, the backbone that connects the sugar moiety 
can be modified (e.g. phosphorothioate (PT) addition) and/or the sugar moi-
ety itself can be altered (e.g. addition of a 2’-O-methyl group (2’-OMe) or a 
2’-O-(2-methoxyethyl) group (2’-MOE)). Alternatively, the sugar moiety can be 
internally coupled to create a ‘locked nucleic acid’ (LNA) or can be exchanged 
for a morpholino-ring (PMO). For a comprehensive overview of different AON 
chemistries, read Khvorova and Watts (2017) [14].
2. Design a forward and reverse primer that generate the amplicon with the se-
quence of interest. Add a Gateway®-compatible attB1 tail to the forward primer 
(5’-GGGGACAAGTTTGTACAAAAAAGCAGGCT-XXX-3’) and attB2 tail to the re-
verse primer (5’-GGGGACCACTTTGTACAAGAAAGCTGGGT-YYY-3’). XXX indicates 
the forward primer sequence and YYY indicates the reverse primer sequence 
from 5’ to 3’.
3. Culture primary fibroblast cells in DMEM supplemented with 20% fetal bovine 
serum, 1% sodium pyruvate and 1% penicillin-streptomycin. Culture HEK293T 
cells in DMEM supplemented with 10% fetal bovine serum, 1% sodium pyru-
vate and 1% penicillin-streptomycin and culture WERI-Rb-1 cells in RPMI 1640 
supplemented with 10% fetal bovine serum, 1% sodium pyruvate and 1% 
penicillin-streptomycin.
4. In case transcripts undergo nonsense-mediated decay, the medium can be 
exchanged by cyclohexamide (use at 100 µg/ml final concentration)-containing 
medium 24 hours after supplementing AONs.
5. Ideally an amplicon should cover flanking exons as well as the exon of interest. 
AON-induced exon skipping can influence the in- and exclusion of other exons 
[15]. Also, the total amplicon length should be chosen in such a way that exon 
skipping results in a markedly different-sized PCR product that can be readily 
distinguished after agarose gel electrophoresis.
6. Casted agarose gels can be stored at 4 oC for up to one month when properly 
sealed in order to prevent them from drying out.
7. Primers for qPCR can be designed using the NCBI primer design tool (https://
www.ncbi.nlm.nih.gov/tools/primer-blast/). Use standard settings, but adjust the 
PCR product size range to 70 - 120 bp and the primer melting temperature range 
to 59 - 61 °C.
8. AONs targeting intron-exon or exon-intron boundaries are not always the most 
effective in skipping or retaining exons. Splice sites often contain higher percent-
ages of A and U-residues, resulting in a weaker AON-RNA binding as compared 
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to more GC-rich regions. Also, exonic sequences often are more suitable to find 
a unique AON-target sequence than intronic sequences and splice sites.
9. GC-content of AONs is important, as a higher GC% leads to a higher AON-RNA 
binding strength. A GC > 60% in a given AON can result in a strong self-hybrid-
ization and render these AONs unable to bind to target pre-mRNA sequences.
10. Preferably, the AON sequence has only one homologous region in the target 
genome. However, if there are no other options, mismatches in the AON’s middle 
region are expected to disrupt binding more than those at either ends of the AON. 
11. We have experienced that extending the incubation time at 25 °C from two hours 
to overnight enhances the recombination efficiency for difficult reactions.
12. As a rule of thumb, we generally analyze three clones per reaction. 
13. Typically AONs are used in a final concentration of 0.1 to 10 µM. 
14. Also 6-well plates can be used to scale up the experiment. We have successfully 
performed splice modulation experiments in a 6-well plate using 1 ml of AON-
containing medium per well.
15. All cell culture reagents should be pre-warmed to the same temperature as at 
which the cells are cultured.
16.  Using a cocktail of AONs can be more effective than using a single AON. For 
the most optimal exon skipping result, make sure the target sequences do not 
overlap. Some exons are only partially skipped when using a single AON and 
therefore might need a combination of AONs to induce complete exon skipping.
17. In order to avoid unnecessary use of reagents, this reaction is scalable.
18. AONs can cross the cell membrane unaided. Supplementing naked AONs to the 
culture medium is often sufficient to induce exon skipping in cells, although the 
use of a transfection reagent significantly enhances the AON uptake efficiency.
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ABSTRACT
Usher syndrome (USH) is the most common cause of combined deaf-blindness in 
man. The hearing loss can be partly compensated by providing patients with hearing 
aids or cochlear implants, but the loss of vision is currently untreatable. In general, 
mutations in the USH2A gene are the most frequent cause of USH explaining up to 
50% of all patients worldwide. The first deep-intronic mutation in the USH2A gene 
(c.7595-2144A>G) was reported in 2012, leading to the insertion of a pseudoexon (PE40) 
into the mature USH2A transcript. When translated, this PE40-containing transcript is 
predicted to result in a truncated non-functional USH2A protein. In this study, we ex-
plored the potential of antisense oligonucleotides (AONs) to prevent aberrant splicing 
of USH2A pre-mRNA as a consequence of the c.7595-2144A>G mutation. Engineered 
2’-O-methylphosphorothioate AONs targeting the PE40 splice acceptor site and/or 
exonic splice enhancer regions displayed significant splice correction potential in both 
patient derived fibroblasts and a minigene splice assay for USH2A c.7595-2144A>G, 
whereas a non-binding sense oligonucleotide had no effect on splicing. Altogether, 
AON-based splice correction could be a promising approach for the development of 
a future treatment for USH2A-associated retinitis pigmentosa caused by the deep-
intronic c.7595-2144A>G mutation. 
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INTRODUCTION
Usher syndrome (USH) and nonsyndromic retinitis pigmentosa (NSRP) are forms of 
inherited retinal dystrophies. Usher syndrome is clinically and genetically heterogeneous 
and by far the most common cause of inherited deaf-blindness in man, with a prevalence 
of approximately 1 in 6,000 individuals.1 Based on the presence and progression of the 
clinical symptoms, Usher syndrome can be classified in three types: type 1 (USH1), type 
2 (USH2), and type 3 (USH3). Approximately two-third of Usher syndrome patients suffer 
from type 2,2 of whom up to 85% have mutations in USH2A.3 USH2 patients present 
with congenital hearing impairment, which can be partly compensated by hearing aids 
or cochlear implants,4 and retinitis pigmentosa (RP). NSRP is more prevalent than Usher 
syndrome, occurring in 1 per 4,000 individuals worldwide,5 of whom up to 23% can be 
explained by mutations in USH2A.6,7 Both USH2 and NSRP patients with mutations in 
USH2A develop night blindness in their late teens as a consequence of photoreceptor 
degeneration.8 This night blindness subsequently progresses from peripheral vision loss 
towards legal blindness around the end of the sixth decade of life.9 However, USH2 pa-
tients have an earlier and faster decline of visual function as compared to NSRP patients 
with USH2A mutations.10
Usher syndrome and other retinal dystrophies for long have been considered as 
incurable disorders. However, recent preclinical studies and ongoing phase 1/2 clinical 
trials using gene augmentation therapy led to promising results in selected groups of 
Usher syndrome, Leber congenital amaurosis and retinitis pigmentosa patients carry-
ing mutations in MYO7A11–14 (ClinicalTrials.gov; NCT02065011) or RPE6515–18. However, 
USH2A gene augmentation is hampered as the size of its coding sequence (15,606 bp; 
Genbank NM_206933) exceeds the cargo capacity of the currently available vehicles 
used for delivery (e.g., adenoassociated or lentiviral vectors). An alternative to gene 
augmentation is gene correction by for instance CRISPR/Cas9-based targeted genome 
repair. Although promising preclinical advances have been made, gene repair is not yet 
fully developed for clinical applications.19 
Mutations in USH2A are mostly private and so far more than 600 different mutations 
have been reported which are distributed all over the gene (e.g., nonsense and mis-
sense mutations, deletions, duplications, large rearrangements, and variants that affect 
splicing (USHbases; http://www.lovd.nl/USH2A)).20,21 However, there are a few mutations 
that originate from a common ancestor (e.g., c.2299delG; p.Glu767fs and c.2276G>T; 
p.Cys759Phe) and are therefore observed more frequently.21–23
In 2012, the first deep-intronic mutation (c.7595-2144A>G) in USH2A was reported 
for which also an ancestral event was suggested in association with the rare variant 
c.6049+76A>T.24 This mutation creates a high-quality splice donor site in intron 40, re-
sulting in the incorporation of a 152-nt pseudoexon (PE40) into the mature transcript24 
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and is predicted to lead to a premature termination of translation (p.Lys2532Thrfs*56). 
With a 4% frequency, this deep-intronic mutation represents the second most frequent 
Usher syndrome type 2A-causing mutation (Usher syndrome type 2A-patient cohort 
from Montpellier (n = 562), unpublished data). Recently, three additional deep-intronic 
mutations were identified in USH2A,25 emphasizing the contribution and frequency of 
deep-intronic mutations to the pathology of Usher syndrome. Subsequent diagnos-
tic screening of the c.7595-2144A>G mutation in Usher syndrome patient cohorts 
identified multiple patients with the mutation in a homo- or compound heterozygous 
state.21,24,26–30 In addition, this mutation is reported (in trans to p.Arg4192His) in a patient 
with NSRP,26 suggesting a wide distribution of the c.7595-2144A>G mutation in both 
USH and NSRP patients.
In this study, we explored the potential of antisense oligonucleotides (AONs) to 
redirect splicing in patient-derived fibroblasts harboring a heterozygous USH2A c.7595-
2144A>G mutation. Both in fibroblasts and in a minigene splice assay, AONs showed 
promising preclinical potential to correct aberrant splicing, which might be of benefit 
for USH2A c.7595-2144A>G patients in the future. 
RESULTS
The deep-intronic c.7595-2144A>G mutation in USH2A creates a high-quality splice 
donor site that leads to a partial exonification of intron 40 (152 nt; PE40) into the mature 
mRNA24 (Fig. 1A, B). This results in a predicted frameshift and premature termination 
of translation. The aim of this study is to assess the effectiveness of AONs targeting the 
PE40 region thereby specifically induce PE40 skipping from USH2A pre-mRNA contain-
ing the c.7595-2144A>G mutation (Fig. 1C). 
Previous studies demonstrated highest exon-skipping efficiencies using AONs 
targeting exonic splice enhancer (ESE) motifs recognized by human SRSF2 (SC35), 
SRSF1 (SF2/ASF) and SRSF5, instead of intron-exon boundaries or other types of splice 
enhancers.31,32 Hence, AONs have been designed (sequences in Table 1) encompass-
ing most predicted SRSF2, SRSF1, and SRSF5 ESE sequence motifs. AON1 targets five 
predicted SRSF1, two SRSF2, five SRSF5, and two hexamer ESE sequences, while AON2 
targets two SRSF2 and one SRSF5 motifs (Supplemental Fig. 1). Guidelines for AON 
design further dictate that AONs should target partially open and partially closed pre-
mRNA structures, which is the case for both AON1 (10 closed and 13 open nucleotides) 
and AON2 (13 closed and 7 open nucleotides). Thermodynamic criteria for AON design 
include a free energy higher than −4 kcal/mol for self-folding, a free energy higher than 
−15 kcal/mol for self-dimerisation and a preferable binding energy higher than 20 kcal/
mol.33 All these criteria were met in the design of both AON1 and 2 (Table 1).
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Figure 1. USH2A splicing and principle of AOn-based splice correction. (A) In wild-type alleles, 
USH2A exons 40 and 41 are recognized and fused during splicing of USH2A pre-mRNA. (B) In case 
the c.7595-2144A>G mutation is present (indicated with an asterisk), a high-quality splice donor site 
is created. As a result, the 152 nt directly upstream are recognized as a pseudoexon and incorporated 
into USH2A mRNA (highlighted with a black background). (c) Addition of AONs complementary to 
PE40 can potentially prevent binding of splice factors to that region (indicated by a cross), thereby 
excluding PE40 from the mature USH2A transcript.
Table 1. Sequences of designed 2’-OMePT AONs.
Name Sequence
AON1 5’-GTGTGATTCTGGAGAGGAAGCTG-3’
AON2 5’-CCCTTAAAAGCCAGCATACA-3’
SON2 5’-TGTATGCTGGCTTTTAAGGG-3’
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Fibroblasts from an USH2 patient, having the USH2A c.7595-2144A>G 
(p.Lys2532Thrfs*56) and c.10636G>A (p.Gly3546Arg) mutations in compound hetero-
zygosity, were obtained in order to evaluate the splice correction potential of both 
AONs. In order to be able to detect PE40-containing USH2A transcripts, NMD inhibition 
using cycloheximide was needed (Supplementary Fig. 2). Unexpectedly, without NMD 
inhibition also the USH2A allele containing the c.10636G>A (p.Gly3546Arg) missense 
mutation could not be amplified. This could be the result of quantity-associated detec-
tion problems or alternatively could be because the missense variant has an effect on 
splicing, resulting in an out of frame transcript that is subjected to NMD. However, 
after NMD inhibition, the presence of this mutation could be confirmed by sequence 
analysis whereas no indications for alternative splice events were obtained. Subsequent 
quantitative RT-PCR analyses revealed that the relative USH2A transcript levels in the 
patient-derived and control fibroblasts were 0.12 ± 0.05% and 0.10 ± 0.03% as com-
pared to the expression levels of the housekeeping gene GUSB, respectively. Because of 
the extremely low expression levels in fibroblasts, USH2A could only be detected after 
using a highly sensitive reverse transcriptase, as was already reported by others.27 
USH2A transcripts from patient-derived fibroblasts were analyzed by RT-PCR using 
primers in exon 39 (forward) and exon 42 (reverse) which revealed the inclusion of PE40 
in mature USH2A mRNA (Fig. 2A), as expected. Transfection of these fibroblasts with 
either AON1, AON2 or with a cocktail of AON1+2 together in a final concentration of 0.5 
µmol/l, resulted in a significant skipping of PE40 (Fig. 2A), whereas no aberrant splice 
events were observed when transfecting these AONs in control fibroblasts (Fig. 2A). RT-
qPCR analyses showed that the total amount of USH2A transcripts was not significantly 
altered in AON-treated cells as compared to SON2-treated cells (AON1: p = 0.0797; 
AON2: p = 0.2039; AON1+2: p = 0.6491 (two-tailed Student’s t-test); Supplementary 
Fig. 3), which indicates that the PE40-containing transcript is not degraded but instead 
is converted into the wild-type transcript as a consequence of AON-treatment. We next 
calculated the relative amount of PE40 incorporation into the USH2A transcript by com-
paring PCR fragment intensities on gel. The ratio of PE40 incorporation was calculated 
for every PCR product. Around half of the USH2A transcripts from untransfected patient 
fibroblasts contained PE40 (0.56 ± 0.03 (ratio ± SEM)) (Fig. 2B). We observed a minimal 
difference in the average ratio of PE40 incorporation between untransfected cells and 
cells transfected with a nonbinding sense oligonucleotide (SON2; 0.44 ± 0.04) (p = 
0.0216) (Fig. 2B), which might be explained by natural variation as a consequence of 
low USH2A transcript levels. Patient fibroblasts transfected with either AON1 or AON2 
separately (1 µmol/l), showed a significantly lower average ratio of PE40 incorporation 
(0.15 ± 0.03; p < 0.0001 and 0.23 ± 0.04; p < 0.01, respectively) as compared to SON2 
(Fig. 2B). Cotransfecting AON1+2 in a 1:1 ratio with the same final concentration of 1 
µmol/l resulted in the nearly complete exclusion of PE40 (0.08 ± 0.02; P < 0.0001 when 
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compared to SON2) (Fig. 2B). AONs 1 and 2 thus both showed the ability to induce 
skipping of PE40 in patient-derived fibroblasts, however the highest degree of splice 
correction was induced using a cocktail of AON1+2.
Quantification of the splice redirection potential of the AONs using RT-qPCR analyses 
appeared to be technically challenging as a result of very low USH2A expression levels 
in fibroblasts, especially in the case of compound heterozygous mutations. For this 
reason, we set up an in vitro minigene splice assay, based on the pCI-NEO plasmid (Fig. 
3A).34 The genomic region of USH2A PE40 (both wild-type and mutant), surrounded by 
722 bp up- and 636 bp downstream sequence, was cloned between RHO exons 3 and 5 
Figure 2. AOn-based splice correction in patient-derived fibroblasts. (A) One representative 
sample of each AON treatment is shown, both for patient-derived and control fibroblasts (upper 
panel). The upper band represents USH2A containing PE40, whereas the lower band is USH2A lack-
ing PE40. ACTB amplification is shown as a loading control (lower panel). (B) For every PCR analysis 
the PE40/(PE40+USH2A lacking PE40) transcript ratio was calculated from the gel intensities of PCR 
products normalized for their fragment length and plotted as a dot, with the mean ratio represented 
by a horizontal line. Samples in which the USH2A transcript lacking PE40 was not amplified were 
excluded from calculations, which was the case for four datapoints (one in both AON2 and SON2 
and two in the non-AON treated cells). An unpaired two-tailed Student’s t-test was used to compare 
calculated ratios between AON-treated and SON-treated patient-derived fibroblasts, showing a sig-
nificant reduction of PE40 incorporation in all three AON treatment (AON1, AON2, and AON1+2) 
conditions (indicated by ***(p < 0.001) or **(p < 0.01)). Grey error bars: SEM; NTC: negative template 
control; U: untreated control; a.u.: arbitrary units.
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to model splice defects as seen in USH2A patients with the c.7595-2144A>G mutation. 
Indeed, as a consequence of the mutation,24,26 the mutant minigene splice assay only 
yielded a transcript consisting of RHO exon 3-USH2A PE40-RHO exon 5 whereas the 
wild-type minigene splice assay only resulted in a transcript containing RHO exons 3 
and 5 (Fig. 3B).
Using an USH2A PE40 minigene splice assay, we tried to induce PE40-skipping from 
the artificial RNA using the same AONs as used to transfect fibroblasts. Cotransfection 
of the PE40 mutant minigene (1 µg) with 0.5 µmol/l of either AON1 or AON2, resulted 
in both cases in a combination of corrected and non-corrected transcripts (Fig. 3B; 
274 bp (corrected) versus 426 bp (noncorrected). Subsequent sequence analysis of the 
noncorrected PCR product derived from AON1-treated samples revealed that the first 
12 bp of PE40 were lacking as a consequence of a second cryptic splice acceptor site 
use. This was neither observed in patient-derived fibroblasts treated with AON1 nor in 
AON2-treated samples. In addition, the AON1-treated minigene splice assay displayed 
Figure 3. USH2A PE40 minigene splice assay to assess AOn efficacy in vitro. (A) Schematic 
representation of the minigene splice assay, with the nucleotide corresponding to the USH2A c.7595-
2144A>G substitution highlighted with an asterisk. The genomic USH2A PE40 sequence (indicated 
with a black background “USH2A PE40”) and flanking sequences (indicated with a fat black line) were 
cloned between RHO exons 3 and 5. The targeting sequence of AON1 and AON2 is schematically 
indicated above the USH2A PE40 region. (B) RT-PCR analysis of RHO ex3-USH2A PE40 wild-type/
mutant-RHO ex5 RNAs, isolated from transfected HEK293T cells that were cultured in the absence or 
presence of AON1, AON2, or AON1 and 2 together. AONs are directed against the aberrant USH2A 
PE40 and used in a final concentration of 0.5 µmol/l. The upper bands represent the aberrant RHO-
USH2A PE40 splice product (426 or 414 bp when AON1-treated), whereas the lower bands represent 
the corrected transcript without USH2A PE40 (274 bp). Also an intermediate splice product was ob-
served after AON1 treatment. SON2 is a nonbinding control sense oligonucleotide and cotransfec-
tion into HEK293T cells with the minigene splice assay only gives rise to the aberrant splice product. 
Water (mQ) was used as a negative control.
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a faint intermediate splice product, most probably resulting from partially skipped PE40 
(Fig. 3B). Sequence analysis of the lower, presumably corrected fragment, showed that it 
indeed represents correct splicing of RHO exon 3 to exon 5. To exclude AON-induced ef-
fects on PE40 splicing independent of the targeted sequence, we reversed the sequence 
of AON2 into a sense orientation (SON2). Cotransfecting the PE40 mutant minigene 
splice assay with the nonbinding SON2 did not result in splice modulation of PE40, 
demonstrating the specificity of the result obtained with the antisense sequences (Fig. 
3C). These results were in total agreement with the results obtained from AON-treated 
patient-derived fibroblasts (Fig. 2A, B). Since both AONs 1 and 2 showed exon-skipping 
potential using the minigene splice assay, we next lowered AON concentrations ranging 
from 1.0 to 0.01 µmol/l in order to determine the minimal concentration at which the 
AONs were still able to induce significant PE40 splice redirection. As shown in Fig. 
4A, B, for both AON1 and AON2, we observed a gradual decrease of PE40-containing 
transcripts to coincide with increasing concentrations of AON. When cotransfecting 
AON1 and 2 as a cocktail, a similar PE40-skipping effect was seen (Fig. 4C). However, in 
Figure 4. Dose-dependent AOn-induced splice correction of USH2A using a minigene splice 
assay. RT-PCR analysis of RHO ex3-USH2A PE40 mutant-RHO ex5 transcripts isolated from trans-
fected HEK293T cells that were cultured in the absence or presence of different end-concentrations 
of AON1 (A), AON2 (B), or AON1+2 (C), ranging from 0 to 1.0 µmol/l. PCR (30 cycles) was performed 
from RHO exon 3 to exon 5, in order to specifically amplify minigene splice assay derived cDNA. The 
lower band (274 bp) represents the transcript without USH2A PE40.
Chapter 3b
192
contrast to what we observed for both AON1 and 2 individually, a steep turning point in 
splice redirection potential was seen between a total AON concentration of 0.1 and 0.05 
µmol/l. In addition, we observed a decrease in target transcripts when applying AON1 
at higher concentrations (0.5 or 1 µmol/l) to our minigene splice assay (Fig. 4A), which 
we attributed as the result of toxicity.
In conclusion, we were able to show that designed AONs are able to induce PE40-
skipping in both patient-derived fibroblasts and in vitro minigene splice assays. 
DISCUSSION
Mutations in USH2A that affect splicing are responsible for Usher syndrome type 2 
and autosomal recessive retinitis pigmentosa. Recent identification of four deep-intronic 
mutations leading to inclusion of PEs underlines the importance of this pathogenic 
mechanism,24,25 that was underestimated a few years ago. In this work, we used the 
c.7595-2144A>G mutation, which represents the second most frequent USH2A muta-
tion in some populations, as a model to initiate the development of an AON-based 
therapy for USH2A-associated retinitis pigmentosa. 
Mutations that affect pre-mRNA splicing represent a significant fraction of disease-
causing mutations, in a variety of inherited disorders.35,36 Different strategies have been 
employed to correct the resulting splice defects, of which AON treatment seems most 
promising. AONs do not alter endogenous transcription levels and also their relative 
ease in design and low production costs can be regarded favorable for AON-based 
therapies.35,37 The sequence-specific properties of AONs make them suitable for inter-
fering with splicing processes for different therapeutic purposes.38,39 Next to skipping of 
(pseudo)exons, AONs have been shown to be able to retain exons that are skipped as 
a consequence of splice site mutations.40,41 In addition, AONs can be used to alter the 
ratio between two naturally occurring alternatively spliced transcripts.38 
Several preclinical proof-of-concept studies for AON-based RNA splice modulation 
therapy have been performed, showing promising results for different genetic disorders 
such as Leber congenital amaurosis, Hutchinson-Gilford progeria syndrome, spinal 
muscular atrophy or Duchenne muscular dystrophy. 31,42–48 As a consequence, AONs are 
now in or beyond different phase 1, 2, or 3 clinical trials to evaluate their therapeutic 
potential and biosafety.49–51 No major adverse effects have been observed in patients 
with Duchenne muscular dystrophy after subcutaneous injections with Drisapersen, 
however mild-to-moderate reactions at the site of injection and proteinuria have been 
observed in most cases.52 Increasing doses of Drisapersen above 6 mg/kg are less well 
tolerated and lead to inflammatory responses.53 The phosphorothioate backbone can 
be immunostimulatory mainly via the nucleic acid recognizing toll like receptors (TLRs) 
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3, 7, 8 and 9 54. Although not proven, direct delivery into the eye will most probably 
circumvent systemic exposure of AONs to TLRs due to the presence of a blood-retinal 
barrier, however, TLR3 expression has also been observed in retinal pigment epithelium 
cells.55 2’-O-methyl modification of the riboses within the phosphorothioate backbone 
has been described to prevent activation of TLR7-9, but not of TLR3 56. As TLR3 recog-
nizes double stranded DNA,56 it is not expected that a TLR3-activated inflammatory 
response will be induced upon an intraocular delivery of AONs.57 
Different guidelines to aid AON design have been described by others.33,37 AONs 
complementary to exonic splice enhancer (ESE) motifs that are targeted by Ser-Argrich 
splice modulators, in particular SRSF1 (SF2/ASF), SRSF2 (formerly known as SC35) and 
SRSF5, have been shown to be most effective in exon skipping.37 Also, it has been shown 
that effective AONs often bind close to the splice acceptor site and the free energy of 
the AON-target complex is higher than that of the target complex and that of the AON 
individually.37 By adopting these guidelines we have designed two different AONs and 
examined the exon skipping potential after single AON addition or after addition of a 
cocktail consisting of the two AONs. AON1 has been designed to target five predicted 
SRSF1, two SRSF2, five SRSF5, and two hexamer ESE sequence motifs, thereby overlap-
ping the PE40 splice acceptor site. The use of AON1 in combination with a minigene 
splice assay results in the use of an alternative splice acceptor site 12 nt downstream 
of the regular PE40 splice acceptor site. Although this effect has not been observed in 
fibroblasts treated with AON1 and/or AON2, we cannot rule out that, due to the low 
level of USH2A expression, we are unable to detect any alternatively spliced transcripts. 
In line with other studies, suggesting that the use of a cocktail of AONs is often more 
potent than using a single AON,58–60 our results show that a combination of AON1+2 is 
indeed more potent than using either AON individually. 
In our study, we show USH2A splice correction in biologically nonrelevant patient-
derived fibroblasts and minigene splice assays. However, this does not result in the 
production of functional USH2A protein. In order to evaluate the effect of AON-induced 
splice correction on the level of photoreceptor maintenance and function, physiological 
relevant cellular and/or animal models will be crucial. Using iPSC technology, it is pos-
sible to generate photoreceptor-like cells from patient-derived keratinocytes or fibro-
blasts, which has already been shown for an USH2A patient having the c.7595-2144A>G 
mutation in compound heterozygosity with the c.12575G>A; p.Arg4192His mutation.26 
The use of photoreceptor-like cells will enable the assessment of potential AON-induced 
off-target effects by sequencing total RNA from those artificial eyecups. For the evalua-
tion of visual function, animal models will be essential. However, the currently available 
Ush2a knockout mouse model only shows a mild retinal degeneration with a very late 
age of onset.61 Zebrafish can be an attractive alternative model for studying Usher syn-
drome-related retinal degeneration.62 Electroretinogram (ERG) traces have been shown 
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to be significantly attenuated in zebrafish Myo7a (USH1b), Ush1c (USH1c), and Pcdh15b 
(USH1f) mutants and morphants.63–65 In addition, morpholino-induced knockdown of 
zebrafish ush2a results in moderate levels of early-onset photoreceptor degeneration in 
larvae (5 days postfertilization).66 Although the effect of human mutations on splicing is 
not always recapitulated in non-human species,67 the c.7595-2144A>G mutation results 
in a consensus (“GTAAG”) splice donor site. Recent advances in CRISPR/Cas9 technology 
now enable the generation of a humanized locus for the USH2A PE40 intronic sequence 
in zebrafish. Future research will determine whether the effect of the c.7595-2144A>G 
mutation is recapitulated in a humanized zebrafish, and whether this model will be 
suitable to evaluate the effect of AON-induced splice correction on the level of visual 
function. 
Once an animal model is present, the next challenge will be the delivery of AONs 
to photoreceptor cells. Systemic drug administration is one possible route for treat-
ing retinal disorders. However, retinal transfer of drugs from the circulating blood is 
strictly regulated by two blood–ocular barrier systems, the blood–aqueous barrier and 
the blood-retinal barrier.45,68,69 In order to effectively overcome these physical barriers, 
AONs need to be delivered directly into the human eye, either via injections of naked 
AONs into the vitreous humor or by using a stabilizing vehicle (e.g., recombinant virus, 
designed nanoparticles, cell penetrating peptides, exosomes, or liposomes).35,70,71 Once 
present in the eye, naked AONs have proven to be able to freely diffuse into all cells 
of the retina to interfere with splicing.45 When using naked AONs, it will be needed to 
repeatedly supplement photoreceptor cells with AONs, since effectiveness will be lost 
over time due to AON degradation or wash out. Intravitreal injections in mice have 
demonstrated that 2’-O-methylphosphorothioate AONs are effective in photoreceptor 
cells for at least one month and probably longer.45 Therefore, we speculate that patients 
will need a few intravitreal AON administrations per year. 
A durable splice correction effect is likely to be achieved by administration of an 
AAV vector expressing AON sequences linked to a modified U7 small nuclear RNA (U7 
snRNA). Via this route, it will be possible to induce the same therapeutic effect as with 
naked AONs, but presumably with a long-lasting effect.72–74 However, traditionally AAVs 
are unable to cross the retinal layers from vitreous humor into photoreceptor cells due 
to the presence of a diffusive barrier made up by the inner limiting membrane.75 In 
addition, also the presence of neutralizing antibodies may reduce successful photo-
receptor infection from intravitreally injected AAVs.76 For this reason, AAVs will need 
to be injected subretinally, limiting the targeted retinal area.77 However, a recent study 
presented a promising rAAV serotype which can be efficiently delivered intravitreally.78 
After transduction, the rAAV DNA strands will form very stable episomal structures, 
from which transcription can take place. Since photoreceptor cells are nondividing cells, 
integration in their genome is not a pre-requisite for success and therefore the use of 
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rAAVs instead of integrating (retro)viruses will lower the risk of potential side effects 
without reducing AON effectiveness. 
Besides presenting with retinal degeneration, Usher syndrome patients suffer from 
congenital hearing impairment. Usher proteins have been shown to be the structural 
components of the fibrous links between hair cell stereocilia and essential for proper 
hair bundle formation and function (reviewed by Kremer et al.79). USH1C encodes 
harmonin, a protein directly connected to the USH2A protein in both hair cells and 
photoreceptors.80 Treatment of an Ush1c mouse model with splice modulating AONs 
anytime during the first thirteen days after birth, results in a restored orientation and 
function of cochlear hair bundles.81 Treatment on this mouse from post-natal day 16 
onwards, which corresponds to five months of gestation in humans, shows no beneficial 
effects anymore. Therefore, AON-based splice correction will probably only be effective 
when administered during or prior to the development of inner ear hair bundles. 
In conclusion, this study shows that administration of engineered AONs to fibroblasts 
of an individual affected by Usher syndrome almost fully restores a splice defect that is 
caused by the frequent deep-intronic c.7595-2144A>G mutation in USH2A. Although 
promising on transcript level, future research is needed to determine the therapeutic 
potential of AON-based splice correction as a treatment to stop or slow down the 
progression of this devastating blinding aspect of Usher syndrome and isolated USH2A-
associated retinitis pigmentosa.
MATERIALS AND METHODS
Antisense oligonucleotides
The sequence of USH2A PE40 was analyzed for the presence of exonic splice en-
hancer motifs using the online ESE finder 3.0 program (http://rulai.cshl.edu/cgi-bin/
tools/ESE3/esefinder.cgi?process=home) with standard settings. The presence of 
RESCUE-ESE sites was determined using the RESCUE-ESE tool (http://genes.mit.edu/
burgelab/rescue-ese/). AONs were subsequently designed to each cover multiple 
SRSF1, SRSF2, SRSF5, or hexamers in PE40. Furthermore, the energetically most stable 
secondary structure of USH2A PE40 (including 25 nucleotides of flanking sequence both 
up- and downstream) was predicted using the RNAStructure software (http://rna.urmc.
rochester.edu/rnastructure.html).82 In addition, we picked sequences to be targeted by 
AONs predicted as “partially open”. With the same webtool, also thermodynamic criteria 
were evaluated: free energy of the AON, of the AON-AON complexes and of binding 
energy between the AON and its target sequence.33 AONs according above criteria were 
designed with a Tm of 58 °C and a GC% between 40–60%. The uniqueness of the AON 
target sequences was determined by BLAST analysis. The two most optimal AONs were 
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purchased from Eurogentec (Liège, Belgium) containing 2’-O-methyl modified riboses 
and a phosphorothioate backbone (sequences are presented in Table 1). As a nonbind-
ing control, a sense orientation of AON2 was also acquired (named SON2). AONs were 
dissolved in phosphate-buffered saline (PBS) before use. 
USH2A qPCR analysis
Total RNA was isolated from fibroblasts using the Nucleospin RNA II isolation kit 
(MACHEREY-NAGEL #740955.50, Düren, Germany), according to manufacturer’s proto-
col. Subsequently, 0.5–1.0 µg of total RNA was used for cDNA synthesis with SuperScript 
III RT (Life Technologies, #11755050, Carlsbad, CA). USH2A was subsequently amplified 
using forward primer 5’-CCAGGGAAAAGAGCAGAGTG-’3 (exon 28) and reverse primer 
5’-GATAGCCTCGCATGAAGGAG-3’ (exon 29). The housekeeping gene GUSB was used 
as a reference using the forward primer 5’-AGAGTGGTGCTGAGGATTGG-’3 (exon 2) and 
reverse primer 5’-GACACGCTAGAGCATGAGGG-3’ (exon 3). GoTaq (Promega A6001) 
was used to amplify USH2A and GUSB cDNA in triplicate in a 7500 HT qPCR machine. 
Analysis of the qPCR data was performed with 7500 software (version 2.3), with the 
CT-threshold set manually. Subsequently, USH2A/GUSB ratios were calculated to obtain 
relative USH2A transcript levels. 
Minigene splice assays 
A plasmid containing the genomic region of RHO encompassing exons 3–5 inserted 
at the EcoRI/SalI sites in the pCI-NEO vector34 was adapted to the Gateway cloning 
system, as previously described.83 Using Gateway cloning technology, human USH2A 
PE40 (wild-type and mutant) together with 722 bp of 5’-flanking and 636 bp of 3’-flank-
ing intronic sequence was inserted in the vector. 
Cell culture
HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
(Sigma-Aldrich D0819, St. Louis, MO) supplemented with 10% (v/v) fetal bovine serum 
(Sigma-Aldrich, F7524) and 1% penicillin-streptomycin (Sigma-Aldrich, P4333). Pri-
mary fibroblasts of an USH2 patient, with compound heterozygous USH2A mutations 
(c.7595-2144A>G and c.10636G>A), were cultured in DMEM (Sigma-Aldrich, D0819) 
supplemented with 20% fetal bovine serum (Sigma-Aldrich, F7524), 1% sodium pyru-
vate (Sigma-Aldrich, S8636) and 1% penicillin-streptomycin (Sigma-Aldrich P4333). All 
cells were passaged twice a week. 
Transfection of AOns in patient-derived fibroblasts
Fibroblasts were seeded at a concentration of 5.0 × 105 cells/well in a 12-well plate. 
Cells were subsequently transfected with AONs using FuGENE HD Transfection Reagent 
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(Promega, E2311, Madison, WI) according to manufacturer’s instructions, in quintupli-
cate. Twenty-four hours after transfection, cells were treated for an additional 16 hours 
with cycloheximide (Sigma-Aldrich, C4859—final concentration of 100 µg/ml in DMEM 
medium with all supplements as described before) prior to RNA isolation in order to 
inhibit nonsense-mediated decay of the USH2A PE40-containing transcripts. 
Transfection of AOns and minigene splice assay in HEK293T cells
One day before transfection, 5.0 × 105 HEK293T cells were seeded in each well 
of a 12-well plate, in a total volume of 0.9 ml medium containing all supplements as 
described before. Transfection mixtures were prepared by combining 1 µl AON in a 
desired concentration as indicated in the graphs, 500 ng of plasmid DNA and 45 µl 
polyethylenimine transfection reagent (PEI). Mixtures were incubated at room tempera-
ture for 10 minutes, before being dropwise added to the cells. Forty-eight hours after 
transfection, cells were collected using a cell scraper and washed with 1x PBS prior to 
RNA isolation. 
RNA isolation and RT-PCR
Total RNA was isolated from transfected HEK293T or fibroblasts using the Nucleospin 
RNA II isolation kit (MACHEREY-NAGEL, 740955.50, Düren, Germany), according to 
manufacturer’s protocol. Subsequently, 0.5–1.0 µg of total RNA was used for cDNA 
synthesis with iScript cDNA synthesis kit (Bio-Rad, 170–8891) or SuperScript III RT (Life 
Technologies, 11755050) for HEK293T and primary fibroblasts, respectively. For the splice 
correction experiments with the minigene splice assay, part of the cDNA was amplified 
under standard PCR conditions using Q5 polymerase (New England Biolabs, M0491L, 
Ipswich, MA) and using forward primer 5’-CGGAGGTCAACAACGAGTCT-3’ and reverse 
primer 5’-AGGTGTAGGGGATGGGAGAC-3’ that are designed for exons 3 and 5 of the 
human RHO gene, respectively. For the splice correction experiments in fibroblasts, part 
of the USH2A cDNA was amplified under standard PCR conditions using Q5 polymerase 
and the primers 5’-GCTCTCCCAGATACCAACTCC-3’ and 5’-GATTCACATGCCTGACCCTC-3’ 
designed for exons 39 and 42, respectively. A PCR amplifying ACTB cDNA using forward 
primer 5’-ACTGGGACGACATGGAGAAG-3’ and reverse primer 5’-CTTCACCACCACAGCT-
GAGA-3’ was employed as a control for the amount of lysed cell material. Every cDNA 
sample was analysed in quintuplicate, yielding in total 25 datapoints per AON. PCR 
products were separated on a standard 1% agarose gel. Fragments presumably rep-
resenting correctly and aberrantly spliced USH2A were excised from the gel, purified 
using Nucleospin Extract II isolation kit (MACHEREYNAGEL, 740609) and sequenced 
from both strands with the ABIPRISM Big Dye Terminator Cycle Sequencing V2.0 Ready 
Reaction kit and the ABIPRISM 3730 DNA analyzer (Applied Biosystems, Foster City, CA). 
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Quantification of PCR product intensities and ratio calculation
PCR products were size separated on a 1% agarose gel, and DNA was visualized 
using ethidium bromide. Gels were photographed with an Isogen Life sciences imager 
using ProXima AQ-4 (v3.0) software and subsequently quantified with ImageJ (v1.46r) 
software. Both PE40-containing fragments and USH2A fragments lacking PE40 were 
covered in a square with an equal surface area, from which the intensity profile was 
subsequently generated. The peaks’ bases were closed manually by drawing a hori-
zontal line, after which the surface of the peaks was calculated, representing USH2A 
PE40-containing transcripts and transcripts lacking PE40. These values were transferred 
to Microsoft Excel 2007 and normalized for their product size (i.e. 1,052 or 900 bp). The 
total amount of USH2A transcripts (i.e. the sum of PE40-containing and PE40-lacking 
band intensities) and the PE40 transcript ratio (i.e., PE40-containing transcripts divided 
by total USH2A transcripts) was calculated per condition. Samples in which the USH2A 
transcript lacking PE40 was not amplified were excluded from calculations, which was 
the case for four PCR products (one in both AON2 and SON2 and two samples in the 
non-AON-treated cells). Each gel image was analyzed twice, from which the average was 
plotted in a dot-plot using GraphPad Prism (v5.03, GraphPad Software, San Diego, CA). 
Statistical analyses were subsequently performed with a two-tailed unpaired Student’s 
t-test using GraphPad Prism. 
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SUPPLEMENTAL FIGURES
Supplemental Figure 1. Predicted ESE sequence motifs in USH2A PE40.
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Supplemental Figure 2. Cycloheximide treatment induces stabilization of PE40 containing tran-
scripts.
Supplemental Figure 3. Quantification of total USH2A transcript level after AON treatment of 
fibroblasts.
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ABSTRACT
The frequent deep-intronic c.7595-2144A>G mutation in intron 40 of USH2A gener-
ates a high quality splice donor site, resulting in the incorporation of a pseudoexon 
(PE40) into the mature transcript that is predicted to prematurely terminate usherin 
translation. Aberrant USH2A pre-mRNA splicing could be corrected in patient-derived 
fibroblasts using antisense oligonucleotides. With the aim to study the effect of the 
c.7595-2144A>G mutation and USH2A splice redirection on retinal function, a human-
ized zebrafish knock-in model was generated in which 670 basepairs of ush2a intron 
40 were exchanged for 557 basepairs of the corresponding human sequence using an 
optimized CRISPR/Cas9-based protocol. However, in the retina of adult homozygous 
humanized zebrafish only 7.4±3.9% of ush2a transcripts contained the human PE40 
sequence and immunohistochemical analyses revealed no differences in usherin 
expression and localization between the retina of humanized and wildtype zebrafish 
larvae. Nevertheless, we were able to partially correct aberrant ush2a splicing using a 
PE40-targeting antisense morpholino. Our results indicate a clear difference in splice 
site recognition by the human and zebrafish splicing machinery. Therefore we propose 
a protocol in which the effect of human splice-modulating mutations is studied in a 
zebrafish-specific cell-based splice assay prior to the generation of a humanized zebra-
fish knock-in model.
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INTRODUCTION
Patients with Usher syndrome (USH) have congenital hearing impairment and de-
velop a progressive loss of vision as a consequence of retinitis pigmentosa (RP). The first 
symptoms of RP become apparent during the second decade of life and often result 
in legal blindness around the age of 60 years 1. Hearing aids and cochlear implants 
can partly ameliorate the auditory phenotype, but for the loss of vision currently no 
treatment options are available 2. Mutations in USH2A are the leading cause of Usher 
syndrome explaining 50 to 70% of all patients worldwide 3. Defects in this gene are 
also the most prevalent cause of non-syndromic retinitis pigmentosa (NSRP) thereby 
accounting for 12-25% of all cases 3, 4. In total, over 600 different mutations have been 
identified in USH2A that are spread throughout the gene (USHbases; http://www.lovd.
nl/USH2A) 5, 6. Most mutations in USH2A are unique or are only found in a few patients. 
However, at least three mutations are known to be derived from a common ances-
tor and are therefore seen more commonly: c.2299delG (p.Glu767fs*21), c.2276G>T 
(p.Cys759Phe) and c.7595-2144A>G (p.Lys2532Thrfs*56) 6, 7.
The c.7595-2144A>G mutation is the first identified deep-intronic mutation in 
USH2A, described by Vaché et al. in 2012 7. This mutation represents 4% of all patho-
genic USH2A alleles identified in a French cohort of 562 Usher syndrome patients, mak-
ing c.7595-2144A>G the second most frequently found mutation in USH2A in France 
8. The c.7595-2144A>G mutation creates a high quality splice donor site in intron 40, 
leading to the incorporation of a pseudoexon (PE40) into the mature USH2A mRNA 7. 
Translation of PE40-containing USH2A transcripts is predicted to result in a truncated 
protein (p.Lys2532Thrfs*56) due to a premature termination of translation. We have 
previously demonstrated that antisense oligonucleotides (AONs) targeting PE40 are 
able to prevent aberrant USH2A pre-mRNA splicing as a consequence of the c.7595-
2144A>G mutation in both a minigene splice assay and patient-derived fibroblasts 8. 
Splice-corrected USH2A transcripts are expected to result in a restored synthesis of 
usherin protein and as such, potentially halt the progression of visual dysfunction in 
patients with USH2A-associated RP caused by the c.7595-2144A>G mutation.
To evaluate the effect of PE40-splice correction at the level of visual function, an ani-
mal model is pivotal. A mouse model with a loss of function mutation in Ush2a develops 
mild retinal degeneration with a late age of onset 9. In contrast, we have recently shown 
that retinal function is impaired in two different ush2a zebrafish mutants, already at five 
days post fertilization 10. Furthermore, the similar retinal morphology and photorecep-
tor anatomy as compared to man 8, 11, make zebrafish an attractive model organism to 
assess the effect of the USH2A c.7595-2144A>G mutation in vivo and to evaluate the 
effect of AON-induced PE40 splice correction at the level of visual function.
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In this study, we employed CRISPR/Cas9 technology to generate a humanized 
zebrafish ush2a knock-in model that contains 557 bp of human USH2A intron 40, 
including the c.7595-2144A>G mutation. Zebrafish homozygous for the humanized 
PE40 allele only sporadically showed inclusion of human PE40 into the mature zebrafish 
ush2a transcript, whereas the effect of the c.7595-2144A>G mutation is fully penetrant 
in patient-derived fibroblasts. To aid future projects that aim to generate humanized 
zebrafish models with the purpose of assessing splice-modulating mutations, we have 
developed a zebrafish-specific minigene splice assay to evaluate splice-site recognition 
by the zebrafish splicing machinery. 
MATERIAL AND METHODS
Zebrafish ethics, husbandry and spawning 
Animal experiments were conducted in accordance with the Dutch guidelines for 
care and use of laboratory animals, with the approval of the Animal Experimentation 
Committee (Dier Experimenten Commissie [DEC]) of the Royal Netherlands Academy 
of Arts and Sciences (Koninklijke Nederlandse Akademie van Wetenschappen [KNAW]) 
(Protocol #RU-DEC 2012–301). Embryos were obtained from natural spawning zebra-
fish. Zebrafish were maintained and raised according standard methods 12.
CRISPR/Cas9 design
In order to identify the PE40-homologous region in zebrafish, we aligned the human 
USH2A PE40 sequence with the zebrafish ush2a sequence using Align X software (Vec-
tor NTI Advance 11.0) with a Gap opening penalty of 15 and a Gap extension penalty 
of 6.66. A gRNA targeting the human USH2A PE40 homologous region in zebrafish 
ush2a intron 40 was designed using the online ZiFiT-Targeter (http://zifit.partners.
org/) 13. Subsequently, oligonucleotides (5’-TAGGGGGAAACGGGGAACGTGA-3’ and 
5’-AAACTCACGTTCCCCGTTTCCC-3’) were ordered from Integrated DNA Technologies. 
The oligonucleotides were cloned into a pDR274 vector and subsequently used as a 
template in an in vitro transcription reaction as previously described 10. To assess the 
efficiency of the designed gRNA, wildtype Tupfel Longfin (TL) zebrafish embryos at a 
one-cell stage were injected with 1 nl of a mixture containing gRNA (180 ng/µl), Cas9 
protein (250 ng/µl; PNA Bio, CP-01), KCl (0.2 M) and phenol red (0.05%; Sigma, P0290) 
as described below. At 2.5 days post fertilization, individual embryos were analyzed 
for the presence of desired mutational events by heteroduplex analysis, using the 
5’-CACAAGGACCTCTGCAATGC-3’ (forward) and 5’-GCAGAAGGGAAAACAAGAGC -3’ 
(reverse) primers. For the generation of humanized ush2a alleles, we co-injected the 
gRNA with Cas9 mRNA that was synthesized from a zebrafish codon-optimized Cas9-
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containing vector (pT3TS-nCas9n; Addgene plasmid 46757). This vector was linearized 
by XbaI (New England Biolabs, #R0145S) and the Cas9-encoding fragment was in vitro 
transcribed using the mMESSAGE mMACHINE® T3 Transcription kit (Ambion life tech-
nologies, #AM1348) according to manufacturer’s protocol. Obtained transcripts were 
purified using the MEGAclear™ Transcription Clean-Up Kit (Ambion life technologies, 
#AM1908).
Donor template vector design and cloning
Two donor template vectors were cloned containing either the human wildtype or 
mutant PE40 USH2A sequence, in order to respectively generate the humanized ush2a-
hum/hum and ush2aPE40/PE40 zebrafish lines. Each donor template contains 557 bp of human 
USH2A intron 40 sequence (with or without the c.7595-2144A>G mutation) and two ho-
mology arms. The entire template for homology directed repair was flanked by the CRISPR 
target sites. The left homology arm (forward: 5’-TCACGTTCCCCGTTTCCCCCAGGCAATAC-
GACAGGGTTATACCG-3’ and reverse: 5’- AATACAATGAAAAGCATTTAAGTTGCCATCTA-3’) 
and the right homology arm (forward: 5’- TAGTTCACGTGATTTAAGGCTTGGCGGCCCGC-3’ 
and reverse: 5’- TCACGTTCCCCGTTTCCCCCGGGAGAAGGCAATTATTACAACTG-3’) includ-
ing the gRNA target sequence (underlined) were amplified in a standard PCR reaction 
using Q5 DNA polymerase (BioKé, #M0491L, Leiden - The Netherlands) with zebrafish 
genomic DNA as a template. The 557 bp of human USH2A intron 40 including PE40 
was amplified from patient-derived genomic DNA isolated from fibroblasts, using 
forward primer 5’-TGCTTTTCATTGTATTAGCAAACTACCCCAAT-3’ and reverse primer 5’- 
TAAATCACGTGAACTATCAAACTGTGAGCATC-3’). Subsequently, the PCR products were 
combined by fusion PCR, cloned into a pCR4-TOPO-vector using the TOPO® TA Clon-
ing® Kit (Thermo Fisher Scientific, 450030, Waltham, MA, USA) and phenol:chloroform 
extracted prior to microinjection.
Microinjections
Injection needles (World Precision Instruments, TW120F-3) were prepared using 
a micropipette puller (Sutter Instrument Company, Model P-97). In order to generate 
the humanized alleles, we injected each zebrafish embryo with Cas9 mRNA (250 pg), 
gRNA (180 pg), KCl (0.2 M), phenol red (0.05%), a ku70 targeting morpholino (1.5 ng) 
and a template vector (25 pg). Injections were performed using a Pneumatic Picopump 
pv280 (World Precision Instruments) injector. After injection, embryos were kept at 28°C 
in E3 embryo medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4, 
supplemented with 0.1% methylene blue).
Chapter 3c
214
Morpholinos
An upf1 splice-blocking morpholino (5’-ttttgggagtttatacctggttgtc-3’), a human 
USH2A PE40 targeting morpholino (5’-ggtcctttaacttgtgtgattctgg-3’), a ku70 splice-
blocking morpholino (5’-AACTTTTTAGGCTCACCTGCATAGT-3’) and a standard control 
morpholino (5’-CCTCTTACCTCAGTTACAATTTATAC-3’) (Gene Tools Inc., USA) were used 
in this study. Morpholinos were diluted to 50 ng/nl stock-solutions in MilliQ water.
Genotyping zebrafish
Genomic DNA was isolated from finclips of adult zebrafish by incubation in 75 µl 
lysis buffer (40 mM NaOH and 0.2 mM EDTA (Invitrogen, #15575-038)) at 95 oC for 20 
minutes. The isolated genomic DNA was ten times diluted and used as a template in two 
PCR reactions with standard conditions. Primers used for amplification of the wildtype 
zebrafish ush2a allele are 5’-CACAAGGACCTCTGCAATGC-3’ and 5’-GCTTGAATGAATT-
GCACTGCT-3’. Primers used for the amplification of the introduced wildtype and PE40 
human sequence are 5’-CTGGCTTTTAAGGGGGAAAC-3’ and 5’-GCTTGAATGAATTGCACT-
GCT-3’. The presence or absence of the PE40-inducing c.7595-2144A>G mutation was 
confirmed by sanger sequencing. 
Transcript analysis
Pools of 15 ush2aPE40/PE40, ush2ahum/hum or wildtype larvae, or single adult zebrafish 
eyes were used to isolate total RNA. Samples were snap frozen in liquid nitrogen and 
subsequently homogenized in Qiazol (Qiagen, 79306) using a 25-gauge 16 mm needle. 
Total RNA was isolated using Qiazol extraction followed by isopropanol precipitation. 
Extracted total RNA was further purified and DNAse treated using a NucleoSpin® RNA 
II Isolation kit (Macherey-Nagel, 740955) according to manufacturer’s protocol. Subse-
quently, 0.3-1.0 µg of total RNA was used for cDNA synthesis using SuperScript VILO 
mastermix reverse transcriptase (Life Technologies, 11755050). PE40 incorporation in 
zebrafish ush2a transcripts was assessed in a PCR analysis using a forward primer in 
ush2a exon 39 (5’-ACGATGAGACGACCACCTTC-3’) and a reverse primer in ush2a exon 41 
(5’-CGCTGGAGGGGTGTTTATAG-3’). Similarly, upf1 splicing was assessed using a forward 
primer in upf1 exon 1 (5’-GCGTCCAGTGGAGAAGAGAG-3’) and a reverse primer in upf1 
exon 3 (5’-TGCAAAACCACTTCTTGCTG-3’). To visualize PE40 incorporation in patient-de-
rived fibroblasts, a forward primer in USH2A exon 39 (5’-GCTCTCCCAGATACCAACTCC-3’) 
and a reverse primers in USH2A exon 42 (5’-GAGGGTCAGGCATGTGAATC-3’) were used. 
Quantitative analysis of ush2a transcripts
Quantitative RT-PCR (RT-qPCR) was used to measure expression levels of ush2a 
transcripts. To determine levels of wildtype ush2a transcripts (ush2a_wildtype), a forward 
primer spanning the boundary of ush2a exons 40 and 41 (5’-TGTTTACTGCACAAGA-
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CAGG-’3) and reverse primer in ush2a exon 41 (5’-GGGCTGAGATGGAGGAGAC-3’) were 
used. The levels of PE40-containing ush2a transcripts (ush2a_PE40) were determined 
using the PE40-specific forward primer 5’-CTACTCAGCCAGAGCAGGAAG-’3 and re-
verse primer 5’-GAGAGGACTGGTGGGTCAAC-3’ in ush2a exon 41. The housekeeping 
gene rpl13a was used as a reference using the forward primer 5’-TCTGGAGGACTGTA-
AGAGGTATGC-’3 and reverse primer 5’-AGACGCACAATCTTGAGAGCAG-3’. ush2a and 
rpl13 amplicons were amplified in triplicate using GoTaq DNA polymerase (Promega, 
#A6001) on a 7900 HT qPCR machine. Analysis of the qPCR data was performed with 
7900 software (version 2.4), using the same threshold for all target genes. Expression of 
ush2a_wildtype and ush2a_PE40 was calculated relative to rpl13a expression using the 
2ˆdCT method. Next, the amount of PE40-containing ush2a transcripts was calculated 
as the percentage of total ush2a transcripts. The latter was calculated as the sum of 
ush2a_wildtype and ush2a_PE40 transcripts. 
Immunofluorescence
Unfixed living zebrafish larvae (5 dpf) were cryoprotected with 10% sucrose in cold 
PBS for 20 minutes, prior to embedding in TissueTek (Sakura) and hereafter slowly fro-
zen down using melting isopentane. After that, cryosections were made at a thickness 
of 7 µm, dried for at least two hours and subsequently permeabilized for 20 minutes 
with 0.01% Tween20 in PBS, followed by a 1 hour blocking step with blocking solution 
(10% normal goat serum and 2% bovine serum albumin in PBS). Antibodies diluted 
in blocking buffer were incubated overnight at 4 °C. Secondary antibodies were also 
diluted in blocking buffer and incubated together with DAPI (1:8000; D1306; Molecular 
Probes) for 1 hour. The following primary antibodies and dilutions were used: rabbit 
anti-usherin-C (1:500; #27640002; Novus Biological) and mouse anti-centrin (1:500; #04-
1624; Millipore). Secondary antibodies (Alexa Fluor 488 goat anti-mouse (A11029) and 
Alexa Fluor 568 goat anti-rabbit (A11011)) derived from Molecular Probes, were used 
in a 1:800 dilution. Sections were post-fixed with 4% PFA for 10 minutes and mounted 
with Prolong Gold Anti-fade (Molecular Probes) and analyzed using an Axioskop2 Mot 
plus fluorescence microscope (Zeiss) equipped with an AxioCam MRC5 camera (Zeiss). 
Images were processed using Axiovision 4.3 (Zeiss) and Adobe Photoshop (Adobe 
Systems).
Generation of zebrafish minigene splice vector
A plasmid containing the genomic region encompassing exons 3 through 5 of zebra-
fish opn1ws2, inserted at the EcoRI/SalI sites in the pCI-NEO vector, was adapted to the 
Gateway cloning system and used for in vivo splicing assays. The plasmid was digested 
with HpaI (cat no. R0105S, New England Biolabs, Ipswich, MA), resulting in the opening 
of the vector between exons 3 and 4. Subsequently, a blunt-end Gateway cloning cas-
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sette containing attR1 and attR2 sites was cloned in the linearized pCI-neo vector using 
the Rapid DNA Ligation Kit (catalog no., 11635379001; Roche) to generate pCI-NEO-
opn1sw2 exon3-5/DEST. Using Gateway cloning technology (Thermo Fisher Scientific), 
557 bp of human USH2A intron 40 sequence (with or without the c.7595-2144A>G 
mutation) was cloned into the pDONR201, resulting in an pENTR vector. Mutagenesis 
PCR was performed to introduce the different mutations in the splice-acceptor site. 
The different pENTR vectors were validated by Sanger sequencing, and 150 ng of each 
were cloned into the destination vector pCI-NEO-opn1sw2 exon3-5/DEST by using the 
Gateway LR Clonase enzyme mix (Thermo Fisher Scientific).
Culturing and transfection of zebrafish cells
Zendo-1 cells were kindly provided by Dr. Jeroen den Hertog and cultured in L15 
medium (Sigma Aldrich, L1518) supplemented with 15% v/v FCS (Sigma F7524), 1% v/v 
penicillin/streptomycin (Sigma Aldrich P4333), 0.5% v/v isoleucine and 1% v/v alanyl-
guanyl (Sigma Aldrich, G8541) at 28oC. Cells were passaged twice per week using a 
standard trypsin (Thermo Fisher Scientific, DF0152-15-9, Carlsbad (CA), USA) protocol. 
One day before transfection, cells were seeded in a six wells plate. Transfection of 1 µg 
plasmid was performed using Lipofectamine® 2000 (Life Technologies, 11668019) in 
Opti-MEM (Life Technologies, 31985047) medium according manufacturer’s protocol. 
Two days after transfection, the cells were collected using a cell scraper and washed 
with 1x PBS prior to RNA isolation using the Nucleospin RNA II isolation kit (MACH-
EREY-NAGEL #740955.50, Düren, Germany), according to manufacturer’s protocol. 1.0 
µg of total RNA was used for cDNA synthesis using SuperScript VILO mastermix reverse 
transcriptase (Life Technologies, #11755050). PE40 incorporation was subsequently 
analyzed in a standard PCR using Q5 DNA polymerase (BioKé, #M0491L, Leiden - The 
Netherlands) with forward primer 5’-TGAATCCTACGTCATGTTCC-’3 and reverse primer 
5’-CCTGAGATGAAGAAGAAGCC-3’.
RESULTS
Generation of a humanized ush2a knock-in zebrafish model
To determine the preferred zebrafish genomic site for incorporation of human 
USH2A PE40, we searched for the PE40 homologous sequence in zebrafish ush2a intron 
40. After sequence alignment, a region with 48.7% sequence similarity to the human 
USH2A PE40 sequence was identified (Fig. 1a). Next, the CRISPR/Cas9 system was ex-
ploited to exchange this sequence for the human USH2A PE40 sequence. A guide RNA 
that was predicted to specifically target the USH2A PE40-homologous region in the 
zebrafish genome was designed for which the efficiency in generating double strand 
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breaks (DSBs) was determined. Small insertions and deletions were found in 13 out 
of 16 (81%) screened larvae (2 dpf) that were injected with a cocktail of gRNA and 
Cas9 protein. Subsequently, we generated a donor template vector to be used by the 
homology-directed repair (HDR) branch of the DNA repair pathway. The donor template 
vector contained 557 bp of human sequence, consisting of PE40 and 208 bp upstream 
and 197 bp downstream flanking sequence. The human sequence was flanked by a 
left (890 bp) and right (1026 bp) homology arm (Fig. 1b). Since injection of a cocktail 
of gRNA, Cas9 mRNA and donor template vector did not result in the integration of a 
detectable amount of human PE40 into the zebrafish genome two days after injection 
(n=24, four pools of eight larvae each), we tried to improve the observed knock-in ef-
ficiency by introducing two adjustments to the CRISPR/Cas9 protocol (Fig. 1c). First, the 
gRNA target sequence flanked by a non-canonical PAM site (‘NAG’) was added to the 
donor template vector both upstream of the left and downstream of the right homology 
arm (Fig. 1b, indicated by black triangles). It was previously demonstrated by Irion and 
colleagues that adding these gRNA target sites resulted in a 20-fold increase of the 
favored knock-in event as compared to using a donor template vector without those 
sites 14. Furthermore, we improved the efficiency of homology-directed DNA repair 
(HDR) by inhibition of the non-homologous end joining (NHEJ) DNA repair pathway. 
The latter was achieved by morpholino-induced suppression of Ku70 expression, which 
is a key component of NHEJ-mediated DNA repair 15. Previous research determined that 
injecting 5.0 ng ku70-targeting morpholino into the yolk of zebrafish embryos resulted 
in optimal NHEJ-inhibition. We injected different amounts of this morpholino (0.1, 0.5 
and 1.0 ng) into one-cell staged embryos to determine the effect on ku70 pre-mRNA 
splicing (Supplemental Fig. 1). We estimated that the volume of the embryonic cells 
in the cleavage phase comprises approximately 30% of the volume of the complete 
embryo, and therefore decided to further increase the dose of ku70-targeting morpho-
lino to roughly match the concentration that results from injecting 5.0 ng morpholino 
in the yolk. To generate knock-in zebrafish, we therefore injected a cocktail of 1.5 ng of 
ku70-targeting morpholino, 180 pg of gRNA, 250 pg of Cas9 mRNA, and 25 pg of the 
donor vector containing gRNA target sites into zebrafish embryos at a one-cell stage 
stage (Fig. 1c). Two days after injection, twenty individual larvae were screened for the 
genomic incorporation of the human wildtype or PE40-mutant USH2A donor sequence. 
We confirmed that 3 out of 20 (15%) injected larvae were positive for the mutant PE40 
USH2A donor sequence. The remainder of the batch of injected zebrafish was raised and 
outcrossed with strain-matched wildtype zebrafish. The offspring was analyzed for the 
presence of the human USH2A PE40 sequence using a genomic PCR-based assay with 
a forward primer in the human PE40 sequence and a reverse primer downstream of the 
right homology arm. Hereby, we found that four out of 19 (21%) adult zebrafish showed 
germline transmission of the humanized ush2a allele. Subsequently, the four germline 
Chapter 3c
218
Figure 1. Strategy for the generation of a humanized ush2aPE40/PE40 transgenic zebrafish model. 
(A) Sequence alignment using the human USH2A PE40 sequence identified a region with 48.7% se-
quence similarity in zebrafish ush2a intron 40. (B) Schematic overview of the designed template vec-
tor that was used to exchange the zebrafish ush2a PE40-corresponding region for the human USH2A 
PE40 sequence. Black triangles indicate gRNA target sites, which are added next to a non-canonical 
PAM (‘NAG’) site in the vector backbone. Homology arms both up- and downstream are indicated by 
a dashed line and the human derived sequence is boxed with PE40 in black. The resulting knock-in 
genotype is schematically presented below the template vector. (C) Composition of the injection 
mixture that was injected into one-cell-stage TL embryos.
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positive zebrafish (two females and two males) were crossed and their progeny (F1) was 
genotyped by PCR analyses (Fig. 2a) followed by Sanger sequencing (Fig. 2b-e). The F1 
zebrafish that were heterozygous for the knock-in allele were used to generate homo-
zygous (F2) knock-in fish that contained 557 bp of the human USH2A sequence with the 
deep-intronic c.7595-2144A>G mutation (ush2aPE40/PE40). The humanized zebrafish with 
the wildtype USH2A intron 40 sequence (ush2ahum/hum) was generated using the same 
strategy. The ush2aPE40/PE40 and ush2ahum/hum lines were distinguished from each other 
by Sanger sequencing. Homozygous knock-in fish were viable, fertile and displayed no 
behavioral or morphological abnormalities. 
Transcriptional analysis of ush2a in the humanized zebrafish model 
The effect of the human c.7595-2144A>G mutation on zebrafish ush2a pre-mRNA 
splicing was analyzed in larvae and adult eyes derived from ush2aPE40/PE40 transgenic 
fish. An RT-PCR analysis using primers in ush2a exon 39 (forward) and exon 41 (reverse) 
demonstrated that the majority of transcripts did not contain human USH2A PE40 (Fig. 
3a). ush2a transcripts of the ush2ahum/hum zebrafish larvae did not contain any human 
USH2A sequences, indicating that the incorporation of human USH2A PE40 sequence in 
the ush2a transcript is the result of the c.7595-2144A>G mutation. Sequence analyses 
Figure 2. Validation of the integration of human USH2A PE40 in zebrafish ush2a intron 40. (A) 
Integration of human PE40 was assessed by genomic PCR analysis. Four adult humanized zebrafish 
(F1) were identified that were heterozygous for the presence of the humanized PE40 allele (lanes 
7, 23, 24, and 38). (B-E) Chromatograms derived from an amplicon spanning the complete PE40 
cassette including up- and downstream homology arms. The sequence junction between zebrafish 
ush2a intron 40 and the upstream homology arm (B), the upstream homology arm and the human 
USH2A sequence (C), the human USH2A sequence and the downstream homology arm (D) and the 
downstream homology arm and zebrafish ush2a intron 40 (E) are indicated by a grey box. Chromato-
grams corresponding to the sequence junctions are shown. The vertical dashed lines indicate the 
sequence junction. 
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of the larger PCR products revealed the incorporation of human PE40 between zebrafish 
ush2a exons 40 and 41. In some transcripts also an alternative splice acceptor site was 
used, 12 nucleotides downstream of the original PE40 splice acceptor site (Fig. 3b, grey 
box). Quantitative RT-PCR analyses were performed to determine the ratio between 
PE40-containing transcripts and transcripts that lack PE40. In ush2aPE40/PE40 larvae, 4.4% 
Figure 3. Human USH2A PE40 incorporation in zebrafish ush2a transcripts. (A) The level of 
human USH2A PE40 incorporation into the zebrafish ush2a transcript is analyzed by RT-PCR using 
cDNA derived from ush2aPE40/PE40, ush2ahum/hum and wildtype larvae, and ush2aPE40/PE40 and wildtype 
adult eyes. The upper band represents ush2a transcripts containing PE40, whereas the lower band 
represents wild-type zebrafish ush2a transcripts. (B) ush2a splicing in ush2aPE40/PE40 transgenic zebra-
fish resulted in a combination of wild-type ush2a transcripts (upper dashed lines) and ush2a tran-
scripts that contain PE40 (lower dashed line). Sporadically, also an alternative splice acceptor site is 
used in human USH2A PE40, leading to a transcript that lacks the initial 12 nucleotides of PE40 (indi-
cated in grey) (C) Quantitative RT-PCR analyses to determine the relative amount of PE40-containing 
ush2a transcripts in ush2aPE40/PE40, ush2ahum/hum and wildtype larvae, and ush2aPE40/PE40 and wildtype 
adult eyes. Data are expressed as mean ± SD. For transcript analysis, RNA from 2 pools of 15 larvae 
were used, and RNA from 6 individual adult eyes was used per genotype. One-way ANOVA followed 
by Holm-Sidak’s multiple comparisons test revealed no significant differences between groups. ND 
= not detectable.
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(± 2.0%) of ush2a transcripts were aberrantly spliced as a consequence of the intro-
duced human USH2A c.7595-2144A>G mutation and contain either the complete PE40 
sequence or PE40 lacking the first 12 nucleotides. Approximately 7.4% (± 3.9%) of ush2a 
transcripts derived from ush2aPE40/PE40 adult eyes contained human USH2A PE40 (Fig. 
3c). Previous experiments using a RHO-based minigene splice assay in human embry-
onic kidney (HEK293T) cells showed that the effect of the c.7595-2144A>G mutation on 
pre-mRNA splicing is fully penetrant, since c.7595-2144A>G results in incorporation of 
PE40 in all observed minigene-derived transcripts8. This result was confirmed in fibro-
blasts derived from a patient with a homozygous USH2A c.7595-2144A>G mutation 
(Supplemental Fig. 2). For this reason, we hypothesized that PE40-containing ush2a 
transcripts are either rapidly degraded via nonsense-mediated decay (NMD) or that 
human USH2A PE40 is poorly recognized by the zebrafish splicing machinery. However, 
quantification of ush2a transcripts in larvae from previously generated ush2a mutant 
zebrafish (ush2armc1/rmc1 and ush2ab1245/b1245) 10, as well as the ush2aPE40/PE40 zebrafish, 
showed no reduction in total amount of ush2a transcripts compared to age and strain 
matched wildtypes (Supplemental Fig. 3). To rule out any potential contribution of 
NMD-pathway to the degradation of PE40-containg ush2a transcripts, we used a previ-
ously published splice-blocking morpholino targeting upf1 that was shown to inactivate 
the NMD pathway 16. upf1 pre-mRNA splicing was indeed significantly altered in the 
ush2aPE40/PE40 larvae after morpholino injection (Fig. 4a). After Sanger sequencing we 
Figure 4. Ush2aPE40/PE40 transcript analysis after NMD inhibition by upf1 knock-down. (A) Char-
acterization of the effect of the upf1 ex1 spMO at 2 dpf by RT-PCR analysis. Injection of 3 ng upf1 
splice-blocking morpholino resulted in the partial skipping of 17 or 29 nt at the 3’ end of upf1 exon 
1, leading to premature termination of Upf1 translation. (B) Characterization of the effect of NMD 
inhibition on stabilization of PE40-containing ush2a transcripts by RT-PCR analysis (2 dpf). PCR (-): 
MQ water PCR control; cntrl MO: control morpholino. 
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identified that the upper upf1 fragment corresponds to the wildtype transcript, whereas 
the lower fragment contains a mixture of transcripts lacking the 3’ 29 or 17 nucleotides 
of upf1 exon 1. At 1 dpf, no correctly spliced upf1 could be detected (Supplemental Fig. 
4), although ush2a transcripts could not be detected yet at this developmental stage. 
At 2.5 dpf, the amount of correctly splice upf1 mRNA was still strongly reduced. While 
similar levels of alternative upf1 splicing were previously shown to inhibit NMD 16, we 
did not observe an increase or stabilization of PE40-containing ush2a transcripts (Fig. 
4b). We therefore conclude that PE40-containing ush2a transcripts are not amenable 
to NMD in zebrafish and that human USH2A PE40 is poorly recognized by the zebrafish 
splicing machinery.
Morpholino-based splice redirection in ush2aPE40/PE40 zebrafish 
Although with low efficiency, human USH2A PE40 was incorporated in part of the ze-
brafish ush2a transcripts. This provided us the opportunity to use a PE40-targeting anti-
sense morpholino in order to redirect aberrant splicing in vivo. We previously designed 
antisense oligonucleotides capable of correcting aberrant splicing of USH2A pre-mRNA 
as a consequence of the c.7595-2144A>G mutation 8. A PE40-targeting morpholino 
(PE40_MO) was designed with a sequence that was highly similar to our previously 
used AON1. RT-PCR analysis using cDNA derived from MO-injected ush2aPE40/PE40 larvae 
showed that injection of 1 ng of PE40_MO already induced splice correction (Fig. 5a). 
The ratio between PE40-containing ush2a transcripts and transcripts lacking PE40 was 
determined by quantitative RT-PCR analyses after injection of 3 ng PE40_MO. Although 
not statistically significant, morpholino (3 ng) treatment decreased the amount of PE40-
containing ush2a transcripts from 4.4% (± 2.0%) in untreated ush2aPE40/PE40 larvae to 
1.3% (± 0.03%) (Fig. 5b), while the total amount of ush2a transcripts was not altered 
after treatment (Fig 5c). 
Immunohistochemical analyses of zebrafish retinas
Inclusion of PE40 in the ush2a transcript is predicted to result in a frameshift and 
premature termination of usherin translation. In order to study the effect on usherin ex-
pression and localization, retinal cryosections from wildtype (WT), knock-out (ush2armc1/
rmc1), ush2aPE40/PE40 and ush2aPE40/PE40 larvae treated with PE40-targeting morpholinos 
(ush2aPE40/PE40 + MO) were analyzed at 5 dpf by immunohistochemistry. The overall 
morphology and retinal lamination was similar in all analyzed retinas. Usherin was 
absent from the retina of homozygous ush2armc1/rmc1 larvae, confirming the specificity 
of the used anti-usherin antibody (Fig. 6b). No differences in usherin localization or 
expression were observed between wildtype and ush2aPE40/PE40 larvae (Fig. 6a, c). Ush2a 
splice correction after PE40_MO injection also had no detectable effect on the level of 
usherin expression (Fig. 6d). These results illustrate that the low abundance of aber-
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rantly spliced ush2a transcripts does not affect the level of usherin protein expression 
and usherin localization in the retina. 
Figure 5. Ush2a splice correction in ush2aPE40/PE40 using a PE40-targeting morpholino. (A) ush2a 
transcripts containing PE40 (upper bands) or transcripts lacking PE40 (lower bands) were amplified 
by RT-PCR and visualized on an agarose gel. Actb amplification is shown as a loading control. PCR(-) 
is a negative template control. (B) Quantitative RT-PCR analysis of transcripts derived from either 
wild-type larvae (WT), untreated ush2aPE40/PE40 larvae (ush2aPE40/PE40) or ush2aPE40/PE40 larvae injected 
with 3 ng of PE40 targeting morpholino (ush2aPE40/PE40 + MO). Per condition, the amount of PE40 
inclusion in the ush2a transcript is presented as the percentage of total ush2a transcripts. Data are 
expressed as mean ± SD of 2 pools of 15 larvae per condition. (C) The total amount of ush2a tran-
scripts (sum of PE40-containing transcripts and transcripts lacking PE40) is plotted as a bar graph. All 
values are normalized to rpl13a expression. Data are expressed as mean ± SD of 2 pools of 15 larvae 
per condition. One-way ANOVA followed by Holm-Sidak’s multiple comparisons test revealed no 
significant differences between groups. ND = not detectable.
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Splice site optimization for the recognition of human USH2A PE40 by the 
zebrafish splicing machinery
We were intrigued by the vast difference in amount of ush2a transcripts that con-
tain PE40 in ush2aPE40/PE40 larvae as compared to USH2A transcripts in patient-derived 
fibroblasts (Supplemental fig. 1) 8. Since we hypothesized that PE40 might be poorly 
recognized by the zebrafish splicing machinery, we used a splice site prediction tool 
(“Berkeley Drosophila Genome Project” http://www.fruitfly.org/seq_tools/splice.html) 
to analyze the strength of the PE40 splice acceptor and splice donor sites. Scores can 
range from 0 (extremely weak) to 1.0 (extremely strong). The PE40 splice acceptor site 
scored <0.1 and the PE40 splice donor site scored 1.0. Next, we compared the human 
USH2A PE40 splice acceptor and splice donor sequences with the human and zebrafish 
splice site consensus sequences as presented by Abril and colleagues 17 (Fig 7a, b). We 
identified three positions in the splice acceptor site of USH2A PE40 that were markedly 
different between the human and zebrafish splice acceptor consensus sequence (G at 
Figure 6. Immunohistochemical analyses using anti-usherin in zebrafish larval retinas (5 dpf). 
Retinal cryosections of wild-type (WT) (A), ush2armc1/rmc1 knock-out (B), ush2aPE40/PE40 (C) and mor-
pholino-injected ush2aPE40/PE40 (D) larvae were analyzed for usherin expression and localization (red 
signal). Anti-centrin antibodies (green) were used to mark the connecting cilium. Nuclei were stained 
with DAPI (blue signal). BB: basal body, CC: connecting cilium, IS: inner segment, ONL: outer nuclear 
layer, OS: outer segment. Scale bar: 10 µm.
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-8, AAG at -11/-12/-13 and C at +1) (Fig. 7b). In order to optimize the weak PE40 
splice acceptor site, ‘AAG’ at position -11/-12/-13 was substituted by ‘TTT’ (M1) and 
‘C’ at position +1 was substituted by ‘G’ (M2). In silico splice-site prediction after the 
introduction of M1 showed an increase in the strength of the splice acceptor site from 
<0.1 to 0.96. Introduction of M2 increased the splice acceptor site score to 0.60. A 
combination of M1 and M2 resulted in a splice acceptor site score of 0.99 (Fig. 7b). In 
order to examine whether PE40 recognition by the zebrafish splicing machinery could 
be enhanced by changing these positions in the splice acceptor site, we developed a 
zebrafish-specific minigene splice assay. For this, a pCI-neo-based vector was generated 
that contained the genomic sequence of zebrafish opn1sw2 spanning exons 3 to 5. 
Human PE40 flanked by 250 bp up- and downstream sequence was cloned between 
opn1sw2 exons 3 and 4 (Fig. 7c). We next introduced M1 and M2 in the minigene splice 
vector (Fig. 7c) and analyzed the transcripts by RT-PCR after transfection in a zebrafish 
epithelium-derived cell line (Zendo-1) (Fig. 7d). The low level of human USH2A PE40 
recognition as a consequence of the c.7595-2144A>G mutation by the zebrafish splic-
ing machinery was mimicked in the zebrafish-specific minigene splice assay (Fig. 7d, 
lane 2). Introduction of either M1 or M1+2 in addition to the c.7595-2144A>G mutation 
resulted in the incorporation of PE40 in nearly all transcripts (Fig. 7d, lanes 4 and 8). 
The contribution of M2 was only minor (Fig. 7d, lane 2 versus 6). Furthermore, the effect 
of M1, M2 and M1+2 was fully dependent on the presence of the c.7595-2144A>G 
mutation (Fig. 7d, lanes 1, 3, 5 and 7).
DISCUSSION
In this study we generated a humanized zebrafish model using an optimized 
CRISPR/Cas9-based protocol. Our aim was to elucidate the pathogenic mechanism un-
derlying USH2A-associated retinal dysfunction as a consequence of the deep-intronic 
c.7595-2144A>G mutation and to determine the therapeutic potential of antisense 
oligonucleotide-based correction of aberrant ush2a pre-mRNA splicing in vivo 8. How-
ever, human USH2A pseudoexon 40 was significantly less efficiently incorporated into 
the zebrafish ush2a transcript than it was in fibroblasts of a patient homozygous for the 
c.7595-2144A>G mutation. 
CRISPR/Cas9-based genome editing has been frequently used to generate cellular 
and animal models with random insertions and deletions. However, models gener-
ated by precise genome editing are only sporadically described 18. Supplementing the 
CRISPR/Cas9 system with a template vector could theoretically result in alleles that 
have incorporated the provided template sequence by a homology-directed repair 
(HDR)-based mechanism. However, using this strategy we were unable to detect any 
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Figure 7. Optimization of human USH2A PE40 splice acceptor site for improved recognition 
by the zebrafish splicing machinery. (A) The nucleotide distribution of the splice donor site found 
in man (h.s.) and zebrafish (d.r.) is displayed for both species per position in one column 17. The PE40 
splice donor sequence is presented under the splice donor sites with the c.7595-2144A>G mutation, 
indicated by an asterisk, present on the +1 position relative to the last nucleotide of PE40. (B) Similar 
as in (A), the PE40 splice acceptor sequence is presented under the consensus splice acceptor sites as 
used in human (h.s.) and zebrafish (d.r.). Based on these comparisons, we choose two sites (M1 and 
M2) that were each predicted to result in a stronger PE40 splice acceptor site, the predicted strength 
of the splice acceptor site is indicated in brackets. (C) A zebrafish-specific minigene splice assay con-
taining the human USH2A PE40 with flanking sequences cloned between zebrafish opn1sw2 exon 3 
and exons 4 + 5 was generated. The plasmids, either containing the c.7595-2144A>G mutation (mut) 
or not (wt), included M1, M2 or M1+2 (indicated by vertical arrows). (D) The effect of the introduc-
tion of M1 and/or M2 on recognition of human USH2A PE40 after expression in zebrafish epithelial 
cells (Zendo-1) determined by RT-PCR using primers targeting opn1sw2 exon 3 and 5. The upper 
band represents transcripts that contain USH2A PE40 whereas the lower bands represent opn1sw2 
transcripts lacking USH2A PE40. untr.: untransfected cells, PCR(-): negative template PCR control. 
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knock-in events in zebrafish larvae. The efficiency of this method is limited by non-
homologous end joining (NHEJ), an alternative DNA repair pathway that competes with 
homology-directed repair (HDR). Therefore, we exploited an improved HDR-mediated 
knock-in strategy containing two adjustments to the existing protocol. First, to promote 
HDR at the expense of NHEJ, we downregulated the expression of ku70, which is a 
key component of NHEJ-mediated DNA repair. The same effect can also be achieved 
by supplementing target cells with a small molecule inhibitor of NHEJ, such as SCR7, 
L755507 or resveratrol 19-21. In case of zebrafish embryos, morpholino-induced inhibi-
tion of NHEJ is preferred due to the temporal effect of morpholinos. For this reason, 
potential morpholino-induced toxicity is diminished after a few days, which is uncertain 
when using SCR7, L755507 or resveratrol in zebrafish larvae. A further increase of the 
HDR-mediated knock-in efficiency by approximately three-fold might be achieved 
by overexpression of Rad52, a protein known to be involved in HDR 22. Our second 
improvement was based on previously published experiments in HEK293T cells that 
demonstrated a more efficient HDR-mediated repair when using a linear DNA template 
as compared to using a circular template vector 23. We used the design of Irion and col-
leagues who showed a significant improvement of the HDR-based knock-in efficiency in 
zebrafish when adding gRNA target sites up- and downstream of the left and right ho-
mology arms, respectively, presumably resulting in the excision of the fragment in vivo 
while circumventing toxic effects that are often observed after injection of linear DNA 14. 
By adding gRNA target sites in the template vector and blocking NHEJ-mediated repair, 
we were able to significantly increase the efficiency of HDR and introduce the human 
PE40 sequence into the zebrafish genome in a targeted manner.
Knock-in animal models recapitulating splice defects as observed in various inher-
ited disorders have been generated with the purpose of studying disease pathology and 
evaluating potential therapeutic strategies 24-29. For Usher syndrome type Ic, a human-
ized mouse has been generated to model the consequences of the recurrent c.216G>A 
mutation in USH1C 30. The c.216G>A mutation activates a cryptic splice donor site that 
results in the skipping of the last 35 nucleotides of exon 3 in both humans and this 
mouse model, although the original splice donor site is predicted to be stronger than 
the c.216G>A-activated cryptic splice site 30. Humanized zebrafish models for deep-
intronic mutations resulting in pseudoexon inclusion have not been generated to our 
knowledge. Nevertheless, zebrafish have been used to model splice-site mutations, for 
instance by disrupting the splice donor site in intron 14 of col6a1 to mimic exon 14 
skipping as observed in patients with collagen I defects (known as Bethlem myopathy) 
31. However, some animal models fail to recapitulate human splice defects, which is also 
the case for our humanized USH2A zebrafish knock-in model. As our data suggests 
that PE40-containing ush2a transcripts are not subjective to NMD, we expect that the 
zebrafish splicing machinery does not efficiently recognize human USH2A PE40. 
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As human and zebrafish consensus splice-site sequences are highly similar 17, it 
is difficult to predict the efficiency of human splice-site recognition by the zebrafish 
splicing machinery purely based on bio-informatic analyses. The consensus splice-site 
sequences in man and mouse are also highly comparable. Nevertheless, differences in 
human splice-site recognition by the murine and human splice machinery have recently 
been reported after modeling a deep-intronic mutation in CEP290 (c.2991+1655A>G) 
and a SNP (c.315-48C) in FECH 32, 33. Further assessment of the observed inter-species 
differential splicing revealed that only the splicing machinery of non-human primates, 
but not that of dog, mouse or Drosophila, efficiently recognizes human (pseudo)ex-
ons 34. Splicing depends on a combination of small nuclear ribonucleoproteins that 
are formed at both the splice donor site of an exon and the splice acceptor site of 
the following exon in combination with a branch point sequence in between the two 
exons. These three genomic motifs are essential, but regulation of splicing involves also 
many other factors such as regulatory proteins and epigenetic marks that could differ 
between species. Therefore, even though splice consensus sequences are highly similar 
between man and zebrafish, a difference in any regulatory condition could explain a 
species-dependent differential splicing of PE40. This once more illustrates the complex-
ity of the splicing processes in different species, and highlights the importance to take 
these differences into account prior to generating humanized animal models to mimic 
disorders caused by splice-modulating mutations.
As human USH2A PE40 is poorly recognized by the zebrafish splicing machinery, we 
introduced an in vitro zebrafish-specific minigene splice assay to a priori verify human 
splice-site recognition for future modeling of human (pseudo-)exons in zebrafish. Using 
this assay, we noticed that modification of the splice acceptor site was sufficient for 
a near complete recognition of human PE40 by the zebrafish splicing machinery in 
cultured zebrafish epithelial Zendo-1 cells, although the translational value of this assay 
still needs to be proven in future in vivo experiments. 
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SUPPLEMENTAL FIGURES
Supplemental figure 1. Characterization of the effect of the ku70 splice-blocking morpholino 
(2 dpf). Injection of various amounts of morpholinos (0.1-1.0 ng) resulted in the skipping of ku70 
exon2 or in the (partial) retention of intron2, leading to a premature termination of translation. PCR 
fragments were analyzed by Sanger sequencing.
Supplemental figure 2. USH2A transcript analysis in fibroblasts derived from a patient with a 
homozygous deep-intronic c.7595-2144A>G mutation in USH2A. Alternative splicing in fibro-
blasts from a control individual (Control) and fibroblasts from a patient that is homozygous for the 
USH2A c.7595-2144A>G mutation (USH2APE40/PE40) is compared using an amplicon spanning PE40 (i.e. 
USH2A exon 39 to 42). The upper band represents transcripts that contain PE40, whereas the lower 
band represents USH2A transcripts without PE40. PCR(-): MilliQ water PCR control.
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Supplemental figure 3. Quantitative RT-PCR of total ush2a transcripts in wildtype and mutant 
ush2a larvae. ush2a expression in ush2armc1/rmc1, ush2ab1245/b1245 and ush2aPE40/PE40 mutant larvae is 
expressed as percentage of ush2a expression in wildtype larvae of the same genetic background. 
ush2a expression is determined relative to rpl13a.  Data are expressed as mean ± SD (n = 2-5 pools 
of larvae).
Supplemental figure 4. upf1 transcript analysis after morpholino knockdown. Characterization 
of the effect of the upf1 ex1 spMO at 1 dpf by RT-PCR analysis. Injection of 3 ng upf1 splice-blocking 
morpholino in ush2aPE40/PE40 larvae resulted in aberrant upf1 splicing in 100% of transcripts.
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ABSTRACT
Usher syndrome (USH) is the most common cause of combined deafblindness in man. 
Mutations in ten different genes have been associated with USH, but approximately half 
of all USH patients can be explained by mutations in USH2A. In addition, mutations in 
USH2A are the most frequent cause of nonsyndromic retinitis pigmentosa. So far, three 
founder mutations have been identified in USH2A, of which two (c.2299delG; p.Glu767fs 
and c.2276G>T; p.Cys759Phe) are located in exon 13. Therefore, this study explores the 
potential of USH2A exon 13-skipping as a future treatment option to prevent or halt 
the progression of retinal dysfunction. USH2A transcripts lacking exon 13 are predicted 
to result in the synthesis of a shortened usherin in which EFG Lam domains 5, 6 and 
7 are missing and EGF-Lam domains 4 and 8 are fused into an EGF-like domain. To 
examine the effect of ush2a exon 13-skipping at the level of visual function, we injected 
zebrafish embryos containing a homozygous protein truncating mutation in this exon 
with antisense phosphorodiamidate morpholino oligomers (PMOs). PMOs successfully 
induced the skipping of exon 13 and treatment resulted in the production of a shortened 
usherin that correctly localizes in the region of the zebrafish photoreceptor connecting 
cilium. Furthermore, treated larvae demonstrated a rescue of ERG responses, indicative 
for an improved retinal function. In conclusion, proof of concept was obtained for exon 
skipping as a future treatment for USH2A-associated retinitis pigmentosa caused by 
mutations in exon 13.
239
Ch
ap
te
r 4
Skipping Of ush2a Exon 13 Prevents Retinal Dysfunction In A Mutant Zebrafish Model
INTRODUCTION
Usher syndrome (USH) is the most common cause of inherited deafblindness in 
man, with a prevalence of approximately 1 in 20,000 individuals (Kimberling et al. 2010). 
Three clinical types of USH (USH1-3) can be distinguished based on the severity and 
progression of the hearing impairment, the age at which the initial visual problems are 
diagnosed and the presence or absence of vestibular dysfunction (Smith et al. 1994). 
Approximately two third of patients with USH suffer from USH2, which is characterized 
by congenital moderate to severe bilateral sensorineural hearing impairment in com-
bination with a slowly progressive loss of visual function as a consequence of retinitis 
pigmentosa (RP) (Millan et al. 2011, Pierrache et al. 2016). Around 85% of USH2 cases 
are explained by mutations in USH2A (Yan and Liu 2010). In addition, defects in this 
gene are also among the most prevalent causes of non-syndromic RP (nsRP), account-
ing for 12-25% of all cases (Seyedahmadi et al. 2004, Hartong, Berson, and Dryja 2006, 
McGee et al. 2010).
The USH2 auditory phenotype can be partially compensated by providing patients 
with hearing aids or cochlear implants (Hartel et al. 2017). However, for the progressive 
loss of vision currently no treatment options are available. Vision loss is the result of 
a gradual deterioration of photoreceptors, with an onset of visual complaints at an 
average age of 15 years for patients with USH2 and 25 years for patients with nsRP (Pier-
rache et al. 2016). This provides a window of opportunity for therapeutic intervention 
to prevent retinal degeneration prior to the manifestation of visual complaints. Several 
gene augmentation therapies for RPE65-, MERTK-, ABCA4-, CHM-, MYO7A-, or RS1-
associated retinal degeneration are currently under clinical evaluation (Grob et al. 2016, 
DiCarlo, Mahajan, and Tsang 2018). Furthermore, supplementing the retina of a whirlin-
deficient mouse with a healthy cDNA copy of Whrn, resulted in the restauration of the 
USH2 protein complex in photoreceptors (Zou et al. 2011). However, the development 
of USH2A gene augmentation therapy is severely hampered by the size of the coding 
sequence (15,606 nucleotides), which largely exceeds the cargo capacity of the cur-
rently used viral vehicles for gene delivery. Using CRISPR/Cas9 gene editing technology, 
researchers were able to successfully repair the prevalent USH2A c.2299delG mutation 
in patient-derived fibroblasts, albeit with a very low efficiency (Fuster-Garcia et al. 2017). 
In addition to low repair efficiencies, also potential off-target effects hamper clinical 
application of gene editing strategies at present. Therefore, the development of alterna-
tive, tailored therapeutic strategies is needed to compensate for the defects in USH2A in 
order to prevent USH2A-associated retinal degeneration in the future.
The transcript encoding the long isoform of usherin is built up by 71 coding exons, 
in which over 600 different mutations have been identified (Baux et al. 2014). In addi-
tion, four deep-intronic mutations have been reported to underlie USH2 (Vache et al. 
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2012, Liquori et al. 2016). Many mutations in USH2A are private, but three mutations are 
derived from a common ancestor and are therefore seen more frequently: c.2299delG, 
p.Glu767fs; c.2276G>T, p.Cys759Phe; and c.7595-2144A>G, p.Lys2532Thrfs*56 (Slijker-
man et al. 2016, Pennings et al. 2004, Aller et al. 2010, Baux et al. 2014). The c.2299delG 
and c.2276G>T mutations are most common, representing 27.8% and 7.1% of all patho-
genic USH2A alleles, respectively, and are both in exon 13 (Baux et al. 2014). As this 
exon consists of a multiple of three nucleotides, skipping the exon could result in the 
production of a slightly shortened protein with a potential residual function. 
In this study we explored the potential of USH2A exon 13 as a future therapeutic 
target for USH2A-associated retinal degeneration using our previously characterized 
ush2armc1/rmc1 zebrafish as a model (Dona et al. 2018). Antisense phosphorodiamidate 
morpholino oligomers (PMOs) were able to specifically induce the skipping of ush2a 
exon 13 in zebrafish larvae, which resulted in the expression of usherinΔex13 that 
properly localized at the photoreceptor periciliary membrane and in a restored retinal 
function. In summary, proof of concept was obtained for an exon skipping strategy 
as a potential future treatment option for patients with RP as a consequence of (a) 
mutation(s) in USH2A exon 13.
MATERIAL AND METHODS
In silico modelling of the effect of USH2A exon 13 skipping on EGF-lam 
protein domain structure
Models of the separate EGF-lam domains were built using the modelling script in 
the YASARA (Krieger et al. 2002) and WHAT IF (Vriend 1990) Twinset with standard 
parameters. The separate domain sequences were used, resulting in a model for each 
domain based on PDB files 4AQS (domain 4, 45% sequence identity), 3TBD (domain 
5, 46% sequence identity), 4AQS (domain 6, 44% sequence identity), 5LF2 (domain 7, 
51% sequence identity, and 1KLO (domain 8, 41% sequence identity) (https://www.rcsb.
org/). To create the fusion model of domains 4 and 8, we used the model for domain 
4 as template and swapped the C-terminal residues for their corresponding residues 
in domain 8. A subsequent energy minimization was performed to remove big errors.
Zebrafish housing and maintenance
Experimental procedures were conducted according to international and institu-
tional guidelines (RU-DEC, 2012-301). Tupfel long fin (TLF) zebrafish and the previously 
described ush2armc1/rmc1 mutants with the c.2337_2342delsinsAC (p.Cys780GlnfsTer32) 
mutation (Dona et al. 2018) were used. Zebrafish eggs were obtained from natural 
spawning. Larvae were maintained and raised by standard methods (Westerfield 2007).
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PMO design and microinjection
PMOs were designed by first assessing the target sequence for SRSF2 (SC35) exonic 
splice enhancer sites (threshold of 3.0) using the online ESE finder 3.0 tool (http://
krainer01.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home). Zebrafish ush2a 
exon 13-targeting PMOs were synthesized by Gene Tools, LCC (USA). PMOs were dis-
solved in mQ water in a stock concentration of 50 mg/µl and stored at -20oC. One nl of 
an injection mix (1-4 ng per PMO and 50% (v/v) 0.5% phenol red) was injected into the 
yolk of 1- to 2-cell-stage embryos with a Pneumatic PicoPump pv280 (World Precision 
Instruments). After injection, embryos were raised at 28.5°C in E3 embryo medium (5 
mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, and 0.33 mM MgSO4) supplemented with 0.1% 
(w/v) methylene blue. PMO sequences are listed in Table 1.
Transcript analysis
Pools of 10-15 larvae (3 dpf, unless otherwise stated) were snap frozen in liquid 
nitrogen and subsequently homogenized in 500 µl Qiazol (Qiagen, #79306) using a 25 
gauge 16 mm needle. Total RNA was isolated using phenol:chloroform extraction and 
precipitated using isopropanol. Extracted total RNA was further purified and DNAse 
treated using the Nucleospin RNA extraction kit (MACHEREY-NAGEL #740955.50) ac-
cording to manufacturer’s instructions. cDNA synthesis from 1 µg of total RNA using 
SuperScript VILO reverse transcriptase kit (#11755050; ThermoFisher Scientific) was 
performed, followed by PCR amplification (primers in zebrafish ush2a exon 11 (5 pmol; 
5’-AGCGCTGTCGGAGTCTCTTC-3’; fwd) and exon 14 (5 pmol; 5’-CTGTGACCGGTCAGT-
GATGG-3’; rev)) using Q5 HF DNA polymerase (# M0491L; New England Biolabs). Ampli-
fied fragments were analyzed by agarose gel electrophoresis (1% agarose in 0.5xTBE) 
and used for Sanger sequencing.
Table 1. Antisense PMO sequences targeting zebrafish ush2a exon 13.
Name Sequence (5’>3’) Targeted motifs
PMO-N1 GCATTTCCTGTGGCTGTGACCCATG SC35 motif 3 and 4
PMO-N2 GTTCTCTGCACCAGTTCTGTAATCC SC35 motif 5 and 6
PMO-N3 TAAGTGGTCAGTGTATCTGCCTACC SC35 motif 18
PMO-P2 AACGGTCACAGGTTAGACCTAAAAATAA Splice acceptor and SC35 motif 1
PMO-P3 GTTACAACGGTCACAGGTTAGACCTAAA Splice acceptor and SC35 motif 1
PMO-P4 AAGCACTAACCTGGTTTACAGGTTCCAC Splice donor and SC35 motif 19 and 20
Control PMO CCTCTTACCTCAGTTACAATTTATAC -
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Immunohistochemistry and quantification of fluorescence signals
Immunohistochemistry on zebrafish larval eyes using rabbit anti-usherin-C (1:500; 
#27640002; Novus Biological) and mouse anti-centrin (1:500; #04-1624) antibodies, 
the secondary antibodies Alexa Fluor 568 goat anti-rabbit (1:8000, A11011, Molecular 
Probes) and Alexa Fluor 488 goat anti-mouse (1:8000, A11029, Molecular Probes) with 
DAPI (1:8000; D1306; Molecular Probes) and subsequent quantification of the signals 
has been performed as previously described (Dona et al. 2018). Plotting of the data and 
statistical analyses were performed using GraphPad Prism v5.03. Saturated intensity 
grey values (value of 255) were excluded from the datasets (five datapoints for wild-type 
samples, seven datapoints for PMO-treated samples and none for untreated ush2armc1/
rmc1), since these values are likely derived from artifacts.
Electroretinogram (ERG) recordings
ERG recordings were performed on isolated larval eyes (6 dpf) as previously de-
scribed (Sirisi et al. 2014). Larvae were dark-adapted for a minimum of 30 minutes prior 
to the measurements and subsequently handled under dim red illumination. Larvae 
were placed on a filter paper in the middle of a plastic recording chamber which was 
filled with 1% agarose, the reference electrode was inserted into the agarose. The eye 
to be measured was removed by a loop made of tungsten wire. The loop was placed 
behind the eye and was pressed down to cut the optic nerve. Meanwhile forceps were 
used to pull the body and discard it. The isolated eye was then positioned to face 
the light source. Under visual control via a standard microscope equipped with red 
illumination (Stemi 2000C, Zeiss, Oberkochen, Germany), a glass microelectrode with 
an opening of approximately 20 µm at the tip was placed against the center of the 
cornea. This electrode was filled with E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM 
CaCl, and 0.33 mM MgSO4), the same in which the embryos were raised and held. The 
electrode was moved with a micromanipulator (M330R, World Precision Instruments 
Inc., Sarasota, USA). A custom-made stimulator was invoked to provide light pulses 
of 100 ms duration, with a light intensity of 7000 lux. It uses a ZEISS XBO 75W light 
source and a fast shutter (Uni-Blitz Model D122, Vincent Associates, Rochester, NY, USA) 
driven by a delay unit interfaced to the main ERG recording setup. Electronic signals 
were amplified 1000 times by a pre-amplifier (P55 A.C. Pre-amplifier, Astro-Med. Inc, 
Grass Technology) with a band pass between 0.1 and 100 Hz, digitized by DAQ Board 
NI PCI-6035E (National Instruments) via NI BNC-2090 accessories and displayed via 
self-developed NI Labview program. 
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RESULTS
Formation of EGF-like fusion domain after targeted USH2A exon 13 
skipping
Wild-type usherin is predicted to contain ten EGF-lam domains (http://smart.embl-
heidelberg.de/). EGF-lam domains typically contain eight cysteine residues that pairwise 
interact by a covalent disulfide bond, necessary for protein folding and stability. These 
EGF-lam domains in usherin harbor multiple protein truncating mutations. Also, 22 out 
of the 80 cysteine residues in these EGF-lam domains have been found to be mutated 
in patients with USH2A-associated RP (USH2A LOVD mutation database, http://www.
lovd.nl/USH2A), of which five reside within exon 13. Unpaired cysteine residues contain 
a reactive free thiol group that can induce unwanted multimerization or crosslinking 
with other proteins. The in frame skipping of exon 13 is predicted to result in the fu-
sion of parts of EGF-lam domains 4 and 8 into a functionally related EGF-like domain 
(Fig. 1A). EGF-like domains contain six cysteine residues that together create three 
disulfide bonds, created by cysteines 1+3, 2+4 and 5+8 in the fused EGF-like domain 
(Wouters et al. 2005). There are 16 amino acids between the fifth and sixth cysteine 
residue in the EGF-like 4-8 fusion domain, which is different from the canonical EGF-like 
cysteine spacing, namely 8 amino acids. However, 3D homology modelling predicted 
normal disulphide bridge formation within the EGF-like 4-8 fusion domain, supporting 
a favorable effect of exon 13 skipping (Fig. 1B). Therefore, skipping of USH2A exon 13 
is predicted to result in a shortened protein with a potential residual function, when 
expressed.
Design and validation of splice modulating antisense morpholinos
To validate exon 13 skipping as a therapeutic strategy, we employed our previously 
characterized mutant zebrafish (ush2armc1/rmc1) that contains a frameshift-inducing muta-
tion in ush2a exon 13 (Dona et al. 2018). The length of USH2A exon 13 is reasonably 
well conserved between human (642 nucleotides) and zebrafish (648 nucleotides). 
Therefore, three antisense PMOs were designed to target the zebrafish ush2a exon 13 
splice acceptor (PMO-P2, PMO-P3) or splice donor sites (PMO-P4). Previous studies 
demonstrated a positive correlation between the exon skipping efficiency of antisense 
oligonucleotides and the presence of exonic splice enhancer (ESE) motifs recognized 
by splice factors SRSF2 (SC35), SRSF1 (SF2/ASF) and SRSF5 or other types of splice 
enhancers (Aartsma-Rus et al. 2009). We analyzed the sequence of zebrafish ush2a exon 
13 for the presence of SC35 splice factor binding sites using the online ESE finder 3.0 
program (http://krainer01.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home). 
Using a stringent threshold of 3.0, the algorithm identified twenty predicted SC35 splice 
factor binding sites (Fig. 2), based on which three additional PMOs (PMO-N1, PMO-N2 
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and PMO-N3) were designed following the previously published guidelines for AON 
design (Aartsma-Rus 2012) (sequences in Table 1). 
Figure 1. In silico modelling of usherin after exon 13 skipping. (A) Schematic representation of 
the domain architecture of wild-type usherin and usherinΔexon13. Individual EGF-lam domains are 
numbered. Skipping of exon 13 results in the exclusion of EGF-lam domains 5, 6 and 7 as well as the 
partial exclusion of EGF-lam domains 4 and 8. The remaining amino acids of EGF-lam domains 4 and 
8 are predicted to form an EGF-like domain with six cysteine residues. The fusion site of this domain is 
located between the fifth cysteine residue of EGF-lam domain 4 and the eighth cysteine derived from 
EGF-lam 8. (B) 3D homology modelling predicts the formation of a properly folded EGF-like domain 
with normal disulphide bridge formations. The predicted structures of usherin EGF-lam domains 4 
(left) to 8 (right) are shown. The amino acids that are encoded by USH2A exon 13 are depicted in 
grey and predicted to be absent after translation of USH2A Δexon13 transcripts. Cysteine residues 
that are present in the EGF-like fusion domain are numbered and indicated in orange. The cysteine 
residues numbered 1 to 5 are derived from EGF-lam domain 4, whereas residue 8 is derived from 
EGF-lam domain 8.
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Different doses (2, 4 or 8 pg) of individual PMOs were injected into the yolk of 
one- to two-cell stage wild-type zebrafish embryos to assess their efficacy in ush2a 
exon 13 skipping. RT-PCR analyses revealed that PMO-N1, PMO-P2 and PMO-P3 were 
able to induce a significant skipping of exon 13, whereas PMO-N2, PMO-N3 or PMO-P4 
were not (Supplemental Fig. 1). Since PMO-N1 targets a different region of exon 13 
than PMO-P2 and PMO-P3 (Fig. 2), we assessed whether the injection of a combination 
of PMO-N1 with either PMO-P2 or PMO-P3 would result in an enhanced efficiency in 
exon 13 skipping. For this purpose, different doses of the PMO-cocktails PMO-N1 + P2 
and PMO-N1 + P3 (2+2 pg, 3+3 pg and 4+4 pg) were injected in wild-type embryos. 
ush2a transcript analysis at three days post injection revealed a near complete skipping 
of zebrafish ush2a exon 13 already after injection of the lowest dose of PMOs (2+2 pg) 
(Fig. 3A). Sanger sequencing of the PCR products confirmed the precise skipping of 
ush2a exon 13, since exon 12 is directly fused to exon 14 (Fig. 3B).
Ush2a exon 13 skipping restores ERG b-wave amplitudes in ush2armc1/rmc1 
larvae
We previously reported that electroretinogram (ERG) traces are significantly reduced 
in ush2armc1/rmc1 larvae (Dona et al. 2018). Here, we recorded ERGs from ush2armc1/rmc1 
larvae that were treated with combinations of ush2a exon 13-targeting PMOs (PMO-N1 
Figure 2. SC35 splice factor binding sites in ush2a exon 13. Target sites of the individual PMOs 
are indicated in the plot. Numbers indicate the first and last nucleotide of the PMO target sequences 
in zebrafish ush2a exon 13. The bars represent the SC35 splice factor binding sites. Prediction scores 
are indicated on the Y-axis and the ush2a sequence on the X-axis.
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+ P2 (4+4 pg) (n=14); PMO-N1 + P3 (4+4 pg) (n=25)) or control PMOs (8 pg) (n=14). 
Larvae were derived from the same clutch. ERGs recorded from uninjected age-, strain-, 
and clutch-matched wild-type (n=10) and ush2armc1/rmc1 (n=11) larvae were used as con-
trols. We first confirmed the efficiency of ush2a exon 13 skipping by RT-PCR analysis of 
RNA derived from PMO-injected larvae (Fig. 4A). Uninjected and control PMO-injected 
ush2armc1/rmc1 mutant larvae demonstrated a significantly reduced b-wave amplitude as 
compared to age- and strain-matched wild-type larvae (p<0.05 (uninjected) and p<0.01 
(control PMO-injected)) (Fig. 4B, C). We observed significantly increased b-wave am-
plitudes after injection of either PMO combination (PMO-N1 + P2 (4+4 pg) or PMO-N1 
+ P3 (4+4 pg)) as compared to untreated or control PMO-injected ush2armc1/rmc1 larvae, 
which is indicative of an improved excitation of the secondary neurons. The ERG b-wave 
amplitudes recorded in ush2armc1/rmc1 larvae after injection with exon 13-targeting PMOs 
were not different from those recorded in age- and strain-matched wild-type larvae 
(Fig. 4B, C).
Figure 3. ush2a exon 13 skipping potential of combinations of morpholinos in wild-type ze-
brafish larvae. (A) RT-PCR analyses to evaluate the ush2a exon 13 skipping potential of different 
combinations of PMOs (PMO-N1 + P2 and PMO-N1 + P3). (B) Chromatogram of the lower fragment 
(488 bp) showing a perfect skipping of ush2a exon 13 after PMO treatment.
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Figure 4 Morpholino-induced exon 
13 skipping restores ERG b-wave 
amplitudes in ush2armc1/rmc1 larvae. 
(A) ush2a transcript analysis after 
injection of ush2a exon 13-target-
ing PMOs. The larger PCR product 
(1096 bp, indicated by ‘ush2a wild-
type’) represents wild-type spliced 
ush2a transcripts, whereas the smaller 
product (448 bp, indicated by ‘ush2a 
Δexon 13’) represents ush2a tran-
scripts lacking exon 13. (B) Average 
ERG b-wave amplitudes recorded in a 
cohort of uninjected or control PMO-
injected ush2armc1/rmc1 larvae (5-6 dpf) 
and age- and strain-matched wild-
type controls. Skipping of ush2a exon 
13 from ush2armc1/rmc1 larvae restored 
ERG b-wave amplitudes to wild-type 
levels (‘n’ in the legend panel indi-
cates the number of injected larvae 
in 2 biological replicates). (C) Average 
maximum b-wave amplitudes record-
ed in uninjected (p<0.05, indicated by 
‘*’) and control PMO-injected (p<0.01, 
indicated by ‘**’) ush2armc1/rmc1 larvae 
are significantly reduced as com-
pared to those recorded in wild-type 
controls (n=10 wild-type, n=11 unin-
jected ush2armc1/rmc1 and n=14 control 
PMO-injected ush2armc1/rmc1; 2 bio-
logical replicates; two-tailed unpaired 
Student’s t-test). B-wave amplitudes 
recorded in PMO-N1 + P2- (p<0.001, 
indicated by ‘***’) or PMO-N1 + P3-
injected (p<0.01, indicated by ‘**’) 
ush2armc1/rmc1 larvae are significantly 
higher as compared to ERG-traces 
from control PMO-injected ush2armc1/
rmc1 mutants from the same clutch, 
while not being significantly differ-
ent from b-wave amplitudes record-
ed from uninjected wild-type larvae 
(PMO-N1 + P2 injected ush2armc1/
rmc1 (n=14), PMO-N1 + P3 injected 
ush2armc1/rmc1 (n=25) and wild-types 
(n=10); 2 biological replicates; two-
tailed unpaired Student’s t-test). n.s., 
not significant.
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Figure 5. Skipping of ush2a exon 13 partially restores the expression of usherin in the pho-
toreceptor periciliary region. (A) Schematic presentation of usherin localization in the zebrafish 
retina. Usherin (red) or usherinΔexon13 (pink) localize at the photoreceptor periciliary region, adja-
cent to the connecting cilium marked by centrin (green). Photoreceptors from ush2armc1/rmc1 larvae 
completely lack usherin. (B) Subcellular localization of usherin in radial cryosections of larval (5 dpf) 
zebrafish retinae using anti-usherin-C antibodies (red signal). Nuclei were stained with DAPI (blue 
signal). In wild-type larvae, usherin is present in the photoreceptor periciliary region. In ush2armc1/
rmc1 larvae, no specific usherin signal could be detected. Skipping of ush2a exon 13 in ush2armc1/
rmc1 larvae (ush2armc1/rmc1 + MO-N1+P3 (1+1 ng)) resulted in a partial restoration of usherin expression 
and localization. RPE: retinal pigment epithelium; OS: outer segment; CC: connecting cilium; IS: inner 
segment; ONL: outer nuclear layer; OPL: outer plexiform layer; IPL: inner plexiform layer. Scale bars 
represent 20 µm. (C) Transcript analysis confirmed that injection of MO-N1+P3 (1+1 ng) efficiently 
induces ush2a exon 13 skipping in ush2armc1/rmc1 larvae. 
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UsherinΔexon13 is expressed and localizes in the photoreceptor 
periciliary region 
We next determined whether skipping of zebrafish ush2a exon 13 in 
the ush2armc1/rmc1 mutant larvae resulted in the synthesis of a shortened usherin protein 
(usherinΔexon13) (Fig. 5A). Antibodies directed against the intracellular region of ze-
brafish usherin were used to stain unfixed cryosections of wild-type larvae, uninjected 
ush2armc1/rmc1 larvae and ush2armc1/rmc1 larvae in which ush2a exon 13 skipping was induced 
by PMO injection (Fig. 5B, red signal). The connecting cilium was marked by antibodies 
directed against centrin (Fig. 5B, green signal). In wild-type larvae usherin localizes in 
the periciliary region, as expected. In the retina of uninjected ush2armc1/rmc1 larvae no 
usherin could be detected. In PMO-treated ush2armc1/rmc1 larvae a partial restoration of 
usherin expression was detected with a proper subcellular localization. The intensity of 
the anti-usherin fluorescence signals was quantified using an automated Fiji script, after 
confirmation of the exon 13 skipping efficiency in the injected larvae (Fig. 5C). Skipping 
of ush2a exon 13 resulted in a small but significant increase of the average fluorescence 
intensity as compared to untreated larvae from the same clutch (34.98 ± 0.14 (Δexon 
13) versus 30.04 ± 0.16 (untreated); p<0.001 (two-tailed Student’s t-test)) (Fig. 5D). This 
further corroborated that exon 13-skipping resulted in the synthesis of usherinΔexon13. 
Figure 5. Skipping of ush2a exon 13 partially restores the expression of usherin in the photo-
receptor periciliary region. (continued)
The upper band represents ush2a transcripts with a wild-type pattern of transcript splicing (WT), 
whereas the lower band represents ush2a transcripts lacking exon 13 (Δexon13). (D) Quantification 
of usherin labeling (red signal) in the photoreceptor periciliary region in PMO-treated ush2armc1/rmc1 
larvae as compared to wild-type and untreated ush2armc1/rmc1 larvae. Each datapoint in the scatter 
graph displays the intensity grey value of a single photoreceptor. Exon 13 skipping results in a sig-
nificant increase of fluorescence intensity as compared to untreated ush2armc1/rmc1 mutants (34.98 ± 
0.14 grayscale value in PMO-treated retinas versus 30.04 ± 0.16 grayscale value in untreated retinas; 
p<0.001 (indicated by ‘***’, two-tailed Student’s t-test)). The average grayscale intensity value as mea-
sured in wild-type retinas was significantly higher as compared to PMO-treated ush2armc1/rmc1 retinas 
(66.42 ± 0.32 versus 34.98 ± 0.14; p<0.001). In total, 10 to 12 eyes were analyzed per condition and 
genotype, of which 31 sections (6580 connecting cilia) of wild-type, 43 sections (8474 connecting 
cilia) of PMO-treated and 21 sections (4201 connecting cilia) of untreated ush2armc1/rmc1 larvae were 
analyzed.
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DISCUSSION
In this study we used PMOs targeting ush2a exon 13 to evaluate exon skipping as a 
therapeutic strategy for the future treatment of USH2A-associated retinal dysfunction. 
A zebrafish model with a frameshift mutation in ush2a exon 13 (ush2armc1/rmc1) lacks 
usherin in the region of the photoreceptor connecting cilium and displays early-onset 
retinal dysfunction (Dona et al. 2018). We here show that skipping of ush2a exon 13 
in larvae of this mutant resulted in a partially restored expression of usherin in the 
region of the photoreceptor connecting cilium. Furthermore, exon 13-skipping restored 
ERG b-wave amplitudes, indicative of an improved retinal function. Our study therefore 
provides proof of concept for an exon skipping strategy as a potential future treatment 
for USH2A-associated retinal dysfunction as a consequence of mutations in exon 13, 
such as the recurrent c.2299delG or c.2276G>T mutations.
In the inner ear, usherin is essential for the maturation of hair bundles that are located 
at the apex of hair cells. Usherin and ADGRV1 together form the transient ankle links 
between adjacent stereocilia and between the tallest stereocilium and the kinocilium 
(Michalski et al. 2007). Hair bundle formation and subsequent mechanotransduction 
requires a very strict and tightly regulated spacing between adjacent stereocilia. This 
is further corroborated by the extremely high conservation of the length and domain 
architecture of the usherin protein throughout the complete vertebrate lineage (Dona et 
al. 2018). Also in the Anthozoan Nematostella vectensis usherin has the same architec-
ture (Tucker 2010). In the latter, Usher proteins are proposed to have a similar function 
in the maturation of stereocilia on cnidocytes, which are specialized cells that fire a barb 
and thread upon touch stimulation (Michel, Sabourault, and Petit 2018). In the retina, 
the large extracellular tails of usherin and ADGRV1 have been proposed to interact 
and together bridge the gap between the opposing membranes of the photoreceptor 
connecting cilium and periciliary region (Maerker et al. 2008, Sorusch et al. 2017). In 
contrast to the situation in the inner ear hair cells, usherin seems redundant for the 
initial development and function of photoreceptors (Maerker et al. 2008), but rather 
fulfills a post-developmental role. As such, usherin seems to be particularly important 
for photoreceptor maintenance (Liu et al. 2007). Therefore, therapeutic strategies that 
rescue the expression of usherin in the functional retina could potentially prevent or 
slow down the progression of photoreceptor degeneration and, as such, preserve visual 
function in patients.
Many mutations in USH2A are private and evenly distributed over the gene. They 
include nonsense, frame-shift, splice-modulating, and missense variants. It is gener-
ally believed that RP due to mutations in this gene is caused by a loss-of-function 
mechanism, although endoplasmic reticulum-stress has been suggested as the disease 
mechanism for missense mutations (Tucker et al. 2013). An alternative for gene aug-
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mentation therapy is the skipping of exons harboring pathogenic mutations, which has 
already been shown to have a high therapeutic potential for Duchenne Muscular Dys-
trophy (DMD) and Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts 
and Leukoencephalopathy (CADASIL). This approach is particularly interesting for large 
genes encoding (structural) proteins that contain series of repetitive protein domains. 
Dystrophin, encoded by the DMD gene, is a rod-shaped structural linker protein con-
sisting of a stretch of 24 spectrin-like domains flanked by protein-protein interaction 
domains that are used to connect the F-actin cytoskeleton to β-dystroglycan (Mendell 
et al. 2013, Mendell et al. 2016). Protein truncating mutations in DMD give rise to the se-
vere DMD, whereas missense mutations generally result into the milder Becker Muscular 
Dystrophy (BMD) (Monaco et al. 1988). This genotype-phenotype correlation was the 
basis of the rationale to correct the DMD reading frame as a therapeutic strategy. This 
was further corroborated by the identification of partial in frame deletions of DMD in 
patients with BMD (Nakamura et al. 2016, Nakamura et al. 2017). Indeed, induced skip-
ping of DMD exon 51 in patients with a protein truncating mutation in this exon resulted 
in an increase of dystrophin-positive fibers and a delayed muscle degeneration (Aoki et 
al. 2012). Usherin is a large structural protein that contains repetitive EGF-lam and FN3 
domains. The in frame USH2A exon 13, the exon in which two founder mutations have 
been identified, encodes part of a stretch of ten EGF-lam domains, that is proposed to 
form a stiff rod-like element (Beck, Hunter, and Engel 1990, Campbell and Bork 1993, 
Yurchenco and Cheng 1993). Skipping of this exon could therefore well result in the 
expression of a slightly shortened protein with residual function.
Exons should meet certain criteria in order to be eligible as a target in therapeutic 
exon-skipping approaches (Niks and Aartsma-Rus 2017). The exclusion of the target 
exon from the transcript should not result in a frameshift. Furthermore, the target exon 
should not encode any essential protein domains. In addition, the Δexon transcript 
should give rise to a protein that is able to fold properly. For example, mutations in 
NOTCH3 typically result in the loss or gain of a cysteine residue in one of the 34 EGF-like 
domains and clinically manifest as CADASIL (Rutten et al. 2014). The skipping of selected, 
mutated exons was shown to result in the formation of EGF-like fusion domains that 
are structurally similar to wild-type EGF-like domains. The resulting shortened NOTCH3 
protein was shown to undergo normal processing and to retain ligand-induced activa-
tion (Rutten et al. 2016). In line with Rutten et al., USH2A exon 13 also seems to fulfill the 
criteria for exon-skipping. This in frame exon (642 nucleotides) encodes multiple EGF-
lam domains and in silico predictions and 3D homology modelling demonstrated that 
EGF-lam domains 4 and 8, that are both in part encoded by exon 13, fuse into a properly 
folded EGF-like domain after skipping of USH2A exon 13. However, the spacing between 
cysteine residues 5 and 6 in the resulting EGF-like 4-8 fusion domain of usherinΔexon13 
is 16 amino acids, which significantly differs from the reported consensus spacing (8 
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amino acids) in EGF-like domains. A certain variation in spacing between the fifth and 
sixth cysteine residue in EGF-like domains is tolerated and has been reported (http://
smart.embl-heidelberg.de/). For example, the spacing between cysteine residues 5 and 
6 in EGF-like domains 1 and 2 of UMODL1, a transmembrane protein in which variants 
have been suggested to be associated with high myopia in the Japanese population 
(Nishizaki et al. 2009), is 18 and 15 amino acids, respectively. 
To assess the functionality of the usherinΔexon13 protein, we employed the recently 
published ush2armc1/rmc1 zebrafish mutant, which has a homozygous protein truncating 
mutation in exon 13 and shows an early onset retinal dysfunction (Dona et al. 2018). 
First of all, a small but significant increase in usherin labeling at the photoreceptor 
periciliary membrane of PMO-treated ush2armc1/rmc1 larvae was observed, which indi-
cates that ush2a Δexon13 transcripts result in the synthesis of a shortened usherin that 
is able to properly localize in the retina. Furthermore, PMO-induced skipping of the 
mutated exon 13 resulted in completely restored ERG b-wave amplitudes, indicative of 
a restored visual function. ERG responses were recorded in larvae (5-6 dpf), which are 
known to have an immature retina. Rods do not significantly contribute to the zebrafish 
ERG until 15 dpf and therefore all responses recorded in these larvae are expected 
to be cone-derived (Branchek 1984, Bilotta, Saszik, and Sutherland 2001). Patients 
with USH2A-associated RP often present with night-blindness as the initial symptom 
of retinal dysfunction, indicating a primary dysfunction of the rods. However, it was 
recently reported that both rod and cone responses were markedly reduced in the ERGs 
of adolescent USH2a patients (Sengillo et al. 2017). Therefore, a restored ERG response 
in zebrafish ush2armc1/rmc1 larvae upon exon 13 skipping is promising for a beneficial 
effect in patients. In summary, we confirmed that usherinΔexon13 is functional based on 
the partially restored usherin expression and improved retinal function in PMO-treated 
ush2armc1/rmc1 larvae. 
The minimal amount of usherinΔexon13 that is required for a normal retinal func-
tion is still unknown. Although, individuals that carry a heterozygous loss of function 
mutation in USH2A are asymptomatic, indicating that about 50% of usherin would 
theoretically be sufficient. The level of usherinΔexon13 expression and localization in 
PMO-treated zebrafish larvae has been determined based on fluorescence intensity 
measurements after immunohistochemistry. Surprisingly little usherinΔexon13 was de-
tected in the retina of injected larvae, even though retinal function was completely 
restored. This either indicates that only a minor amount of usherin is sufficient for 
retinal function, or that the total amount of usherin expression after PMO treatment 
was significantly under estimated. Quantification of protein expression levels based on 
immunohistochemistry is semi-quantitative at best. More direct quantification meth-
ods, such as Western blotting, would be more accurate although these are technically 
challenging due to the large size of usherin. Alternatively, restoration of expression 
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and subcellular localization of key usherin interaction partners, such as Whrna and 
Whrnb, which have been previously shown to be reduced in untreated ush2armc1/rmc1 
larvae (Dona et al. 2018), could serve as biomarker for therapeutic efficacy. In addition, 
functional analyses can be extended with visual-motor response measurements, which 
were previously found to be attenuated in ush2armc1/rmc1 larvae (Dona, Van den Bos, and 
Van Wyk Manuscript in preparation).
In conclusion, proof of concept was obtained for exon-skipping as a potential 
therapeutic strategy for USH2A-associated RP. Zebrafish and human photoreceptor 
anatomy and morphology is highly similar (Slijkerman et al. 2015). As such, we expect 
that skipping of USH2A exon 13 in patients with a mutation in this exon will likely result 
in a similar beneficial effect as observed in zebrafish. However, future studies using 
iPSC-derived 3D retinal organoids generated from skin biopsies of patients having 
mutations in USH2A exon 13 and subsequent Phase I/II clinical trials will determine the 
translational value of the results obtained from our zebrafish studies. 
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SUPPLEMENTAL FIGURES
Supplemental Figure 1. Evaluation of the ush2a exon 13 skipping potential of different PMOs. 
(A-C) PMOs that are able to induce ush2a exon 13-skipping are marked with a black bar. Transcripts 
with a wild-type splicing pattern lead to a PCR product of 1096 nucleotides and ush2a Δexon 13 tran-
scripts to a PCR product of 448 nucleotides. PMO-N1, PMO-P2 and PMO-P3 (indicated with a black 
bar) show a significant exon 13 skipping potential after injection in zebrafish embryos. The PMO-P3 
(4 ng) sample was run twice on the agarose gel. RT-PCR analysis of the PMO-N1 (2 ng) sample failed 
for technical reasons. Injection of PMO-N2, PMO-N3 and PMO-P4 did not result in a significant skip-
ping of ush2a exon 13. Efficacy of PMOs N1 and N2 was tested at 3 days post injection. The effect 
of PMO-N3, PMO-P2, PMO-P3 and PMO-P4 was evaluated at 5 days post injection. mQ: negative 
(water) control.
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ADDRESSING DEFECTS IN USH2A TO TREAT USHER SyNDROME OR NON-
SyNDROMIC RETINITIS PIGMENTOSA
It is devastating to lose both the auditory and visual senses as it will significantly 
reduce a person’s ability to perceive the world. Hearing aids and cochlear implants can 
partially compensate for severe to profound hearing impairment, but so far vision loss 
caused by progressive retinal degeneration as a consequence of retinitis pigmentosa 
(RP) is untreatable in patients with Usher syndrome. The development of therapeutic 
strategies will therefore have a large impact on patients and society. As mutations 
underlying Usher syndrome are most frequently found in USH2A (McGee et al. 2010) 
and mutations in USH2A are also the most frequent cause of non-syndromic RP (nsRP) 
(Seyedahmadi et al. 2004), the research described in this thesis focused on the devel-
opment of a potential treatment option for USH2A-associated disease. To do so, the 
zebrafish is extensively used to model USH2A-associated retinal dysfunction (chapter 
2b), to further unravel the function of the USH2 protein complex by isolation of in vivo-
assembled Usher syndrome-associated protein complexes (chapter 2c) and to develop 
and validate a therapeutic exon skipping strategy targeting USH2A transcripts (chapter 
3 and 4). These studies provide a better understanding of the role of USH2 proteins, 
such as usherin, in the retina and attempt to lay a solid foundation to delay retinal 
degeneration in patients in the future. In this chapter, the impact of the studies in this 
thesis will be discussed as well as future challenges.
IMPROvEMENTS IN GENETICALLy DIAGNOSING PATIENTS WITH USHER 
SyNDROME
Patients with Usher syndrome type 2a are born hearing impaired and usually fail the 
Newborn Hearing Screening Test. The first clinical signs of RP become apparent around 
puberty and therefore the clinical diagnosis of Usher syndrome is eventually made in 
the third decade of life at a mean age of 26 years (Pierrache et al. 2016). However, due to 
the introduction of genetic screening for hearing impairment in out-patient-clinics over 
the past decades, patients with Usher syndrome are nowadays often diagnosed before 
the onset of the retinal phenotype. A genetic diagnosis early in life is important as it will 
provide patients with a general understanding of the disease and as such will provide 
a prognosis for future functioning. Also other family members might benefit from a 
genetic diagnosis in their family planning. Furthermore, genetic therapies are devel-
oped for specific genetic defects and therefore knowledge of the genotype could make 
patients potentially eligible for treatment. In addition, the identification of pathogenic 
mutations in novel or known genes could result in the development of therapeutic op-
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tions, since existing treatment options could be redirected to newly identified mutations 
and genes. Currently, the underlying genetic cause of disease is most often identified by 
sequencing the coding regions of a patient’s genome, referred to as ‘exome sequencing’. 
By exome sequencing the underlying genetic defect is identified in approximately 63% 
of patients with RP (Haer-Wigman et al. 2017), and in 33.5% of patients with hearing 
impairment (Zazo Seco et al. 2017). For patients with USH, exome sequencing results 
in approximately 70 to 75% of the cases in a genetic diagnosis (Krawitz et al. 2014, 
Besnard et al. 2014). This percentage can be increased to 93 when combining exome 
sequencing with analyzing copy number variations, as observed in a cohort of Usher 
syndrome cases (Bonnet et al. 2016). However, the remaining 7% of Usher syndrome 
patients require an alternative strategy to identify the underlying genetic defect. Future 
genetic diagnostics should therefore include the analysis of intronic and regulatory 
sequences by using whole genome sequencing and transcript analysis.
Whole genome sequencing (WGS) will play a more and more important role in 
future DNA diagnostics to also identify deep-intronic mutations. These mutations could 
be ideal candidates for an AON-based splice redirection therapy, as was demonstrated 
for the USH2A c.7595-2144A>G mutation in this thesis (chapter 3b). Currently, the 
high costs prevent the application of genome sequencing in routine DNA diagnostics. 
However, this might change as costs have been continuously decreased during the last 
decade, driven by the ongoing rat-race for the first ‘$1000 dollar genome’ (Mardis 2006, 
Park and Kim 2016). Once financially feasible, the extraction of the underlying genetic 
defect from all benign intronic variants will raise another limitation for the applicability 
of genome sequencing. The pathogenicity of genetic variants that lead to alterations 
in amino acid sequence (e.g. missense variants) or in expression levels (e.g. nucleotide 
variants in regulatory sequences) can be addressed by in vitro cell-based assays or re-
quire the generation of a model organism containing the variant to evaluate the impact 
on a functional level. On the other hand, splice-modulating variants, that result in a 
(partial) skipping of exons or in the incorporation of a pseudoexon, can be identified by 
transcriptome sequencing. In order to analyze USH2A pre-mRNA splicing, it is essential 
to have access to cells that express the gene. As patient-derived photoreceptors and 
hair cells cannot be extracted without causing permanent damage, there is a high need 
for alternative assays and cellular models to analyze the effects of potential splice-
interfering variants in vitro.
In chapter 3b, we used patient-derived fibroblasts to analyze the effect of the 
deep-intronic c.7595-2144A>G mutation on USH2A pre-mRNA splicing, despite the 
extremely low level of USH2A expression in these cells. A more robust expression 
of USH2A can be obtained by dedifferentiating patient-derived fibroblasts or blood 
cells into induced pluripotent stem cells (iPSCs). Subsequently, USH2A expression is 
further increased when iPSCs are differentiated into photoreceptor-like cells, but this is 
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a labor-intensive and time-consuming process. Alternatively, splicing can be analyzed 
by cloning midigene vectors that contain, if possible, multiple exons and introns of the 
same gene (Sangermano et al. 2018) (chapter 3b and 3c). In conclusion, extending DNA 
diagnostics by WGS in combination with transcript analysis will expand the mutational 
spectrum of USH2A by the identification of novel deep-intronic splice-modulating vari-
ants, which can be targets for an AON-based splice correction therapy.
ZEBRAFISH AS A MODEL TO STUDy THE FUNCTION OF USH2 PROTEINS
Zebrafish as an animal model to study USH2A-associated retinitis 
pigmentosa
Wild-type and knock-out mice have been pivotal in understanding the role of Usher 
proteins in the inner ear (overview in chapter 1). The retina of mice deficient for genes 
associated with Usher syndrome type 2, however, is generally only mildly affected. 
Studying retinal dysfunction as a consequence of defects in USH2A, therefore requires 
different models. As the human retina is a highly specialized tissue with many different 
cell-types, mimicking retinal architecture in a dish is challenging. Furthermore, iPSC-
derived photoreceptors are currently not yet perfectly suited to study the function of 
usherin, as they have an underdeveloped outer segment, connecting cilium and pericili-
ary region. Additionally, the lack of supporting cells prevents the formation of a mature 
retina using iPSC-derived photoreceptors, which makes these cultures unsuitable to use 
in functional assays such as electroretinogram (ERG) measurements at this point. There-
fore, we used the zebrafish retina to study the effect of usherin depletion. The zebrafish 
is an attractive model organisms to study the effect of mutations in ush2a at the level 
of retinal function, since photoreceptor anatomy is highly similar in man and zebrafish 
(reviewed in chapter 2a). Also, usherin is highly conserved between zebrafish and man 
(chapter 2b). Various other benefits that underline the suitability of the zebrafish to 
study inherited retinal dystrophies are described after comparing all vertebrate animal 
models used in retinal research (chapter 2a). However, the capacity of zebrafish to 
regenerate damaged cells and tissues is a disadvantage for studying a progressive reti-
nal degenerative disorder (chapter 2b). Blocking the regeneration in zebrafish might 
induce a progressive retinal phenotype. For this reason, two temperature-sensitive 
mutant zebrafish that have been classified as regeneration deficient, nightcap (ncp) or 
no blastema (nbl), could potentially be used (Poss et al. 2002, Makino et al. 2005). These 
two mutant zebrafish were shown to lack cone photoreceptor regeneration upon light 
damage after a temperature shift. Alternatively, other organisms such as pigs, sheep, 
cats, dogs or non-human primates that are used to study inherited retinal dystrophies 
(chapter 2a) (Mowat et al. 2017, Ikeda et al. 2018, Ross et al. 2012, Rah et al. 2005), 
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without the ability to regenerate photoreceptors, could be used for studying the long-
term effect of USH2A mutations. Although progressive retinal degeneration might be 
prevented by its regenerative capacities, the zebrafish is still an excellent model to study 
the pathogenesis underlying ush2a-associated retinal dysfunction (chapter 2b).
Functions of the USH2 interactome
The specific loss of the intracellular region of usherin leads to a reduced visual func-
tion in zebrafish as determined by ERG recordings, even when the extracellular region 
of usherin is still anchored and present at the proper subcellular location (ush2ab1245 
mutant zebrafish) (chapter 2b). Apart from the suggested structural role for usherin in 
maintaining the proper spacing between the apical inner segment and the connecting 
cilium, together with ADGRV1 (Maerker et al. 2008), our data indicate that the intracel-
lular region of usherin has an additional function. The localization of whirlin, one of the 
key organizers of the Usher protein complex at the photoreceptor periciliary membrane, 
depends on the presence of the intracellular region of usherin in photoreceptors of both 
zebrafish (chapter 2b) and mouse (Yang et al. 2010). As loss of function mutations in 
USH2A probably also result in the absence of whirlin at specific subcellular regions of 
the human photoreceptor, unraveling the function(s) of whirlin is likely instrumental 
in understanding the underlying pathogenic mechanisms of retinal degeneration in 
Usher syndrome type 2 and may lead to the development of novel mechanism-based 
therapeutic strategies.
One way to unravel the molecular function of whirlin is the identification of novel 
interacting proteins. These interactors can potentially be used as biomarkers for moni-
toring disease progression or assessing future therapeutic efficacy. Previous research 
aiming on the dissection of the Usher interactome used conventional cell-based co-
purification assays or pull-down techniques (Kremer et al. 2006, Reiners et al. 2006, 
Bauss et al. 2014, Boldt et al. 2016, Sorusch et al. 2017). However, the cells that were 
generally used, such as HEK293T, lack the expression of photoreceptor-specific proteins. 
As such, these previous assays could have missed important clues for photoreceptor-
specific functions. Pull-down experiments using retinal lysates can detect interactions 
with retina-specific proteins, but fail to detect in vivo-assembled protein modules. To 
address previous shortcomings and to expand the whirlin interactome in the retina, we 
generated a transgenic zebrafish that expresses Strep/FLAG-tagged Whrna (SF-Whrna) 
in photoreceptors. We used the eyes of this zebrafish for the isolation of in vivo-
assembled SF-Whrna-associated protein complexes (chapter 2c). This approach yielded 
Preso1 (encoded by FRMPD4), LRRC8-channel subunits and Kir2.3-channel subunits as 
novel Whrna-associated candidate interaction partners.
Preso1 points towards a role in α-transducin translocation. It has been reported 
that the retina of whirlin knock-out mice contains an elevated threshold, from 200 lux 
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to 700 lux light intensity, for the light-dependent translocation of α-transducin from 
the outer to the inner segment of rod photoreceptors (Tian et al. 2014). The retention 
of α-transducin in the outer segment under light conditions is believed to result in the 
observed photoreceptor degeneration in these mice, as well as in mice lacking myosin 
VIIa (Tian et al. 2014). Transducin, a heterotrimeric G-protein consisting of an α, β and γ 
subunit, is essential in the visual cycle. The inactive α-subunit (α-transducin) binds GDP 
and interacts with the other two subunits for anchoring in the outer segment disk mem-
brane (Slepak and Hurley 2008). Light-activated rhodopsin activates α-transducin by 
inducing the conversion of GDP to GTP. Subsequently, α-transducin is released from the 
other subunits and activates phosphodiesterases (PDEs). In the wild-type mouse retina, 
bright light stimulation leads to the accumulation of 90% of activated α-transducin in 
the inner segment of rods within ten minutes of light exposure, possibly to alleviate the 
rods from light sensitivity and metabolic stress (Tian et al. 2014, Sokolov et al. 2002). 
The subsequent deactivation of α-transducin is considered to be the activating step that 
will heterotrimerize α-, β- and γ-transducin and relocate the complex to the membrane 
of outer segment disks (Slepak and Hurley 2008, Lobanova et al. 2007). Therefore, the 
increased light intensity threshold for α-transducin translocation in the whirler mouse 
retina may be indicative for an impaired deactivation of α-transducin. Preso1, identified 
as a direct interaction partner of whirlin, directed our attention to the GAP-inhibiting 
protein G protein signaling modulator 2 (GPSM2, also known as LGN). In the inner ear, 
GPSM2 is an interaction partner of both whirlin and Preso1 and known to be essential 
for stereocilia elongation (Mauriac et al. 2017). Interestingly, GPSM2 is also present in 
the rod inner segment where it sequestrates inactive α-transducin (Kerov, Natochin, 
and Artemyev 2005). These studies indicate that whirlin, Preso1 and GPSM2 may act 
as regulatory complex of inactive α-transducin by preventing reallocation to the outer 
segment disk membrane under bright light conditions. Based on our findings, a similar 
retinal phenotype as observed in patients with Usher syndrome type 2 might occur in 
individuals with mutations in GPSM2 or FRMPD4. However, patients with mutations in 
FRMPD4 have not been described to display retinal defects and mutations in GPSM2 
have only been reported in patients clinically diagnosed with Chudley-McCullough 
Syndrome (OMIM: 609245), of which typical features include congenital sensorineural 
hearing loss and complex brain malformations, without retinal degeneration. The oldest 
patient described with mutations in GPSM2 was at an age of 26 years when undergoing 
the clinical examinations (Doherty et al. 2012). Potential retinal dysfunction as a conse-
quence of GPSM2 mutations may become apparent later in life. To determine whether 
or not murine Frmpd4 is essential for the maintenance of photoreceptors, it would 
be essential to analyze the retina of Frmpd4 knock-out mice for α-transducin cycling 
defects and signs of retinal degeneration after treatment of a similar lighting regime 
(>700 lux light intensity) as the whirler mouse model by Tian et al. (2014). In conclusion, 
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our result that whirlin is able to directly interact with Preso1 points towards a possible 
function of whirlin, Preso1 and GPSM2 in the deactivation of α-transducin in rods.
Studying the direct interaction between whirlin and Kir2.3 might well provide a bet-
ter understanding if and how whirlin is involved in the regulation of vesicle docking at 
the base of the photoreceptor connecting cilium (chapter 2c), as has been suggested 
by others (Maerker et al. 2008, Sorusch et al. 2017, Overlack et al. 2011). Kir2.3 is a 
voltage-gated potassium channel that transports extracellular potassium into the cell 
(Hibino et al. 2010). The presence of Kir2.3 in the cell membrane is balanced by the 
amount of Kir2.3-containing vesicles that is allowed to dock and by the amount of Kir2.3 
that is again retrieved from the target membrane. At the target membrane, the docking 
process is regulated by TIP-1, which prevents the docking of Kir2.3-containing vesicles, 
and a complex of CASK and LIN7C to accept these vesicles (Yan et al. 2009). Dark-
adapted photoreceptors have a continuous influx of sodium ions via cGMP-dependent 
Na+-channels (Trudeau and Zagotta 2003). To counteract this influx, sodium ions are 
actively pumped out of the photoreceptor by Na+/K+-channels (encoded by the SLC24 
gene family, reviewed by Schnetkamp et al. 2014), thereby inducing an influx of K+ 
ions. Upon light-induced activation of the visual cycle, cGMP is converted into GMP 
which induces the closure of cGMP-dependent Na+-channels. As a consequence, the 
photoreceptor membrane hyperpolarizes, since the still open K+-channels result in a 
decrease of the intracellular K+ concentration. An equilibrium in the K+ concentration 
may be reached by an upregulation of inwardly rectifying Kir2.3-channels in the outer 
membrane of light-adapted photoreceptors. We hypothesize that the latter process is 
organized by a protein complex containing at least whirlin, CASK and LIN7C (chapter 
2c). Future studies analyzing the dark/light-associated membrane shuttling of Kir2.3 
could possibly elucidate whether or not Kir2.3-channels play a role in balancing the 
potassium concentration in light-adapted rods and unravel the potential regulatory 
function of whirlin as anchor for the upregulation of Kir2.3 expression at the membrane.
GENE EDITING
CRISPR/Cas9 technology
Editing genomic DNA by altering the nucleotide sequence has been pivotal in 
studying a broad spectrum of human diseases by the generation of cellular and animal 
models. Patients would benefit from genome editing when the underlying mutation 
could be repaired in vivo or when the technique is used to evaluate variants of unknown 
pathogenicity that are discovered in exome sequencing or WGS efforts. For instance, 
the long debate about the contribution of a Pde6b nucleotide variant and/or a viral 
intronic insertion to the retinal phenotype in the rd1 mouse model has recently come 
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to an end after using a CRISPR/Cas9 approach to independently repair either of the two 
potentially causative variants (Wu et al. 2016). Several targeted genome modification 
methods have been developed in the past years, such as homologous recombination, 
transcription activator-like effector nucleases (TALENs) and Zinc-finger nucleases (ZFNs). 
These methods are generally difficult to use due to their complex design and their 
dependence on specific sequence motifs (described in chapter 2a). The introduction 
of the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system 
has positively changed the ease of genome editing (Cong et al. 2013). The system is 
capable of inducing DNA double strand breaks (DSBs) in a targeted manner (Fig. 1) 
and introduces mutations with an unprecedented ease and efficiency. The introduction 
of this system marks the beginning of a booming era of genome editing (Jinek et al. 
Figure 1. Schematic overview of the CRISPR/Cas9 complex bound to DnA. (A) Cas9 (indicated 
in brown color) is the endonuclease that can induce a double strand break (DSB). To direct Cas9 to 
the target DNA (in green), a guide RNA (gRNA) that binds Cas9 and that is complementary to the tar-
get DNA is essential. In addition, the protospacer adjacent motif (PAM, indicated in red) is necessary 
for Cas9 to bind and cleave the target DNA sequence. Upon a DSB, there are two major natural DNA 
repair mechanisms to fuse the two DNA-ends together. (B) Non-homologous endjoining (NHEJ) 
directly ligates the two DNA ends and potentially results in the introduction of small insertions or de-
letions (in/del). (C) Alternatively, homology-direct repair (HDR) uses a template DNA sequence that 
is either present on the second allele or supplemented to the CRISPR/Cas9 components to precisely 
repair the broken DNA strands (repair). Figure adapted from: https://commons.wikimedia.org/wiki/
File:GRNA-Cas9.png.
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2012, Cong et al. 2013, Jinek et al. 2013, Cho et al. 2013). The CRISPR/Cas9 technology 
has been extensively used in the research presented in this thesis to generate zebrafish 
models for ush2a (chapters 2b and 4c), but also holds great promise for a clinical 
use. Currently, however, the two major hurdles for a clinical application of CRISPR/Cas9 
are potential off-target DNA editing and the low efficiency of homology-directed gene 
repair in differentiated cells. Recent developments to address these issues, in addition 
to what has already been described in chapter 2a and 4c, will be discussed in more 
detail in the following sections.
Reduction of CRISPR/Cas9-induced off-target effects
Efforts are ongoing to design gRNAs that lead to reduced off-target binding without 
affecting on-target effects, such as reducing the length of gRNAs (Fu et al. 2014), the 
addition of two G-nucleotides to the 5’ end of a gRNA (Cho et al. 2014), the develop-
ment of off-target prediction software based on sequence similarity to other genomic 
sequences (Doench et al. 2016) or the use of ‘nickases’ and derivatives thereof (Ran et 
al. 2013). To further reduce off-target binding of Cas9, both the labs led by Keith Young 
and Feng Zhang have experimentally optimized the Cas9 protein by mutating the amino 
acids that have been identified in being responsible for non-specific Cas9-DNA binding 
(Kleinstiver et al. 2016, Slaymaker et al. 2016). Further research revealed that it was not 
the weakened binding to DNA that increased the specificity of Cas9 to induce double 
strand breaks (DSBs), but that the proofreading domain REC3 in Cas9 triggers a state of 
inactivity upon mismatches (Chen et al. 2017). By exploiting this knowledge, a hyper-
accurate Cas9 variant (HypaCas9) was created that contains an improved proofreading 
capacity with even less off-target effects while not reducing on-target efficiency (Chen 
et al. 2017). Simultaneously, other endonucleases that are similar to Cas9 have been 
discovered, such as smaller Cas9 variants or Cpf1 (Ran et al. 2015, Zetsche et al. 2015). 
Reduction of the levels of off-target editing by combining the optimizations on gRNA 
design and endonucleases might improve the applicability of in vivo gene editing as a 
future therapeutic strategy.
Low HDR-based repair efficiencies hamper clinical use of CRISPR/Cas9-
mediated gene repair
Endonucleases, such as Cas9, induce a DSB that is repaired by DNA repair mecha-
nisms. Subsequently, the DSB is generally repaired by either non-homologous end 
joining (NHEJ)-based repair that results in small insertions or deletions or homology 
directed repair (HDR) that results in the precise repair of the damaged DNA strand 
by using a donor sequence as template. However, post-mitotic cells generally do not 
depend on HDR to repair a DSB, but rather use NHEJ-mediated DNA repair. In vivo DNA 
repair mechanisms in photoreceptors are not extensively studied. As photoreceptors 
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are fully differentiated, non-dividing cells, it can be expected that HDR-based gene 
repair in photoreceptors may not be as straightforward as observed in mitotic cells in 
vitro. The first study using CRISPR/Cas9-mediated correction of a mutation underly-
ing Usher syndrome has recently been published (Fuster-Garcia et al. 2017). However, 
only 1.7% of the USH2A alleles in patient-derived fibroblasts containing the c.2299delG 
mutation was repaired. These results illustrate that an in vivo repair of this mutation 
in non-dividing photoreceptors will most probably be difficult and highly inefficient. 
Furthermore, differences between species could have to be taken into account when 
translating results derived from animal models to man. In contrast to the human retina, 
in which the lens and cornea filter UV-light, mice have a fourth cone type that is sensi-
tive for UV light. As a consequence, the murine retina is exposed to elevated levels of 
UV-light compared to humans and therefore potentially needs more active DNA repair 
mechanisms (Yanik et al. 2017). Taking into account that gene editing relies on HDR-
mediated DNA repair, in vivo validated lab-results using murine retinas could therefore 
overrepresent the efficiency of gene repair as would be obtained when applied to the 
human retina. However, also in rat photoreceptors Suzuki and colleagues were not able 
to knock-in a DNA sequence of interest using a homology template construct after in-
troduction of a DSB, despite the presence of UV-sensitive cones in the rat retina (Suzuki 
et al. 2016). When using an adapted donor vector that contains homology-independent 
targeted integration (HITI)-sites, the authors were able to generate a NHEJ-dependent 
method for a targeted genomic sequence integration in retinal cells. Using this method, 
the missing exon 2 of Mertk could be successfully inserted at the right position in the 
genome of photoreceptors of the Royal College of Surgeons rat to avoid RP from mani-
festing (Suzuki et al. 2016). Future clinical applications of genome editing in retinal cells 
therefore potentially need to rely on an NHEJ- instead of an HDR-mediated strategy for 
efficient DNA repair.
Alternative strategies using CRISPR/Cas9 to potentially treat Usher 
syndrome
Besides precisely repairing a mutation, disruption of a dominant pathogenic allele 
could already alleviate the phenotype. However, applications for Usher syndrome seem 
to be limited due to the recessive inheritance pattern of the disease. Nevertheless, part 
of the retinal phenotype in patients with Usher syndrome might be caused by ER-stress 
as a consequence of misfolded proteins due to missense mutations (Tucker et al. 2013). 
Silencing of the corresponding pathogenic allele might therefore potentially circumvent 
ER-stress-induced apoptosis of photoreceptors. Dominant mutations in RHO are a com-
mon cause of RP (8-10%) (Latella et al. 2016), in which photoreceptor degeneration 
due to ER-stress plays an important role in the clinical manifestation (Comitato et al. 
2016). Lower levels of rhodopsin expression do not lead to haploinsufficiency, thereby 
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making it possible to use CRISPR/Cas9 to disrupt the mutated allele without the need 
for an additional gene augmentation strategy (Bakondi et al. 2016). Both a mouse and 
rat model containing dominant mutations in Rho (S334* in rat and P23H in mouse) were 
protected from retinal degeneration after in vivo treatment (Bakondi et al. 2016, Latella 
et al. 2016). The same strategy has been performed to silence a dominant allele for 
KRT12 in mice, in which the mutation creates a PAM site that was used for allele-specific 
targeting of the Cas9 (Courtney et al. 2016). Gene disruption of pathogenic USH2A 
alleles that induce ER-stress might therefore be part of a future therapeutic approach to 
treat Usher syndrome when future gene augmentation strategies allow this for USH2A. 
Alternatively, future applications of CRISPR/Cas9-based editing might not only be 
applied to DNA, but rather focus on transcripts. Editing of transcripts circumvents the 
generation of potential off-target mutations in the genome with a long-lasting effect, 
since any off-target effects on RNA level will be transient as they will be ‘washed out’ 
by newly generated transcripts. Consequently, life-time administration is required, 
which enables the clinician to optimize dosage regimes to yield sufficient amounts 
of repaired transcripts. Cas9 can be directed to target RNA molecules by addition of 
a PAMmer that introduces a protospacer adjacent motif (PAM) in trans (Nelles et al. 
2016). More recently, an endogenous RNA endonuclease family (Cas13a (also known 
as C2c2), Cas13b, Cas13c and Cas13d) has been identified, functionally similar to Cas9 
or Cpf1 (Abudayyeh et al. 2016, Shmakov et al. 2017, Smargon et al. 2017, Yan et al. 
2018, Konermann et al. 2018). RNA editing can also be achieved by coupling the RNA 
editing enzyme Adenosine Deaminase Acting on RNA (ADAR2) to aninactive (‘dead’) 
Cas13b, which circumvents the need for an RNA sequence protospacer flanking site 
(PFS, similar to PAM in DNA) motif. ADAR2 deaminates adenosine into inosine, the latter 
being functionally similar to guanosine, and is therefore more specific (Cox et al. 2017). 
Collectively, these studies highlight the feasibility of RNA editing as future alternative 
to repairing mutations at the level of DNA.
AON-INDUCED SPLICE REDIRECTION
AOns as splice modulating molecules
Gene editing or gene augmentation seem promising therapeutic strategies for sev-
eral hereditary disorders, but are not yet readily available for clinical application to treat 
patients with Usher syndrome type 2a. Next to the previously mentioned limitations for 
gene editing, the large protein coding sequence of USH2A currently hampers a gene 
augmentation strategy. Full length USH2A cDNA (15.6 kb) exceeds by far the 4.7 kb 
cargo capacity of currently available therapeutic AAV vectors. To develop a treatment 
for the near future, we focused on splice modulation. Others have demonstrated that 
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splicing can be redirected by application of either antisense oligonucleotides (AONs), 
other small molecules or modified proteins (Pagliarini, La Rosa, and Sette 2017). Small 
molecules can, for instance, stabilize the binding of splice factors to the 5’ splice site 
of SMN2 exon 7 and thereby efficiently induce exon inclusion (Woll et al. 2016). Simi-
larly, when modifying exon-specific U1 snRNAs (ExSpe U1s), the same result could be 
achieved (Dal Mas et al. 2015). However, the ease of design by following existing in 
silico guidelines make AONs easily adaptable for many target transcripts and AONs are 
therefore the preferred splice-modulating molecules (Aartsma-Rus 2012, Aartsma-Rus 
et al. 2009). AONs can be therapeutically used in two ways (Scotti and Swanson 2016). 
First, upon binding to mRNA, an RNAse-mediated degradation of the targeted mRNA 
molecule can be induced. Secondly, AONs can bind to pre-mRNA and thereby block 
certain motifs from being recognized by the spliceosome. Depending on the sequence 
motif that is targeted, AONs result in the skipping or inclusion of exons from or in the 
mature transcript, respectively.
Usher syndrome is a recessively inherited disease which holds an advantage for splice 
modulation therapy. Correction of only part, presumably half or less, of the transcripts 
is already expected to prevent or halt the progression of the phenotype. Therefore, 
besides patients that are homozygous for the USH2A c.7595-2144A>G mutation or 
mutations in USH2A exon 13, also patients that are compound heterozygous for these 
mutations are eligible for an AON-based PE40 or exon 13 exon-skipping treatment, 
increasing the population that could benefit from one therapy.
Future clinical evaluation of retinal AON treatment
The clinical development of AONs targeting USH2A PE40 (chapters 3B and 3C) or 
USH2A exon 13 (chapter 4) could potentially benefit from the experiences of clinical 
studies using a similar approach. Splice-modulating AONs have been evaluated for 
the treatment of Duchene muscular dystrophy (DMD) and spinal muscular dystrophy 
(SMA). Currently, for both diseases AON treatments have obtained market authoriza-
tion. Eteplirsen (Exondys51, Sarepta Therapeutics), a phosphorodiamidate morpholino 
oligomer (PMO) was approved for treating DMD in the U.S.A. in September 2016 (Lim, 
Maruyama, and Yokota 2017, Aartsma-Rus and Krieg 2017), while in Europe Eteplirsen is 
currently under review at the European Medicines Agency (EMA) 1. Nusinersen (Spinraza, 
Biogen), a 2ʹ-O-methoxyethyl (2’OMOE) phosphorothioate-modified AON, was allowed 
to treat SMA in both the U.S.A. (December 2016) and Europe (April 2017) (Ottesen 2017, 
Press release EMA 2017 2). An exon skipping AON similar to Eteplirsen, named Dris-
1  https://musculardystrophynews.com/2017A/01/03/chmp-reviewing-eteplirsen-as-duchenne-muscular-dystro-
phy-treatment-in-europe/
2  First medicine for spinal muscular atrophy: http://www.ema.europa.eu/docs/en_GB/document_library/Press_re-
lease/2017/04/WC500226270.pdf
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apersen and based on a 2’OMe PT backbone, was rejected for market approval by the 
Food and Drug Administration (FDA) in early 2016 due to the lack of substantial clinical 
benefit. This led to questions on the design of the trial (Hoffman and McNally 2014). The 
primary outcome measurement in this trial was the distance that DMD patients walked 
during a six-minute walking test. Mainly older individuals were included in the trial, 
as it was anticipated that these individuals could potentially show a larger improve-
ment during the six-minute walking test (Hoffman and McNally 2014). However, muscle 
cells in patients degenerate and are replaced by fibrofatty tissue. As younger patients 
still have a larger amount of myofibers, they are probably more suitable to determine 
the effectiveness of a treatment (Merlini and Sabatelli 2015). Similar to the irreversible 
degeneration of muscle fibers in DMD patients, also degenerated photoreceptors in 
patients with USH2A-associated retinal degeneration will not be restored upon splice 
redirection therapy. The best clinical effect can therefore be expected when initiating 
treatment in an early or even pre-symptomatic stage of the disease to prevent photo-
receptors from degenerating.
The amount of usherin that results from splice redirection treatment cannot be 
directly quantified in the patient’s retina. Similar difficulties have been observed in the 
design of clinical studies that analyzed the effect of DMD splice correction in muscle 
tissue. Also, several semi-quantitative methods have been used, such as western blot-
ting of the large dystrophin protein (427 kDa) or immunofluorescence analysis of tissue, 
that made the comparison of different experiments challenging (Merlini and Sabatelli 
2015). Future evaluations should therefore make use of more sophisticated methods 
of imaging and analysis of patient-derived material, such as mass spectrometry or 
other quantitative techniques (Merlini and Sabatelli 2015). But, protein levels alone are 
not always directly correlated to disease progression as became apparent when two 
Eteplirsen treated patients lost their ability to walk despite of an observed consistent 
increase in dystrophin-positive fibers (Merlini and Sabatelli 2015, Mendell et al. 2013). 
Instead of a six minute functional walking test for DMD patients, researchers pointed 
out that the primary outcome measurement to analyze treatment efficacy should be 
focused on monitoring cell defects and the underlying pathomechanism of disease 
(Aartsma-Rus 2014, Merlini and Sabatelli 2015). Evaluation of iPSC-derived photorecep-
tors containing defects in USH2A pointed towards a possible increase in ER stress as a 
consequence of protein accumulation (Tucker et al. 2013). Thioflavin T, a fluorescent dye 
that binds protein aggregates and is otherwise known as Pittsburgh Compound-B, is 
already used to image plaque formation in patients with Alzheimer’s disease (Cai, Innis, 
and Pike 2007) and could therefore potentially also be employed as in vivo monitor of 
retinal ER-stress (Beriault and Werstuck 2013).
Novel readouts for photoreceptor functioning could also be determined by study-
ing the identified interaction partners of the USH2 proteins. In chapter 2c we found 
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novel whirlin-interaction candidates (Preso1, Kir2.3 and LRRC8-channels) that may have 
a function in the homeostasis of K+-ions or other molecules. We and others already 
demonstrated that whirlin and usherin are mutually dependent on each other for their 
localization at the photoreceptor periciliary membrane (chapter 2b) (Yang et al. 2010), 
making the presence of whirlin at this subcellular compartment a biomarker for proper 
localization of usherin. In contrast, the RPE65-encoded retinal pigment epithelium-
specific isomerohydrolase RPE65 is an enzyme that functions in the visual cycle. Patients 
with mutations in RPE65 present with severe retinal dystrophies in the form of either 
Leber congenital amaurosis or early-onset RP (Astuti et al. 2016). Upon RPE65 gene 
augmentation therapy, the visual function of these patients could be partially rescued 
as became clear in an obstacle course (Maguire et al. 2008). Treated patients had an 
increased ability to navigate through the course, which was indicative for a clinical suc-
cess. Since photoreceptors in patients with Usher syndrome degenerate slowly, such a 
visual improvement is probably not to be expected when functional usherin expression 
is restored. Therefore, a detailed phenotypic analysis of multiple patients, performed 
by a combination of methods and techniques, could potentially generate an accurate 
model for the future distinguishment of a therapeutic benefit from the natural course of 
the disease (Sujirakul et al. 2015, Lambertus et al. 2017).
TREATMENT POSSIBILITIES FOR HEARING IMPAIRMENT IN PATIENTS 
WITH USHER SyNDROME TyPE 2
Besides retinal degeneration, patients with USH demonstrate congenital progressive 
hearing impairment. Since the retina is clinically unaffected during childhood, there is 
likely a window of opportunity for therapeutic intervention and therefore the research 
in this thesis was mainly focused on prevention of retinal degeneration. Furthermore, 
there is currently no treatment for USH2A-associated RP, whereas hearing aids or 
cochlear implants can partially compensate for the hearing loss (Hartel et al. 2017). 
However, these devices are far from perfect. Cochlear implants give a broad spatial 
neuronal activation due to the limited number and size of the electrodes, leading to 
poor frequency resolution and poor speech recognition in a noisy environment (Zeng 
2017). Therefore, the development of additional treatment options for the inner ear is 
desired. Once the clinical effect of exon skipping is validated for the retina, it could also 
be explored as potential treatment for the progressive hearing impairment in patients 
with Usher syndrome type 2a.
Fibrous-links between stereocilia and between stereocilia and the kinocilium are, 
among other proteins, made up and anchored by USH1- and USH2-proteins and are 
essential for normal cochlear development (overview in chapter 1). In mice, the cochlea 
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matures until around postnatal day twenty. Hence, augmentation of USH-associated 
genes in the immature cochlea of mouse models that are defective for Ush1c or Whrn 
rescued hearing when delivered at the first days after birth (Pan et al. 2017, Isgrig et al. 
2017). Similarly, vestibular function of a mouse model with defects in Ush1c could be 
restored upon AON-based splice correction at day one after birth (Vijayakumar et al. 
2017), whereas the effectiveness of treatment decreased when performed at 4, 5 or 15 
days after birth. This coincides with the completion of vestibular hair cell development 
in mice between postnatal day two and ten (Vijayakumar et al. 2017). The same holds 
true for the functional rescue of hearing in this mouse model, since preservation of 
outer hair cell function requires AON treatment before postnatal day five in order to 
be effective (Ponnath et al. 2018). In contrast, the human cochlea is already mature at 
birth and hair cells do not regenerate. Therefore, the therapeutic strategies that were 
employed postnatally in the mouse cochlea, seem not applicable to humans.
Confirming a post-developmental role of usherin in the cochlea will determine 
whether or not patients with mutations in USH2A might benefit from a postnatally 
applied treatment to halt the progressive deterioration of hearing. Comparing patients 
with two protein truncating mutations in USH2A with patients having one or two mis-
sense mutations in this gene demonstrated that hearing impairment in the first group is 
more severe and progressive, thereby possibly indicating a post-developmental role for 
usherin (Hartel et al. 2016). However, usherin could not be detected in mature stereo-
cilia of rats when using an antibody against the intracellular region (van Wijk et al. 2006) 
and also mass spectrometry data from inner and outer hair cells from adult mice did 
not detect any usherin (Liu et al. 2014). In contrast, usherin-encoding transcripts were 
identified after RT-PCR analysis using RNA derived from adult rat and mouse cochlear 
tissue (Huang et al. 2002). This implies that either the smaller usherin isoform A has a 
function in the adult cochlea, that the protein is present in undetectable amounts or 
that usherin functions in other cell types than hair cells in the mature cochlea. Indeed, 
immunohistochemical analysis of the spiral ganglion cells demonstrated the presence 
of usherin, ADGRV1 and whirlin in the cell bodies of the spiral ganglion neurons in adult 
rats (van Wijk et al. 2006). As for photoreceptors, dysfunction of neurons in the spiral 
ganglia as a consequence of mutations in USH2A might only become apparent later in 
life leading to progression of the hearing impairment in patients. Also, a cochlea-specific 
exon has been identified that encodes an additional 24 amino acids in the intracellular 
region of usherin, suggesting a cochlea-specific function (Adato et al. 2005). Using the 
cochlea-specific intracellular domain of usherin to screen for candidate interactors, by 
for instance yeast two-hybrid screenings using a cDNA library derived from matured 
cochlea or even spiral ganglion cells, could unravel the post-developmental role of 
usherin in the cochlea.
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In contrast to therapeutic strategies that are applied on matured cells containing a 
defect in Usher syndrome-associated genes, future stem cell-based therapeutic strate-
gies potentially can replace non-functional hair cells by in vitro grown hair cells to 
reverse the hearing phenotype. However, stem cell-based strategies are under develop-
ment and currently not ready for clinical application. Both autologous transplantation 
options as well as allogeneic options are exploited. The first option would be ideal 
as it will prevent potential immune responses after supplementation. An autologous 
cell transplant, however, requires repairing the mutation that underlies the hearing 
impairment before resupplementation. The first human subject has recently been 
treated by an autologous CRISPR/Cas9-treated T-cell injection in a phase I study against 
lungcancer (ClinicalTrials.gov Identifier: NCT02793856) (Cyranoski 2016). Although the 
resupplemented T-cells in this study contained a disruption of the gene coding for the 
PD-1 protein (“Programmed Death-1”) instead of a precisely repaired mutation. For this 
purpose, patient-derived fibroblasts should be dedifferentiated into iPSCs, repaired and 
subsequently be differentiated into sensory epithelia prior to be supplemented to the 
cochlea (Koehler et al. 2013, Oshima et al. 2010). However, besides gene repair and 
differentiation protocols that have to be optimized, also difficulties in the supplementa-
tion of stem cell-based therapies into the cochlea limit the clinical application at pres-
ent. Reaching the cochlea is difficult and each surgical procedure contains the risk of 
damaging the delicate membranous labyrinth. Furthermore, supplemented cells should 
be able to mature and integrate into the existing neuronal network in situ without the 
risk of developing into tumorous tissues. Other than the supplementation of stem cells, 
research focuses on activating the regenerative capacity in man that, for instance, has 
been observed in avian hair cells. Quiescent murine supporting cells could be activated 
to develop into hair cells upon supplementation of mice cochlear explants devoided of 
hair cells with a cocktail of small molecules (McLean et al. 2017). Since these regener-
ated cells still contain the underlying genetic defect, also regeneration strategies have 
to be combined with gene repair. 
AONs have a demonstrated capacity to prevent USH2A-associated retinal dysfunc-
tion (chapter 4) and would therefore be a logical first choice to also apply in the inner 
ear as treatment. The cochlea is protected from the systemic blood circulation by en-
dothelial cells in the stria vascularis that are connected by tight junctions, known as the 
blood-labyrinth barrier (Jahnke 1975, Shi 2016). Therefore, the organ of Corti or spiral 
ganglia can be best reached by AONs through diffusion in the perilymph (reviewed 
by Swan et al. 2008). AONs can enter the perilymph after diffusion through the round 
window membrane, to which they can be delivered by intratympanic injection. For 
a durable effect, transport vehicles that slowly release AONs, such as microimplants 
(Arnold et al. 2005), biodegradable hydrogels (Endo et al. 2005, Paulson et al. 2008) 
or encapsulating nanoparticles (Tamura et al. 2005, Ge et al. 2007, Kim et al. 2015), are 
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under development. Alternatively, AONs can be directly delivered into the inner ear 
upon cochleostomy, but this method has the risk to induce the formation of hydrops or 
fibrosis (Ishiyama et al. 2016). A further option is injection into the endolymphatic sac, 
of which injections of adenoviral vectors resulted in the targeting of mainly the marginal 
cells in the striavascularis and the supporting cells in the organ of Corti (Yamasoba et 
al. 1999). Once the cell type responsible for the USH2A-associated progressive hearing 
impairment has been unraveled, the appropriate method of AON addition into the inner 
ear can be determined. 
SPLICE MODULATION THERAPy FOR USHER SyNDROME
The aim of the research described in this thesis was to evaluate the potential of 
splice modulation as therapeutic strategy for patients with Usher syndrome type 2a. 
Pre-clinical proof-of-concept for this exon skipping approach was obtained using a 
zebrafish model with a protein truncating mutation in ush2a exon13 (chapter 2b and 
4). The predicted domains in usherin are conserved between zebrafish and man and the 
overall photoreceptor morphology is highly similar between the two species (chapter 
2b). Therefore, the effect of ush2a exon 13 skipping in zebrafish is likely indicative for 
a therapeutic effect of exon 13 skipping in patients with mutations in the orthologous 
exon. Additionally, the genetic architecture of USH2A exon 13 is similar between zebra-
fish and man, allowing for a similar AON design. Indeed, ongoing efforts show that 
AONs designed to target human USH2A exon 13 are able to induce exon 13 skipping in 
iPSC-derived photoreceptor precursor cells (unpublished data). The next step is to clini-
cally evaluate the effect of exon skipping in order to determine whether AON-induced 
skipping of USH2A exon 13 will be safe and will stop or slow down the progression of 
retinal degeneration in patients.
The number of patients with Usher syndrome that would benefit from an exon 
skipping therapy is highest for USH2A exon 13. However, using the experiments from 
this thesis as guidelines for AON design, efficacy testing and the validation in patient-
derived cells or in animal models (chapter 3 and 4) for other exons, more patients could 
benefit relatively quickly. Additionally, also a combination of exons could potentially 
be skipped to increase the amount of patients that are eligible for an exon skipping 
therapy (Aslesh, Maruyama, and Yokota 2018). A similar treatment is expected to be 
applicable to prevent visual dysfunction as a consequence of a mutation in other genes 
encoding large Usher proteins with a repetitive domain structure, such as ADGRV1, 
protocadherin-15 or cadherin-23. Based on the results in this thesis, a therapeutic op-
tion for patients with selected mutations in USH2A might be in sight.
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Usher syndrome is the most common cause of combined deaf- and blindness. 
Approximately 1 in 6,000 individuals has bi-allelic mutations in either one of the ten 
Usher-associated genes that lead to this autosomal recessively inherited disorder. Three 
clinical types of Usher syndrome can be distinguished, USH1, USH2 and USH3, based 
on the age of onset, the presence or absence, the severity and the progression of thes 
ymptoms (overview in Chapter 1). The majority of patients present with Usher syn-
drome type 2 (USH2), which is characterized by congenital moderate-to-severe bilateral 
hearing impairment and retinitis pigmentosa (RP) that becomes apparent around the 
end of the second decade of life. About 85% of USH2 patients have mutations in USH2A. 
Additionally, mutations in USH2A are the most frequent cause of autosomal recessively 
inherited non-syndromic RP (arRP). For this reason, the aim of the research in this thesis 
was to (1) improve the understanding of the underlying molecular pathogenesis of 
USH2-associated retinal degeneration and (2) to evaluate the potential of splice modu-
lation as a future treatment option for patients with mutations in USH2A.
Usher-associated proteins have a restricted expression profile and are predomi-
nantly expressed in the inner ear hair cells and retinal photoreceptors, in which they 
exert a specialized function. Hence, designing in vitro assays to study the USH2 proteins 
is challenging. The role of USH-associated proteins in the inner ear has been largely 
determined by studying wild-type and knock-out mouse models for the associated 
Usher syndrome genes, but the retina in these mice models is mostly not, or only mildly, 
affected. This indicates the presence of anatomical or physiological differences between 
murine and human photoreceptors that limit the suitability of rodent models to study 
the pathogenesis of Usher syndrome-associated retinal degeneration. To identify these 
and other differences between vertebrate animal models, we reviewed all species for 
which animal models for inherited retinal dystrophies have been generated and charac-
terized. We compared their retinal morphology, the observed phenotypes and discussed 
their suitability for different research purposes (chapter 2a). Based on the comparative 
analyses in chapter 2a, the zebrafish was identified as an attractive model organism to 
study Usher-associated proteins and was therefore used as model to study the role of 
USH2 proteins and complexes in the retina. Chapter 2b describes the generation and 
characterization of two targeted ush2a knock-out zebrafish models (ush2armc1/rmc1 and 
ush2ab1245/b1245). Analysis of the mutant retinas demonstrated that ush2armc1/rmc1 mutant 
zebrafish completely lack the ush2a-encoded protein usherin, whereas in the retina 
of ush2ab1245/b1245 zebrafish usherin could still be detected with antibodies recognizing 
the N-terminal ectodomain. We concluded that usherin lacking the intracellular region 
is still properly localizing to the photoreceptor periciliary membrane of ush2ab1245/b1245 
mutant zebrafish. Both mutants showed a reduced retinal function as was determined 
by electroretinogram recordings from homozygous larvae, largely in the absence of 
apoptotic photoreceptors. Challenging these mutants with constant bright light for 72 
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hours resulted in a significant increase in the amount of apoptotic cells in the outer 
nuclear layer (ONL) as compared to strain- and age-matched wild-types. Histological 
analysis of adult mutant zebrafish eyes revealed no signs of progressive retinal de-
generation, possibly due to the regenerative capacities of zebrafish. In conclusion, 
these zebrafish mutants are considered to be suitable for studying USH2A-associated 
retinal dysfunction and will likely play an important role in the future in elucidating the 
retinal pathogenesis that leads to photoreceptor degeneration in patients with Usher 
syndrome. 
To better understand the molecular function of the USH2 protein complex(es) in the 
retina, we expanded the known USH2 protein interactome by the identification of novel 
candidate interacting partners of the USH2 scaffold protein whirlin (Chapter 2c). We 
generated a transgenic zebrafish that expresses Strep/FLAG-tagged Whrna (SF-Whrna), 
the whirlin ortholog with the highest binding-affinity for usherin, under the control of 
a photoreceptor-specific promoter. A single-step affinity purification was performed to 
isolate Whrna-associated protein complexes from the adult zebrafish retina and subse-
quent mass spectrometry analysis unveiled that these complexes consisted of, among 
others, Preso1, Kir2.3 and LRRC8-channels. The human orthologs of Kir2.3 and Preso1 
directly interacted with human whirlin in a yeast two-hybrid assay, indicating that our 
novel approach is able to identify relevant novel interactors. Furthermore, Preso1 was 
already indirectly associated with whirlin in the inner ear and Kir2.3 has been shown to 
be part of a CASK-mediated mechanism of vesicle acceptance. Based on these data, we 
hypothesize that Kir2.3 channels, together with whirlin, LIN7C, CASK, and potentially 
other proteins, are involved in the regulation of cargo vesicle acceptance at the base of 
the photoreceptor connecting cilium.
In Chapter 3, we demonstrate that AONs are able to correct aberrant USH2A pre-
mRNA splicing caused by the deep intronic c.7595-2144A>G mutation in USH2A intron 
40. The c.7595-2144A>G mutation generates a high quality splice donor site that results 
in the inclusion of a 152 nucleotide pseudoexon (PE40) into the mature USH2A transcript 
predicted to result in premature termination of usherin translation. Pseudoexons are 
ideal targets for an AON-based treatment, since splice correction results in a wild-type 
transcript. To identify AONs with efficient exon skipping characteristics, we compiled a 
step-by-step protocol (chapter 3a). The designed AONs targeting USH2A PE40 were 
able to efficiently redirect USH2A splicing in fibroblasts from patients with the c.7595-
2144A>G mutation (chapter 3b). To evaluate the effect of AON-based splice correction 
at the level of retina function, we generated a CRISPR/Cas9-based humanized zebrafish 
model in which human USH2A PE40 with flanking sequences was introduced in intron 
40 of the zebrafish ush2a gene (chapter 3c). However, human USH2A PE40 was poorly 
recognized by the zebrafish splicing machinery. For this reason, we developed a zebra-
fish-specific cell-based minigene splice assay to evaluate human splice site recognition 
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by the zebrafish splicing machinery, prior to generating humanized zebrafish knock-in 
models. In case of USH2A PE40, we adapted the human PE40 splice acceptor site to-
wards the zebrafish splice acceptor consensus sequence. This modification resulted in a 
significantly improved recognition of human PE40 by the zebrafish splicing machinery. 
In conclusion, we have shown that AONs are able to efficiently prevent the inclusion of 
PE40 in the USH2A transcript in patient-derived fibroblasts. These results indicate that 
AON-based splice correction has the potential to become a future treatment option for 
patients with USH2A-associated retinal degeneration caused by the c.7595-2144A>G 
mutation.
Chapter 4 describes the effect of zebrafish ush2a exon 13 skipping on retina func-
tion. Using an optimized dose of exon 13-targeting morpholinos, exon 13 could be 
efficiently skipped from ush2a transcripts in zebrafish larvae. Treatment of our previ-
ously generated ush2armc1/rmc1 mutant zebrafish with these morpholinos resulted in a 
partial rescue of usherin expression at the photoreceptor periciliary membrane and in 
restored electroretinogram b wave amplitudes. Therefore, this study provides in vivo 
proof-of-concept that early retinal dysfunction as a consequence of mutations in ush2a 
exon 13 can be rescued by skipping of this exon in zebrafish. 
In conclusion, the studies described in this thesis use cell and zebrafish models to 
expand the USH2 protein network with novel interaction candidates and to provide 
proof-of-concept for an exon skipping as a therapeutic strategy. Future research will 
determine whether AON-induced skipping of exon 13 in selected patients with USH2A-
associated retinal degeneration results in a similar therapeutic effect in man (chapter 
5). By following the protocol described in chapter 3a, AONs can be relatively easily 
designed to target other (combinations of) exons in USH2A or other USH genes. There-
fore, once AONs targeting USH2A exon 13 have proven to be effective in halting or 
preventing retinal degeneration, potentially also patients with mutations in other exons, 
either in USH2A or other USH genes, could similarly benefit from a splice redirection 
therapy in the future (chapter 5).
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Usher syndroom is de meest voorkomende oorzaak van gecombineerde doofheid 
en blindheid. Ongeveer 1 op de 6.000 personen heeft bi-allelische mutaties in één van 
de tien met Usher syndroom geassocieerde genen. Er zijn drie klinische typen Usher 
syndroom te onderscheiden, USH1, USH2 en USH3, op basis van de leeftijd waarop de 
ziekte tot uiting komt, en de aan- of afwezigheid, de ernst en progressie van de symp-
tomen (overzicht in hoofdstuk 1). De meerderheid van de patiënten presenteert zich 
met Usher syndroom type 2 (USH2) dat wordt gekenmerkt door aangeboren, matige tot 
ernstige bilaterale gehoorstoornissen en retinitis pigmentosa (RP) die rond het einde 
van de tiener jaren tot uiting komt. Ongeveer 85% van de patiënten met USH2 heeft 
mutaties in het USH2A-gen. Bovendien zijn mutaties in dit gen de meest voorkomende 
oorzaak van autosomaal recessief overervende niet-syndromale RP (arRP). Om deze re-
denen was het doel van het onderzoek in dit proefschrift om (1) het inzicht te vergroten 
in de onderliggende moleculaire pathogenese van USH2-geassocieerde retinadegene-
ratie en (2) om het mogelijk positieve effect te onderzoeken van splice-modulatie als 
toekomstige behandeloptie voor patiënten met mutaties in USH2A.
De eiwitten gecodeerd door de USH-genen komen beperkt tot expressie en zijn 
voornamelijk aanwezig in de haarcellen van het binnenoor en de fotoreceptoren in de 
retina, waarin ze een specifieke functie vervullen. Daarom is het ontwerpen van in vitro 
testen om de USH2-eiwitten te bestuderen een uitdaging. De rol van USH-eiwitten in het 
binnenoor werd grotendeels bepaald door het bestuderen van wild-type en knock-out 
muismodellen voor genen die geassocieerd zijn met Usher syndroom, maar het netvlies 
in deze muismodellen is meestal niet, of slechts licht, afwijkend. Dit toont de aanwezig-
heid van anatomische of fysiologische verschillen aan tussen menselijke fotoreceptoren 
en die van de muis. Door deze verschillen zijn knaagdiermodellen ongeschikt om de 
pathogenese van retinadegeneratie bij Usher syndroom te bestuderen. Om deze en 
andere verschillen tussen de gewervelde dieren te identificeren, hebben we alle soorten 
met elkaar vergeleken waarvan diermodellen voor een erfelijke retinadystrofie zijn ge-
genereerd en gekarakteriseerd. We keken hierbij naar de morfologie van de retina, de 
waargenomen fenotypes en we bediscussieerden hun geschiktheid voor verschillende 
onderzoeksdoeleinden (hoofdstuk 2a). Op basis van deze vergelijkende analyses werd 
de zebravis geïdentificeerd als een aantrekkelijk modelorganisme om USH-eiwitten te 
bestuderen en werd deze als model gebruikt om de rol van USH2-eiwitten en -com-
plexen in het netvlies te bestuderen. Hoofdstuk 2b beschrijft het genereren en ka-
rakteriseren van twee ush2a knock-out zebravis modellen (ush2armc1/rmc1 en ush2ab1245/
b1245). Analyse van de ush2armc1/rmc1 zebravis toonde aan dat het door ush2a gecodeerde 
eiwit usherin mist. Daarentegen kon in de retina van de ush2ab1245/b1245 zebravis usherin 
nog steeds worden gedetecteerd met antilichamen die het N-terminale ectodomein 
herkennen. Deze analysen lieten zien dat usherin zonder de intracellulaire regio nog 
steeds goed gelokaliseerd is in het periciliaire membraan van fotoreceptoren in de 
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ush2ab1245/b1245 zebravis. Beide mutanten vertoonden een verminderde netvliesfunctie 
zoals werd bepaald door elektroretinografie van homozygoot-mutante larven met in 
hun netvlies weinig apoptotische fotoreceptoren. Het blootstellen van deze mutanten 
aan fel licht gedurende 72 uur resulteerde in een significante toename van het aantal 
apoptotische cellen in de buitenste nucleaire laag (ONL) ten opzichte van wild-type 
larven met dezelfde genetische achtergrond en leeftijd na deze blootstelling. Histo-
logische analyse van ogen van volwassen mutante zebravissen liet geen tekenen zien 
van progressieve retinadegeneratie. Dit is mogelijk het gevolg van de regeneratieve 
vermogens van de zebravis. Concluderend worden deze zebravis mutanten geschikt 
geacht voor het bestuderen van USH2A-geassocieerde retina disfunctie. Daarom zullen 
deze vissen waarschijnlijk een belangrijke rol gaan spelen bij het ophelderen van de 
moleculaire mechanismen die leiden tot fotoreceptor degeneratie bij patiënten met 
Usher syndroom.
Om de moleculaire functie van de USH2-eiwitcomplexen in het netvlies beter te 
begrijpen, hebben we nieuwe (kandidaat) interactiepartners van het USH2-eiwit whirlin 
geïdentificeerd (hoofdstuk 2c). We hebben een transgene zebravis gemaakt die Strep/
FLAG-getagd Whrna (SF-Whrna), de whirlin-ortholoog in zebravis met de hoogste bin-
dingsaffiniteit voor usherin, onder de controle van een fotoreceptor specifieke promoter 
tot expressie brengt. Door middel van een enkele affiniteitszuivering werden Whrna-
geassocieerde eiwitcomplexen uit de retina van volwassen zebravissen geïsoleerd en 
met behulp van massaspectrometrie geanalyseerd. De geïsoleerde eiwitcomplexen 
bevatten onder andere Preso1, Kir2.3 en componenten van LRRC8-kanalen. De humane 
orthologen van Kir2.3 en Preso1 lieten een directe interactie zien met het menselijke 
whirlin in een ‘yeast two-hybrid’-test, wat aangeeft dat onze nieuwe benadering in staat 
is om relevante nieuwe interactoren te identificeren. Bovendien was Preso1 al eerder 
indirect geassocieerd met whirlin in het binnenoor en is aangetoond dat Kir2.3 deel uit-
maakt van een CASK-gemedieerd mechanisme van het aannemen van transportblaasjes 
in de cel. Op basis van deze gegevens veronderstellen we dat Kir2.3-kanalen, samen 
met whirlin, LIN7C, CASK en mogelijk andere eiwitten, betrokken zijn bij de regulatie 
en het aannemen van transportblaasjes aan de basis van het ‘connecting’ cilium in 
fotoreceptoren.
In Hoofdstuk 3 laten we zien dat antisense oligonucleotiden (AONs) de afwijkende 
splicing van USH2A pre-mRNA kunnen corrigeren die wordt veroorzaakt door de diep-
intronische c.7595-2144A>G mutatie in USH2A intron 40. De c.7595-2144A>G mutatie 
genereert een splice donor site van hoge kwaliteit die resulteert in de inclusie van een 
pseudoexon (PE40) in het mature USH2A-transcript. Deze inclusie wordt voorspeld te 
resulteren in voortijdige beëindiging van de usherin-eiwitsynthese. Pseudoexonen zijn 
ideale targets voor behandeling met AONs, omdat correctie van de afwijkende splicing 
(exon-skipping) resulteert in een normaal mRNA. Om AONs met efficiënte exon-
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skipping kenmerken te identificeren, hebben we een stapsgewijs protocol opgesteld 
(hoofdstuk 3a). De ontworpen AONs, gericht tegen USH2A PE40, waren in staat om 
USH2A RNA-splicing efficiënt te corrigeren in fibroblasten van patiënten met de c.7595-
2144A>G mutatie (hoofdstuk 3b). Om het effect van de AONs op retina functie te 
evalueren, hebben we met CRISPR/Cas9 een gehumaniseerd zebravismodel gemaakt 
waarin het menselijke USH2A PE40 met flankerend DNA is geïntroduceerd in intron 
40 van het zebrafish ush2a-gen (hoofdstuk 3c). Het menselijke USH2A PE40 werd 
echter slecht herkend door de zebravis splicing-machinerie. Om deze reden hebben we 
een test ontwikkeld, waarbij we gebruik maken van gekweekte zebraviscellen, om de 
herkenning van humane splice-sites door de zebravis splicing-machinerie te evalueren, 
voorafgaand aan het genereren van gehumaniseerde zebravismodellen. In het geval van 
USH2A PE40 hebben we de menselijke PE40 acceptor site aangepast aan de consensus 
sequentie van de zebravis acceptor site. Deze modificatie resulteerde in een significant 
verbeterde herkenning van het menselijke PE40 door de zebravis splicing-machinerie. 
Concluderend hebben we aangetoond dat AONs in staat zijn de inclusie van PE40 in 
het USH2A-RNA efficiënt te voorkomen in fibroblasten afkomstig van patiënten. Deze 
resultaten laten zien dat splice-correctie met AONs potentie heeft als toekomstige be-
handelmethode voor retinadegeneratie bij patiënten met de c.7595-2144A>G mutatie.
In hoofdstuk 4 is het effect beschreven van het overslaan van zebravis ush2a exon 
13 op retinafunctie. Met een geoptimaliseerde dosis morfolino’s gericht tegen exon 13, 
kan dit exon efficiënt worden overgeslagen in ush2a-RNA in zebravislarven. Behande-
ling van onze eerder gegenereerde ush2armc1/rmc1 mutante zebravis met deze morfo-
lino’s resulteerde in een gedeeltelijk herstel van de aanwezigheid van usherin in het 
periciliaire membraan van fotoreceptoren. Ook werd er een herstel van de amplitude 
van b-golven gemeten bij electroretinografie. Daarom biedt deze studie in vivo ‘proof 
of concept’ dat vroege retinadisfunctie als gevolg van mutaties in ush2a exon 13 kan 
worden voorkomen door het overslaan van dit exon in de zebravis.
Samenvattend kunnen we stellen dat de in dit proefschrift beschreven studies 
met cel- en zebravis-modellen het USH2-eiwitnetwerk hebben uitgebreid en ‘proof of 
concept’ hebben geleverd voor het overslaan van een exon als therapeutische strate-
gie. Toekomstig onderzoek zal bepalen of overslaan van exon 13 van het USH2A-gen 
met behulp van AONs bij specifieke patiënten met retinadegeneratie resulteert in een 
vergelijkbaar therapeutisch effect in de mens (hoofdstuk 5). Door het volgen van het 
protocol dat is beschreven in hoofdstuk 3a, kunnen AONs relatief eenvoudig worden 
ontworpen om andere (combinaties van) exonen over te slaan in USH2A of andere genen 
geassocieerd met Usher syndroom. Als AONs gericht tegen USH2A exon 13 effectief 
blijken te zijn in het stoppen of voorkomen van retinadegeneratie, kunnen mogelijk ook 
patiënten met mutaties in andere exonen, hetzij in USH2A of andere USH-genen, in de 
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toekomst profiteren van een behandeling die afwijkende splicing van RNA corrigeert 
(hoofdstuk 5).
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